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THE MICROBE 
The microbe is so very small 
Y ou cannot make him out at all, 
but many sanguine people hope 
To see him through a microscope.
His jointed tongue that lies beneath 
A hundred curious rows of teeth;
His seven tufted tails with lots 
of loverly pink and purple spots,
On each of which a pattern stands.
Composed of forty separate bands;
His eyebrows are of tender green.
All these have never yet been seen- 
But scientists, who ought to laiow,
Assure us that they must be so...
Oh! Let us never, never doubt 
What nobody is sure about!
By Hilaire Belloc, reproduced with kind permission o f  the publishers, Random House, UK 
limited. Taken from  complete Verse, Hilaire Belloc, Pimlico, London, p. 246.
Abstract
A series o f P4 (Cbz and t-Boc) N-protected potential substrates and inhibitors, 
containing the Pi to P4 substrate recognition sequence of the type 2 adenovirus proteinase 
(Leu-Ala-Gly-Gly) were prepared by solution phase peptide coupling techniques and tested 
for activity against the proteinase. The potential substrates contained the amide and ester 
moieties at the Pi carbonyl position and the potential inhibitors contained the alcohol, acid, 
bromide, aldehyde, ketone, dimethylacetal, nitrile, alkenic, malonyl and epoxysuccinate 
moieties at the Pi carbonyl position.
The esters, the t-Boc urethane and the /7-nitroanilide moieties were substrates for the 
proteinase and the acid and the amides did not bind to the proteinase. Preliminary results 
show that the other inhibitors were mostly noncompetitive inhibitors for the adenovirus 
proteinase with approximate K fs between 15 and 200 pmol dm'^.
The test results indicate that: the amides must contain a carbonyl group at P2’ to bind to 
the proteinase; the loss of the P i’ amine product is the rate limiting step for the hydrolysis 
of a substrate by the adenovirus proteinase; the P acid product leaves before the P ’ amine 
product, which is in complete contrast to classical cysteine proteinases such as papain; little 
protonation o f the P i’amide nitrogen or the Pi carbonyl oxygen of the adenovirus 
proteinase-substrate complex occurs before the nucleophilic attack on the Pi carbonyl 
carbon o f the adenorirus proteinase-substrate complex.
Abbreviations
A alanyl
Arg arginyl
Asn asparaginyl
Asp aspartyl
B asparaginyl or aspartyl
C cysteinyl
Cbz carbobenzyloxy
CE capillary electrophoresis
^^C-NMR carbon-13 nuclear magnetic resonance
Cys cysteinyl
D aspartyl
dCMP deoxyribosyl cytosyl monophosphate residue
DMF dimethyl formamide
DMSO dimethyl sulphoxide
DNA deoxyribosyl nucleic acid
DPF diisopropyl fluorophosphate
DTT dithiothreitol
E glutamyl
F phenylalanyl
G glycyl
Gin glutaminyl
H histidinyl
His liistidinyl
^H-NMR proton nuclear magnetic resonance
I isoleucyl
m cF /50-butyl chloroformate
IF initiation factor
iPr2EtN diisopropyl ethylamine
K lysinyl
Km Michaeiis constant
L leucyl
M methionyl
MeOH methanol
mRMA messenger ribonucleic acid
N asparaginyl
NEM N-ethyl maleimide
NMM N-methyl morpholine
NMM.HC1 N-methyl morpholine hydrochloride
P prolinyl
PAH phenylalanine hydroxylase
PCMP parachloromercury benzoate
PK protein kinase
PKU phenylketonuria
PMSF phenyl sulphonium methyl fluoride
POL viral polymerase
pTP preterminal protein
Q glutaminyl
R arginyl
RNA ribosyl nucleic acid
S serinyl
SBTI soya bean trypsin inhibitor
Ser serinyl
STEM scanning transmission electron microscope
T threonyl
t-Boc ferriajy-butoxycarbonyl
TBTU 0-benzotriazole-1 -yl-N, N, N ’, N ’-tetramethyluronium tetrafluoroborate
TEA trifluoroacetyl
THF tetrahydrofuran
V valinyl
Vmax maximal rate
W tryptophanyl
X any aminoacid residue
Y tyrosinyl
Z glutaminyl or glutamyl
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1.0.1 Infection
1.0 The Adenovirus
1.0.1 Infection
In 1953 Rowe isolated a new cytopathogenic agent from the tissue culture fluid o f 
spontaneously degenerating human adenoidial tissue.^ The agent could infect other healthy 
cells and specific antibodies could be raised from rabbits to neutralize the agents activity, 
although the agent could not be grown on bacteriological media. Rowe concluded that the 
adenoidal degradation product was either a virus or a rickettsaie (parasitic microorganism, 
intermediate in structure between bacteria and viruses). Since then the cytopathogenic 
agent has been identified as a virus and 47 different human serotypes have been 
discovered. Serotypes 1-5 and 7 are endemic to the western world where they are a major 
factor in acute respiratory disease (serotypes 4 and 7),^ pharyngoconjunctival fever 
(serotypes 3, 7, 14),^ keratoconjunctivitus (serotypes 3, 7 and SŸ and gastroenteritis 
(serotypes 40 and 41).^
Adenovirus infections of immunocompromised patients are overwhelming^ and are 
usually fatal. In these cases evidence o f adenovirus has been found in the lungs, liv e r,^  
kidneys^ and the gastric tract. Indeed Rowe showed that human gamma-globulin could 
prevent the cytopathic effect of the adenovirus when added to infected cells. ^
Childhood infections with adenovirus 12 give an enhanced risk of coeliac disease and 
dermatitis herpetiformis^, while adenovirus 1 and 2 have been linlred with infant 
intussusception of the bowel.^ Adenovirus may also be one cause of persistent 
inflammatory arthritis^ and childhood acute myocarditis.^*  ^ One Adenovirus group 
(serotypes 12, 18 and 31) is highly oncogenic in animals^ and there is some evidence that 
adenoviral DNA has been found in neurogenic tumors.
1.0.2 Structure
1.0.2 Structure
Adenovirus particles are non-enveloped, regular icosahedra of 1500Â diameter with a 
mass of 150 MDa. The virus particle contains a linear double stranded DNA genome and is 
built up from eleven different structural proteins/ The protein coat (capsid) consists of two 
hundred and forty hexons and twelve pentons. A penton is situated at each vertex, 
suiTounded by five hexons. A fibre projects from each penton and its length depends on the 
serotype of the virus^ (Fig. 1.1 a and b on page 3).^^
Each hexon is a trimer of three identical polypeptide chains. The base of each monomer 
consists of a pair o f antiparallel eight-stranded (3-barrels, which lock together in a 
pseudo-hexagonal ring in the trimer. The hexons form a close-packed hexagonal array on the 
virus surface. Protein IX links nine hexons in the centre of each face of the virus particle, 
while proteins VI and V m  bridge hexons between adjacent faces. The structure of the 
adenovirus 2 is shown in Fig. 1.2 on page 4.^  ^ The positions o f the hexon (II), penton base 
(in), fibre (IV) and polypeptide IX are certain but the positions of polypeptides Ha, VI and 
V ni are tentatively assigned based on a 3-dimensional image construction of the intact 
virus. The 3-dimensional image construction was based on the low resolution electron 
crystallographic structure of the hexon and multiple images from an image-enhanced 
scanning transmission electron microscope (STEM) of the virus in different orientations.^^
The virus core is composed of the double stranded DNA genome and four different 
polypeptides. One of these polypeptides (the terminal protein) caps each end of the double 
stranded DNA. The protein-DNA linlcs occur through serine hydroxyl groups and 
deoxyribose cytosyl monophosphate residues (Fig. 1.3 on page 5). This is called the 
pTP-dCMP complex. The other three polypeptides are involved in the positioning and 
paclcing of the DNA during viral particle assembly.^
1.0.2 structure
a)
b)
Fig. 1.1: Electronmicrographs o f an adenovirus, 
a) to show the icosohedral array and h) to show the fibres. *
* reproduced with kind permission of Academic Press Ltd, London, England.
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CAPSID
-  Vl(
Terminal  DNA
IX ▼
Fig. 1.2: Schematic representation o f an adenovirus.
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terminal protein
^Ser
010 = P = 0  Io
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replication
O—base base-
viral DNA
Fig. 1.3: Positioning o f the terminal protein on the viral DNA.
1.0.3 Life cycle
The life cycle of the virus is divided into 2 phases; early phase (E), when virus 
penetration, transcription and translation occurs and late phase (L), during which duplication, 
and new virus assembly occurs.^
The adenovirus enters a cell through receptor mediated endocytosis. Initially the head of 
the fibre attaches to a specific receptor on the cell’s surface'^ and the vesicles enclose the 
virus. Here the virus disrupts the membrane of the endocytic vesicles so that when the 
capsid is ruptured the viral contents are released into the cytoplasm. This process is aided 
by the penton base,^^ which may bind to av integrin receptors, and the acidic pH^^ of the 
endocytic vesicle.
The pentons are lost at this stage^ ® and the virus is transported across the cytoplasm using 
the hexons which bind to the cell microtubules.^^ When the virus reaches the nucleus, viral 
DNA enters, leaving many of the viral proteins in the cytoplasm.^^
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Each region of the viral genome codes for a specific polypeptide, which is required for 
virus formation (Fig. 1.4). The arrow in Fig. 1.4 indicates transcription direction and the 
functions of the genome regions are listed in Table 1.1.
E1A E1B
3
S'
E3
L4 L5
■<  IV 32
-<------------
E2A
E2B
Fig 1.4: The adenovinis type 2 genome.
E4
Region of Genome mRNA codes for;
E lA  and ElB proteins that control transformation function
E2A DNA binding protein
E2B DNA polymerase and terminal protein
E3 protein that suppress the immune system and 
prevents host cell growth^^
E4 Viral assembly proteins
IV. transcriptional activator^^
LI and L2 penton proteins
L3 hexon protein and a 23kDa proteinase^"^
L4 hexon-stabilizing protein
L5 fibre proteins
Table 1.1: The function o f  various regions o f  the adenovirus genome.
1.0.3 Life cycle
Regulation of viral transcription (the process whereby mRNA is synthesized from a DNA 
template) is complex, and not fully resolved. However it is postulated that the E l A region is 
transcribed first, and that some of this mRNA codes for a protein that enables the other early 
regions, (given the prefix E in Fig. 1.3) to be transcribed. It is thought that a host 
transcription repressor for the other early regions exists, and the E lA  protein either binds to 
the repressor or inhibits its synthesis, allowing transcription of the other early regions.''
The mRNA then leaves the nucleus through a nuclear pore and enters the cytoplasm 
where it is translated into polyprotein by host enzymes. Cellular protein synthesis is regulated 
by an initiation factor (IF), which must reach the nucleus before transcription can begin. 
When the mRNA reaches the cytoplasm translation occurs and new protein is produced.
Control occurs via a protein kinase (PK), which phosphorylates the IF, making it inactive. 
The PK is activated by the mRNA used to synthesize the protein. In this way genes can be 
turned on and off The adenovirus inhibits PK, so that the mRNA that codes for a viral DNA 
polymerase (POL) can be made. Duplication can then commence. Viral DNA is a 
competitive inhibitor of PK, so IF is not inactivated and viral protein production can 
continue.
Duplication of the viral DNA is also complex, and not fully resolved. The 3’-OH of the 
pTP-dCMP complex acts as a primer for the new strand of DNA, using one strand of viral 
DNA as the template.^'’ Then POL binds to the pTP-dCMP complex, aided by a viral 
single-strand specific DNA-binding protein. The pTP-dCMP complex elongation is catalysed 
by POL and requires three host proteins; nuclear factor I, nuclear factor III and a 
topoisomerase (nuclear factor 11).^^
Meanwhile, in the cytoplasm hexons and pentons are assembled from their constituent 
monomers. A scaffold protein ensures correct association of the hexon monomers. The
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capsid is produced from the hexons, pentons and other structural proteins, while the core 
polypeptides and the viral DNA are injected into the capsid. As the new virus matures, the 
proteins; pVI, pVII, lllcDa,^^ pTP,^^ pVTII, Illa^® and pMu^  ^ are cleaved by a 231cDa 
protease, encoded by the L3 region of the genome.
The newly formed infectious viruses are then released by cell lysis. The virus has two 
strategies for inducing this; the first is to prevent cell growth, as the viral E3 protein removes 
epidermal growth factor receptors from the surface of the host cell,^^ preventing the host cell 
from receiving any growth factor. The second strategy, is to cleave the protein fibre network, 
that gives the cell structural integrity, with the 23kDa protease.^^
1.0.4 Therapeutic uses
Recently there has been considerable interest in gene therapy to treat genetic disorders^^ 
such as cystic fibrosis '^^ and cancer.^^ This involves the transfer and expression of DNA into 
affected cells by means of a vector, a task for which adenovirus may be suitable.
Replication-deficient adenovirus vectors have been used to transfer the E. coli 
P-galactosidase gene to rat brain cells both in vivo^^ and in vitro, r a t  primary hepatocytes 
in vitro^^ and into fetal rabbits in utero}^ This gene has also been transferred to the airway 
epithelial cells of sheep in vivo^^
Human pancreatic lipase has also been transferred to sheep’s gall bladders in vivo^^ and 
human phenylalanine hydroxylase (PAH) gene has been transferred into PAH-deficient mice 
in vivo using adenovirus replication-deficient vectors. A lack of PAH causes phenylketouria 
(PKU) which produces severe mental retardation in children. '^^
Adenovirus vectors are particularly suitable as they can infect postmitotic cells^^ and do 
not incorporate DNA into the host genome, minimizing the risk of m utagenesis .A  clinical
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trial is cun’ently in progress to determine whether adenovirus can transfer the normal gene to 
the nasal epithelium of cystic fibrosis suffers
The E lA  product of the adenovirus type 5 can act as a tumor suppressor gene for the neu 
gene in rats both m vivo and in vitro/^ Over-expression of the human neu gene can result in 
many types of cancer eg. breast, ovary/^ lungs/"* stomach"*  ^ and colon/*^ The E lA  region 
of the adenovirus may provide a useful tool for the development of therapeutic agents 
against these cancers.
1.1 Solution mechanisms for amide bond hydrolysis
In solution there are three possible mechanisms to hydrolyse an amide bond; a) base 
catalysed, b) acid catalysed and c) strong acid catalysed.
1.1.0 Base catalysed hydrolysis of an amide bond
In the base catalysed hydrolysis mechanism (Scheme 1.1) the nucleophilicity of the 
nucleophile (water in the uncatalysed hydrolysis) is increased by changing the nucleophile for 
a hydroxide ion, so that the rate of hydrolysis is speeded up. The use of *^0-labelled amides 
has shown that, during the base catalysed hydrolysis of primary and secondary amides, 
oxygen exchange in the starting material is r a p i d . T h i s  fits with the observation that the 
amide anion is a poorer leaving group than the hydroxide ion, so it is more likely that the 
hydroxide ion will leave before the amide anion in the tetrahedral intermediate (1) (Scheme 
1.1). Therefore k_i is greater than k% and k.2  must be the rate determining step of the base 
catalysed hydrolysis."*  ^ In the case of an *^0-labelled amide, either the unlabelled attacking 
hydroxide, or labelled hydroxide, produced from proton exchange between the tetrahedral 
intermediate (2) and the solvent (Scheme 1.2) could leave before the amide anion. If the
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labelled hydroxide leaves before the amide anion, the carbonyl oxygen of the amide starting 
material loses some of the ^^0-label. Tertiary amides show no similar oxygen exchange and 
this has led to the suggestion that oxygen equilibration is actually mediated by a proton from 
the nitrogen (Fig. 1.5).'^^
O -o. .R' kg
R aN -^R - + ‘OH  ----    o. mX .k-l RgN OH |(^
(1 )
M O
■ R '^O H  + 'NR: "  , n A „ .  + NHRa
oILR' ^ 0
Scheme 1.1; The based catalysed hydrolysis o f  an amide bond.
" V  AR a N '^ 'S C    R a N '^ R ' +
(2)
HaO
‘V  1RaN ^ ’®0H -■ R a N - ^ R ' + ' “OH
Scheme 1.2: Hydroxide exchange during the based catalysed hydrolysis o f  an amide bond.
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I IR - C — N - R '1 !O— H
Fig. 1.5:
The mechanism o f oxygen equilibration in primary and secondary amide hydrolysis.
As k_i is much greater than kg the base catalysed hydrolysis of amides in aqueous solution 
is not a very efficient process. However in non aqueous conditions i.e. using a small excess 
of water, excess potasium tertiary-butoxide as a base and ether as the solvent (Scheme 1.3), 
amide hydrolysis is rapid and the tetrahedral intermediate (3) (Scheme 1.3) formed is now a 
dianion which expels the negatively charged nitrogen rapidly."*^
° B ■ + HaO ’R  ^ p -  + -8[I P  MgU M l
RgN R' _ B|_| RgN OH - BH
R g N ^ Q -  R g N - ^ O ”
B" = t-B u C
Scheme 1.3: The non-aqueous base catalysed hydrolysis o f  an amide bond.
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1.1.1 Acid catalysed hydrolysis of an amide bond
Acid catalysed hydrolysis of an amide bond is more complex as it is possible to polarise 
the carbon-oxygen bond by protonation of the carbonyl oxygen, or to polarise the carbon- 
nitrogen bond by protonation of the amide nitrogen. Both of these methods create a greater 
positive charge on the carbonyl carbon, compared to the unprotonated amide and enhance 
the electrophilicity of the carbonyl carbon. Oxygen protonation would result in an addition 
type hydrolysis mechanism, whereas nitrogen protonation would lead to as SnI type 
hydrolysis mechanism. In solution spectroscopy has shown that oxygen protonation
predominates in 100% acid solution. The methyl protons of dimethylformamide in sulphuric 
acid still appear as a doublet of singlets (the cis and trans methyl group are not equivalent as 
rotation of the carbon-nitrogen bond is restricted by the conjugation of the nitrogen lone pair 
and the carbonyl bond) so the carbon-nitrogen bond rotation is still restricted. If the amide 
nitrogen was protonated, the lone pair of the nitrogen would not be available for 
delocalisation with the carbonyl group and carbon nitrogen bond rotation would not be 
restricted so a singlet would be observed for the methyl signals of dimethylformamide.The 
proton signal for a proton attached to the oxygen of an amide has also been observed at 
-90°C for dimethylformamide in fluorosulphuric acid, (10.40 ppm, referenced to trimethyl 
silane).^^ Acid hydrolysis usually occurs by the addition mechanism (Scheme 1.5).^  ^ No 
oxygen exchange occurs, unlike the basic hydrolysis mechanism as kg is greater than Ici. The 
breakdown of the protonated nitrogen tetrahedral intermediate (4) (Scheme 1.4) should be 
fastest when one of the electron pairs of each oxygen is antiperiplanar to the lone pair in the 
amine leaving g r o u p . T h e  a-diamino alcohol (5) is an analogue of the tetrahedral transition 
state (4) and breaks down to give the primary amine (7a) and not the lactam (7b) (Scheme
1.5 on page 1 3 ) . The alcohol (5) is formed in conformation (5a) from the axial attack of
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hydroxide at carbon-2 of the amidine (6). As both inversion of the ring and the secondary 
amine are slow compared to the breakdown of the alcohol (5), the secondary amine lone pair 
is unlikely to become antiperiplanar to the primary amine lone pair, so the lactam (7b) is not 
formed. By contrast both the primary amine and the alcohol groups rotate freely, allowing 
the alcohol (5) to adopt conformation (5b), where one of the alcohol lone pairs and the 
secondary amine lone pair are antiperiplanar to the primary amine lone pair so the primary 
amine (7a) is formed.
R ^ N ^ R ' + RgN" R'
0  'R OH
1+ + H2O kg
R gN '^^R ' RgN OH2
•R OH + 0 ^ "
HRgN-^O H  -,.....— n o A p , ,  + NHR2
" (4)
HO R' + H +
Scheme 1.4: The acidic hydrolysis mechanism o f an amide bond.
OR C>0A" o ^ H0 0 ^
A - ^ h> 0"
(6) (5a) , (5b)
A 1NH3 + ,  M ,------ / " N H s
H 1 ^  NHg
(7a)
Scheme 1.5: The acid catalysed hydrolysis o f  a cyclic a-diamino alcohol (5).
1.1 Solution mechanisms for amide bond hydrolysis ______________ 14
1.1.2 Strong acid catalysed hydrolysis of an amide bond
In above 80% acid solution, 4-nitroacetanilide,^^ 4-nitrobenzamide, benzamide and 
4-methoxybenzamide^^ follow the SnI type mechanism (Scheme 1.6 on page 14). The amide 
nitrogen becomes protonated and very slowly breaks down to give a carbocation and the free 
amine. The carbocation is rapidly attacked by water to give the carboxylic acid, after 
deprotonation. This mechanism is probably observed for the benzamides, as the carbocation 
can be stabilised by the conjugating aromatic ring, which partially délocalisés the positive 
charge, associated with the carbonyl carbon.
O O
J t ,  +  H+ . + J LR’ RaN-^ R'
H
 .  g
NHRa + ’R - C = 0  + HgO '  H g O '^ R '
slow
H O '^ R ’
Scheme 1.6 : The strong acid catalysed hydrolysis mechanism fo r  an amide bond.
1.2 The Mechanism and inhibition of cysteine proteinases
1.2.1 Classical cysteine proteinases
There are 3 classes of cysteine proteinases^ a) plant b) animal and c) bacterial. Plant 
tissue cysteine proteinases are the most studied as the enzymes are readily available from 
fruit. Papain is found in Carica papaya (tropical papaya fruit), actinidin is found in Actinida 
chinensis (kiwiffuit) and bromelain is found in Anaus comosus (pineapple). These enzymes
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have broad specificities and attack a wide range of substrates. Their function is probably to 
protect the ripening fruit from attack by insects, fungi
Animal tissue cysteine proteinases are found mostly in liver, spleen and kidney cell 
lysosomes. They are usually called cathepsins, although not all cathepsins are cysteine 
proteinases. These enzymes are involved in intracellular protein degradation and are named 
after the specific proteins they cleave. Cathepsin N  acts on the N-terminal peptides of 
collagen while cathepsin P is thought to convert proinsulin to insulin.
Bacterial cysteine proteinases such as the streptococcal proteinase isolated from hemolytic 
streptococci^^ and clostripain, isolated from Clostridium histolyticumf^ have very broad 
specificity and are most likely digestive enzymes.
Both plant and animal cysteine proteinases have a characteristic 2-domain structure as 
shown for papain in Fig.l.ba.^^ The sequence homology between the two groups of 
proteinase is poor (less than 50%), however there are only small differences in the 
polypeptide fold that contains the proteinase’s active site.^^ The poor homology comes from 
the deletions and perturbations that give rise to a particular proteinase’s substrate specificity.
The active site of papain (Fig. 1.6b) is in a deep extended cleft, between two domains. 
The side chains o f a cysteine (Cys-25 in papain) and a histidine (His-159 in papain) are 
closely associated. In papain, the imidazole ring of His-159 is hydrogen bonded to the side 
chain of Asn-175 and can rotate by 30° about Cp-Cy in response to the changes in the 
protonation state of the Sy in Cys-25. This rotation is probably very important during 
catalysis.^^
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a)
Deep Extended Cleft
Cys 25
Substrate
Gn 19
Asn 175
Hs 159
Fig 1.6: The structure of papain,^^ a) the entire protein, b) the active site.
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In the thiol proteinases the essential nucleophile is provided by a cysteine residue. A thiol 
group is a poor nucleophile and a thiolate nucleophile is a good nucleophile. However the 
normal pKa of a thiol group is 9, so there should be little formation of a thiolate nucleophile 
at the pH o f maximal activity (pH 4-7). However, various spectroscopic techniques 
(fluorescence/^ and have indicated that the Cys-His couple is present as an
ion pair in the pH range o f the proteinase’s activity. Three different states of the thiol- 
imidazole pair are possible depending on the pH (Fig. 1.7).
a) SH Him b) s n»™* HInf SH im
pH < 4.0 pH 4 - 8.5
c) S «*M«i Im 
pH > 8.5
Fig. 1.7; The possible protonation states o f  the thiol-imidazole pair: a) Protonated;
b) Neutral and c) Deprotonated.
At less than pH 4, the protonated form of the Cys-His pair (Fig. 1.7a) of papain 
predominates and papain is inactive. This suggests that the nucleophilicity of the thiol group 
is too low for proteolytic hydrolysis to occur. Above pH 8.5, the deprotonated form of the 
Cys-His pair o f papain (Fig. 1.7c) predominates and papain is also inactive. The thiolate 
nucleophile by itself is unable to catalyse the hydrolysis of a substrate, suggesting that the 
imidazole may be present as an imidazolium ion in the active form of papain, as proton 
donation to the substrate would also be possible from the imidazolium ion. At the medium 
pH range, the Cys-His ion pair predominates (Fig. 1.7b) and papain is active. Both a thiolate 
nucleophile and a imidazolium, proton donor are required for proteolytic hydrolysis. Plots of 
the rate o f acylation as functions of pH are bell shaped with a maxima at pH 6 and two pK
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values at 4.0 and 8.5, corresponding to the formation and decomposition of the Cys-His ion 
pair, respectively.^^
It is surprising that the thiolate-imidazolium ion pair exists at the middle pH range as the 
imidazole base (pKa of the conjugate acid 6.1) is usually considered as being too weak to 
deprotonate at thiol group (pKa 9). Energy calculations on model systems, suggested that 
the presence o f the imidazole group of His-159 adjacent to Cys-25 increases the probability 
of ion pair formation.^^ More significantly, Cys-25 is situated at the end of the N-terminus of 
a long a-helix, where a slight positive charge exists at the N-terminus and a slight negative 
charge exists at the carboxy end terminus. Cys-25 is in a positively charged environment 
which favours the transfer of a proton from the thiol group of Cys-25 to the imidazole ring 
of His-159.^^ Molecular orbital calculations using models for Cys-25, His-159, Asn-175 and 
the a-helix also confirm this. When the contributions of all the surface groups to the 
overall electrostatic field of papain were found, the effect due to the a-helix accounted for 
half of the positive environment and the other half was due to Asp-158. The local electric 
field surrounding the Cys and the His residues in each particular proteinase would govern the 
exact protonation state o f the Cys-His pair at any given pH and account for the differences in 
the pH range o f the classical thiol proteinases.
The role of Asp-158 (papain) has been a source of controversy, in early studies it was 
assumed that a carboxyl group was responsible for the low pKa of 4, observed in pH activity 
studies.^^ More recently this pKa has been shown to be due to the thiolate imidazolium pair 
(see previous).
The crystal structures of both papain and actinidin show that the carboxyl group of 
Asp-158 (Asp-161 in actinidin) is turned away from the active site and forms a hydrogen 
bond to the main chain amido proton of residue 136 (139 in actinidin).^^ The Asp residue is
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far too distant from the catalytic site (7.7Â away from Cys-25 and 5.5Â away from His-159 
in papain) to be involved directly in catalysis. The crystal structures also show precisely the 
same arrangenent of the Asp and His residues, even though the crystals were grown at pH 
9.3 and 8, respectively. If an Asp-His ion pair also formed part of the catalytic apparatus of 
the proteinase it should have been present at pH 6.0.
Actinidin and ficin have an Asp residue in a sequentially equivalent position to Asp-158 in 
papain and the corresponding residue in bromelain and cathepsin H is an Asn residue. 
However in cathepsin B, the corresponding residue to Asp-158 in papain is a Gly residue. 
There are no neighbouring substituents to compensate for such a change, so unless the 
mechanisms o f these proteinases are different, which is unlikely, as they have broad structural 
and kinetic similarity, the direct involvment of a carboxyl group in catalysis can be ruled out 
and the Cys-His ion pair is the essential catalytic apparatus.
These findings lead to the proposed catalytic mechanism^^ of papain as given in Scheme 
1.7. The formation of the enzyme substrate complex is followed by attack of the thiolate 
group of Cys-25 on the carbon of the Pi carbonyl group (Scheme 1.7, structure b). The 
resultant negatively charged intermediate is stabilised by two hydrogen bonds; one between 
the oxyanion and the Cys-25 amido hydrogen and the other between the oxyanion and the 
side chain amido group of Gin-19 (Scheme 1.7, structure c).
The amide bond is cleaved by His-159 donating a proton to the P i’ amide nitrogen which 
now forms the leaving group. (Scheme 1.7, structure c) The free P i’ amine diffuses away 
from the active site and the Pi remains attached to the proteinase as a thioester. The 
proteinase’s Cys-His couple is reprotonated by nucleophilic attack of a water molecule on 
the thio-ester, releasing the Pi acid from the enzyme’s active site (Scheme 1.7, structure d).
1.2.1 Classical cysteine proteinases 20
G ln-19
Cys-25 N,
—H
Cys-25
His-159
G ln-19
Cys-25 N.
:n - h
Cys-25
His-159
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Scheme 1.7: The catalytic mechanism oipapain.
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ki[S] EiS
Scheme 1.8: The vector diagram ofpapain’s double intermediate mechanism.
The vector diagram of the double intermediate mechanism of papain is given in 
Scheme 1.8, where Ei is the free enzyme, EiS is the substrate enzyme complex. Pi 
is the free amine product, E iS’ is the enzyme product two complex and P2 is the 
acid product. An expression for the reaction rate (v) can be found from using the 
King and Altman method^® as follows;
Each enzyme species [EXi], i = (1 - n), can be written as shown in Table 1.2, where; 
[EXi] = sum of the terms in the vector diagrams of the species [EXi] 1.2.1
Enzyme species Kinetic terms
[El] kaks + Liks
[EiS] kik3[S]
[EiS'l kikz[S]
Table 1.2: The Mnetic terms o f  the enzyme species involved in the double
intermediate mechanism.
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The rate is given by equation 1.2.2;
V = d[Pi] = k2[EiS] 1.2.2
dt
Substituting the value of [EiS] from Table 1.2 into 1.2.2 gives equation 1.2.3;
V = kik2lc3[S] 1.2.3 
The total enzyme concentration (Eo) is by equation 1.2.4;
[Eo] = [El] + [EiS] + [EiS'l 1.2.4
Dividing through equation 1.2.3 by Eo on top and the expression for Eq in 1.2.4 on 
the bottom results in equation 1.2.5 and factorising equation 1.2.5 gives equations 
1.2.6 and 1.2.7;
V =  kik2k3[S][Eo]____  1.2.5
kzks + k-iks + kiksïS] +kik2[S]
V = kik2k3[S][Eo] 1.2.6
k3(k2 + Ici) + ki[S](k3 + k2)
V = k*3(k3 + k2)~‘[S][Eo1 1.2.7
k 3 ( k 2  +  I < l l ) ( k , ( k 3 + k 2 ) ) - ‘ +  [ S ]
The Michaelis Menten equation is defined in equation 1.2.8, where Vmax is the 
maximal velocity and Km is the combined equilibrium constant for an enzyme 
catalysed reaction (the Michaelis constant);
V = Vmax[S] 1.2.8
Km+[S]
Comparing equation 1.2.7 and 1.2.8 gives Km and Vmax for the double intermediate 
mechanism (equation 1.2.9).
Vmax ~ lC2k3[Eo] Km ~ ks(k2 + k-i) 1.2.9
k3 + k2 ki(k3 + k2)
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1.2.3 Enzyme Inhibition
In general terms, a proteinase inhibitor is a reagent that when added to a mixture of the 
proteinase and substrate, causes a decrease in rate of substrate cleavage. (Reagents such as 
guanidinium chloride, succinic anhydride, organic solvents also decrease the rate of activity 
as they cause perturbations in the enzyme’s protein structure. These are usually considered 
as non-specific inactivators rather than inhibitors.)^^
If  proteolysis can be restored by dilution o f the inhibitor solution or by gel filtration of the 
inhibitor, substrate and proteinase mixture, the inhibition is defined as reversible. If  dilution 
fails ot restore proteolysis, the inhibition is defined as irreversible. On rare occasions some 
reversible inhibitors bind to their proteinase with such high affinities, that the inhibition is 
complete at equimolar concentrations in dilute solutions. Dilution of this type of mixture 
results in the inhibitor-proteinase complex dissociating too slowly to be observed. A 
reversible inhibitor that behaves in this manner is refered to as tight binding.
1.2.3.1 Reversible inhibitors
A general reversible inhibitor could interact with an enzyme in a number of ways; by 
competing with the substrate for the active site or by binding to one or more of the catalytic 
complexes. The substrate may or may not be able to interact with the enzyme / inhibitor 
complex (Scheme 1.9 on page 24). All possible interactions between the enzyme and 
inhibitor are shown in Scheme 1.9. If a particular inhibitor does not interact with an enzyme 
species, then the forward and reverse rate constants are zero. Kg is the binding constant of 
the substrate to the free enzyme E and Ki is the dissociation constant for the EI complex. 
The inhibitor changes the enzyme’s affinity for S by a factor a  and vice versa, while the rate 
of decomposition of EIS to the product is modified by a factor p.
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Scheme 1.9: The possible modes o f  inhibition as a reverible inhibitor.
The effect of the inhibitor on Km and Vm can be found as follows;
The various equilibrium constants for reversible inhibition are defined in Table 1.3.
Equilibrium constant Kinetic terms Concentration terms
Ki lC4 [E][I]
lC4 [EI]
oKi k-2 [ES][I].
IC2 [EIS]
Kg k-l [E][S]
ki [ESI
(xKs 1^ 3 [EI][S]
k3 [EIS]
Table 1.3: The kinetic and concentration terms o f  the equilibrium constants involved in
reversible inhibition.
If [S] »  [I], the proportion of S turned over by the enzyme is negligible, so [I] and [S] 
are constant. The equilibrium concentrations of the species [EX i] (Table 1.4) are found from
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the rate constants in Scheme 1.8 and Table 1.3 by the King Altman method^® as mentioned 
previously in section 1.2.2 page 21 .
Enzyme species Kinetic terms
[E] Lik-2k3[S] + k-ilC2lC4 + k.iI{_3lC4 + k2k.3k.4M
[ES] k .2 k ik 3 [S ]^  + k.3kile4[S] + k ik s k -^ H C S ]  + k 1k .2k .4i S ]
[EIS] k z k i k a P l iS ] "  +  k ik 2 k .4 [ S ] [ I ]  +  k - ik 3 k 4 [ I ] [ S ]  +  k i k s k i i S J P ] '
[EI] k 2 k ik .3 [ I ] [ S ]  + k.iIc2k4P] + k.ik.3k4[I] + k 2 k .3 k 4 P ]^
Table 1.4: The equilibrium concentrations o f  the species [EXJ in Mnetic terms.
From Table 1.4 it can be seen that; 
(ocKi)Ks = W ci
K ;(ocK .)
kzki
k.4k.3
IC4IC3
1.2.10
1.2.11
As the rate o f formation of EIS is not path dependent, equation 1.2.12 follows from
Scheme 1.8 and equations 1.2.10 and 1.2.11;
k-4k-3 “  Ic-zk-i
k4lc3 IWci
k - 4 l c . 3 k 2 k i  =  k - 2 k - i k 4 k 3
Table 1.4 defines equation 1.2.14;
[E] = k.il{_2k3[S] + L 1IC2IC.4 + L 1IC.3IC4 + k2k.3lc4[I]
Dividing equation 1.2.14 by kik2k3 gives equation 1.2.15;
[E] = k.ik-2[S] + k-ik.2k.4 + k ^ k .4 + lc3k.4[I]
1.2.12
1.2.13
1.2.14
1.2.15
kik2k3 kik] kik2k3 kiks
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Substituting equilibrium constants in equation 1.2,16 and using the relationship in 
equation 1.2.13 gives;
[E] = kik2k3aKiKs{[S] + lc4 + L3L 4 + l^M ) 1.2.16
k3 L2IC3 ki
Equation 1.2.16 can be simplified to equation 1.2.17.
E = aYKîKs 1.2.17
Where Y = kik2k3{[S] + + IC.3IC4 + k4[I]}
1(3 k-2k3 ki
A similar procedure can be adopted for the other [E X i] species giving equations 
1.2.18;
E S = a Y [ S ] K i  E IS  = Y [S ][I]  E I  = a Y [ I ]K s  1.2.18
The total enzyme concentration Eo is given by equation 1.2.19;
Eo =  E  +  E S + E I  +  E IS  1.2.19
The maximal velocity is defined by equation 1.2.20;
Vmax = ksEo 1.2.20
The rate o f reaction v is given by equation 1.2.21 fi*om Scheme 1.8;
V =  1(5[ES] + pksfEIS] 1.2.21
Substituting equations 1.2.17 and 1.2.18 into equation 1.2.21 dividing by equation 
1.2.19 and substituting in equation 1.2.20 gives equation 1.2.22;
V = Vmax[S]{aICi + p[I]} 1.2.22
[S ] [ I ] + a { K iK s  +  [S ]K i+ K s[I]}
Inverting equation 1.2.22 gives equation 1.2.23;
J _  = [S ][I]  + g{K iK s + [S]K i +K,[I]} 1.2.23
V Vmax[S](aKiH-p[I]}
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Scheme 1.8 and equation 1.2.23 can be used to define different types of inhibition 
(depending on the values o f a  and P) as follows;
1.2.3.1.1 Fully competitive inhibition
Fully competitive inhibition arises when a  = ~ and p = 0. At a suitable [I], the
bound inhibitor completely prevents the substrate binding to the free enzyme.
Substituting these values of a  and P into equation 1.2.23 and assuming that
[S][I]a^ = 0 gives equation 1.2.24;
1 = 1 + Km {1 + [I]} 1.2.24
V V m «  [SjV m ax K i
(Vmax)'^  is unaltered and the apparent (Km)‘  ^ is changed by a factor of 1 + [ I ] (K j) '\  A 
double reciprocal plot consists of a series of non-parallel lines that intersect the y axis 
at (Vmax)’  ^as shown in Fig. 1.8a on page 29. The inhibitor competes with the substrate 
for the enzyme’s active site, so the inhibitor can be displaced at high [S]. (Vmax)*^  can 
be found from the 1/v axis intercept of the double reciprocal plot. K; can be found 
from a graph of the double reciprocal plot gradients verses [I], where the new gradient 
is given by Km(VmaxKi)'  ^ and the new y intercept is given by KmVmax"\
1.2.3.1.2 Uncompetitive inhibition
Uncompetitive inhibition arises when a  < 1 and 0 < p < 1. I binds to ES 
preferentially over E, S binds to EI rather than E and EIS turns over less rapidly than 
ES. Substituting these values of a  and P into equation 1.2.23 and assuming that [I] is 
small compared to K, gives equation 1.2.25;
J _  = J _  { l + M i  + Km 1.2.25
V Vmax CCKj Vmax[S]
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(Vmax)"^  is altered by a factor of 1 + [I](Ki)'^ and the apparent (Km)'  ^ is unchanged 
as the inhibitor does not affect the substrate binding to the enzyme. A double 
reciprocal plot consists of a series of parallel lines as shown in Fig. 1.8b. Vmax and Ki 
can be found from a graph of the 1/v axis intercepts of the double reciprocal plot 
verses [I], where (Vmax)'^  is given by the new intercept and (aVmaxKi)'  ^ is given by 
the new gradient.
1.2.3.1.3 Non-competitive inhibition
Fully non-competitive inhibition arises when a  == 1 and p = 0. The bound 
inhibitor does not affect the binding of the substrate (and vice versa) but product 
formation is prevented as I has a similar affinity for E and ES. Substituting these 
values into equation 1.2.23 gives equation 1.2.26;
J _  = J _  {1+M} + Km {1+[I]} 1.2.26
V Vmax Ki [S]Vmax K
(Vmax)'^  and the apparent (Km)'  ^ are changed by a factor of 1 + [I](Ki)’\  as the 
inhibitor binds to both the free enzyme and another enzyme complex. If P is non­
zero the apparent Ki is made up of two terms one deriving from the affect of a  and 
the other arising from the effect of p. A double reciprocal plot consists of a series of 
non-parallel lines as shown in Fig. 1.8c. Vmax and Ki can be found from a graph of 
the gradients of the double reciprocal plot verses [I]. KmVmax'^  Is given by the new y 
axis intercept and Km(VmaxKi)’  ^is given by the new gradient.
Partial non-competitive inhibition arises when a  — 1 and 0 < P < 1. The bound 
inhibitor does not affect the substrate binding to the free enzyme but product 
formation from EIS is slower than from ES. Kinetically partial non-competitive 
inhibition is identical to frill non-competitive inhibition.
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uncom petitive inhibition non-com petitive inhibition
1/8 1/S
com petitive inhibition
1/V,max
1/S
Fig. 1.8: Double reciprocal plots fo r  a) competitive inhibition, b) uncompetitive inhibition
and c) non-competitive inhibition
1.2.3.2 Irreversible inhibitors
Irreversible inhibitors act by binding tightly to the enzyme or one of the intermediates 
preventing catalytic activity. The binding is usually covalent and stoichiometric (often 1:1), 
so they have activity at a similar concentration to the enzyme and are therefore usually more 
potent inhibitors that reversible inhibitors. Irreversible inhibitors are characterized by their 
velocity of inactivation and can not be displaced by the substrate. Irreversible inhibitors are 
usually quite reactive molecules and tend to have short half lifes in vivo.
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Some irreversible inhibitors (suicide inhibitors) are present in an inactive form 
which becomes activated by partial turn-over by the enzyme. Upon partial turnover a 
reactive, tight binding intermediate is formed that stops further turnover of the 
substrate. These have longer half lives in vivo as the inactive form of the molecule is 
usually not veiy reactive.
1.2.4 Thermodynamic analysis of proteinase catalysis
The hydrolysis of a substrate by a proteinase can be described by two equations 
(equation 1.2.27 and 1.2.28);
k = A exp(-AG^ZRT) 1.2.27
AG^ = AH^ - TAS'^
"t" _ _ . . fWhere AG is the change in Gibbs free energy of activation , AH is the change
• ^in enthalpy of activation, T is the temperature; AS is the change in entropy of 
activation; k is the rate constant; A is the frequency factor and R is the gas constant.
If the following reaction is considered:
where the substrate (S) is hydrolysed to form the products (P) via a transition state 
complex (S...P) . The rate of a proteinase catalysed reaction is faster than the same 
reaction uncatalysed. The energy profile of the uncatalysed reaction is shown in Fig. 
1.9a on page 31.
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It can be seen that if S has sufficient energy to overcome the barrier AG , P is formed via 
the transition state (S...P) . The reverse reaction is also possible if P has sufficient energy to 
overcome AG and AG° and S is reformed. If the barrier, AG is lowered, the process will be
speeded up at a given temperature, as a greater proportion of S has enough energy to
4» 4°overcome AG and a greater proportion of P has sufficient energy to overcome AG and
4“ . . 4*AG°. This can be achieved by either reducing AH or raising AS .
a) b)
( P - .S )
AG
AG
(E...S...P)
ES
EPE + S
ES
AG3EP
AG° E + P
Fig. 1.9: The energy profile o f  a) an uncatalysed and b) a proteinase catalysed hydrolysis.
A proteinase can achieve this by preferentially binding to and stabilising (S...P) relative to 
the reactants and products (Fig. 1.9b).
It should be noted that the standard Gibbs free energy change (AG°) and the equilibrium 
constant (Keq) are unchanged and the proteinase, unless adapted otherwise will catalyse both 
forward and reverse reactions until equilibrium is reached. Proteinases are very specific, 
usually catalysing only one type of hydrolysis, under veiy limited chemical and physical 
conditions. They are usually enantiomerically selective.
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Proteinases are proteins with aininoacids linked in a specific sequence. They have a coiled 
structure folded into a specific shape and are stabilised by hydrogen bonds between amido 
hydrogens and carbonyl oxygens of the polypeptide chain, along with ionic and hydrophobic 
interactions between the side chains of aminoacid residues. Certain functional groups are 
brought together by the folding process to form the active site o f the proteinase, and are 
responsible for the catalytic activity of the proteinase. These aininoacids are often found in 
different areas of the polypeptide chain. Occasionally the proteinase may require agents 
(cofactors) other that the substrate which supply specific chemical functions that are not 
possible with the proteinase alone.
1.2.6 The 23kDa adenovirus proteinase
1.2.5.1 Substrate specificity
The adenovims proteinase will cleave pTP, pVI, pVII,^^ PVIII,^^ pllla,^^ llkDa^* and 
pMu^“ proteins. These cleavages are vital for viral maturation and infectivity. A mutant virus 
with inactive proteinase can still produce these proteins and assemble virus particles, but the 
new virus particles are non-infectious.^'*
A proteinase catalyses the cleavage of specific peptide bonds in a polypeptide substrate 
(Fig. 1.10); where residues in the substrate as designated P and those of the proteinase are 
designated S. The residues are then numbered outwards from the cleaved bond and those 
residues on the carboxy side are designated prime.
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CLEAVAGE
P3 P2 Pi P'l P’2 P ’3
P4 P’4
NH2 CO2H Substrate
S3 S2 Si S'l S'2 S'3
S4 S-4
Enzyme
Fig. 1.10: The cleavage o f  a substrate by a proteinase.
Comparison of the cleavage sequences of these precursor proteins gave the following 
substrate recognition sequence for the enzyme^^ (Fig. 1.11) where usually Ala-Gly or 
Gly-Ala bonds are cleaved, although in special cases Gly-Phe, Arg-Gly and Phe-Gly bonds 
are also cleaved;^^
?4 P3 P2 Pi P i’ P4 P3 P2 Pi Pi'
(ML) X G G X or (ML) X G X G
Fig. 1.11: Substrate specificity o f  the adenovirus proteinase.
A search of all the adenoviral proteins with this consensus sequence gave the known 
substrates for the proteinase as well as the penton, hexon, 52kDa, E21kDa, 14.5IcDa and 
D-172 proteins. It is known that the mutant virus with inactive proteinase is defective at 
uncoating^^ so it may be that the proteinase cleaves the hexon and the penton in vivo.
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1.2.5.2 Inhibitor studies
The proteinase is active at neutral pH and was unaffected by pepstatin/"^ a general aspartyl 
proteinase inhibitor, so is unlikely to be an aspartyl proteinase/^ Pepstatin 
(3-methylbutanoyl“(2S)“Valinyl-(2S)-valinyl-(3S,4S)-4-araino-3-hydroxy-6 methylheptanoyl 
alanyl (3S,4S)-4-amino-3-hydroxy-6 methylheptanoic acid) (8), shown in Fig. 1.12, is a tight 
binding inhibitor of aspartic proteinases (dissociation constant 45.7 pmol dm'  ^ in the case of 
pepsin).^^ It is believed that pepstatin (8) mimics the tetrahedral intermediate for amide bond 
hydrolysis.^^
Me..Me. kjia Me^ .Me
N ' ,0 H
Me g  O H Me H ’O H
Fig. 1.12: Pepstatin (8).
The proteinase was also unaffected by ethylenediaminetetraacetic acid*® so is unlikely to 
be a metalloproteinase.^* This suggests that the adenovirus proteinase is either a cysteine or a 
serine proteinase. Usually these 2 classes of proteinase can be distinguished by the effects of 
a range of inhibitors given in Table 1.5 on page 36. However sequence alignments showing 
conserved active site residues are often required for absolute proof.
The partially purified adenoviral proteinase is inhibited by diisopropylfluorophosphate 
(DFP) (9) and partially inhibited by benzylsulphonyl fluoride (PMSF) (10), thus implying that 
the adenovirus proteinase is a chymotrypsin-like serine proteinase.^®
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However upon further purification of the proteinase, it was found that general thiol 
attacking reagents; copper (II) ions, Zn (II) ions,^ ® iodoacetate (11), N-ethylmaleimide 
(NEM) (12), dithiodipyridine (13) and parachloro mercury benzoate (PCMB) (14) all inhibit 
the enzyme/^ Dithiodipyridine (13) also inhibited the proteinase at pH 5.0, suggesting that 
there is a thiol present with a very low pKa. Such a thiol group can be found in the active site 
of a cysteine proteinase,^* At pH 3-5, dithiodipyridine (13) is regarded as a specific active 
site titrant for cysteine proteinases.*^ Soybean trypsin inhibitor (SBTI) (15) and chymostatin 
(16) did not effect the enzyme.*^'
However E-64 (17) (see Section 2.2.1) and Leupeptin (18) (Fig. 1.13,*  ^see Section 2.1.4 
for inhibition of a cysteine proteinase by an aldehyde) also failed to inhibit the proteinase,^'^ 
although they are general cysteine proteinase inhibitors. All these inhibitors have bulky 
residues in the P1-P4 binding sites and considering the binding requirements of the proteinase, 
it is suggested that these inhibitors may not fit into the proteinase’s active site.
HgN
NHg
Fig. 1.13: Leupeptin (18).
Other cysteine proteinases can also be inhibited by PMSF (10),*° although PMSF (10) is 
usually regarded as a more potent inhibitor of serine proteinases. Overall this evidence 
suggests that the adenovirus proteinase is a cysteine proteinase. *°
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inhibitor serine proteinase cysteine proteinase
DFP (9) inhibited unaffected
PMSF (10) inhibited unaffected
SBTI (IS) inhibited unaffected
chymo statin (16) inhibited unaffected
iodoacetate (11) unaffected inhibited
dithiodipyridine (13) unaffected inhibited
PCMB (14) unaffected inhibited
E-64 (17) unafffected inhibited
leupeptin (18) unaffected inhibited
optimum pH 7-9 4-7
Table 1.5: Specific inhibitors fo r  cysteine and serine proteinases.
1.2.5,3 Cofactor requirement
The gene encoding for the 231cDa proteinase was cloned and expressed into insect cells 
infected with baculovirus^^ and E. colL '^  ^ Upon purification to homogeneity the proteinase 
was found to be inactive. Activity could be recovered by the addition of heat-inactivated 
wild-type virus suggesting that a cofactor present in the heat-inactivated adenovirus was 
required for catalytic a c t i v i ty .T h e  residual fraction, left after complete adenovirus 
extraction, also restored catalytic activity. This fraction was analysed and found to contain a 
number o f adenoviral structural proteins and adenoviral DNA. Purified adenoviral DNA on 
its own did not produce any activity.
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If dithiothreitol (DTT) (19), a reducing agent added to biological samples to prevent 
aerial oxidation, was added to the recombinant enzyme before the residual fraction, the 
proteinase was not activated. However if DTT (19) was added to a mixture of recombinant 
enzyme and the residual fraction after 15 min, the proteinase activity was enhanced. This 
suggested that the recombinant enzyme is activated by a factor present in the residual extract 
and that this activation is inhibited by reducing agents such as DTT (19).^^
The proteins in the residual fraction were separated, purified and tested for proteinase 
activation. Two different fractions produced proteinase activation and were identified as the 
reduced and oxidised (cys-bridged dimer) form of an undecanomic peptide;
GVQSLKRRRCF
Where G = glycyl; V = valinyl; Q = glutaminyl; S = serinyl; L = leucinyl; K = lysinyl; R = 
arginyl; C = cysteinyl; A = alanyl and F = phenylalanyl. This sequence is identical to the 
eleven C-terminal amino acid residues of the adenoviral structural protein pVI, a known 
substrate for the adenoviral proteinase. pVI also activates the proteinase. Neither 
GVQSLKRRRAF or KRRRCF could activate the proteinase, indicating that the Cys residue 
and the first five N-terminal amino acids were important for activation. The oxidised (dimer) 
form was found to be the actual cofactor for the proteinase. Activation by the reduced form 
of the peptide was due to traces o f the dimer.
It is believed that the cofactor is catalysing the oxidation / reduction of specific residues in 
the proteinase, and that a thiol disulphide interaction may be taking place. It is interesting to 
note that a catalytically inactive form of papain (propapain) exists where Cys-25 forms a 
disulphide bridge with Cys-22, leaving Cys-63 free. Propapain can be converted back to
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papain by cleaving the Cys-22-Cys-25 link, forming a Cys-22-Cys-63 disulphide bond in 
place of the Cys-22-Cys-25 disulphide bond/^ It could be that in vivo the newly translated 
proteinase folds into an inactive structure with the active site cysteine being involved in 
intramolecular disulphide bonding. During maturation the high concentration of pVI could 
activate the proteinase by disulphide interchange, leaving the active site cysteine free.*  ^ This 
represents a novel way of ensuring that the proteinase is only active when required.
The proteinase can be further activated by DNA, RNA, polyglutamic acid and 
polyaspartic acid, ie. polymers with a high negative charge density. In vivo viral DNA may 
act as a scaffold for the assembly of proteinase complexes, or the proteinase complex could 
use the DNA as a guide wire, travelling along the DNA as it cleaves the precursor proteins.^^ 
It is known that the proteinase is associated with viral cores.
1.2.5,4 Site directed mutagenesis
The proteinase has been sequenced in 12 different adenovirus serotypes and is highly 
conserved across serotypes, but contains no recognisable motifs in common with other 
loiown proteinases^^’ ^  The proteinase sequences for twelve adenovirus serotypes were 
aligned and the results are shown in Fig. 1.14 on page 39.^* where N = asparginyl; D = 
aspartyl; E = glutamyl; H  = histidinyl; I = isoleucinyl; M = methionyl; P = prolinyl; T = 
threonyl; W = tryptophanyl and Y = tryrosinyl.
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Type 4 4  5 4 . . 9 5  1 0 4 1 2 2 18 2
Avian 1 . . TGSRASGGMH . .TGL.RQPDRC . .ACGLFSALIF . . NSAYFRAHQE. .
Murine 1 . . TASRETGGVH . .SAVSSSSSKC . .ACGLFCVLFL . .NSLYFRLHVE..
Canine 1 . .TAGRETGGVH . . SAIASTPDRC . .ACGLFCCMFL . .NSAYFRAHAA. .
Bovine 7 . . TGPREQGGIH . .SAL.SSPDKC . . SCGLFCVFFL . .KSLYFRQNEE..
Bovine 3 . .TAGRETGGVH . . SALTSTADRC . .ACGLFCCMFL . .HSPHFVKHAA..
Type 41 TAGRETGGVH . . SAIiASTPDHC . .ACGLFCCMFL . .HSPYFRRHRE..
Type 40 TAGRETGGVH . . SALASTPDHC . .ACGLFCCMFL . . RSPYFQRHCE. .
Type 12 - .TAGRETGGVH . . SALAATKDRC . .ACGLFCCMFL . . LSPYFRHNRE. .
Type 2 . . TAGRETGGVH . .SAIASSPDRC . .ACGLFCCMFL . .HSPYFRSHSA. .
Type 3 . . TAGRETGGEH . . SALA. TKDRC . .ACGLFCCMFL . .H SSYFRSH SA. .
Type 4 . . TAGRETGGEH . . SALA. TKDRC . . RCG. FSAACS . .HSAYFRSHSA..
Type 5 . . TAGRETGGVH . .SAIASSPDRC . .ACGLFCCMFL . .HSPYFRSHSA. .
Fig. 1.14: The sequence alignments o f  the twelve sequenced adenovims proteinases.
There are two conserved serine residues (Ser-95 and Ser-182, based on adenovirus 2 
sequences), one conserved histidine residue (His-54) and two conserved cysteine residues 
(Cys-104 and Cys-122). Various mutants of the adenovirus 2 proteinase were made and are 
described in Table 1.16 on page 40,^ ®’ ®^
Mutations of Ser-95 and Ser-182 to Ala (mutants 1 and 2) enhanced activity, so neither is 
important catalytically.*^ However when Cys-104 or Cys-122 were changed to Ala (mutants 
3 and 4)**’ and His-54 (mutant 5) was mutated to Arg*^ activity was lost. This leads to the
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conclusion that the adenovirus proteinase is a cysteine proteinase as the only conserved 
residues that are essential for catalytic activity are His and Cys.**’ *^  However when Cys'122 
was mutated to Gly** (mutant 6) catalytic activity remained, unlike mutant 7 where Cys-104 
was changed to gly and no activity remained.** This suggests that Cys-104 is the active site 
nucleophile** and activation of the proteinase may involve a conformational change which is 
promoted by the interaction of the cofactor. In mutant 6 this interaction is still possible due 
to the small size of the glycine residue.*^
Mutant residue altered residue changed to activity cf wild type
1 Ser-182 Ala 164%
2 Ser-95 Ala 110%
3 Cys-104 Ala 3%
4 Cys-122 Ala 0%
5 His-54 Arg 0%
6 Cys-122 Gly 81%
7 Cys-104 Gly 0%
Table 1.6: Mutants o f the adenovirus proteinase.
12,5.5 Possible mechanisms for the adenovirus proteinase
The adenovirus proteinase requires one histidine residue (His-54)**’ *^  and two cysteine 
residues (Cys-104 and Cys-122) for activity.*^ Cys-104 is thought to be the active site 
nucleophile,** while Cys-122 and the cofactor are involved in enzyme activation.*^ Inhibition 
by dithiopipyridine (13) indicated the presence o f a thiol with a very low pKa, as would be
1.2.5 The 23kDa adenovirus proteinase 41
found in the active site of a cysteine p ro te inase . I t  could be proposed that Cys-104 and 
His-59 form an ion pair as part of the active site of the adenovirus type 2 proteinase.
A summary o f the possible double intermediate mechanism of the adenovirus proteinase is 
shown in Scheme 1.10.
kilSol EaS
Pi
Scheme 1.10; The Adenoviral Proteinase's double intermediate mechanism.
Initially, the cofactor binds to the inactive proteinase (Ei) changing its conformation and 
activating it to give E2. The substrate then binds, it is not Icnown whether acid interactions 
with the Pi carbonyl, and / or base interactions with the Pi’ amido nitrogen are important. 
The nucleophilic thiolate (Cys-104) then attacks the Pi carbonyl carbon giving a stabilised 
tetrahedral intermediate (E2S), which collapses upon attack of a water molecule to give two 
products, Pi and P2, The final step, involves product debinding, however it is not known 
which product ie. the P (free acid) or the P ’ (free amine) side, leaves first. The proteinase 
still hydrolyses a substrate by a double intermediate mechanism and the rate is still defined by 
equation 1.2.8 page 22, but Km and Vmax can not be defined in rate terms by the King Altman 
method^® until the order of product debinding is known.
2.0 A im s ___________ _ _______
2.0 Aims
The adenovirus proteinase is a rather unusual enzyme. Site directed mutagenesis (Section 
1.2.5.4) and inhibitor profile studies (Section 1.2.5.2) have shown that the proteinase belongs 
in the cysteine class of proteinases, however the adenovirus proteinase does not behave like a 
typical cysteine proteinase (Section 1.2.5).
The adenovirus proteinase is partially inhibited by some serine proteinase inhibitors 
(Section 1.2.5.2) but, remarkably is not inhibited by some typical cysteine proteinase 
inhibitors (Section 1.2.5.2). Site directed mutagenesis as described in Section 1.2.5.4 has 
shown that, of the two conserved cysteine residues (Cys-104 and Cys-122), and the one 
conserved histidine residue (His-54), each is required to be intact for normal levels of 
catalytic hydrolysis a c t i v i t y . A l t e r a t i o n  of His-54 or Cys-104 residues, gives rise to 
completely inactive proteinase. However some activity remains if Cys-122 is replaced by a 
glycyl r e s id u e .A  thiol-containing cofactor (GVQSKRRRCF) is also required for proteinase 
activity, and once activated the proteinase can perform many catalytic cycles (Section 
1.2.5.]).^'*
After the activation o f the proteinase by the cofactor, the enzyme is able to catalyse the 
hydrolysis o f substrates. This is believed to occur by way o f a double intermediate type 
mechanism (Section 1.2.5.5), in which the order of product release is controlled by the 
proteinase but at the start of our studies, this was not Icnown. The function of the three 
catalytically essential residues His-54, Cys-104 and Cys-122 is unknown. Furthermore, since 
there was no X-ray crystallographic data available for the proteinase, it was not known 
which other residues might participate in catalysis, or form hydrogen bonds or Van der 
Waals contacts with the intermediates involved in the hydrolysis o f a substrate.
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The major objective of our research was to probe the mechanism of the adenovirus 
proteinase by the use of mechanism-based inhibitors to help elucidate the active site structure 
of the proteinase.
2.1 The synthesis of reversible Inhibitors
For a compound to serve as a mechanistic probe for an enzyme, the compound should 
specifically recognise the protein, bind to the active site and then further react in some way. 
Mechanistic probes can be substrates or inhibitors but in general, for proteinases, information 
on potential for binding has been derived fi'om careful analysis of substrate structure-activity 
relationships. Such analyses reveal which substituents can interact strongly with polar, 
charged or hydrophobic groups at the active site of the enzyme. Where inhibitors are 
required, for biomedicinal and pharmacological studies, as is often the case, it is desirable 
that these substituents are placed in a framework that is inert towards proteolytic hydrolysis.
Prior to the work described here, no information or reports of the existence of specific 
inhibitors for the adenovirus proteinase had been published. We believed that the general 
binding requirements of the proteinase could be satisfied by the use of the substrate 
recognition sequence in the structure of the inhibitor and, therefore, chose to implement such 
a strategy.
The adenovirus proteinase has a very specific substrate recognition sequence; 
(M, L, I)X^GG-X^ (section 1.2.5.1), where X  ^ and X^ can be any residue and where the 
scissile bond is between the second glycyl residue and residue X^.^' Thus it seemed 
sensible to use the sequence (2S)-leucyl (2S)-alanyl glycyl glycine, to satisfy the binding 
requirements for the proteinase in each series of potential inhibitor structures, where 
variations are introduced in place of the X  ^residue.
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In order to measure the activity of the potential inhibitors it was necessary to consider 
possible assay procedures. One type o f assay that had been employed in the Kemp group 
involved monitoring the change in absorbance of a chromophore that had reacted with the 
amino group produced from the hydrolysis of the substrate. So that this type of assay can be 
performed successfully, it is necessary to ensure that the leucine residue in the inhibitor is 
N-protected. To achieve this we chose to use carbobenzyloxy (Cbz), tertiary-butoxy 
carbonyl (t-Boc) and trifluoroacetyl (TFA) protection, as the starting reagents are cheap, 
readily available and reliable. Indeed, in the event, the N-protection of leucine with these 
protecting groups was achieved in high yields ie, 88%, 91% and 82% respectively. Upon 
testing the compounds with the proteinase, the chromophore assay procedure was found to 
be unreliable and the cleavage of the substrate was followed by capillary electrophoresis 
(CE) insead, so N-protection of the leucine residue was not actually necessary.
2.1.Q Rationale for the amide tetrapeptides
Using a series of simple amides in which the terminal leucyl amino group was either 
unprotected or N-protected with Cbz- or t-Boc-, the Pi glycyl residue carboxy group was 
aminated to give a series of allcyl amides (Fig. 2.1). It was expected that it should be possible 
to determine the size of the S’ binding pocket from structure-activity relationships data. This 
series of amides (Fig. 2.1) also possess different nitrogen leaving groups, so that if the rate 
determining step in the proteolytic hydrolysis o f the amides involves breaking or forming a 
nitrogen bond, it was anticipated that different rates of proteolytic hydrolysis might be 
observed.
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Me Me—(H, /  H p
R X Number
-OCOCH2C6H5 -MI2 (19)
-OCOCH2C6H5 -NHMe (2 0 )
-OCOCH2C6H5 -NM!e2 (21)
-OCOCH2C6H5 -NMeEt (22)
-OCOCH2C6H5 -N(OMe)Me (23)
-0C(CH3)3 -]S[-p]sro2”B z (24)
-H -NH2 (25)
-H -NHMe (26)
Fig. 2.1: The series o f  simple amides.
In considering the synthesis of the amides (Fig. 2.1) and taking carbobenzyIoxy-(2S)- 
leucyi (2S)-alanyi glycyl glycyl amide, Cbz-Leu-Ala-Gly-Gly-NH2 (19), as an example, the 
amide (19) can be disconnected in a stepwise manner (Scheme 2.1), or a convergent manner 
(Scheme 2.2). The stepwise disconnection of Cbz-Leu-Ala-Gly-Gly-NH2 (19) results in 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycine (27) and glycyl amide (28). It was envisaged 
that the tripeptide (27) could be prepared from carbobenzyloxy-(2S)-leucyl (2S)-alanine (29) 
and glycine t-butyl ester (30), followed by carboxyl group deprotection.
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The convergent disconnection of Cbz-Leu-Ala-Gly-Gly-NHi (19) results in Cbz-Leu-Ala 
(29) and glycyl-glycyi amide (31). It was expected that Cbz-Leu-Ala (29) could be prepared 
from carbobenzyloxy-(2S)-leucine (32) and (2S)-alanine methyl ester (33), followed by ester 
hydrolysis and Gly-gly amide (31) would be prepared from carbobenzyloxy-glycine (34) and 
glycyl amide (28), followed by N-deprotection.
Comparison of the convergent and the linear, stepwise approach, shows that if more than 
one tetrapeptide amide is prepared, the convergent approach requires the synthesis of several 
different glycyl glycyl amide dipeptides and the different glycyl amides, and the convergent 
approach requires the synthesis of the different glycyl amides only. As more than one amide 
would be prepared the stepwise method of synthesis appears to be better, as overall this 
method takes fewer steps than the convergent synthesis.
H O
.A.
I II 'V
H O Me H H 6  H
( 1 9 )
Me 
Me —(
H O
( 2 8 )
H O Me  H H O IH
H O
H O Me'  H H O
( 2 9 )  ( 3 0 )
Scheme 2.1: The stepwise disconnection o f a tetrapeptide amide.
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Me 
Me—(H \  H O H O
(19)
H o Me" H H O H
Me
u '" ^  H O  V j?
(29) (31)
Me- H O  H O
Cbz^J^XL ^OH
H O  + Me" H H O +  H
(32) (33) (34) (28)
Scheme 2.2: The convergent disconnection o f  a tetrapeptide amide.
The key steps in the formation of the tetrapeptides consist of amide bond formation. 
There are numerous methods to form the amide bonds, such as the acid chloride,azide,^^ 
activated ester,anhydride^^ and carbodiimide r o u t e s . W e  chose the mixed anhydride^^ 
approach where possible as usually, this method is quick, high yielding and the products do 
not require extensive purification. Racémisation of sensitive amino acids is also avoided by 
the use of a bullcy base such as N-methylmorpholine (NMM) and a non-polar solvent such as 
THF or dichloromethane.^^
The amide bond is formed by the use o f an alkyl chloroformate such as /w-butyl 
chloroformate (i-BCF) and a base (NMM) which react to form an activated uronium species
(35) (Scheme 2.3), The NMM is then displaced by an N-protected amino acid to give an
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unsymmetrical, unstable anhydride (36) and N-methyl morpholine hydrochloride, after 
proton exchange. These two steps are very facile, and the formation o f N-methyl morpholine 
hydrochloride is observed instantaneously upon the addition of the alkyl chloroformate, to a 
mixture of NMM and the N-protected amino acid in THF at -20°C. On addition of the 
0-protected amino acid, the mixed anhydride is attacked slowly to give the new peptide, 
carbon dioxide and wo-butyl alcohol.
' [ [ 1 + 1  Cl----------- I ,  A
Ü  T'"6 (35)
C H y  H I
(36) 'V - v o - '  "
R*
H
O'
Scheme 2.3: The mixed anhydride peptide coupling reaction.
2.1.0.0 Synthesis of the tetrapeptide amides
2 . 1 . 0 . 0 . 0  S y n t h e s i s  o f  C a r b o b e n z y l o x y  ( 2 S ) - l e u c y l  ( 2 S ) - a i a n y l  g l y c i n e  ( 2 7 )
Carbobenzyloxy (2S)-leucine (32)^ ® was coupled with methyl (2S)-alaninate 
hydrochloride (33)^^ using the mixed anhydride procedure^^ to give methyl carbobenzyloxy- 
(2S)-Ieucyl (2S)-alaninate (37) in a yield of 95% after recrystallisation from ether / hexane 
(M.p.91°C; lit.,^* 92-93 °C) (Scheme 2.4). Treatment of the product (37) with 1 mol dm'  ^
sodium hydroxide at 35®C for 3.5 hours and acidification gave carbobenzyloxy-(2S)-leucyl 
(2S)-alanine (29) in 88% yield after recrystallisation from ether / hexane (M.p. 146-147°C;
2.1 The synthesis o f reversible inhibitors _____     49
152-153°C) (Scheme 2.4). Both and ^^C-NMR spectra showed the complete 
disappearence of the methyl ester signals.
Further extension of Cbz-Leu-Ala (29) was achieved using the mixed anhydride method^^ 
and t-butyl glycinate acetate salt (30) to give t-butyl carbobenzyloxy-(2S)-leucyl (2S)-aIanyl 
glycinate (38) in a yield of 88% after recrystallisation fi'om acetone / water (M.p. 
111-112°C). Cbz-Leu-Aia-Gly-OtBu (38) displayed the expected properties and showed the 
appearance of a singlet at 1.43 ppm coresponding to the t-butyl ester signal and a doublet at 
3.98 ppm coresponding to the glycyl methylene group and a triplet at 6.94 ppm 
coresponding to the glycyl amide nitrogen proton in the ^H-NMR spectrum.
Removal of the t-butyl ester under acidic conditions^®® gave carbobenzyloxy-(2S)-leucyl 
(2S)-alanyl glycine (27) in 83% yield after recrystallisation from acetone / ether (M.p. 
131°C). The and NMR spectra showed the complete disappearance of the t-butyl 
ester signal.
M e .
I .  -  I I I .
O  N
H O  M e  H
/^l8.
H O
iv . - V i .  ^ O HO  IN
H o M e  H H O
(27)
R e a g e n ts
I. NMM, i-BCF in THF at -15°C , 5  min. ii. Ala Me ester.HCI (3 3 ) ,  NMM in DMF a t -1S°C,
5 min ->  r.t. 2  h ours ->  (37). iii. NaOH in MeOH a t 35 “G, 41/2 hours; then  HOI to  pH 2. iv. 
NMM, i-BCF in T H F a t -15°C , 5  min. v . Gly t-Bu e s te r  ace ta te , NMM in THF a t -IS^C ,
5 min ->  r.t., 2  h o u rs  ->  (38). v l. 95%  formic acid, 3  hours.
Scheme 2.4: The synthesis o f Cbz-(2S)-leucyl (2S)-alanylglycine (27).
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Initially an attempt was made to prepare the Cbz-Leu-Ala-GIy (27) through the hydrolysis 
of ethyl carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycinate (39) which was itself prepared 
from the mixed anhydride coupling of ethyl glycinate hydrochloride (40) and Cbz-Leu-Ala 
(2.11) (M.p. 129°C). However Cbz-Leu-Ala-Gly-OEt (39) was resistant to base catalysed 
hydrolysis, under either aqueous methanol or anhydrous conditions (sodium t-butoxide and 
one equivalent of w a t e r ) S i n c e  the Cbz-group is not stable to acidic hydrolysis this route 
was abandoned in favour of the pathway to Cbz-Leu-Ala-Gly (27) depicted in Scheme 2.4.
2 . 1 . 0 . 0 . 1  S y n t h e s i s  o f  t “b u t o x y c a r b o n y l - ( 2 S ) - l e u c y l  ( 2 8 ) - a ! a n y l  g l y c i n e  ( 4 6 )
t-Butoxycarbonyl (2S)-leucine (41)^ ®^  was coupled with methyl (2S)-alaninate 
hydrochloride (33) using the mixed anhydride procedure^^ to give methyl t-butoxycarbonyl- 
(2S)-leucyl (2S)-alaninate (42) in 98% yield after recrystallisation from ether / hexane 
(M.p.llO°C; lit.,^ ®^  114-116°C) (Scheme 2.5). Treatment of the product (42) with 
1 mol dm'^ sodium hydroxide at 35°C for 3.5 hours and acidification gave t-butoxycarbonyl- 
(2S)-leucyl (2S)-alanine (43) in 82% yield after recrystallisation from ether / petroleum ether 
(M.p. 135°C; lit.,^ ®'^  132-133°C). Both the and ^^C-NMR spectra showed the complete 
disappearence of the methyl ester signal at 3.75 ppm and 53.84 ppm respectively.
Further extension of t-Boc-Leu-Ala (43) was achieved using the mixed anhydride 
method^^ and benzyl glycinate tosylate salt (44)^ ®^  to give benzyl t-butoxycarbonyl-(2S)- 
leucyl (2S)-alanyl glycinate (45) as a monohydrate in 88% yield after recrystallisation from 
acetone / water (M.p. 68-69°C) ( Scheme 2.5). The ^H-NMR spectrum showed that the Gly 
a-protons were diastereotopic rather than equivalent and appeared as a two doublets at 4.08 
and 4.03 ppm due to the effect of the chiral carbon centre in the adjacent Ala residue.
The benzyl ester was removed from t-Boc-Leu-Ala-Gly-OBz (45) by treatment with 
palladium (II) acetate, dimethylethylsilane and triethylamine/®*" then methanol to give
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t-butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycine (46) in 96% yield after trituration from 
acetone / ether (M.p. 111-112°C).
The possible palladium (II) acetate mechanism is shown is Scheme 2.6 on page 53. 
Oxidative addition o f dimethylethylsilane to palladium (II) acetate (16 electron species, 
oxidation state II) results in the cleavage of the silicon-hydrogen bond and the formation of 
complex (47) (18 electron species, oxidation state IV). The reductive elimination of acetic 
acid and the oxidative addition o f the benzyl ester (45) to complex (47) results in the 
cleavage of the benzylic-oxygen bond of the benzyl ester (45) and the formation of complex 
(48) (18 electron species, oxidation state IV). Rotation of the groups attached to the metal 
centre allows the dimethylethylsilyl group and the peptidic carboxylate group to align next to 
one another so the reductive formation of the palladium bound silyl ester (51) and the 
addition of triethylamine results in the formation of complex (49) (18 electron species, 
oxidation state II). The loss af triethylamine and oxidative addition of acetic acid (binding in 
the X manner) results in the cleavage of the oxygen-proton bond o f the acetic acid and the 
formation of complex (50) (18 electron species, oxidation state IV). The triethylamine may 
not necessarily bind to the palladium resulting in a 16 electron complex which could gain 
acetic acid in a similar manner to the 18 electron complex (49) to give complex (50). If  the 
triethylamine does not interact with the palladium metal centre, the triethylamine could be 
added to prevent any acetic acid generated in situ from hydrolysing the palladium complexes 
formed during the catalytic cycle.
Loss of dimethylethylsilyl t-butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycinate (51) and the 
acetate binding in the X manner changing its binding mode to the LX manner results in the 
formation of complex (52). Rotation of the groups attached to the metal centre allows the 
hydrogen attom and the benzyl group to align next to one another so reductive elimination of 
toluene can occur from complex (52) to release palladium (II) acetate which is available for
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further catalytic cycles. Upon addition of methanol, the silyl ester (51) is attacked by the 
methanol to give t-Boc-Leu-Ala-Gly (46) and dimethylethylsilylmethoxide.
Catalytic hydrogenolysis of t-Boc-Leu-Ala-Gly-OBz (45) was also attempted in methanol 
but was accompanied by 10% transestérification to the methyl ester. Addition of small 
amounts of water to the methanol solvent to prevent the transestérification, resulted in the 
precipitation of the starting material. So this approach was abandoned and the method shown 
in Scheme 2.5 was used to prepare t-Boc-Leu-Ala-Gly (46). Both and ^^C-NMR spectra 
showed the complete disappearence of the benzyl ester signals. In the spectrum,
the Gly a-protons remained non-equivalent and the signals appeared as two doublets at 3.96 
ppm and 3.89 ppm. The structure o f t-Boc-Leu-Ala-Gly (46) was also confirmed by IR 
spectroscopy, microanalysis and by mass spectrometry.
Me.
I .  -  I I I .  I o
(43)
iv . - v l . -O H
H O M e ' n  H
(46)
R e a g e n ts
i. NMM, i-BCF In T H F a t -15°C, 5  min. Ii. Ala Me ester.HCI (3 3 ) , NMM in DMF a t -15°C,
5 min ->  r.t. 2  h o u rs  ->  (42). III. NaOH in MeOH a t 35°C , 41/2 hours; then  HCI to  pH 2. iv. 
NMM, i-BCF in THF a t -15°C, 5  min. v. Giy Bz e s te r  tosy late  (44), NMM In THF a t -15“C, 5  min 
->  r.t., 2 hours ->  (45). vi. P d (0 Ac)2, MegEtBiH, EtgN in ace to n e  5 min., then  com pound  
(45), 12 hours; th en  MeOH 3 hours.
Scheme 2.5: The synthesis o f t-Boc-(2S)4eucyl (2S)-alanylglycine (2.24).
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0*^ "O
orMe
SiEtMea
(47)J
-AcOH 
■f RCOaBz
H ...Q
I (52)
SiEtMea 
O.
° y ô  °
Me
O + MeOH Q
p A o ^S iE tM e, -------------- ^
j - MeOSiEtMea
+ EtgN
H NEtç
C r 'o X
(50) J  rMe Me
Q ^O S iE taM e + AcOH
R ------- -
O. _o -EtgN % O^OSiEtaMePd--'“VR
I (49)
R = Cbz-Leu-Ala-NHCHî
Scheme 2.6;
The benzyl ester deprotection mechanism o f Pd(0Ac)2 , dimethylethylsilane and methanol.
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2 . 1 . 0 . 0 . 2  S y n t h e s i s  o f  t h e  g l y c y l  a m i d e s
Glycyl amide hydrochloride (28) and glycyl-N-methyl amide hydrochloride (53) were 
prepared by stirring methyl glycinate hydrochloride (54)^ ^^  ^ in a concentrated aqueous 
solution of the appropriate amine for 2 days/°^ The yields were 90% and 78% respectively, 
after recrystallisation from methanol (M.p. decomp. 182°C; lit.,^^  ^ 200-203°C and 148°C; 
lit.,^ *^  ^ 153.5-156°C respectively). In the case of the N-methyl amide (53), the signal for the 
methyl group attached to the nitrogen-atom appeared at 2.61 ppm and 28.56 ppm in the ^H- 
and ^^C-NMR spectra.
It was envisaged that an analogous procedure could be used for the preparation of 
glycyl-N,N-dimethylamide (55) but after repeated attempts, only impure glycyl-N, 
N-dimethylamide (55) could be obtained and therefore an alternative route was investigated, 
as outlined below.
t-Butoxycarbonyl-glycine ( 5 6 ) and aqueous dimethylamine were coupled using the 
mixed anhydride method^^ to give t-butoxycarbonyl-glycyl-N, N-dimethylamide (57), in 40% 
yield after recrystallisation from methanol (M.p. 74°C). The low yield from the reaction was 
probably due to the use of aqueous dimethylamine which presumably causes some hydrolysis 
of the mixed anhydride (Scheme 2.7). Acid catalysed h yd r o l y s i s o f  the product (57) gave 
glycyl-N,N-dimethylamide (55), in 53% yield after reciystallisation from methanol /  ether. 
Gly-N,N-dimethylamide (55) displayed the expected spectral signals and gave satisfactory 
elemental analysis. A sharp melting point for glycyI-N,N-dimethylamide (55) could not be 
obtained as the crystals were too hygroscopic.
As expected, the ^H- and ^^C-NMR spectra also showed that the two methyl groups 
attached to the amide nitrogen in both t-Boc-glycyl-N,N-dimethylamide (57) and glycyl-N, 
N-dimethylamide (55) were not equivalent. This arises as the carbon nitrogen bond obtains 
some double bond character from the delocalisation of the nitrogen lone pair within the
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carbonyl bond. Rotation about the carbon nitrogen bond is restricted and when the methyl 
group is cis to the oxygen of the amide bond it is in a different enviroment, to that when the 
methyl group is trans to the oxygen of the amide bond. Thus two signals are observed, one 
for each methyl group in both the and ^^C-NMR spectra.
An analogous procedure was used for the preparation of t-butoxycarbonyl-glycyl 
N-methyl,N-ethylamide (58) (M.p. 86°C) and t-butoxycarbonyl-glycyl
N ,0 ’-dimethylhydroxylamide (59) (M.p.l01°C) in yields of 67% and 81%, respectively, after 
recrystallisation from methanol. Both of the t-Boc-protected amides showed the expected 
spectral characteristics and gave satisfactory microanalyses.
Acid catalysed hydrolysis o f t-Boc-Gly-N-methyl,N-ethylamide (58) and t-Boc-Gly- 
N ,0 ’-dimethylhydroxylamide (59) gave glycyI-N-methyl,N-ethylamide (60) and glycyl-N,0 ’- 
dimethylhydroxylamide hydrochloride (61) in a yields of 99% and 93% respectively. Both 
^H- and NMR spectra, showed the complete loss of the t-butyl signal and the products of
the hydrolysis were water soluble.
The and ^^C-NMR spectra of t-Boc-Gly-N-methyl,N-ethylamide (58), t-Boc-Gly-
N, O ' -dimethylhydroxylamide (59), Gly-N-methyl,N-ethylamide, (60) and Gly-N,0’- 
dimethylhydroxylamide hydrochloride (61) showed that these compounds were present as cis 
and trans isomers (the allcyl amide signals and the a-proton / a-carbon signals were 
doubled). This is ascribed to the restricted rotation about the carbon-nitrogen bond of the 
amide which is very slow on the NMR time scale. The activation energy for rotation, which 
causes the loss of amide resonance is about 80 kJ mol'^ and therefore both environments are 
observed by NMR spectroscopy (Fig. 2.2).
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I H O  i. I H O
o O R
(56)
iii. H.,'H O
01" R
R e a g e n ts
i. N-methyl m orpho line (NMM), i-BCF In THF at -15°C, 5 min. R = R' = Mo;
ii. NHMog (aq) a t  -15°C , 5 min -»  r.t. 2 hours (57). R = Et, R' = Me; ii. 
NHMeEt.HCI, NMM in a t -15°C , 5 min -»  r.t. 2 hours -> (58). R = Me, R* = 
OMe; Ii. NHM e(OM e).HCI, NMM In a t -1 S^C, 5  m i n r . t .  2  h o u r s ->
(59). iii. Ethyl a c e ta te  sa tu ra te d  with HCI, -5°C, 1 hour; R = R ' = Me
(55), R = Et, R ’ = Me (60) a n d  R = Me, R ' = OMe (61).
Scheme 2.7: The preparation o f various glycyl amides.
Me EtI
H O  H Ocis trans
Fig. 2.2: Cis and trans glycyl-N-methyl, N-ethyl amide, (2.36).
2 . 1 . 0 . 0 . 3  S y n t h e s i s  o f  t h e  N - p r o t e c t e d  a n d  u n p r o t e c t e d  t e t r a p e p t i d e  a m i d e s
The mixed anhydride procedure^^ failed to couple Cbz-Leu-Ala-Gly (27) (Section
2.1.0.0.0) to the glycyl amides (Section 2.1.0.0.2) in several instances, due to the low 
solubility of the reactants in THF at -20°C. So the carboxylic acid of Cbz-Leu-Ala-Gly (27) 
was activated with 0-benzotriazole-l-yl-N, N, N ’, N ’-tetramethyluronium tetrafluoroborate 
(TBTU)^^^ in THF at 20°C, and then through reaction with the appropriate glycyl amide and 
diisopropylethylamine over night gave the following Cbz-protected tetrapeptide amides 
(Scheme 2.8 and Table 2.1), namely carbobenzyloxy-(2S)-leucyI (2S)-alanyl glycyl glycyl-
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amide (19), carbobenzyIoxy-(2S)-Ieucyl (2S)-aIanyl glycyl glycyl-N-methyl-amide (20), 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl-N, N-dimethyl-amide (21), carbobenzyloxy- 
(2S)-leucyl (2S)-alanyl glycyl glycyl-N-methyl N-ethyl amide (22) and carboben2yloxy-(2S)- 
leucyl (2S)-alanyl glycyl-N-, O’-dimethylhydroxylamide (23). Yields and melting points are 
given in Table 2.1 and Fig. 2.1. Full preparative details and spectral data are given in the 
experimental Section, pages 157-241.
c l : "
H Ô M s H H
(27)
MeMe.
O
H O Me H H
.R'
Reagents
i.) TBTU , 2  eq . i-PrgEtN a n d  Gly-NRR’.HCI in THF, 12 hours.
Scheme 2.8: The preparation o f the Cbz-protected tetrapeptide amides.
Compound R R’ % yield M.p / °C
19 H H 49 196-198
20 H Me 68 213
21 Me Me 34 163
22 Me Et 64 170
23 OMe Me 63 141-142
Table 2.1: The percentage yields and melting points of the Cbz-protected tetrapeptide
amides.
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The TBTU mechanism of amide bond foiTnation is shown is Scheme 2.9. The carboxylic 
acid moiety of Cbz-Leu-Ala-Gly (27) attacks the TBTU to give the tetrahedral intermediate 
(62), after deprotonation. Elimination o f hydroxybenzotriazole anion results in the resonance 
stabilised intermediate (63), which is nucleophilically atttacked by the amine functionality of 
the amide (in this case Gly-amide) to give N, N, N, ’N ’-tetramethylurea, 
hydroxybenzotriazole and the amide bond after deprotonation.
NM02 _______ ^  \ . N M 62
IVIe2N-V ^  M e2N '^
O -N "I 'N  0 -N " 'N
PF«- / /  \
0  HN(i-Pr)2Et PFg" [ 0  NMea
R q  NMes R ^ O ^ N M e a
HaR'N b-N ''^^N
(62) y - L  (28)
o
y "  °     „ A , . k
R = Cbz-Leu-Ala-NHCH2  
R' = CH2 CONH2
Scheme 2.9: The TBTU mechanism of amide bondformation.
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The carboxylic acid of t-Boc-Leu-Ala-Gly (46) (Section 2.1.0.0.1) was activated with 
TBTU“  ^ in THF at 20°C. Reaction of the activated ester with glycyl N-p-nitro anilide 
hydrochloride (64) and diisopropylethylamine over night gave t-butoxycarbonyl-(2S)-leucyl 
(2S)-alanyl glycyl glycyl-^-nitroanilide (24) in 83% yield after recrystallisation from methanol 
/e ther (M.p. 188°C).
Unfortunately the Cbz-Leu-AIa-Gly-Gly-NH2 (19) and the Cbz-Leu-Ala-Gly-Gly-NHMe
(20) were too insoluble in water to be tested for biological activity. Therefore the 
N-protection was removed to make the amides water soluble. Hydrogenolysis of the 
Cbz-Leu-Ala-Gly-Gly-NHi (19) and the Cbz-Leu-Ala-Gly-Gly-NHMe (20) in acetic acid for 
3 hours gave (2S)-leucyl (2S)-alanyl glycyl glycyl amide, acetate salt (25) (M.p. 126°C 
(decomp)) and (2S)-leucyl (2S)-alanyl glycyl glycyl-N-methyl amide, acetate salt (26) (M.p. 
130°C) in 92% and 94% yields respectively. These amides were isolated as their acetate salts 
and their structures were confirmed by ^H-, ^^C-NMR and IR spectroscopy and mass 
spectrometry.
2.1.1 Rationale for the ester tetrapeptides
Although esters are unable to provide a potentially key H-bonding donor, some 
proteinases are able to process ester substrates, for example chymotrypsin.^^^ In the ester 
moiety, rotation about the carbon alkyl oxygen bond is not restricted as little delocalisation 
of the allcyl oxygen lone pair into the carbonyl bond occurs (unlike the carbon nitrogen bond 
in an amide, see Fig. 2.3). Thus the ester moiety is able to adopt more conformations than an 
amide bond.
It seemed reasonable to expect that the proteinase would bind to the tetrapeptide esters 
(Fig. 2.4 and Table 2.2), but whether the esters would act as substrates or inhibitors was 
unknown. In order to test this possibility some esters were prepared.
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a) S- o b) 6“ o
R ^ V ? '  m
I 6-
Fig. 2.3: Comparison o f  a) The amide moiety and h) The ester moiety.
2.1.1,0, Synthesis of the tetrapeptide esters
The carboxylic acid of Cbz-Leu-Ala-GIy (27) (section 2.1.0.0.1) was activated with 
TBTU^^^ in THF at 20°C. Reaction of the activated ester with the appropriate glycyl ester 
and diisopropylethylamine overnight gave the following Cbz-protected tetrapeptide esters; 
methyl carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65), ethyl carbobenzyloxy- 
(2S)-leucyl (2S)-alanyl glycyl glycinate (66) and t-butyl carbobenzyloxy-(2S)-leucyl (2S)- 
alanyi glycinate (67). Yields and melting points are given in Table 2.2 and Fig. 2.4 on page 
61, full preparative details and spectral data are given in the experimental Section, pages 157 
-241.
Initially a convergent strategy (Section 2.1.0, Scheme 2.2) was employed to prepare 
Cbz-Leu-Ala-Gly-Gly-OMe and (65) and Cbz-Leu-Ala-Gly-Gly-OEt (66); Carbobenzyloxy- 
glycine (34)^^  ^ and methyl glycinate hydrochloride ( 5 4 ) were coupled using the mixed 
anhydride procedure^^ to give methyl carbobenzyloxy-glycyl glycinate (68) in 61% yield after 
recrystallisation from ether / petroleum ether (M.p. 63°C; lit.,^^  ^ 63-65°C) (Scheme 2.10). A 
similar procedure was used to prepare ethyl carbobenzyloxy-glycyl glycinate (69) from 
Cbz-glycine (34) and ethyl glycinate hydrochloride (40).^^  ^ The compound was afforded in 
59% yield after recrystallisation from ether / petroleum ether (M.p. 78°C; lit.,^^  ^ 78-80°C). 
Removal of the Cbz-protection from Cbz-Gly-Gly-OMe (68) was achieved by catalytic 
hydrogenolysis in methanol for four hours to give methyl glycyl glycinate (70) in 81% yield
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(M.p. (decomp.) 209°C) (Scheme 2.10). A similar procedure was used to prepare ethyl 
glycyl glycinate (71) from ethyl carbobenzyloxy-glycyl glycinate (69) and the product was 
obtained in 81% yield (M.p. 80°C) (Scheme 2.10). Unfortunately Gly-Gly-OMe (70) and 
Gly-Gly-OEt (71) were too insoluble in THF, dichloromethane or dimethylformamide to be 
coupled to Cbz-Leu-Ala (29).
Me.
H O  H O
H o Me H H q 
Fig. 2.4: The N~protected tetrapeptide esters.
Compound R R ’ % yield M.p. / °C
65 Cbz Me 62 145-146
66 Cbz Et 63 142-144
67 Cbz t-Bu 72 hygroscopic
72 t-Boc Bz 65 hygroscopic
73 t-Boc t-Bu 75 153
Table 2.2\The percentage yields and melting points o f the N-protected tetrapeptide esters.
oA. i. .  ii.
H O
■ \\
(34) R = Me (68); Et (69).
I I I .
H
R eagents
I. NMM, i-BOF in THF a t -15“C, 5 min; R = Me; ii. NMM and Gly methyl ester HOI in THF at -15°C, 
5 min r.t., 2 hours. R =. Et; ii. NMM and Gly ethyl ester HOI in THF at -15°G, 5 min -> r.t.,
2 hours, ill. Hg Pd \  C 3 hours.
Schem e 2.10: The preparation o f Gly-Gly-OMe (70) and Gly-Gly-OEt (71).
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The carboxylic acid of t-Boc-Leu-Ala-Gly (46) (section 2.1.0.0.1) was activated with 
TBTU^^^ in THF at 20°C. Reaction of the activated ester with the appropriate glycyl ester 
and diisopropylethylamine over night gave the following t-Boc-protected tetrapeptide esters; 
benzyl t-butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycyl glycinate (72) and t-butyl 
t-butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycyl glycinate (73), see Fig. 2.4 and Table 2.2. All 
of the structures of the N-protected tetrapeptide esters (65) to (67) and (72) to (73) were 
confirmed by ^H-NMR, ^^C-NMR, IR spectroscopy, mass spectrometry and microanalysis.
Ethyl (2S)-leucyl (2S)-alanyl glycyl glycinate (74) was prepared through catalytic 
hydrogenolysis of Cbz-Leu-Ala-Gly-Gly-OEt (66) in quantitative yield.
2.1.2 Rationale for the acid and alcohol tetrapeptides
N-(Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl)-1-amino, 2-hydroxy ethane (75) has 
the ability to accept hydrogen bonds from the Pi carbonyl binding pocket or the P i’ amide 
binding pocket in the proteinase, depending on where the alcohol moiety binds to the 
proteinase (Fig. 2.5). Therefore, it was expected that inhibition of the proteinase by N-(Cbz- 
Leu-Ala-Gly)-1 -amino-2-hydroxyethane (75) might indicate that hydrogen bonding 
interactions between the proteinase and the carbonyl oxygen at Pi or the amide nitrogen at 
P i’ of a substrate are important.
Cbz-(2S)-leucyl (2S)-alanyl glycyl glycine (76) is the hypothetical acid hydrolysis product 
of the amide (section 2.1.0) and ester (Section 2.1.1) potential substrates. As Cbz-Leu-Ala- 
Gly-Gly (76) has similar binding requirements to the potential substrates, product inhibition 
of the proteinase may occur. In the case of papain, benzoyl glycine is a competitive inhibitor 
(Ki 8 3 0  mmol
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Fig. 2.5: The possible interactions o f  Chz-Leu-Ala-Gly-ethanolamine (75) with the 
Pi-Pi ’ binding pockets o f  the proteinase; a) substrate; b) alcohol binding in Pj ’ amide 
nitrogen pocket; c) alcohol binding in Pi carbonyl oxygen pocket.
2.1.2 Synthesis of the tetrapeptide aicohol and acid
The carboxylic acid of carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycine (27) (section
2.1.0.0.1) was activated with TBTU^^^ in THF at 20°C. Reaction o f the activated ester with 
ethanolamine and diisopropylethylamine overnight gave N-(Cbz-Leu-Ala-Gly)-2-amino- 
ethanol (75).
Sodium Cbz-Leu-Ala-Gly-Gly (76) was prepared by the base catalysed hydrolysis of 
Cbz-Leu-Ala-Gly-Gly-OMe (65) in methanol for 4.5 hours at 35°C. Both N-(Cbz-Leu-Ala- 
Gly)-1-amino 2-hydroxy ethane (75) and Cbz-Leu-Ala-Gly-Gly (76) showed the expected 
signals in their IR, ^H- and ^^C-NMR spectra.
2.1.3 Rationale for the design of the nitrile potential inhibitors
N-acetyl-phenylalanyl aminoacetonitrile is a competitive inhibitor of papain (K, 
0.73 The nitrile functionality binds covalently to the active site of papain, forming a
thioimidate adduct (Scheme 2.11). The presence of the thioimidate adduct was demonstrated 
in the ^^C-NMR spectra of [l-^^C]-(N-benzoyl)-aminoacetonitrile (11)}^^ When a 50% molar 
excess of the nitrile (77) was added to papain a major new signal appeared at 182 ppm, with
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a corresponding loss in intensity of the nitrile signal at 118 ppm. The new signal’s chemical 
shift is entirely consistent with the formation of the proposed thioimidate adduct (Fig. 2.6), 
since the signal falls between the range of thioamide carbons (200-210 ppm) and peptide 
carbons (160-170 ppm).^^° No evidence of nitrile hydrolysis by papain was observed.
Scheme 2.11: Formation o f the thioimidate adduct from  a nitrile in papains active site.
The nitrile functionality was included into the Leu-Ala-Gly-Gly sequence to give 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl aminoacetonitrile (78) and 
t-butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycyl aminoacetonitrile (79) (Fig 2.6 on page 65), 
in order to see if the adenovirus proteinase could be inhibited by the nitrile functionality. 
Carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2S)-alanyl aminoacetonitrile (SO) and 
carbobenzyloxy-(2S)-leucyI (2S)-alanyl (2R)-alanyl aminoacetonitrile (81) (Fig. 2.6) were 
also prepared to investigate whether the proteinase requires a glycyl residue at of the 
cyanide inhibitors.
Once it was established that Cbz-Leu-Ala-Gly-aminoacetonitrile (78) and t-Boc-Leu-Ala- 
Gly-aminoacetonitrile (79) inhibited the adenovirus proteinase, it was necessary to probe the 
binding interactions present between the P side of the tetrapeptide cyanide inhibitors and the 
S side o f the proteinase. The series of trifluoroacetyl protected cyanides (Fig. 2.7 on page 
65) were prepared to investigate the importance of the P4, P3 and P2 residues in the binding 
of the tetrapeptide inhibitors.
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V 9  H
T  X  T  „H o  Me H H O
Compound R R^
78 Cbz H H
79 t-Boc H H
80 Cbz H Me
82 Cbz Me H
Fig. 2.6: The Cbz- and t-Boc protected tetrapeptide nitrite inhibitors.
MeMe,
H o  Me H H O
H O
Ô Me H H Ô
(83)
Ü
H O
(84)
H O
(85)
Fig 2.7: The TFA-protected nitrile inhibitors.
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[l-^^C]-Carbobenzyioxy-(2S)-leucyl (2S)-alanyl glycyl aminoacetonitrile (86) (Fig 2.8) 
was prepared to establish whether Cbz-Leu-Ala-Gly-aminoacetonitrile (78) inhibited the 
adenovirus proteinase by forming a thioimidate adduct. Potentially, this could be achieved by 
examining mixtures of the activated proteinase and the ^^C-labelled inhibitor by ^^C-NMR 
spectroscopy.
" = label
(86)
Fig. 2.8; The ^^C-labelled cyanide inhibitor.
2.1.3.0 The synthesis of the potential nitrile inhibitors
2 . 1 . 3 . 0 . 0  T h e  s y n t h e s i s  o f  t h e  C b z -  a n d  t - B o c  p r o t e c t e d  n i t r i i e s
The carboxylic acid of Cbz-Leu-Ala-Gly (27) (section 2.1.0.0.1) was activated with 
TBTU^^^ in THF at 20°C. Reaction of the activated ester with aminoacetonitrile 
hydrochloride (85) and diisopropylethylamine overnight afforded Cbz-Leu-Ala-Gly- 
aminoacetonitrile (78) in 78% yield after recrystallisation from methanol / ether (M.p. 
159°C). Similarly t-Boc-Leu-Ala-Gly-aminoacetonitrile (79) was prepared from t-Boc-Leu- 
Ala-Gly (46) (section 2.1.0.0.1) and aminoacetonitrile hydrochloride (85) in 57% yield after 
recrystallisation from methanol / ether (M.p 162°C).
Carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2S)-alanyl aminoacetonitrile (80) was prepared 
as outlined below; Cbz-Leu-Ala (29) (Section 2.1.0.0.0) was coupled with methyl 
(2S)-alaninate hydrochloride (33) using the mixed anhydride procedure^^ to give methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2S)-alaninate (87) in 87% yield after
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recrystallisation from acetone / water (M.p. 149-150°C; lit./^^ 172-173°C) (Scheme 2.12). 
Alkaline hydrolysis of Cbz-Leu-AIa-Ala-OMe (87) in methanol gave carbobenzyloxy-(2S)- 
leucyl (2S)-alanyl (2S)-alanine (88) in 71% yield after recrystallisation from methanol / ether. 
(M.p. 84-86°C). The and ^^C-NMR spectra showed the complete disappearance of the 
methyl ester signal (Scheme 2.12). The carboxylic acid of Cbz-Leu-Ala-Ala (88) was 
activated with TBTU^^^ in THF at 20°C. Reaction of the activated ester with 
aminoacetonitrile hydrochloride (85) and diisopropylethylamine overnight gave 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2S)-alanyl aminoacetonitrile (80) in 66% yield after 
recrystallisation from methanol / ether (M.p. 161-162°C) (Scheme 2.12).
Me Me
\  H O \
H O Me H H O Me H A O
(29) R = H and R' = Me (88) 
R = Me and R' = H (91)
Me 
Me-{
IV .
R = H and R' = Me (80) 
R = Me and R' = H (81)
R e a g e n ts
i. NMM, i-BCF in THF at -15=0, 5  min. R = H an d  R' = Me; ii. NMM, Ala-Me e s te r . HOI (33), at 
-15°C ,5 min r.t., 2  hours -»  (87). iii. NaOH in MeOH at 3 5 = 0 ,4 1 /2  hours; th en  HOI pH 
3 (88). R = Me an d  R' = H; ii. NMM, (2R)-Aia-t-Bu este r. HOAo (89) a t -1 5 = 0 ,5  min
r.t., 2  hours (90). iii. formic acid , 3 hours ->  (91). iv. i-Pr2EtN, TBTU, 
am inoacetonitrile  hydroch loride in THF, 12 hours.
Scheme 2.12: The preparation o f  the nitriies containing alanine at the P2  position.
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Carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2R)-alanyl aminoacetonitrile (81) was prepared 
as follows; Cbz-Leu-Ala (29) (Section 2 .1.0.0.0) was coupled with t-butyl (2R)-alaninate 
hydrochloride (89) using the mixed anhydride procedure^^ to afford t-butyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2R)-alaninate (90) in 79% yield after 
recrystallisation from acetone / water (M.p. 121-122°C) (Scheme 2.12). Acidic hydrolysis of 
Cbz-Leu-Ala-(2R)-Ala-0t-Bu (90) gave carbobenzyloxy-(2S)-leucyl (2S)-alanyl 
(2R)-alanine (91) in 58% yield after recrystallisation from methanol / ether (M.p. 82-84°C). 
The ^H- and ^^C-NMR spectra showed the complete disappearance of the t-butyl ester signal 
(Scheme 2.12). The carboxylic acid of Cbz-Leu-Ala-(2R)-Ala (91) was activated with 
TBTU^^^ in THF at 20°C. Reaction o f the activated ester with aminoacetonitrile 
hydrochloride (85) overnight gave carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2R)-alanyl 
aminoacetonitrile (81) in 66% yield after recrystallisation from methanol / ether (M.p. 
140°C) (Scheme 2.12).
All the structures of the N-protected tetrapeptide cyanides were confirmed by ^H-NMR, 
^^C-NMR and IR spectroscopy, microanalysis and mass spectrometry.
2 . 1 . 3 . 0 . 1  T h e  s y n t h e s i s  o f  t h e  T F A  p r o t e c t e d  n i t r i i e s
Trifluoroacetyl-(2S)-leucine (92)^^  ^ was coupled with benzyl (2S)-alaninate tosylate (93) 
using the mixed anhydride procedure^^ to give benzyl trifluoroacetyI-(2S)-leucyl 
(2S)-alaninate (94) in 77% yield (Scheme 2.13 on page 70). Treatment of TFA-Leu-Ala- 
OBz (94) with palladium (II) acetate, dimethylethylsilane and triethylamine^^^ and then 
methanol gave triftuoroacetyl-(2S)-leucyl (2S)-alanine (95) in 83% yield after 
recrystallisation from dichloromethane / hexane (M.p. 92°C) (Scheme 2.13). Both the ^H- 
and ^^C-NMR spectra showed the complete disappearence of the benzyl ester signals. The 
^H- and ^^C-NMR spectra also showed that TFA-Leu-Ala (95) was present in two
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conformations, as most of signals for the leucine and the alanine residues were doubled. The 
spectra were complex at room temperature but at -50°C the signals of the two isomers could 
be distinguished.
Molecular dynamics at elevated temperature (500 K),“ indicated that two different 
backbone conformations of the leucyl residue were possible. A 7-membered ring is formed 
from a hydrogen bond between the nitrogen hydrogen of the alanine residue and the carbonyl 
oxygen of the trifluoroacetyl group where the leucyl side chain is either equatorial (C7eq 
comformation, Fig. 2.9) or axial (C7ax conformation Fig. 2.9). Samples taken from the 
dynamics every ps were reoptimised using the AMBER force field and showed that the C7eq 
conformation has an energy range between -20.9 to -13.8 IcJ mol'^ and the the C7ax 
conformation has an energy range between -13.0 to -11.3 kJ m o l'\ There is a low energy 
difference between the two conformers (5.3 ±4.5 IdF mol" )^ so it is reasonable to assume that 
at room temperature, both conformations would be populated.
a) b)
Fig. 2.9: The two possible isomers o f  TFA-Leu-Ala (95); 
a) The C7eq conformation and h) The C7ax conformation.
M olecular m echanics energies are relative energies compared w ith an  arbitaey zero. These calculations 
were perform ed by D r J. Wilkie.
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Further extension of TFA-Leu-Ala (95) was achieved using the mixed anhydride method^^ 
and glycine benzyl ester tosylate (44) to give the monohydrate of benzyl 
trifluoroacetyl-(2S)-leucyl (2S)-alanyl glycinate (96) in 88% yield after recrystallisation from 
acetone / water (M.p. 121°C) (Scheme 2.13). In the and ^^C-NMR spectra the same 
peak doubling as occured for TFA-Leu-Ala (95), also occurred for TFA-Leu-Ala-Gly-OBz
(96).
Me Me Me Me
(92)
iv.-vi. o \  H O
(97)
OH
V I I .
F3C'
(82)
R e a g e n ts
i. NMM, i-BCF in THF a t -15°G, 5  min; ii. T hen  NMM and  Ala Bz ester , tosy la te  
(93) in T H F a t -15°C , 5  min ->  r.t., 2 h ours (94). Hi, Pd(0 Ac)2, EtgN, 
Me2EtSiH  In d ich lo rom ethane 5 min, th en  com pound (94), 12 hours; then  
MeOH , 3  hou rs . Iv. NMM, I-BCF in THF at -15°C, 5 min; v .Then NMM an d  G ly 
Bz e s te r  in TH F at -15°C , 5 min ->  r.t,, 2  hours -> (96). vi. Pd(0 Ac)2, EtaN, 
Me2EtSIH In d ich lo rom ethane 5 min, th en  com pound (96), 12 hours; then 
MeOH , 3  h o u rs , vii. TBTU, l-Pr2EtN and  am inoacetonitrile hydrochloride In 
THF, 12  hou rs .
Scheme 2.13: The synthesis o f TFA-(2S)-leucyl (2S)-alanyl glycyl aminoacetonitrile (82).
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The benzyl ester was removed from benzyl TFA-leu-Ala-Gly (96) by treatment with 
palladium (II) acetate, dimethylethylsilane, triethylamine^®® and then methanol to give 
trifluoroacetyl-(2S)-leucyl (2S)-alanyl glycine (97) in 46% yield (Scheme 2.13 on page 70). 
Both and ^^C-NMR spectra showed the complete disappearence of the benzyl ester 
signals.
The carboxylic acid of TFA-Leu-Ala-Gly (97) was activated with TBTU^^^ in THF at 
20°C. Reaction of the activated ester with aminoacetonitrile hydrochloride (85) and 
diisopropylethylamine overnight to give trifluoroacetyl-(2S)-leucyl (2S)-alanyl glycyl 
aminoacetonitrile (82) in 82% yield after chromatography on silica eluting with 
dichloromethane / petroleum ether (3:1), then ethyl acetate (Scheme 2.13).
The structures of the TFA-protected compounds (94) to (97) and (82) were also 
confirmed by IR and mass spectrometry.
TrifIuoroacetyl-(2S)-alanyl glycyl aminoacetonitrile (83) was prepared as described 
below; trifluoroacetyl alanine (98)^^  ^ was coupled with benzyl glycinate tosylate (44) using 
the mixed anhydride procedure^^ to give benzyl trifluoroacetyl-(2S)-alanyl glycinate (99) in 
96% yield after recrystallisation from dichloromethane / hexane (M.p. 84-86°C) (Scheme
2.14). Treatment of TFA-Ala-Gly-OBz (99) with palladium (II) acetate, dimethylethylsilane 
and triethylamine;^®^ then methanol gave trifluoroacetyl-(2S)-alanyl glycine (100) in 63% 
yield (Scheme 2.14). Both ^H- and ^^C-NMR spectra showed the complete disappearence of 
the benzyl ester signals. The carboxylic acid of TFA-Ala-Gly (100) was activated with 
TBTU^^^ in THF at 20°C. Reaction of the activated ester with aminoacetonitrile 
hydrochloride (85) overnight gave trifluoroacetyI-(2S)-alanyl glycyl aminoacetonitrile (83) in 
35% yield after recrystallisation from dichloromethane / hexane (M.p. 149°C) (Scheme
2.14).
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H O  H O
(98) (100)
I I I . O H CHsH O
F3C
H O  H
(83)
Reagents
I. NMM, i-BCF in THF a t -15“C, 5 min; then  NMM and  Gly Bz ester. Tosy late  
(44) in THF a t -15®C, 5 min r.t., 2 h ours ->  (99). ii. Pd(OAc)2, EtgN, 
M e2EtSIH In d ich lo rom ethane  5 min, th en  com pound  (99), 12 hours; then  
M eOH , 3  hours , iii. TBTU, l-Pr2EtN an d  am inoacetonitrile hydrochloride in 
THF, 12 hours.
Scheme 2.14: The preparation o f  TFA-Ala-Gly-aminoacetonitrile (83).
Trifluoroacetyl-glycyl aminoacetonitrile (84) was prepared by activating the carboxylic 
acid of TFA-Gly (101)^ '^  ^with TBTU^^^ in THF at 20°C. Reaction of the activated ester with 
aminoacetonitrile hydrochloride (85) and diisopropylamine overnight gave 
trifluoroacetyl-glycyl aminoacetonitrile (84) in 57% yield after recrystallisation from 
methanol (M.p. 143°C) (Scheme 2.15). The structures of the TFA-protected compounds
(99) to (101), (83) and (84) were also confirmed by IR and mass spectrometry.
O P H
H O 
(101)
H O 
(84)
R e a g e n ts
I. TBTU , l-PrgEtN a n d  am inoacetonitrile hydroch loride In THF, 12 hours.
Scheme 2.15: The preparation o f TFA-Gly-aminoacetonitrile (84).
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2 . 1 . 3 . 0 . 2  T h e  s y n t h e s i s  o f  [ 1 - ^ ^ C ] » c a r b o b e n z y l o x y - ( 2 S ) - l e u c y i  
( 2 S ) - a l a n y l  g l y c y l  a m i n o a c e t o n i t r i l e  ( 8 6 )
[l-^^C]-Carbobenzyloxy-(2S)-Ieucyl (2S)-alanyl glycyl aminoacetonitrile (86) was 
prepared to establish whether Cbz-Leu-Ala-Gly-aminoacetonitrile (78) inhibited the 
adenovirus proteinase by forming a hemithioimidate adduct, see Section 2.1.3 page 66.
[l-^^C]-Aminoacetonitrile (102) was prepared as described below; formaldehyde and 
ammonium chloride were carefully treated with [l-^^C]-potassium cyanide and acetic acid^^  ^
to give [l-^^C]-methylene aminoacetonitrile (103) in 15% yield (Scheme 2.15). 
[ 1 - C]-methylene aminoacetonitrile (103) was hydrolysed with ethanolic hydrochloric acid 
to give [l-^^C]-aminoacetonitrile hydrochloride (102) in 96% yield (Scheme 2.15). The 
procedures had been optimised first with unlabelled potassium cyanide to give methylene 
aminoacetonitrile (104) and aminoacetonitrile hydrochloride (85) in similar yields of 24% and 
13% respectively.
S  I- Ï  ».
H C rH 3 N "^‘^CN
(103) ' (102)
ill.
H Ô Me H H o
(86)
R e a g e n ts
i. K^®CN, 2  NH4CI in HgO at -5°C. th en  HOAo in HgO -5°C , 1 hour. II. HCI in 
Eton a t .5"C , 1hour. ill. Cbz-Leu-Ala-Gly (27) TBTU an d  l-PrgEtN in THF,
12 hours.
Scheme 2.16: The preparation o f [l-^CJ-Ghz-Leu-Ala-Gly-aminoacetonitrile (86).
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The carboxylic acid of Cbz-Leu-Ala-Gly (27) (section 2.1.0.0.1) was activated with 
TBTU^“  in THF at 20°C. Reaction of the activated ester with [l-^^C]-aminoacetonitrile 
hydrochloride (102) and diisopropylethylamine overnight to give [l-^^C]-carbobenzyloxy- 
(2S)-leucyl (2S)-alanyl glycyl aminoacetonitrile (86) in 90% yield after recrystallisation from 
methanol / ether (Scheme 2.16).
Initially the synthesis of aminoacetonitrile (85) was attempted from Cbz-Gly (34) by the 
use of halodecarboxylation. (Scheme 2.17 on page 75). This was in order to avoid the use of 
potassium cyanide under acidic conditions which liberates hydrogen cyanide. Cbz-glycine 
(34) was halodecarboxylated with 1.1 equivalents of lead (IV) tetracetate and 1.1 equivalents 
of lithium chloride. Carbobenzyloxy-1-amino- 1-acetoxymethane (105) was isolated in 
67% yield (Scheme 2.17). The structure was confirmed by ^H-NMR where the glycyl a - 
protons appeared as a doublet at 5.29 ppm with a coupling constant of 7.6 Hz to the 
urethane proton and the acetoxy-protons appeared as a singlet at 2.05 ppm and by ^^C-NMR 
which showed that the benzylic carbon and the glycyl a-carbon appeared at 67.82 and 67.12 
ppm and the acetoxyl carbonyl carbon and methyl carbon appeared at 172.27 and 21.46 ppm 
respectively. Further characterisation was not possible as Cbz-1-amino-1-acetoxymethane 
(105) was too sensitive to moisture. The expected product of 
carbobenzyloxy-1 -amino-1 -chloromethane (106) was not obtained as acetolysis of Cbz-1- 
amino 1-chloromethane (106) occurs due to the presence of acetic acid formed in situ.
Treatment of Cbz-1-amino-1-acetoxymethane (105) with potassium cyanide in refiuxing 
acetonitrile for 3 hours gave carbobenzyloxy-aminoacetonitrile (107) in 68% yield The 
structure was confirmed by ^H-NMR which showed that the glycyl a-protons occurred as a 
doublet at 4.04 ppm with a coupling constant of 7.6 Hz to the urethane proton and that the 
acetoxy-protons signal had completely disappeared. Deprotection of the Cbz group was
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attempted by catalytic hydrogenolysis and by treatment with trimethylsilyl bromide^^^ but 
both methods failed due to over reduction and lack of reaction respectively.
O o
II H O  H
(34) (106)
I I .
I I I .
O O
O '^ N ^ O '^ C H g
H (105)
O
0 '^ N ‘^ C NIH
(107)
R e a g e n t s
i. P b (0 Ac)4 in M eCN, 10 min, then  LiCI and h ea t until 80  -90°C, 2hours.
ii. AcOH in  situ . iii. KCN MeCN a t reflux, 3  hours.
Scheme 2.17: The attempted preparation o f aminoacetonitrile (85).
2.1.4 Rationale for the aldehyde, methyl-ketones, dimethylaceta! 
and alkenic potential inhibitors
Acetyl-(2S)-phenylalanyl glycinal (108) is a potent competitive inhibitor of papain 
(5.2 nmol dm'^)."^ 95% of the aldehyde (108) actually exists in the hydrated diol form 
(Scheme 2.18 on page 76) and it was unknown whether the aldehyde form or the hydrated 
diol form of the aldehyde was responsible for the inhibition of papain.
It was suspected that the unhydrated, aldehyde form of acetyl phenylalanyl glycinal (108) 
bound covalently to the active site of papain, forming a hemithioacetal adduct (Scheme 2.19 
on page 76).^^^
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(108)
HoO H OH
H o
HgC
H 0
Scheme 2.18:
The equilibrium between the aldehyde and the diol functionality o f  (3-amido aldehydes.
H
u V  H 9  H K  >0H
H3CA
(108)
R = CHgCgHg
Scheme 2.19: The formation o f  the hemithioacetal adduct between papain 
and acetyl phenylalanyl glycinal (108).
The hemithioacetal adduct between papain and [l-^^C]-acetyl phenylalanyl glycinal (109) 
was observed from ^^C-NMR spectroscopy of a mixture of [l-^^C]-acetyl phenylalanyl 
glycinal (109) and papain (both inhibitor and proteinase were at a final concentration of 
70 mmol dm’^ ). When the two solutions were mixed, the ^^C-NMR spectrum of the 
^^C-labelled aldehyde (109) showed the presence of a major new signal at 74.9 ppm and the 
hydrate signal at 88.2 ppm and the aldehyde signal at 200.9 ppm had disappeared. The new 
resonance at 74.9 ppm was assigned as a hemithioacetal adduct, formed from papain and the 
aldehyde. The asymmetric carbon signal of the hemithioacetal formed from acetaldehyde
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and 1-mercaptoethanol occurs at 73.27 ppm, which is in close agreement to the new signal 
(74.9 ppm) observed when papain and [ l - ‘^ C]-acetyl-phenylalanyl glycinal (109) are mixed. 
The 13.3 ppm shift is too large to be accounted for by the diol form of [l-^^C]-acetyl 
phenylalanyl glycinal (109) binding to papain instead of hemithioacetal formation.
A methyl ketone can also inhibit a cysteine proteinase in a similar manner to an aldehyde 
by forming a hemithioketal adduct. The methyl ketone does not usually bind as well as the 
aldehyde and a 100 fold fall in Ki is usually observed for the methyl ketone compared to the 
aldehyde. The electron donating capacity of the methyl group in the case of the methyl 
ketone reduces the electrophilicity of the carbonyl carbon compared to the aldehyde. So the 
thiol nucleophile does not attack the ketone carbonyl carbon as readily as the aldehyde 
carbonyl carbon. Therefore the equilibrium constant for the formation of the tetrahedral 
intermediate is smaller for the methylketone than for the aldehyde.
l-((2R)“phenylalanyl (2 S)-phenylalanyl (2S)-arganyl)-chloromethane (110) irreversibly 
inhibits cathepsin B (beef spleen) ([I] = 2.5 nmol dm '\ t% = 11.5 min).^^  ^ There are two 
possible mechanisms for the inactivation (Scheme 2.20).
p A A c i  R - X . /S  + Clr
f  II iv.
R. .0
4- Cl
— A
s  ‘ ^I R = {2R)-Phe-{2S)-Phe-(2S)-NHG{CH2CH20H2NHC{NH)NH2)H
Scheme 2.20; The possible mechanisms for the inactivation o f a cysteine proteinase
by a chloromethyl ketone.
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In the first mechanism the thiolate group is attacked directly by the chloromethyl group to 
give the acylated proteinase (step i, Scheme 2.20). In the second mechanism the thiolate 
group attacks the carbonyl carbon and forms a tetrahedral intermediate (step ii, Scheme
2.20). The sulphur then displaces chloride ion to give a sulphonium ion (step iii) which 
rearranges to form the acylated proteinase (step iv).
At the present time these possibilities have not been distinguished. The second 
mechanism however, is more attractive as the proteinase treats the chloromethylketone as a 
substrate up to the inadvertent formation of the sulphonium ion.^^^
The dimethyl acetal functionality may have the capacity to mimic the amide bond, as one 
of the methoxy groups could replace the carbonyl group in the substrate and the other 
methoxy group could replace the nitrogen of the amide bond of the substrate (Fig. 2.10).
\  \
H O u  H O H
CHg H
Fig. 2.10: The possible binding interactions o f  the proteinase 
with: a) the dimethyl acetal functionality and b) the amide functionality.
It may also be possible for carbon-carbon double bonds to mimic the amide bond and bind 
in the Pi carbonyl binding pocket on the proteinase. Any proton donor present to polarise the 
carbonyl bond of the amide bond to be cleaved may also be able to polarise the 
carbon-carbon double bond (Fig. 2.11).
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a) b) C)
Fig. 2.11: The possible interactions o f  an alkene with the active site o f  a proteinase; 
a) alkene; h) alkene in the active site and c) the amide bond in the active site.
The aldehyde, methyl ketones, dimethyl acetal and alkene functionalities were included 
into the substrate recognition sequence of the adenovirus proteinase (Fig. 2.12), to give a 
series of potential inhibitors that would probe the electronic enviroment of the Pi-Pi’ binding 
pocket of the proteinase.
\  H O
H O  Me H H
Compound R X
111 H CHO
112 Cbz CHO
113 t-Boc CH(0Me>2
114 Cbz CH(0Me)2
115 Cbz HC=CH2
116 Cbz COMe
117 Cbz COCH2CI
118 Cbz MeC=CH2
Fig 2.12: The aldehyde, methyl ketones, dimethyl acetal and alkene potential inhibitors.
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2 . 1 . 4 . 0  T h e  s y n t h e s i s  o f  t h e  a l d e h y d e  m e t h y l - k e t o n e s ,  d i m e t h y l a c e t a l  a n d  
a l k e n i c  p o t e n t i a l  i n h i b i t o r s
(2S)-Leucyl (2S)-alanyl glycyl aminoacetaldehyde (111) and carbobenzyloxy-(2S)-leucyl 
(2S)-alanyl glycyl amino acetaldehyde (112) (Fig. 2.15) were initially prepared from the 
acidic hydrolysis of t-butoxycarbonyl-(2S)-Ieucyl (2S)-alanyl glycyl amino acetaldehyde 
dimethyl acetal (113) and carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl amino acetaldehyde 
dimethyl acetal (114) respectively. However these methods failed due to polymerisation and 
dimérisation respectively (Section 2.1.4.0.0). Ozonolysis o f carbobenzyloxy-(2S)-leucyl 
(2S)-alanyl glycyl 1-amino prop-2-ene (115) proved to be the successful method of 
preparation of Cbz-Leu-Ala-Gly amino acetaldehyde (112) (Section 2.1.4.0.2).
Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl 3-aminopropanone (116) and 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl 3 -amino-1 -chloropropanone (117) were 
initially prepared from various diazoketones (Section 2.1.4.0.1) but these also failed due to 
polymerisation. Again, ozonolysis of carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl 1-amino
2-methyl prop-2-ene (118) proved to be the successful method of preparation of Cbz-Leu- 
Ala-Gly 3-amino propan-2-one (116) (Section 2.1.4.0.2).
2 . 1 . 4 . 0 . 0  T h e  u n s u c e s s f u l  s y n t h e s e s  o f  t e t r a p e p t i d e  a l d e h y d e s
t-Butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycyl aminoacetaldehyde dimethyl acetal (113) 
was prepared as outlined below: Cbz-glycine (34) and aminoacetaldehyde dimethyl acetal 
(119) were coupled using the mixed anhydride procedure^^ to give carbobenzyloxy-glycyl- 
aminoacetaldehyde dimethyl acetal (120) in 88% yield (Found: [M + H]^ 163.1083 
CfiHisNaOs requires 163.1083) (Scheme 2.21). Hydrogenolysis of the 
Cbz-Gly-aminoacetaldehyde dimethyl acetal (120) for 3 hours gave 
glycyl-aminoacetaldehyde dimethyl acetal (121) and this was coupled to t-Boc-Leu-Ala (43)
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(Section 2.1.0.0.1) using the mixed anhydride method^" to give t-butoxycarbonyl-(2S)-leucyI 
(2S)-alanyl glycyl aminoacetaldehyde dimethyl acetal (113) in 83% yield after 
recrystallisation from methanol / ether (M.p. 156-158 C) (Scheme 2.21). Carbobenzyloxy- 
(2S)-leucyl (2S)-alanyl glycyl aminoacetaldehyde dimethyl acetal (114) was similarly 
prepared from Cbz-Leu-Ala (29) (Section 2.1.0.0.0) and Gly-aminoacetaldehyde dimethyl 
acetal (121) in 75% yield after recrystallisation from methanol / ether (M.p. 149-151°C) 
(Scheme 2.18). The assigned structures of t-Boc-Leu-Ala-Gly-aminoacetaldehyde dimethyl 
acetal (113) and Cbz-Leu-Ala-Gly-aminoacetaldehyde dimethyl acetal (114) were confirmed 
by ^^C-NMR and IR spectroscopy, microanalysis and by their accurate mass and mass 
fragmentation patterns.
' v n r^  H O
(34)
iv.-v.
H OCH3
H O
(121)
M e.
H O  H O C H 3
"0 CH3
H O  Me H H
Î NMM i-BCF in THF a t -15°G , 5 min; ii. am inoacetaidehyde (119) in THF at -15°C , 5 min 
X  r.t., 2  h ours -»  (120). iii. Hg P d  \  0  3  hours. R = C(CH3)g; iv. t-Boc-Leu-Aia (43), NMM. 
i-BCF in THF a t -15°C ; v . T h en  (121) 5  min -> r.t., 2  hours (113). R = CHgCgHg; 
iv.Cbz-Leu-Aia (29), NMM, I-BCF in THF a t -15°C; v .T h e n  (121) 5  m in ->  r.t., 2  hours 
-^ (1 1 4 ) .
Scheme 2.21; The preparation o f the Cbz- and t-Boc protected tetrapeptide dimethyl
acetals.
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Originally, preparation of (2S)-leucyl-(2S)-alanyl-glycyl-aminoacetaldehyde (111) was 
attempted by the acid catalysed hydrolysis of the urethane and dimethyl acetal moieties of 
t-Boc-LeU“Ala-Gly-aminoacetaldehyde dimethyl acetal (112) in aqueous methanol. However 
only polymeric material was isolated as determined by and ^^C-NMR spectroscopy. It 
appeared that the aldehyde and amino functionalities had condensed (Scheme 2.22).
Me 
M e—(
\  H O H O
HgN- Y  X
O Me H Y M \  o Me H H O
A
H+(111)
( + H'^  transfer)
Me 
M e— (
Me
M e—(\  f H O
N
0  Me H H
+  o  Me H H 
H
(-HgO,  -H+)
HoN
( O Me' H H O
O Me H H O
Polymer
Scheme 2.22: The self-condensation o f the unprotected aldehyde.
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If the free amino group of Leu-Ala-Gly-aminoacetaldehyde (111) was N-protected the 
polymerisation problem may be avoided so Cbz-(2S)-Ieucyl (2S)-alanyI glycyl 
aminoacetaldehyde dimethylacetal (112) was treated with hydrochloric acid in methanol. 
However only impure N, N ’-di(carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl)-2, 4-diamino- 
but-2-enal (122), as determined by ^H- and ^^C-NMR spectroscopy and low resolution mass 
spectrometry, was isolated. Condensation had probably occured by the acid catalysed 
énolisation of the aldehyde moieties (Scheme 2.23).
H P Me
°  A H MS g
,C bz
(112)
(112) (+ transfer)
O H H Me p  H
H P Me
H O
Me
n  Ù II Me
-HgO
-H+
C bz
MeC bz
Me
Me
Me (122)
Scheme 2.23 : The condensation o f the Cbz-protected aldehyde.
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Pure N, N ’-*di(carbobenzyloxy-(2S)-leucyI (2S)-alanyl glycyI)-2, 4-diamino-but-2-enal (122) 
was prepared from the Cbz-Leu-Ala-Gly-aminoacetaldehyde dimethyl acetal (114), 
trimethylsilyl bromide and a propene acid trap in dry tetrahydrofuran in 45% yield after 
recrystallisation from methanol ether. The product displayed the correct mass, (FAB) 891 [M 
+ H]^ 100%). Trimethylsilyl iodide^^^ also gave N, N ’-di(carbobenzyloxy-(2S)-leucyl (2S)- 
alanyl glycyl)-2, 4-diamino-but-2-enal (122) under similar conditions but the product was 
contaminated with iodine which formed from the decomposition of the trimethylsilyliodide 
under the reaction conditions used.
It is noted that the dimer, N, N ’-di(carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl)-2, 4- 
diamino-but-2-enal (122) might still have the ability to interact with the proteinase either as 
for an aldehyde or as a Michael acceptor (Section 2.2.0).
2.1.4.0,1 The attempted syntheses of tetrapeptide ketones
Initially the mixed anhydride^^ of Cbz-Leu-Ala-Gly-Gly (76) was treated with 
diazomethane^^"^ to give Cbz-(2S)-leucyl (2S)-alanyl glycyl 1-amino 3-diazo propanone (123) 
(Fig. 2.13).
Me.
o
Me
(123) N -
Fig. 2.13: Cbz-Leu-Ala-Gly-1-amino 3-diazo propanone (123).
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The diazoketone (123) was then treated with excess hydroiodic acid to yield 
carbobenzyloxy-(2S)-Ieucyi (2S)-alanyl glycyi 3-aminopropanone (116). However, a 
complex mixture of products resulted as determined by ^H- and ^^C-NMR spectroscopy. It 
was believed that the formation of the impurities might be avoided by preparing 
1-aminopropanone hydrochloride (124) and 1-amino 3-chloro-propanone hydrochloride
(125) directly, as these compounds contain fewer ftmctional groups to promote side 
reactions. 1-Aminopropanone hydrochloride (124) and 1-amino 3-chloro-propanone 
hydrochloride (125) could then be coupled to Cbz-Leu-Ala-Gly (27) to give 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyi 3-amino propanone (116) and 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyi 3-amino 1-chloro propanone (117) 
respectively.
1-Aminopropanone hydrochloride (124) was prepared as described below; The mixed 
anhydride of TFA-glycine (101) and diazomethane were reacted to give trifluoroacetyl-1- 
amino- 3-diazo propanone (126) (umax 2970 and 2255 cm“^ CHN2) (Scheme 2.24). The 
diazoketone (126) was then directly treated with excess hydroiodic acid to give 
trifluoroacetyl-1-aminopropanone (127) in 56% yield (M.p. 57-58°C). TFA-deprotection of 
trifluoroacetyl-1-aminopropanone (127) in refluxing hydrochloric acid for 5 hours gave 
1-amino propanone hydrochloride (124) in 91% yield (Found: [M + H - HCl]^ 74,0601. 
CsHgNO requires 74.0606). The diazoketone (126) was also treated with hydrochloric acid 
to give trifluoroacetyl-1-amino-3-cliloro-propanone (128) in 57% yield (M.p. 53-55°C) 
(Scheme 2.24). TFA deprotection of trifluoroacetyl-1-amino-3-chloro-propanone (128) gave
1-amino-3-chloro-propanone hydrochloride (125). The chloromethylketone (125) was rather 
impure as judged by ^H- and ^^C-NMR spectroscopy and further reaction with 
Cbz-Leu-Ala-Gly (27) was not attempted.
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O
H O 
(101)
FaC
OA H
O- N
FgC
oA H N, “N
(126)
O
F a C - ^ N - ^  
H O 
(127)
CH,
IV .
O
H O 
(128)
HCI X = H (124) 
|!| ^  = 01(125)
R e a g e n ts
i. i-BCF, NMM in THF at -15°C, 5  min, th en lO  CHgNg in e th er exciuded from iight 
a t -15°C , 5  min r.t., 2 h o u r s . ii, 1 .2 HI in d ich lorom ethane exc luded from th e  
light, 2  h ours , iii. HCI in d ich lorom ethane exciuded  from th e  iight, 2 hours. Iv.
5M HCI reflux, 2  hours.
Scheme 2.24: The preparation o f 1-amino propanone hydrochloride (124) and
1-amino 3-chloro propanone hydrochloiide (125).
The difference in reactivity of hydrochloric acid and hydroiodic acid can be explained by 
the difference in charge distribution about the carbon-halogen bond. In the case of the chloro 
compound, chlorine is more electronegative than carbon so a. partial bond polarisation exists 
with a partial negative charge residing on the chloride o f the carbon-chloride bond. Therefore 
nucleophilic attack at the chloride is rather unlikely. For the iodo compound, iodine is less 
electronegative than carbon so a partial positive charge resides on the iodide of the 
carbon-iodide bond. This allows nucleophilic attack of the iodine of the carbon-iodide bond 
by another iodide from the solution giving the methyl ketone (Scheme 2.25 and 2.26).
2.1 The synthesis o f  reversible inhibitors ________________
cr
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-Ng II
   (128)
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Scheme 2.25; The formation o f a chloromethyl ketone.
FoC-^  N.A A
H+
Â , ^ O H a  ________ .  F a C ^ N ^ = " '
I I  H OFaC" 'NH O 'H
Scheme 2.26: The formation o f a methyl ketone.
The mixed anhydride^^ of Cbz-Leu-Ala-Gly (27) (Section 2.1.0.0.0) was treated with 
pre-neutralised 1-aminopropanone hydrochloride (124) but only polymer and the tripeptide 
were isolated as determined by TLC, ^H- and ^^C-NMR spectroscopy.
The preparation of carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyi 3-amino propanone 
(116) was also attempted using Cbz-(2S)-leucyl (2S)-alanyl glycyi glycyi- N- 0 ’- 
dimethylhydroxylamide (23), but even using four equivalents of methyl magnesium bromide
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in THF and refluxing for four hours gave no reaction. The N-, O’-dimethyl hydroxylamide 
(Weinreb amide) group allows only one equivalent of Grignard reagent to attack the amide 
carbonyl as the magnesium ion is co-ordinated to the methoxy group on the amide as well as 
the oxyanion forming a stable complex (Fig. 2.14).^^^
M s o  Mg^
Me
Fig 2.14: The Weinreb amide complex foim edwith one equivalent to Grignard reagent
2 . 1 . 4 . 0 . 2  T h e  s u c c e s s f u l  s y n t h e s i s  o f  t h e  t e t r a p e p t i d e  a l d e h y d e  a n d  k e t o n e
The carboxylic acid of carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycine (27) (section
2 .1.0.0.1) was activated with TBTU^“  in THF at 20°C. Reaction of the activated ester with 
allylamine and diisopropylethylamine overnight gave N-(carbobenzyloxy-(2S)-leucyl 
(2S)-alanyl glycyi)-1-amino prop-2-ene (115) in 40% yield after recrystallisation fi'om 
acetone ether (M.p. 114°C). N-(Carbobenzyloxy-(2S)-Ieucyl (2S)-aianyl glycyi)-1-amino
2-methyl prop-2-ene (117) was similarly prepared from carbobenzyloxy-Leu-Ala-Gly (27) 
(Section 2 .1.0.0.0) and 2-methyl allylamine in 32% yield after recrystallisation from acetone / 
ether (M.p. 148°C). The structures of the allyl amides (115) and (117) were confirmed by 
^H-NMR, ^^C-NMR, IR spectroscopy, microanalysis and mass spectrometry.
Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyi aminoacetaldehyde (112) was prepared by 
ozonolysis^^^ of Cbz-Leu-Ala-Gly-l-aminoprop-2-ene (115) in 70% yield (m/z 3%, 
[M]^ 452). It should be noted that the aldehyde (112) exists primarily in the hydrated, diol
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(129) form"^ (Fig. 2.15). Carbobenzyloxy-(2S)-Ieucyl (2S)-aIanyI glycyi l-amino-2-methyl 
propanone (116) was similarly prepared from N-(Cbz-Leu-Ala-Gly)-1-amino 2-methyl 
prop-2-ene (118) in 88% yield (Found: [M + 449.2406. C22H33N4O6 requires 449.2400).
The structures of the aldehyde (112) and methyl ketone (116) were confirmed 
^^C-NMR and IR spectroscopy, microanalysis and low resolution mass spectrometry.
MeMe.
(129)
Fig. 2.15: The hydrated diol form  (129) o f  Chz-Leu-Ala-Gly-aminoacetaldehyde (112).
2.2 The synthesis of Irreversible inhibitors
Irreversible inhibitors act by binding tightly to the enzyme or one o f the intermediates, 
preventing catalytic activity. The binding is usually covalent and stoicheometric. See 
Introduction, Section 1.2.3.2.
2.2.0 Rationale for the design o f  potential inhibitors containing 
bromide and Michael acceptor moieties
It was expected that N-(Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl)-2-bromo 
ethylamine (130) might have the capacity to mimic a typical substrate for the adenovirus 
proteinase. The bromide might interact with a proton donor present in the Pi-Pi’ amide 
nitrogen binding pocket (Scheme 2.27). I f  such an interaction was possible, the thiolate 
present in the proteinase’s active site might nucleophilically displace the bromide fiom the 
carbon-bromide bond. This could lead to irreversible alkylation of the proteinase (Scheme
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2.27). It is probably unlikely that the bromide could mimic the carbonyl group of the amide 
and bind in the Pi-Pi’ amide carbonyl binding pocket as the carbon-bromide bond is too 
long. The Van der Waal’s radius for bromine is very large (0.91 nm) compared to oxygen in 
an amide bond (0.15 nm). The average carbon-bromide bond length is 0.194 nm compared to 
the average carbon-oxygen bond length of 0.123 nm.
\  I
a) 1  ]• "
(
Scheme 2.27; The tetrapeptide bromide’spossible interaction with the proteinase; 
a) substrate; b) tetrapeptide bromide.
The unsaturated ester, N-(acetyl-(2S)-phenylalanyl 2-carboxymethyl 1-amino but-2-ene 
(131) is a competitive irreversible inhibitor of papain (kz =1.82 mol dm'^ s'^ ).^^  ^ , N-(acetyl- 
Phe-1 -carboxymethyl 2-amino but-2-ene (131) slowly and irreversibly allcylates the active 
site thiolate of papain in a Michael fashion (Scheme 2.28 on page 91).
The unsaturated ester functionality of (131) was included in the substrate recognition 
sequence of the adenovirus proteinase to give 0-(carboben2yloxy-(2S)-leucyl (2S)-alanyl 
glycyi-l-carboxymethyl-2-hydroxybut-2-ene (132) (Fig. 2.16). It was expected that 
0-(Cbz-Leu-Ala-Gly)-l-carboxymethyl-2-hydroxybut-2-ene (132) might inhibit the
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adenovirus proteinase in a similar manner to N-(acetyI-Phe-l-carboxymethyl,2-aminobut-2- 
ene (131) inhibiting papain.
.+
H ,oA X
H O
M  1 Me
.H
H O
Scheme 2.28: The irreversible alkylation o f papain by the Michael acceptor (131).
The unsaturated ester functionality of (131) was included in the substrate recognition 
sequence o f the adenovirus proteinase to give 0-(carbobenzyIoxy-(2S)-leucyl (2S)-alanyl 
glycyi-l-carboxymethyl-2-hydroxybut-2-ene (132) (Fig. 2.16). It was expected that
0-(Cbz-Leu-Ala-Gly-1 -carboxymethyl-2-hydroxybut-2-ene (132) might inhibit the
adenovirus proteinase in a similar manner to N-(acetyl-Phe)-1 -carboxymethyl,2-aminobut-2- 
ene (131) inhibiting papain.
H 0 Me H H
( 1 3 2 )
Fig. 2.16: 0-(Cbz-Leu-Ala-Gly)-l-carboxymethyly2-hydroxybut-2-ene (132).
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2.2M.0 The synthesis of bromide and Michaei acceptor containing 
inhibitors
The carboxylic acid of Cbz-Leu-Ala-Gly (27) (section 2.1.0.0.1) was activated with 
TBTU^^^ in THF at 20®C. Reaction of the activated ester with the 2-bromo-ethylamine and 
diisopropylethylamine overnight to give N-(carbobenzyloxy-(2S)-leucyl (2S)-alanyI glycyl)-
2-bromoethylamine (130) as the monohydrate in 70% yield after recrystallisation from 
acetone / ether (M.p. 107°C). 0-(Carbobenzyloxy-(2S)-leucyl-(2S)-alanyl-glycyl),
l-carboxymethyl-4-hydroxybut-2-ene (132) was prepared from Cbz-Leu-Ala-Gly (27) 
(Section 2.1.0.0.1), methyl y-bromocrotonate and sodium hydrogen carbonate in dimethyl 
formamide^^* in 35% yield after chromatography on silica eluting with dichloromethane, then 
1% methanol in dichloromethane through to 5% methanol in dichloromethane and 
recrystallisation from methanol / ether (M.p. 89°C). The structures of the bromide (130) and 
the Michael acceptor (132) were confirmed by H-NMR, ^^C-NMR, IR spectroscopy, 
microanalysis and mass spectrometry.
2.2.1 Rationale for the epoxysuccinate based potential inhibitors
E-64 (pM-(RR-3-/râr?75-carboxyoxirane-2-carbonyl)-(2S)-leucyl]-aniido(4-guanido) butane 
(17) (Fig. 2.17) was isolated^^^ from cultures o f Aspergillus jamonicus and is a potent highly 
selective irreversible inhibitor of cysteine proteinases^^^ (rate constant for the inactivation of 
papain 6.38 x 10  ^ mol dm'^ s'^ ).^ "^ ® The (SS)-epoxy succinate analogue of E-64 (133) (Fig. 
2.17) is also a weaker irreversible inhibitor of cysteine proteinases (rate constant for the 
inactivation of papain 6.09 x lO'* mol dm'^ s'^ ).^^  ^(RR)-E-64 (17) does not all<ylate free thiols 
in solution at physiological pH^^  ^and (RR)-E-64 (17) does not inhibit the adenovirus type 2 
p ro te in a se .I t should be noted that the peptide backbones of E-64 (17) and the derivatives 
of E-64 run from right to left rather than the usual peptide direction of left to right.
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HoN. .N
17
H H. Jl, m
HoN' "N
1^ ®- Me
! X "  J l  H (SS)
O H H O II(133)
Fig. 2.17: The (RR) isomer and the (SS) isomer o f E-64.
It was suggested that the nucleophilic thiolate of papain became allcylated by attacldng the 
epoxysuccinyl moiety of (RR)-E-64 (17). '^^  ^ However, the nucleophilic cysteine residue 
(Cys-25 in papain) could become alkylated by attacking either C-2 or C-3 of the epoxide 
ring. The mechanism of inactivation of papain by (RR)-E-64 (17) was determined from 
^^C-NMR spectroscopy of a mixture of papain and [3-^^C]-Ep-475 ([3-^^C]-pSr-(RR-3-^ra/25- 
carboxyoxirane-2-carbonyl)-(2S)-leucyl]-amido(3-methyl) butane) (134) (Fig. 2.18), a 
closely related derivative o f (RR)-E-64 (17).
^®C-label
" o
Ep-475 (134)
Fig. 2.18: [3J^CJ-Ep-475 (134).
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When [3-^^C]-Ep-475 (134) was added to papain (both the concetrations of papain and 
Ep”475 (134) were at 1.7 mmol dm'^), a new signal was observed at 76.6 ppm. This 
corresponded with the disappearence of the C-3 epoxide signal at 52.5 ppm.
If [3-^^C]-Ep"475 (134) was treated with benzyl mercaptan at pH 10, two products were 
observed, one corresponding to the attack o f benzyl mercaptan anion at C-2 (135) and one 
from the attack of benzyl mercaptan anion at C-3 (136) (Fig. 2.24). The ^^ C signal of C-3 
appeared at 53 ppm when the benzyl mercaptan anion has attacked the C-3 carbon to give a 
P-thioamide at C-3 (compound (135)) and the ^^ C signal of C-3 appears at 73 ppm when the 
benzyl mercaptan anion has attacked the C-2 carbon to give a P-hydroxyamide at C-3 
(compound (136)).
N(135) I
= ' ‘^ C-label
(136) H {  H ^  OH
Fig. 2.19: The two possible products from benzyl mecaptan anion 
attack on [3-^C]-Ep~475 (134) ; a) C-3 attack and b) C-2 attack.
By comparison of the new ^^ C signal observed when papain nucleophilically attacked 
[3-^^C]-Ep-475 (134) with the ^^ C signals observed when benzylmercaptan attacks 
[3-^^C]-Ep-475 (134), it was concluded that papain attacked [3-^^C]-Ep-475 (134) at the 
C-2 carbon of the epoxide (Scheme 2.29). '^^^
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COgH
Ep-475 (134)
^^C-label
P H H. ?
Scheme 2.29: The aïîcylation o f  papain by [ 3 -^C]-Ep-475 (134)
If the structure of E-64 (17) could be modified to fit into the adenovirus proteinase’s 
active site, a potentially very potent inhibitor for the adenovirus proteinase could be 
produced. Our first modifications of the E-64 (17) structure were to include a substrate 
recognition sequence for the adenovirus proteinase and then simplify the trans epoxide such 
that the peptide backbone could be conserved. These considerations give (±)-0- 
(carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyi)-!-hydroxy-2,3-oxirane propane (137) (Fig.
2.20) as a potential inhibitor. The stereochemistry of the adenovirus proteinase’s active site is 
not known, so all isomers were considered as being worth synthesizing.
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Me—(
Me 
Me—(
H O M® H H O H O
P4 P3 P2 P1 PT 
peptide back bone
Fig. 2.20: a) E-64 (17); b) (±)-0-(Cbz-Leu-Ala-Gly)-glycidol (137)
and c) substrate.
2,2,1 M The attempted synthesis of (±)-0-‘(Cbz-Leu~Ala-Gly)-glycidol
(137)
Numerous attempts to couple Cbz-Leu-Ala-Gly (27) (Section 2.1.0.0.1) to (±)-glycidol 
via the mixed anhydride/^ dicyclohexylcarbodiimide / p-dimethylaminopyridine^'^^ and 
trimethylsilylchloride / activated ester procedures failed, giving a complex mixture
of products, including Cbz-Leu-Ala-Gly (27), the ring opened epoxide and (±)-glycidol. The 
acid chloride^® and TBTU^^^ activated ester couplings were not attempted as any 
hydrochloric acid or hydroxybenzotriazole produced in situ might cleave the epoxide
•  ^ 144moiety.
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2,2.1,1 Rationale for the N~protected N-((2S)-leucyl (2S)-alanyl)- A/- 
(3~trans-carboxyoxirane~2'-methoxycarbonyiybutane 
ethylene diamines
The E-64 (17) structure was further modified by reintroducing the ^aMJ-epoxysuccinyl 
moiety and changing the position of the P2-P1 amide link by one C-atom towards the P ’ 
direction to give N-(carbobenzyloxy-(2S)-leucyl (2S)-alanyl)- N ’-(3-trans-carboxyoxirane-2- 
methoxycarbonyl)-butane ethylene diamine (138) and N-(t-butoxycarbonyl-(2S)-leucyl (2S)- 
alanyl)- N ’-(3-trans-carboxyoxirane-2-methoxycarbonyl)-butane ethylene diamine (139) 
(Scheme 2.30).
The tetrapeptide epoxides (138) and (139) were disconnected to give N-(carbobenzyloxy- 
(2S)-leucyl (2S)-alanyl)-ethylenediamine (140) and methyl (2R,3R)-2,3 epoxysuccinate (141) 
and N-(t-butoxycarbonyl-(2S)-leucyl (2S)-alanyl)-ethylenediamine (142) and methyl (2R, 
3R)-2, 3 epoxysuccinate (141), respectively (Scheme 2.30).
Me 
Me—(
N'
H O Me H H
OMe
Me 
Me—(
R = Bz (138); 
R = t-Bu (139).
o  u \  H o
- A W fH o  Me H H
R = Bz(141 ); 
R = t-Bu (142).
HO, OMe
O O H
(141)
Scheme 2.30: The disconnection o f epoxides (138) and (139).
2.2 The synthesis o f  irreversible inhibitors _________ _ ______________ _
2 . 2 . 1 . 1 . 0  T h e  a t t e m p t e d  s y n t h e s i s  o f  N - ( C b Z “L e u - A l a ) - e t h y l e n e  d i a m i n e  ( 1 4 0 )
The first attempted synthesis of N-(carbobenzyloxy-(2S)-Ieucyl (2S)-aianyi)- 
ethylenediamine (140) was carried out using diethyl phosphonate protection. 
Aminoacetonitrile hydrochloride (85) was N-protected with diethyl phosphonate (144)^ ^^  ^ to 
give diethyl aminoacetonitrile phosphonate (143) in 98% yield (m/z (Cl) 193 [M + H ]\ 
100%) (Scheme 2.31).
+ i. or ii. H
C r H g N ^ C N  -
H(85)
R = OEt(146); 
R = Ph (149).
H
H o M e  H H
R e a g e n ts
I. R = OEt; CCI4, H PO (O E t)2 (144) EtgN, 0°C, 2 hours -> (143). ii. R = Ph; 
P h2P 0 CI, NMM in d ich lo rom ethane , 0“C, 2  hours -> (143). iii. Ha, Pd /  G in  
MeOH, R = OEt; 3  h o u rs  ->  (146), R = Ph; 2  d ays -> (149). iv. Cbz-LA, 
NMM, I-BCF In THF a t -15°C , 5 min. (146) o r (149) in THF at - 1 5 ° 0 ,5 min 
r.t., 2 hou rs .
Scheme 2.31: The attempted preparation o f N-(Cbz-Leu-Ala)-ethylene diamine (140).
The m e c h a n i s m f o r  the formation of diethyl aminoacetonitrile phosphonate (143) is 
shown in Scheme 2.32. The diethyl phosphite (144) was deprotonated by triethylamine and 
nucleophilically attacked by carbon tetrachloride to give triethylamine hydrochloride and a 
trichloromethyl phosphonate (145). The amino group of aminoacetonitrile displaces the 
trichloromethyl group from the trichloromethyl phosphonate (145) which after proton 
exchange gives chloroform and diethyl aminoacetonitrile phosphonate (143).
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0 ■ o " +1 I NEtgH
(EtO)2P<^    (EtO)2Pv^
(144) NEta 4 -ClgCAci
O- (145) (143)
£ h (B0)2pANC N ON{!, proton transfer ^
NEt3.HCI CHCIg
Scheme 2.32: The mechanism o f  the formation o f  aminoacetonitrile phosphonate (143)
Reduction of the nitrile group of diethyl aminoacetonitrile phosphonate (143) with 
hydrogen and palladium dispersed in charcoal gave N-(diethyl phosphonate) ethylenediamine 
(146) in 90% yield (m/z (Cl) 197 [M + H]^, 100%). The mixed anhydride of Cbz-Leu-Ala 
(29) (Section 2 .1.0 .0 .0) was treated with N-(diethyl phosphonate) ethylenediamine (146) to 
give N-(Carbobenzyloxy-(2S)-Leucyl (2S)-Alanyl)- N ’-(diethylphosphonate)-ethylene 
diamine (147). However, a complex mixture o f products resulted as observed by ^H- and 
^^C-NMR spectroscopy. It appeared that aminolysis of the ethoxy groups in the diethyl 
phosphonate protecting group might have occurred.
It was hoped that replacing the offending diethyl phosphonate protecting group with the 
diphenyl phosphine oxide protecting group might prevent the aminolysis. N-(Diphenyl 
phospliine oxide)-aminoacetonitrile (148) was prepared from aminoacetonitrile hydrochloride 
(2.59), NMM and diphenylphosphoryl chloride in THF at 0°C in 52% yield after 
recrystallisation from methanol / ether (Found: [M + H]^ 257.0838. C14H 13N2OP requires 
257.0844) (Scheme 2.32). Hydrogenation of N-(diphenyl phosphine oxide)-aminoacetonitrile
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(148) for 2 days gave N-(diphenyl phosphine oxide)-ethylenediamine (149) in 98% yield 
(M.p. 58-59°C). Unfortunately the reaction of the mixed anhydride of Cbz-Leu-Ala (29) 
(Section 2.1.0.0.0) with N-(diphenyl phosphine oxide)-ethylenediamine (149) did not give 
N-(carbobenzyloxy-(2S)-leucyl (2S)-alanyl)-,N’-(diphenylphosphine oxide)-ethylenediamine 
(150), but a complex mixture o f products as observed by ^H- and ^^C-NMR spectroscopy.
The third attempted synthesis of N-(Cbz-Leu-Ala)-ethylenediamine (140) involved the 
coupling of N-trityl-ethylenediamine (151) to Cbz-Leu-Ala (29) (Section 2.1.0.0.0). It was 
hoped that N-trityl-ethylenediamine (151) could be prepared from N-trityl-glycyl amide 
(154) as described below; N-trityl-glycine (152) was prepared from glycine, 
trimethylsilylchloride, NMM and trityl chloride (trityl = triphenylmethyl) in 60% yield after 
recrystallisation from methanol (M.p. 179°C, lit.,^ '^  ^ 178-179°C) (Scheme 2.33). Previous 
methods '^^^ gave mixtures of products as determined by TLC and and ^^C-NMR 
spectroscopy. N-trityl-glycine (152) was treated with diazomethane '^^* to give methyl 
N-trityl-glycinate (153) in 98% yield after recrystallisation from methanol /  ether (M.p. 
99°C) (Scheme 2.33). Treatment of methyl N-trityl-glycinate (153) with sodamide in liquid 
ammonia '^^^ gave N-trityl-glycinamide (154) in 70% yield after recrystallisation from water 
(M.p. 179°C) (Scheme 2.33).
The reduction of N-trityl-glycinamide (154) proved to be very problematic; sodium 
borohydride / cobalt (II) chloride (hydrated), sodium acylborohydride^^^ and 
borontrihydride.THF complex^^^ all caused over reduction of the trityl group as judged by 
^H- and ^^C-NMR spectroscopy. Lithium aluminium hydride^^  ^ smoothly reduced the amide 
moiety to N-trityl ethanolamine (155) as determined by mass spectrometry, ^H- and 
^^C-NMR spectroscopy (Scheme 2.33).
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H O  II- H O  '''•
( 1 5 2 )
V. P h aC ^^^^O H
H O  
(154)
H
(155)
Reagents
i. 2.2 TMS-CI, 2.2 NMM, 0°C, 10 min -> refiux, 15 min. Ii.
NMM, trityl-CI, reflux, 2  hours. Then MeOH 1 hour. iii.
CH2N2, MeOH, 0°C, 2  hours -» (153). iv. NaNH2, llq. NHi.
-78°C,1 hour. v. UAIH4, 4 hours.
Scheme 2.33: The attempted preparation o f  N-trityl-ethylenediamine (151).
2 . 2 . 1 . 1 . 1  T h e  s y n t h e s i s  o f  t h e  e p o x y s u c c i n y l  m o n o a l k y l  e s t e r s
Optically pure potassium methyl (2R,3R)-erythro 2,3-epoxysuccinate (141) was also 
prepared. (2R,3R)-dimethyl tartrate was brominated with 30% hydrogen bromide in acetic 
acid to give (2R,3S) dimethyl-threo-2-acetoxy-3-bromosuccinate (156) in 32% yield (b.p. 
136°C at 1.5 mm Hg; lit.,^^  ^ 83-86°C at 0.1 mm Hg) (Scheme 2.28). The acetoxy group of 
(2R,3S)-dimethyl threo-2-acetoxy-3 -bromosuccinate (156) was hydrolysed in methanol in 
the prescence of catalytic hydrogen bromide in acetic acid to give the (2R,3S)-dimethyl threo
3-bromo-2-hydroxysuccinate (157) in 31% yield (b.p. 145°C at 1.4 mm Hg; lit.,^^  ^80-82°C 
at 0.03 mm Hg) (Scheme 2.34).
Deprotonation of the alcohol with sodium methoxide allowed the formation of (2R,3R) 
dimethyl epoxysuccinate (158) in a yield of 58% after recrystallisation from methanol (M.p. 
72°C; lit.,^ '^ '^  77-78°C) (Scheme 2.28). (2R,3R) dimethyl epoxysuccinate (158) was partially 
saponified^ '^^ to give potassium (2R,3R) methyl epoxysuccinate (141) in 94% yield (M,p. 
decomp. 148°C) (Scheme 2.34).
2.2 The synthesis o f irreversible inhibitors 102
CO2R
-O H
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COgR
(2R, 3R)
R = Me 
R = Et
ÇO2R 
OAc 
“ Br 
CO2R
(2R, 38)
R = Me (156) 
R = Et (160)
ill.
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R = Me (141) 
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R e a g e n ts
i. HBr /  HOAo, 0°C, 30  min, 2  h o u rs  r.t. ii. cat. HBr dry ROH, refiux, 
2 h o u rs , iii. N aO R , ROH, 0°C, 2  hours , iv. KOH, ROH 0°C, 2 hours.
Scheme 2.34;
The preparation o f potassium methyl (2R,3R)~erythro 2,3-epoxy succinate (141).
Potassium (2R,3R) ethyl epoxysuccinate (159) '^^ '^  (decomp. 133°C lit./'^  decomp. 159°C) 
was prepared similarly from (2R,3R) diethyl tartrate giving (2R,3S)-erythro diethyl 2- 
acetoxy-3 -bromosuccinate (160), (2R,3S)-erythro diethyl 2-hydroxy-3-bromosuccinate (161) 
and (2R,3R) ethyl epoxysuccinate (162) in yields of 50%, 72%, 75% and 44% respectively 
(Scheme 2 .34)." '
Potassium (2S,3S) ethyl epoxysuccinate (163) (Scheme 2.35) was prepared similarly from
(2S,3S) diethyl tartrate giving (2S,3R)-threo diethyl 2-acetoxy-3-bromosuccinate (164), 
(2S,3R)-threo diethyl 2-hydroxy-3-bromosuccinate (165) and (28,3S) ethyl epoxysuccinate 
(166) in yields of 45%, 79%, 84% and 73% respective ly.All  the epoxysuccinates and their 
precursors gave satisfactory ^H-NMR, ^^C-NMR, IR and low resolution mass spectrometry 
spectra.
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COgEt EtOaC* (163)
HO- HWO
OH 
COgEt H bOgK 
(2S, 3S) (SS)
Scheme 2.35; Potassium (2S, 3S) ethyl epoxy succinate (163).
A similar procedure was adopted to prepare a racemic mixture of (2R,3S) and (2S,3R) 
potassium ethyl epoxysuccinate (167) (Fig. 2.21) from (RS)-diethyl tartrate. However 
hydrolysis of the mixture of (2R,3R) and (2S,3S)-diethyl bromoacetoxysuccinate (168) 
produced only diethyl tartrate. A second procedure was also attempted, involving the 
formation of disodium czj-epoxysuccinate (169) from the sodium tungstate catalysed 
epoxidation o f maleic acid with alkaline hydrogen peroxide.
EtOgC-'Po h-'T2o
EtOgC^
H“*"
bOgK
(23,3R) (2R,3S)
Fig; 2.21; (±)-cispotassium ethyl epoxy succinate (167).
Estérification of disodium cw-epoxy succinate (169) using either an acid catalysed^^^ or a 
bromoalkyl^^* procedure failed, producing a mixture of diols as judged by ^H- and ^^C-NMR 
spectroscopy. The (2R,3S) and the (2S,3R) potassium ethyl epoxysuccinates (167) were 
probably more unstable than potassium (2S,3S) ethyl epoxysuccinate (163) and potassium 
(2R,3R) ethyl epoxysuccinate (159). The carboxyl groups are on the same face of the 
molecule for the (2R,3S) and the (2S,3R) forms so that the opposite face to the carbonyl
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2 . 2 . 1 . 1 . 2  T h e  a t t e m p t e d  s y n t h e s i s  o f  N » ( t “B o c - L e u » A l a ) - N ’- ( 2 S ,  3 S ) - [ ( 3 - t r a n s - »  
c a r b o x y o x î r a n e - 2 - m e t h o x y c a r b o n y l )  b u t a n e ]  e t h y l e n e d i a m i n e  ( 1 3 9 )
The synthesis of N-(t-Boc-Leu-AJa)-N’-(2S,3S)-[(3-trans-carboxyoxirane-2- 
methoxycarbonyl) butane] ethylenediamine (139) was attempted as follows; The carboxylic 
acid of t-Boc-Leu-Ala (43) (section 2.1.0.0.1) was activated with TBTU^^^ in THF at 20°C. 
Reaction of the activated ester with aminoacetonitrile hydrochloride (85) and 
diisopropylethylamine overnight gave t-butoxycarbonyl-(2S)-leucyl-(2S)-alanyl 
aminoacetonitrile (170) in 84% yield after recrystallisation from methanol / ether (M.p. 
134°C) (Scheme 2.36). Reduction of t-Boc-Leu-Ala-aminoacetonitrile (170) with hydrogen 
and palladium dispersed in carbon gave N-(t-butoxycarbonyl-(2S)-leucyl (2S)-alanyl)- 
ethylenediamine (142) in 98% yield (M.p. 99-102°C) (Scheme 2.36). ^H- and ^^C-NMR 
spectra showed the complete disappearence o f the nitrile group and the appearence of a 
mono acylated ethylene diamine moiety.
The final coupling of the N-(t-Boc-Leu-Ala)-ethylenediamine (142) to methyl (2R,3R)-2,
3-epoxysuccinate (141) was attempted using the mixed anhydride and the 
pentafiuorophenyl^^* activated ester methods. However, both reactions gave the ring opened 
products (171) or (172), as determined by ^H- and ^^C-NMR spectroscopy (Scheme 2.36). 
Even when three equivalents of methyl (2R,3R)-2, 3-epoxysuccinate (141) were used the 
same products resulted, indicating that the release in ring strain upon ring opening the 
epoxide is more favourable than amide formation.
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Me Me
Me
t-Boc OH
(43)
Me
(170)
Me
ii. H
R = t-Boc-LA-NHCHgCHg- (142)
:
III. H O H OH O
R ''^ y  "OMe
O OH 0
(171) (172)
R e a g e n t s
i. i-PrgEtN, TBTU, aminoacetonitrile hydrochloride (85) in THF, 12 hours.
Ii. Hg /  Pd / C in MeOH , 2 day s .  Iii. Coupling to methyl (2R, 3R) epoxysuccinate (141).
Scheme 2.36; The attempted preparation o f  N-(t-Boc-Leu-Ala)-N'-(2S,3S)- 
[(3-trans-carhoxyoxirane-2-methoxycarbonyl) butane] ethylenediamine (139).
2.2.1.2 Rationale for the N-protected 0-((2S)-Ieucyl (2S)-alanyl)- N'- 
(3-trans-carboxyoxirane-2-methoxycarbony!)-butane 
ethanolamines
It was expected that changing the P2-P1 bond from an amide to an ester bond (Scheme 
2.37) to give (2R,3R)-0-[trans-carbonyl oxiran-2-yl 3-(ethoxycarbonyl) butane] N- 
(carbobenzyloxy-(2S)-leucyl (2S)-alanyl)-ethanolamine (173) (Scheme 2.37) as the new 
target compound, might prevent the ring opening o f the epoxide moiety in section 2 .2 .1.1.2 .
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As the alcohol (174) (Scheme 2.37) required for the formation of the Pz-Pi ester bond is less 
nucleophilic than the amine (142) (Scheme 2.36) from section 2.2.1.1 which ring opened the 
epoxide moiety during the formation of N-(t-Boc-Leu-Ala)-N’-(2S,3S)-[(3-/ra7?i- 
carboxyoxirane-2-methoxycarbonyl) butane] ethylenediamine (139). (2R,3R)-0 -[/?'a«5- 
carbonyl oxiran-2-yl 3-(ethoxycarbonyl) butane] N-(carbobenzyloxy-(2S)-leucyl (2S)- 
alanyl)-ethanolamine (173) could be disconnected to give N-(carbobenzyloxy-(2S)-leucyl 
(2S)-alanyl)-ethanolamine (174) and (2R,3R) ethyl epoxysuccinate (159) (Scheme 2.37).
(2S,3S)-0 -[/7*a/?5-carbonyl oxiran-2-yl 3-(ethoxycarbonyl) butane] N-(carbobenzyloxy-(2S)- 
leucyl (2S)-alanyl)-ethanolamine (175) (Fig. 2.29) could similarly be disconnected to give N- 
(carbobenzyloxy-(2 S)-leucyl (2S)-alanyl)-ethanolamine (174) and (2S,3S) ethyl epoxy 
succinate (163).
o
Me
Me
(2S, 3S)
(175)
Me 
M e—( (2R, 3R)O
A
Me
M e - (
O u  \  H O
O Me H H 
(174)
W h
o
If OEt (173)
HO
' h tO
(159)
OEt
Scheme 2.37: Disconnection o f epoxides (173) and (175).
2.2 The synthesis o f  irreversible inhibitors     107
2 . 2 . 1 . 2 . 0  S y n t h e s i s  o f  t h e  N - p r o t e c t e d  0 - ( { 2 S ) - l e u c y l  ( 2 S ) - a l a n y l ) -  N ’- ( 3 -  
t r a n s - c a r b o x y o x i r a n e - 2 - m e t h o x y c a r b o n y l ) - b u t a n e  e t h a n o l a m i n e s
N-(Cbz-Leu-Ala)-ethanolamine (174) was prepared from the mixed anhydride of 
Cbz-Leu-Ala (29) (Section 2 .1.0.0.0) and ethanolamine in 72% yield after recrystallisation 
from acetone / ether (M.p. 140°C). The mixed anhydride^^ of (2R,3R) ethyl epoxy succinate 
(159) was reacted with N-(Cbz-Leu-Ala)-ethanolamine (174) to give (2R,3R) 0-[trans~ 
carbonyl oxiran-2-yI 3-(ethoxycarbonyl) butane] N-(carbobenzyloxy-(2S)-leucyl-(2S)- 
alanyl)-ethanolamine (173) in 41% yield after chromatography on silica eluting with ethyl 
acetate (M.p. 128°C). (2S,3S) 0-[^rara-carbonyl oxiran-2-yl 3-(ethoxycarbonyl) butane] 
N-(carbobenzyloxy-(2S)-leucyl-(2S)-alanyl)-ethanolamine (175) was prepared in a similar 
manner from (2S,3S) ethyl epoxysuccinate (163) and N-(Cbz-Leu-Ala)-ethanolamine (174) 
in 37% yield after chromatography on silica eluting with ethyl acetate. (M.p. 150-151°C). 
The structures of N-(Cbz-Leu-Ala)-ethanolamine (174) and the epoxides (173) and (175) 
were confirmed by ^H-NMR, ^^C-NMR, IR spectroscopy, microanalysis and mass 
spectrometry.
2.3 Results
2.3.0 The amide substrates
To assess the activity of the synthetic compounds, Kemp’s assay procedures were used in 
which acetyl-leucyl (2S)-arginyl glycyi (2S)-alanyl glycyi (2S)-arginyl (2 S)-serinyl 
(2S)-arginine (Km = 3.4 mmol dm'^) was used as the substrate, see Section 3.1, pages 242 - 
256. Other experiments utilised ^H-NMR spectroscopy to monitor activity, see Section 3.1.
None of the tetrapeptide simple amides (19) - (23) inhibited or were hydrolysed by the 
proteinase in 4 hours as judged by ^H-NMR spectroscopy (Table 2.3 on page 108). 
Cbz-Leu-AIa-Gly-Gly-NHi (19) and Cbz-Leu-Ala-GIy-Gly-NHMe (20) were not soluble in
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the assay mixture so the N-protection from both of these amides was removed and 
Leu-Ala-Gly-Gly-NH2 acetate salt (25) and Leu-Ala-Gly-Gly-NHMe acetate salt (26) were 
tested instead. However Leu-Ala-Gly-Gly-NH2 acetate salt (25) and 
Leu-Ala-Gly-Gly-NHMe acetate salt (26) also failed to inhibit or be hydrolysed by the 
proteinase. The removal of the Cbz protection was not significant as Leu-Ala-Gly-Gly-OEt 
(74) was hydrolysed at a similar rate to Cbz-Leu-Ala-Gly-Gly-OEt (66),
Compound Reduction of initial rate / % ^
Cbz-Leu-Ala-Gly-Gly-NH2 (19) not soluble
Cbz-Leu-Ala-Gly-Gly-NHMe (20) not soluble
Cbz-Leu-Ala-Gly-Gly-NMe2 (21) 0
Cbz-Leu-Ala-Gly-Gly-NMeEt (22) 0
Cbz-Leu-Ala-Gly-Gly-NMe(OMe) (23) 0
t-Boc-LGu-Aia-Gly-Gly-]SlHC6H ^-N 02 (24) 26.5"
Leu-Ala-Gly-Gly-NHz • HO Ac (25) 0
Leu-Ala-Gly-Gly-NHMe . HO Ac (26) 0
Table 2.3; Percentage inhibitions fo r  various amides.
“ T he inhibitors were tested a t 1.35 raM  in 0.6%  DM SO solution, 680 |jM  substrate, 1.54 jiM  activating
peptide and  200 nM  proteinase, using 2 m M  phosphate buffer witli 100 m M  N aCl a t pH 7.8 a t 37°C 
against a  contro l that contained no inhibitor. These assays were performed by Dr. H eather Murray.
^ The inhibitors were tested a t 33.8 pM  in 0.4%  DM SO solution, 680 pM  substrate, 1.54 pM  activating
peptide and  296 nM  proteinase, using 2 m M  tris buffer w ith 100 mM  NaC l at pH 8.0 a t 37°C against a  
control that contained no inhibitor. The t-Boc group was also hydrolysed and 33%  o f the urethane had 
been hydrolysed to the free am ine t-BuGH and presumably carbon dioxide.
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The simple amides (19) - (23), (25) and (26) therefore do not bind to the proteinase, 
despite possessing the target sequence Leu-Ala-Gly-Gly and additional interactions with the 
S’ side of the proteinase are necessary for proteolytic hydrolysis of an amide substrate.
The more bulky and polar, t-Boc-Leu-Ala-Gly-Gly-NHC(îH5-/?-N02 (2.40) gave an initial 
substrate hydrolysis rate reduction of 27% and after 1 hour 67% of the /?-nitro anilide 
functionality had been hydrolysed by the proteinase.The rate of hydrolysis of the / 7-nitro 
anilide was slow compared to the natural substrates for the proteinase.
“ The substrate w as tested a t 2,92 mmol dm ‘^  in  0.4%  ^Hg-DMSO solution, 283 pm ol dm*^ activating
peptide an d  2.47pm ol dm'^ proteinase, using 2 mmol dm'^ phosphate buffer at pD 7.2 a t 20°C.
2.3.1 The ester substrates
The proteinase is not specific for the amide bond and ester bonds are cleaved at 
comparable rates to the natural substrates (Table 2.4). Considering the 
Cbz-Leu-Ala-Gly-GIy-esters (65) - (67), as the size and hydrophobicity o f the parent alcohol 
increases, the inhibition of the initial rate increases from 0% for Cbz-Leu-AJa-Gly-Gly-OMe 
(65) to 13% for Cbz-Leu-Ala-Gly-Gly-OtBu (67) (Table 2.4). The use of initial rates avoids 
complications due to turn over of the inhibitor, thus the degree of inhibition can give a 
measure o f the binding constant for the inhibitor. From this it can be seen that the more 
hydrophobic esters bind more readily to the proteinase.
However, the rate of proteolytic hydrolysis follows the opposite trend and as the size and 
hydrophobicity of the parent alcohol increases, the rate of hydrolysis decreases from 100% in 
less than 10 min for Cbz-Leu-Ala-Gly-GIy-OMe (65) to 60% hydrolysis in 10 min for 
Cbz-Leu-Ala-Gly-Gly-OtBu (67). All the esters were hydrolysed to give 
Cbz-Leu-Ala-Gly-Gly (76) and the appropriate alcohol as judged by ^H-NMR spectroscopy.
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t-Boc-Leu-Ala-Gly-Gly-OBz (72) did not inhibit the proteinase and was not hydrolysed 
by the proteinase after 3 hours. So t-Boc-Leu-Ala-Gly-Gly-OBz (72) does not bind to the 
adenovirus proteinase. Cbz-Leu-Ala-Gly-Gly (76), the acid hydrolysis product of an ester 
substrate, also failed to inhibit the proteinase. N-(Cbz-Leu-Ala-Gly)-ethanolamine (75) gave 
an initial rate percentage inhibition of 15% so the proteinase is able interact with an alcohol 
functionality in the Pi carbonyl position or the P i’ amide nitrogen position.
compound Reduction of 
initial rate / %“
Ester hydrolysis rate as 
judged by 'H-NMR.'’
Cbz-Leu-Ala-Gly-Gly-OMe (65) 0 100% in under 10 min.
Cbz-Leu-Ala-Gly-Gly-OEt (66) 5 98% in 10 min.
Cbz-Leu-Ala-Gly-Gly-OtBu (67) 13 60% in 10 min.
t-Boc-Leu-Ala-Gly-Gly-OtBu (73) 13 85% in 10 min.°
t-Boc-Leu-Ala-Gly-Gly-OBz (72) 0 0 after 3 hours.
Cbz-Leu-Ala-Gly-Gly (76) 0 not applicable
Cbz-Leu-Ala-Gly-Gly-NHCHaCHaOH (75) 15 not applicable
Table 2.4: Percentage inhibitions and hydrolysis rates o f  various esters.
“ The inliibitors were tested at 33.8 p,mol dm'^ in  0.4%  DM SO solution, 680 |xmol dm ^ substrate, 1.54
fxmoi dm'^ activating peptide and 296 nmol dm'^ proteinase, using 2 mmol dm'^ tris buffer w ith 100 
mmol dm'^ NaCl a t pH  8.0 at 37°C against a control that contained no inhibitor.
^ The inliibitors were tested at 2.92 mmol dm'^ in  0.4%  ^H^-DMSO solution, 283 pmol dm'^ activating
peptide and  .47 pm ol dm'^ proteinase, using 2 mmol dm'^ phosphate buffer at pD 7.2 at 20°C. 
c Partial t-Boc hydrloysis to t-BuOH and the free am ine after 3 hours.
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2.3.2 The t-butyl urethane substrates
If a t-Boc containing substrate ie, t-Boc-Leu-Ala-Gly-Gly-OtBu (73) or 
t-Boc-Leu-Ala-Gly-Gly-NHCgHs /P-NO2 (72) the t-Boc-group is also hydrolysed to give the 
amine, t-butanol and presumably carbon dioxide.
The t-butyl urethane hydrolysis was only observed if the proteinase was present and the 
hydrolysis was not due to the hydrolysis products adversely affecting the buffer, as a pD of
7.2 was maintained throughout the hydrolysis period. A pH of below 3, or above 12 and 
heating at 150°C in solution would be required to hydrolyse the urethane group non- 
enzymatically.^^^
2.3.3 Reversible inhibitors
Preliminary results show that most of the inhibitors in Table 2.5 were noncompetitive 
inhibitors (Section 1.2.3.1.) of the adenovirus proteinase. The double reciprocal (Lineweaver 
Burke) graphs are given in Appendix A. The most potent noncompetitive inhibitor is Cbz- 
Leu-Ala-Gly-aminoacetonitrile (78) with an approximate Kj of 15 |amol dm'^. N ’N ’- 
(dicarboxybenzyl-Leu-Ala-Gly)-2,4-diamino-but-2-ene aldehyde (122) was the best 
competitive inhibitor for the adenovirus proteinase with an approximate K; of 6 pmol dm*^  
(Table 2.5 on page 112). Significantly, this inhibitor is also the only inhibitor that contains 
residues on the PT side. Cbz-Leu-Ala-Gly-aminoacetaldehyde (112) and 0-(Cbz-Leu-Ala- 
Gly)-l-carboxymethyl,4-hydroxybut-2-ene (132) were also potent inhibitors for the 
adenovirus proteinase, both having estimated K fs of 10 juimol dm'^. It was not possible to 
find the actual K i’s for the aldehyde (112) and the Michael acceptor (132) from double 
reciprocal plots as the proteinase denatured, in several instances before the necessary 
measurements could be taken.
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X-Leu“Ala-Gly-Y inhibition‘s / IC Type inhibition*
X = Cbz,
Y = NHCH2CN(78)
52 15 noncompetitive
X = t-Boc,
Y = NHCH2CN(79)
46 20 noncompetitive
X = Cbz,
Y = NHCH2CH=CH2 (115)
17 130** na®
X = Cbz,
Y = NHCH2CMe=CH2 (118)
27 45 noncompetitive
X = Cbz,
Y = NHCH2CH(OMe)2 (114)
20 96 noncompetitive
X = t-Boc,
Y = NHCH2CH(OMe)2 (113)
12 200 *^ na®
X = Cbz,
Y = NHCH2CMeO (116)
17 130s* na®
X = Cbz,
Y = NHCH2CH0(112)
68 10*^ na®
X = Cbz,
Y = NHCR=CHCH2NH-GAL-Cbz, 
R = CHO(122),
89 6 competitive
X = Cbz, (132)
Y = 0CH2CH=CHC02Me {£)
66 10 *^ na®
Table 2.5: Percentage inhibitions, Ki and type for various reversible inhibitors.
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Footnotes for Table 2.5.
“ M easured as a  reduction in  initial rate.
 ^ T he inhibitors w ere tested at 33.8 p.mol dm*^ in  0.4%  DM SO  solution, 680 jjimol dm"^ substrate, 1.54 
nm ol dm'^ activating peptide and  296 nm ol dm'^ proteinase, using 2 mmoldm'^ tris buffer w ith 100 
m m o l dm ’^  N aC l a t pH  8.0 a t 37°C against a  contro l that contained no inhibitor.
° approxim ate Ki m easured in  p-mol dm'^.
E stim ated  Ki, assum ing a  linear relationship betw een initial-rate-% -inhibition and Ki.
® na =  not applicable.
* determ ined from  rate experim ents using 5 different [S] and  3 different [I]. Each rate was determined 
once.
Unexpectedly, proteinase pre-incubated with the Michael acceptor, 0-(carboxybenzyl- 
Leu-Ala-Gly)-1 -carboxymethyl,4-hydroxybut-2-ene (132), showed no inactivation with 
preincubation times of 3, 5 and 7 min. So the Michael acceptor (132) was also a reversible 
inhibitor, rather than an irreversible inhibitor as expected from inhibitor studies with other 
cysteine proteinases (Section 2 .2 .0).
The Cbz-protected tetrapeptide inhibitors, ie. Cbz-Leu-Ala-Gly-aminoacetonitrile (78) 
and Cbz-Leu-Ala-Gly-aminoacetaldehyde dimethyl acetal (114) were better than their 
corresponding t-Boc-protected analogues, ie. t-Boc-Leu-Ala-Gly-aminoacetonitrile (79) and 
t-Boc-Leu-Ala-Gly-aminoacetaldehyde dimethyl acetal (113) (Table 2.5),
2,3,3.0 NitrUes
The nature o f the P4 N-protection affects the degree of binding of 
Leu-Ala-Gly-aminoacetonitrile inhibitors to the proteinase (Table 2.6 on page 114, 
compounds (78), (79) and (82)). The proteinase prefers a polarisable 7C-electron system in 
the Ps-Pe position of a substrate to a lipophilic, t-butyl group, or an electron rich
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trifluoromethyl group. No hydrolysis o f Cbz-Leu-Ala-Gly-aminoacetonitrile (78) was 
observed at low proteinase concentration by *H-NMR spectroscopy.®
Successive removal of the P4 and P3 residues of TFA-Leu-Ala-Gly-aminoacetonitrile (78) 
resulted in the total loss of inhibition. The P 4  leucine residue is responsible for most of the 
binding interactions of the nitrile inhibitor with the proteinase and removal of the P4 leucine 
residue results in a 90% loss of inhibition (Table 2 .6).
Compound reduction of initial 
rate % “
reduction of initial 
rate Vo
Cbz-Leu-Ala-Gly-NHCHaCN (78) 52 95
t-Boc-Leu-Ala-Gly-NHCHzCN (79) 46 54
Cbz-Leu-Ala-Ala-NHCHzCN (80) 26 not applicable
Cbz-Leu-Ala-(2R)-Ala-NHCH2CN (81) 16 not applicable
TFA-Leu-Ala-Gly-NHCH2CN (82) not applicable 50
TFA-Ala-Gly-NH2CH2CN (83) not applicable 5
TFA-Gly-NH2CH2CN (84) 0 0
NH2CH2CN.HCI (85) 0 0
Table 2.6 : Percentage inhibitions fo r  various nitriles.
The inhibitors were tested a t 2.92nimol dm'^ in 0.4%  ^He-DMSO solution, 283|imoI dm'^ activating
peptide and  2.47pm ol dm'^ proteinase, using 2mmoI dm*^ phosphate buffer at pD 7.2 at 20°C.
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Footnotes for Table 2.6.
® T he inhibitors were tested a t 1.35 mm ol dm'^ in  0.6%  DM SO solution, 680 fj, mol dm'^ substrate, 1.54
jim ol dm'^ activating peptide and 200 nmol dm'^ proteinase, using 2 mmol dm'^ phosphate buffer with 
lOOmmol dm'^ N aCl at pH  7.8 a t 37°C against a control that contained no inliibitor.
^ T he inhibitors were tested at 33.8 pm o l dm'^ in  0.4%  DM SO solution, 680p, mol dm ‘^  substrate, 1.54
fxmol dm'^ activating peptide and  296 nm ol dm'^ proteinase , using 2 mmol dm*^ tris buffer w ith 100 
m m o l dm"^ N aC l at pH 8.0 at 37° C against a  control that contained no inhibitor by D r H eather Murray.
Replacement of the P2 glycine residue of Cbz-Leu-Ala-Gly-aminoacetonitrile (78) with 
(2S)-alanyl, ie. Cbz-Leu-Ala-Ala-aminoacetonitrile (80) or (2R)-alanyl, ie. 
Cbz-Leu-AIa-(2R)-Ala-aminoacetonitriIe (81) results in a 50% and 70% loss of binding to 
the proteinase, respectively. So although, either a (28) or (2R)-alanyl residue can replace the 
P2 glycyl residue in the nitrile inhibitor, the P2 binding site binds a glycine residue 
preferentially. Unfortunately there is no data available on the binding preferences of the P2 
binding position of typical substrates for the proteinase.
2,3.3. f  The ^^C-labelled nitrile /  proteinase ^^C~NMR experiments
Mixtures o f the activated proteinase and [ 1 -*^C]-Cbz-Leu-Ala-Gly-aminoacetonitrile (86) 
where studied by *^C-NMR spectroscopy to establish whether the nitrile inhibitor (86) and 
the adenovirus proteinase form a thioamidate adduct in a similar manner to papain (Section 
2.1.3).
The first *^C-NMR experiment (conditions and concentrations in Table 2.7 on page 116) 
of the proteinase and [ 1 -*^C]-Cbz-Leu-Ala-Gly-aminoacetonitrile (86) showed that 
[l-*^C]-Cbz-Leu-Ala-Gly-aminoacetonitrile (86) formed a thioamidate adduct with the 
mercaptoethanol, that had been added to stabilise the proteinase. Any thioamidate adduct
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formed between the proteinase and the *^C-labeIled inhibitor would be masked by the 
mercaptoethanoI-*^C-labelled inhibitor adduct.
The experiment was repeated (experiment 2, conditions and concentrations in Table 2.7), 
using slightly more proteinase and less inhibitor so the ratio between the bound and unbound 
forms of the *^C-labelled inhibitor (86) was lower, and omitting the mercaptoethanol. 
However, after 3 hours of acquisition, only the signal due to the unbound *^C-labelled 
inhibitor (86) was present. No evidence of a thioamidate adduct was observed. A small 
sample of proteinase, taken from the experiment before the addition of the *^C-labelled 
inhibitor (86) and incubated for an hour at 25°C, before proteolytic assay, showed no 
activity. Further studies carried out by Dr Kemp at the St Andrews Biochemistry department, 
showed that the proteinase was not active in D2O.
Experiment 1 2 3
Proteinase 23.9 nmol 52.2 nmol 217 nmol
Activating peptide 2.39 i^mol 6.40 p,mol 21.7 pmol
DMSO 2.2% 0.6% 0.04%
1% mercaptoethanol 
solution
8.6% 0 0
*^C-labelled inhibitor 2310 nmol 694 nmol 868 nmol
Buffer 50 mmol dm'^ Tris 
pD8.0
50 mmol dm'^ Tris 
pD 8.0
50 mmol dm''’ 
phosphate pD 7.2
Solvent D2O D2O H2O + 10% D2O
Table 2.7: The moles o f  reagents used in the ‘^C-NMR experiments 1-3 to determine 
whether or not the proteinase forms a thioamidate adduct with the nitrile inhibitors.
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A third *^C-1SIMR experiment (experiment 3, concentrations and conditions in Table 2.7) 
was attempted using a 10 mm NMR tube, to increase the sensitivity of the *^C-NMR 
experiment, 10% D2O in H2O was used as the solvent and phosphate buffer instead of Tris 
buffer to avoid extra signals in the *^C-1SIMR spectrum. However, after 3 hours of 
acquisition, only the signal due to the unbound *^C-labelled inhibitor (86) was present. No 
evidence of a thioamidate adduct was observed. A small sample of proteinase, taken from the 
experiment before the addition of the *^C-labelled inhibitor (86) and incubated for 30 min. at 
25°C, before the proteolytic assay was carried out, again showed no activity. It would appear 
that the proteinase is inactivated by one or more of the conditions used in the NMR assay. 
Consequentially the proteinase was too unstable, to see whether or not a hemithioamidate 
adduct formed between the nitrile inhibitor and the proteinase by *^C-NMR techniques.
2.3.4 Irreversible Inhibitors
The epoxides (173) and (175) and the bromide (130) were moderate inliibitors of the 
proteinase (Table 2.8 on page 118). Both epoxides were stable in the assay buffer, and after 
they had been in the buffer for 1 hour, showed no signs of ring opening detectable by 
*HNMR spectroscopy.
It was possible that the epoxides (173) and (175) and the bromide (130) irreversibly 
alkylated the proteinase, but bound poorly to the proteinase. However, preincubation of 
these inhibitors with the proteinase for 3, 5 or 7 min prior to the addition of the substrate did 
not result in any significant inactivation of the proteinase with time. Therefore the epoxides 
(173) and (175) and the bromide (130) do not irreversibly inhibit the adenovirus type 2 
proteinase.
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inhibitor Reduction of initial 
rate / %>“
Me
Me—( Q
18
Me °
11
Me ^ M e-/
9
Table 2.8: percentage inhibitions o f  various potential irreversible inhibitors.
T he inhibitors were tested a t 33.8 iim inol dm'^ in 0.4%  DM SO solution, 680 p.mol dm'^ substrate, 1.54 
nm m oi dm'^ activating peptide and 296 nmol dm'^ proteinase, using 2 mmol dm'^ tris buffer w ith 100 
mm o l dm'^ NaCl at pH  8.0 a t 37°C against a control that contained no inhibitor.
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2.4 Discussion
2.4.0 The simple amides
None of the simple amides (Table 2.3, Section 2.3.0) bound to the proteinase as no 
inhibition or hydrolysis was observed. However t-Boc-Leu-Ala-Gly-Gly-/?-nitroanilide (24) 
bound to the proteinase (26.5%-initial-rate percentage-inhibition) and was hydrolysed fairly 
slowly (67% of the /7-nitroanilide functionality was hydrolysed after 1 hour) compared to the 
esters (Table 2.4, section 2.3.1) and the natural substrates for the proteinase. The lack of 
hydrolysis of Leu-Ala-Gly-Gly-NH2 (25) was particularly interesting, as papain hydrolyses 
the amide functionality (benzoyl-Gly-amide (176), I<s = 0.2 mol dm'^).*^°
All the simple amides contain the P 1-P 4 sequence of residues, but there are no residues on 
the P ’ side of a substrate. The proteinase, does not require a specific sequence of amino acids 
on the P ’ side o f a substrate^^’ but may require further interactions with the peptide 
backbone of the P ’ side of a substrate for it to bind. The simple amides do not possess the 
necessary P ’ amide bond and so cannot bind to the proteinase.
t-Boc-Leu-Ala-Gly-Gly- p-nitroanilide (24) contains a large, polar p-nitroanilide group 
corresponding to both the P T  and P 2 ’ residues and is hydrolysed by the proteinase. The 
/>-nitroanilide group is therefore able to fulfill the role of the P ’-binding group.
Comparison of the amide back bone of a substrate with the p-nitroanilide group (Fig. 
2.22) shows that one of the oxygens of the /?-nitro group of the /?-nitroanilide lies in a similar 
position to the carbonyl oxygen of the P2’ residue. The dihedral angles of the substrate are 
not loiown and therefore the exact positions of the carbonyl groups of the substrate cannot 
be known.
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H O  H O  H O  H
Me O
H o  Me' H A O |!|
Fig. 2.22:
A comparison o f  a) the amide backone o f  a substrate with b) the p-nitroanilide gt'oup.
This suggests that the proteinase requires a carbonyl group at the P2’ position to 
successfiilly bind and hydrolyse an amide substrate. The other simple amides lack any such 
âinctional group and so cannot bind to the proteinase and function niether as substrates or 
inhibitors.
/7-Nitroaniline may also be able to fulfill this requirement in a similar manner to the 
/?-nitroanilide (24). This could cause amine product inhibition of the proteinase, particularly 
as /7-nitroaniline is rather insoluble in water and would account for the slow rate of 
hydrolysis of the p-nitroanilide group.
2.4.1 The ester substrates
In contrast to the amides all the esters (Table 2.4, section 2.3.1), except 
Cbz-Leu-Ala-Gly-Gly-OBz (72) bound to the proteinase. However the ester functionality 
can adopt more conformations than the amide functionality as rotation about the oxygen- 
all<yl bond is not restricted. In an amide bond the carbonyl bond and the amide nitrogen lone
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pair are in conjugation so the nitrogen-carbon and the carbon-oxygen bonds are coplanar to 
obtain maximal TC-orbital over-lap.
The adenovirus proteinase may bind an amide substrate in a conformation that strains the 
Pi-PT amide bond so the .Pi carbonyl group and the PT amide nitrogen are no longer 
co-planar. The PT amide electrons would relocalise on the nitrogen, destabilising the amide 
bond and facilitating its hydrolysis. A proton situated in close proximity to the PT amide 
nitrogen would also achieve the same result by polarising the delocalised amide nitrogen lone 
pair back towards the nitrogen in the amide bond.
The simple amides can not adopt this ‘strained conformation’ as they do not interact with 
the P2’ carbonyl binding pocket. An ester faces no energy penalty if the Pi carbonyl carbon 
and the allcyl-oxygen are not co-planar, so the ester can adopt the ‘binding conformation’ 
without the need for the P2’ carbonyl interaction with the proteinase.
As the size and hydrophobicity of the alcohol increases, the degree of binding to the 
proteinase also increases (Table 2.4, section 2.3.1). The binding order of the esters could be 
due to solubility effects, if the active site of the proteinase is hydrophobic. The more 
lipophilic the the ester, the less soluble the ester will be in water so the more likely the ester 
will bind to the proteinase to avoid the polar environment in solution. Alternatively the 
proteinase usually binds a glycine or alanine residue at PT^  ^ so the binding order of the esters 
could also be due to possible binding interactions with the ST side of the proteinase. The 
t-butyl ester and to a lesser extent the ethyl ester are able to mimic the size and shape of the 
glycine or alanine residue at PT whereas the methyl ester is too small (Fig. 2.23).
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a) 9  H
H O
b) Jt ^ \ M e
'Me
d)
Me
0
Me
Fig. 2.23:
Comparison o f  a) the substrate; b) t-butyl ester; c) ethyl ester and d) methyl ester,
t-Boc-Leu-Ala-GIy-GIy-OBz (72) failed to bind to the proteinase. While the benzyl ester 
is of similar size to the p-nitroanilide group (Fig. 2.24) it does not occupy the same space or 
possess the same charge distribution. It therefore seems likely that the benzyl ester cannot fit 
into the active site of the proteinase.
a)  H O
V
b) o_
Pi
Fig. 2.24:
The comparison o f a) The benzyl ester and b) The p-nitroanilide group.
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The order of the rates of hydrolysis of the esters by the proteinase (Table 2.4, Section
2.3.1) follows the opposite trend to the binding order of the esters. If neither of the products 
of the ester hydrolysis bound to the proteinase, the substrate was saturating the en2yme’s 
active site and the binding of the substrate was the rate limiting step then the order of 
hydrolysis would follow the opposite trend to that observed. The better the substrate binds 
to the proteinase (Fig. 2,25a on page 124), the lower the energy of the transition state 
complex, [ES]^ compared to the unbound substrate and enzyme, [E + S] and the lower the 
change in Gibbs free energy of activation (AGa^ < AGi^). As the change in activation energy 
is inversely proportional to the rate of reaction (Section 1.2.4, equation 1.2.27), the better 
the substrate binds to the proteinase, the faster the reaction rate.
If  the substrate was not saturating the proteinase’s active site and the substrate binding 
was the rate limiting step, the order of ester hydrolysis would also follow the opposite trend 
to that observed, as is the case when the substrate is saturating the active site of the enzyme. 
However two effects are responsible; the substrate binds better to the proteinase so the 
activation energy falls and [ES] increases. Both these effects increase the rate of hydrolysis 
as the substrate binds better to the enzyme.
If  the substrate was saturating the enzyme’s active site and the binding of the substrate 
was not the rate limiting step (Fig. 2.25b), the rate of hydrolysis of the esters would follow 
the observed trend. The better the substrate binds to the enzyme, the lower in energy the 
enzyme-substrate complex, [ES] and the higher the change in Gibbs free energy of activation 
(AG4^  > AGs^) and the slower the reaction rate.
If the substrate was not saturating the proteinase’s active site and the substrate binding 
was not the rate limiting step, the Idnetics are rather complex. As Km falls the [ES] increases 
so the rate of reaction is increased, however ES also becomes lower in energy so the barrier 
height for the reaction increases, slowing the reaction rate down. These two effects are
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antagonistic and which dominates depends on how close the substrate is to saturating the 
enzyme’s active site. As the active site of the enzyme becomes saturated, the degree of 
binding of the substrate to the enzyme is less important and the overall reaction rate is 
dominated by the barrier height, to an increasing extent. The binding of the esters to the 
proteinase does not appear to be rate limiting so the active site of the enzyme must be close 
to saturation with the substrate or saturated with substrate.
a )
{ES]'
AGf
[E S]'
(E P]
a g |
AGg
[ES]
[EP]
[ES]'
AG4
b) [E P]'
AGi
[EP]'
[ES]
AGg[ES]'
[E + S]
[ES]
[EP]
AG4
Fig. 2.25: A comparison o f the energy diagi^ams fo r  two substrates with different binding 
affinities fo r  a proteinase a) when the enzyme is saturated by the substrate and b) when the
enzyme is not saturated by the substrate.
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On hydrolysis, each of the esters, Cbz-Leu-Ala-Gly-Gly-OMe (65), 
Cbz-Leu-Ala-GIy-Gly-OEt (66) and Cbz-Leu-AIa-Gly-Gly-O-tBu (67) gives the same acid 
hydrolysis product (Cbz-Leu-Ala-Gly-Gly (76)), and the appropriate alcohol.
Cbz-Leu-Ala-Gly-Gly (76) does not inhibit the adenovirus proteinase (Table 2.4, section
2.3.1). This is in contrast to papain where the acid hydrolysis product (N-benzoyl-glycine
(177), Ki 17 mM) does inhibit the proteinase. The lack of inhibition of Cbz-Leu-Ala-Gly- 
Gly (76) could be due to a charge repulsion effect between the negatively charged 
carboxylate acid functionality and either the proteinase or the amine product, as the acid will 
not be protonated at pH 8 .
The proteinase may bind the alcohol product significantly and slow down departure from 
the active site following hydrolysis of the ester bond. The rate limiting step in the proteolytic 
hydrolysis o f the ester bond could change from the binding of the substrate to the loss of the 
alcohol product and the observed rate of hydrolysis would also be followed.
The observed changes in the rates of ester hydrolysis could also be due to an electronic 
effect encountered during the rate limiting step of the hydrolysis mechanism of the 
proteinase. If the brealcing of the carbon-nitrogen bond was the rate limiting step, as is the 
case for papain, then the nature of the leaving group may play a major role in determining 
the reaction rate.
The rate of hydrolysis of the esters would decrease with the size of the allcyl chain of the 
alcohol, if the oxygen leaving group left as an alkoxide. The electron donating capacity of an 
alkyl chain increases with the size of an alicyl chain, so an alkoxide would be progressively 
destabilised if the size of the allcyl chain increases, as more negative charge would be pushed 
onto the already negatively charged oxygen. This situation would result in a slower rate of 
hydrolysis as the size of the alcohol side chain increases, which is in agreement with the rates 
of ester hydrolysis presented in proteinase Table 2.4, Section 2.3.1.
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The effect o f the leaving group on the rate of hydrolysis is more complex, if the oxygen 
leaving group is an oxonium species, two opposite effects control the basicity of the alkyl 
oxygen as the size of the alkyl chain increases. The basicity of the alkyl oxygen would 
increase as the size of the alkyl chain increases due to the increasing capacity of the allcyl 
chain to donate electrons to the alkyl oxygen, however as the allcyl chain increases in size, it 
starts to hinder the approach of the in coming proton so after a certain size, the basicity of 
the allcyl oxygen will start to decrease. The point at which the size of the ester might start to 
hinder the in coming proton would depend on the direction of alkyl oxygen protonation by 
the proteinase, which is unlcnown. However, the fact that t-butyl esters are hydrolysed at 
similar rates to the methyl and ethyl esters argues against rate limiting steric effects in 
attacking the carbonyl group.
2.4.2 The t-butyl-urethane substrate
The proteinase hydrolysed the t-Boc-nitrogen protecting group from 
t-Boc-Leu-Ala-Gly-Gly- ^ -nitroanilide (24) and t-Boc-Leu-Ala-Gly-Gly-OtBu (73) at a slow 
rate to give the free amine, t-butanol and presumably carbon dioxide (Section 2 .3 .2).
The urethane hydrolysis was not due to an acidic environment in the P5 binding pocket, as 
the acid product of the hydrolysis does not bind to the proteinase (section 2.4.1), so the 
t-butyl urethane hydrolysis would finish at the same time as the hydrolysis of the Pi-Pi’ bond. 
This was not observed as t-butyl urethane hydrolysis continued after the hydrolysis of the 
Pi-Pi’ bond.
The t-butyl urethane hydrolysis was also not due to the hydrolysis products adversely 
affecting the buffer, as a pD of 7.2 was maintained throughout the 3 hour hydrolysis 
procedure and the controls, where the proteinase was omitted showed no hydrolysis of the 
t-butyl urethane.
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The residues in the t-Boc-protected substrate may shift towards the S’ side of the 
proteinase, the leucine residue would occupy the PT position and the t-butyl urethane would 
occupy the Pi position. The t-butyl urethane’s size is not very different to the glycine or 
alanine residue, that usually occupys the Pi position (Fig. 2.26). However, the electrostatic 
requirements of the urethane are different to the Pi residue as an oxygen takes the place of 
the a-carbon of the aminoacid residue. Once the t-butyl urethane has bound in the Pi-PT 
position, the proteinase could then presumably hydrolyse the t-butyl urethane functionality in 
a similar manner to the amide and ester bond.
Pg Pi Pi' Pg Pa
H O  H O  H
H O  H O  H O
Me 
M e—\
H 6  Me B  H O
Me 
M e—\
P  \  H 0  H
. X  ^  ,N 
H Ô Me H H o
Fig 2.26: 4^ comparison o f  a) The substrate; b) The t-Boc-protected substrate and c) The
Cbz-protected substt'ate.
It would also be possible for the Cbz-protected substrates to shift towards the S’ side of 
the proteinase, however in this case the benzyl group may be too big to fit into Si so no 
hydrolysis of the benzyl urethane was detected.
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2.4.3 The possible mechanism of hydrolysis of the esters
If  the possible solution mechanisms and products of ester hydrolysis in solution are 
compared to the products of proteolytic ester hydrolysis, it may be possible to gain an insight 
into the mechanism of the adenovirus proteinase. There are six observed solution 
mechanisms of ester bond hydrolysis; Aac2 (Scheme 2.38), Bal2 (Scheme 2.39), AacI 
(Scheme 2.40), Bac2 (Scheme 2.41), B alI (Scheme 2.42) and AalI (Scheme 2.43). The 
A ac2  mechanism (Scheme 2.38) involves the protonation of the carbonyl oxygen to give a 
carbocation (178) which is nucleophilically attacked by water to give the tetrahedral 
intermediate (179). Proton exchange gives the tetrahedral intermediate (180) which 
eliminates the alcohol to give the carboxylic acid after deprotonation.
n n. H,o O'"
r A q -  R 'T 'o '” ' ====■' -
(178) ^  + H (179)
O '"  O
r  —  ' °
(180)
Scheme 2.38 : The Aac2 mechanism o f ester hydrolysis.
The Bal2 mechanism (Scheme 2.39) is rather rare as the carbonyl group must be 
extremely hindered as the hydroxide ion directly attacks the allcyl group of the ester to give 
the alcohol and the carboxylate as the products. This mechanism has been observed for the 
hydrolysis of (3-butyrolactone (181) and P-propiolactone (182) under neutral conditions. 
The other mechanisms are considered below.
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Scheme 2.39: The Bal2 mechanism o f ester hydrolysis.
It is likely that the proteolytic hydrolysis of the ester and amide bonds proceeds by the 
same mechanism, so only the ester hydrolysis mechanisms involving acyl-oxygen bond 
cleavage are considered as allcyl-nitrogen bond cleavage does not occur during amide 
hydrolysis ie. the A a c I ,  A ac2  and B ac2  mechanisms. These mechanisms are very similar to 
the solution methods of amide hydrolysis discussed previously in Section 1.1.
The A a c I mechanism (Scheme 2 .4 0 )  is rather rare in solution, and occurs when the water 
nucleophile is prevented from attacking the carbonyl carbon by a bulky acyl group eg 2 , 4 ,  6 -  
trimethyl benzyl. The alkyl oxygen of the ester becomes protonated to give the 
carbocation ( 1 8 3 )  and the alcohol is eliminated to give the carbocation ( 1 8 4 )  which is 
hydrated and deprotonated to give the carboxylic acid.
rA q-R' = ? = =  f,A +-R ' —  rA = 0
H (184)
(183)
HgO o  -H+ o
   o J L .x H— —  R'IH
Scheme 2.40: The AacI ^ster hydrolysis mechanism.
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In solution, the add ( A ac2  mechanism, Scheme 2 .3 8 )  or the base catalysed ( B ac2  
mechanism, Scheme 2.41) hydrolysis of Cbz-Leu-AIa-Gly-Gly-OMe (65) and 
Cbz-Leu-Ala-Gly-Gly-OEt (66) would give rise to Cbz-Leu-Ala-Gly-Gly (76) and the 
appropriate alcohol, the same products as observed for the proteolytic hydrolysis of these 
compounds. However, in solution both the acid and base catalysed hydrolysis of 
Cbz-Leu-Ala-Gly-Gly-OtBu (67) give different alkyl hydrolysis products (t-butanol in strong 
base, isobutene in weakly basic and neutral solution and t-butanol in strongly acidic 
solution), as the t-butyl group can form a stabilised carbocation in solution. The 
proteolytic hydrolysis of Cbz-Leu-Ala-Gly-Gly-OtBu (67) gives t-butanol as the only alkyl 
hydrolysis product.
In a strongly basic solution, the t-butyl ester is hydrolysed by a Bac2 mechanism to give 
t-butanol and the carboxylic acid as products (Scheme 2.41). The t-butoxide anion is 
nucleophilically displaced from the t-butyl ester by the hydroxide ion to give the carboxylic 
acid, which is deprotonated by the t-butoxide anion to give t-butanol and the carboxylate ion 
(Scheme 2.41).
« A - k  —  A
   H . ^ J <
Scheme 2.41: The Bac2 hydrolysis mechanism.
However, in a neutral, or a wealdy basic solution a t-butyl ester is hydrolysed by a BalI 
mechanism (Scheme 2.42). The solvation of the t-butyl ester results in alkyl-oxygen bond
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cleavage to give the carboxylate anion and the t-butyl cation which is deprotonated by a 
hydroxide ion to give isobutene/^^
HoO -OH
Scheme 2.42: The BalI  hydrolysis mechanism.
In acidic solution, t-butyl ester hydrolysis occurs via an AalI mechanism (Scheme 2.43). 
Protonation of the carbonyl oxygen results in a carbocation (185) which in turn eliminates a 
t-butyl carbocation leaving the carboxylic acid. In strongly acidic solution, the t-butyl 
carbocation becomes hydrated, giving t-butanol, as it is unlikely that one of the methyl 
groups of the t-butyl carbocation will lose a proton in strongly acidic solution. However in 
dilute acid the t-butyl carbocation will deprotonate more readily giving isobutene. Some 
t-butanol will be produced as this process occurs in competition with hydration described 
above.
+
(185) w eak
acid strongacid
Scheme 2.43 : The AalI hydrolysis mechanism.
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The proteinase may possess any of the catalytic functionalities involved in the solution 
hydrolysis, as the proteinase can have both ‘acidic’ and ‘basic’ enviroments together in its 
active site. In addition, the proteolytic hydrolysis mechanism can proceed in either a 
sequential, or a concerted manner.
Alkyl oxygen protonation may also be possible in the proteinase active site, as the 
proteinase has the capacity to protonate specific groups on a substrate in a regioselective 
manner and they need not be the most basic site in solution. Alkyl oxygen protonation of a 
t-butyl ester would result in the rapid elimination of the t-butyl carbocation, leaving the 
carboxylic acid. This t-butyl carbocation could either deprotonate, giving isobutene, or be 
hydrated to give t-butanol and the catalytic hydroxonium ion (Scheme 2.44).
I O H +  I O I o
+ 1 
H - H +
A
Scheme 2.44: Allcyl oxgen protonation o f  a t-butyl ester to effect hydrolysis.
The proteinase catalysed the hydrolysis of Cbz-Leu-Ala-Gly-Gly-OtBu (67) and 
t-Boc-Leu-Ala-Gly-Gly-OtBu (73) to give Cbz-Leu-Ala-Gly-Gly (76) or t-Boc-Leu-Ala- 
Gly-Gly (186) and t-butanol. If the first step in the hydrolysis of the ester bond involved 
significant protonation of the carbonyl carbon or protonation of the alkyl oxygen, the t-butyl 
ester would decompose to give the carboxylic acid and the t-butyl carbocation, before the 
thiolate nucleophile could attack the carbonyl carbon. The carboxylic acid would then diffuse 
away from the active site of the proteinase, but the fate of the t-butyl carbocation is more 
complex. The carbocation could either react further with the proteinase or be released into
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the solvent. The proteinase should not stabilise the carbocation as that particular binding 
pocket is suited to binding an amide nitrogen and is likely to involve hydrogen bond donors 
or Lewis acids, both of which will greatly destabilise any carbocation present. The 
carbocation could also alkylate a susceptable group within the proteinase but this would 
probably lead to inactivation of the proteinase. However as Cbz-Leu-Ala-Gly-Gly-OtBu (67) 
and t-Boc-Leu-Ala-Gly-Gly-OtBu (73) are substrates alkylation of the proteinase does not 
occur. The carbocation has no alternative but to diffuse away from the active site of the 
proteinase into the solution, where at the weakly alkaline pH the t-butyl carbocation would 
be deprotonated to give isobutene.
As no significant amounts of isobutene were observed (detected by the loss of the t-butyl 
signals in the ^H-NMR spectra) during the hydrolysis of Cbz-Leu-Ala-Gly-Gly-OtBu (67) 
and t-Boc-Leu-Ala-Gly-GIy-OtBu (73), the proteinase is unlikely to catalyse the hydrolysis 
of an ester bond and consequently an amide bond, by significant protonation of the carbonyl 
oxygen or the leaving group in the first step.
As the adenovirus proteinase should catalyse the hydrolysis of ail its substrates by the 
same mechanism, the only mechanism which would produce t-butanol is the strong base 
catalysed hydrolysis mechanism ( B a c 2 )  (Scheme 2.41).
2.4.4 The hydrolysis of the t-butyl urethane
A predominantly base catalysed hydrolysis mechanism as described above is consistent 
with the proteolytic hydrolysis of the t-butyl urethane substrate, which resulted in the free 
amine, t-butanol and carbon dioxide (section 2.3.2).
As is the case for the t-butyl ester (section 2,4.3), protonation of the carbonyl oxygen 
(Scheme 2.45) or the urethane nitrogen (Scheme 2.46) would result in the production of 
isobutene rather than the observed hydrolysis product of t-butanol.
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Scheme 2.45: The hydrolysis o f  a t-butyl urethane by protonation o f the carbonyl oxygen.
H ' 'H
- H +
A
Scheme 2.46: The hydrolysis o f a t-butyl urethane by protonation o f  the urethane nitrogen.
In a predominantly base catalysed proteolytic mechanism, a thiolate nucleophile attacks 
the urethane giving a tetrahedral intermediate (187) (Scheme 2.47). The tetrahedral 
intermediate (187) can either eliminate t-butoxide leaving a thiourethane (188) (step i. 
Scheme 2.47) or an amide anion leaving a thioester (189) (step ii. Scheme 2.47). 
Energetically step i (Scheme 2.47) would be favoured over step ii (Scheme 2.47) as 
t-butoxide is a better leaving group than an amide anion,
A thiourethane bond is very similar to an amide bond and water is not a sufficiently strong 
nucleophile to hydrolyse it. The ability of the nitrogen to act as a leaving group must be 
enhanced, for example by protonation. In this case the thiourethane (188) would be attacked
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by water or hydroxide (from the protonation of the t-butoxide ion to give t-butanol) and 
decompose to give carbon dioxide, the free enzyme and the amine (step iii, Scheme 2.47). 
Enhancing the ability of the nitrogen as a leaving group, may cause it to leave in preference 
to the oxygen leaving group. The thioformate (189) could then be hydrolysed by water or 
hydroxide (from the protonation of the amide anion to give the amine) to give carbon 
dioxide, t-butanol and the free enzyme (step iii. Scheme 2.47).
O- (187) 
RN'  
S  H
II.
\ H 
(188) 111. HpO
C O ,
0 s
(189) \
H
1'
Scheme 2.47: The possible methods o f hydrolysis o f a t-butyl urethane.
Thus elimination of either oxygen or nitrogen as the first leaving group, gives rise to the 
same final products, so it is not possible to distinguish these two mechanisms. Both 
mechanisms require that the urethane nitrogen, and consequently the amide nitrogen, in the 
case of a natural substrate, to be protonated at some point during the hydrolysis pathway. 
This N-protonation cannot occur prior to the attack of the thiolate nucleophile as the t-butyl 
urethane and the t-butyl ester do not decompose to give isobutene instead of t-butanol.
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2.4.5 The epoxide Inhibitors
(2R,3R)-0-[trans-carbonyl oxiran-2-yl 3-(ethoxycarbonyl) butane] N-(Cbz-Leu-Ala-)- 
ethanolanine (173) and (2S,3S)-0-[trans-carbonyl oxiran-2-yl 3-(ethoxycarbonyl) butane] N- 
(Cbz-Leu-AIa-)-ethanolanine (175) are weak reversible inhibitors for the adenovirus 
proteinase and no evidence of irreversible inhibition could be found (Section 2.3.4).
Both (RR) E-64 (17) and (SS) E-64 (133) (Fig 2.24) are potent irreversible inhibitors of 
papain (Section 2.2.1). This difference in activity towards epoxides between papain and the 
adenovirus proteinase could represent a major difference in mechanism between papain and 
the adenovirus proteinase.
R ? " . A ( 17 )  OH ( E - 6 4 )
Ps  P4 Ps  Pg Pi  Pi '
H O  H O H O  H
H O  H O  H O
(substrate)
Me
M._( (2R. 3R) o
H O  Mo H H O
Fig. 2.27:
A comparison o f a) E-64 (17); b) The substrate back-bone and c) The epoxide (173).
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Comparing the structure o f the epoxide (173) to that of the substrate (Fig. 2.27), shows 
that the epoxide (173) has a carbonyl group corresponding to both the Pi and P f  a-carbons. 
While the P2 carbonyl group has been exchanged for a methylene group. E-64 (17) (Fig. 
2.27) similarly has carbonyl groups at the Pi a-carbon position and the P f  a-carbon 
position. However the peptide backbone is completely disrupted from the P2 residue 
onwards. These differences are not important for papain and E-64 (17) binds irreversibly to 
papain.
The loss of the P2 carbonyl from the epoxides (173) and (175) is unlikely to be significant, 
as the P2-P1 residues are not sufficient, by themselves to bind to the proteinase (Section 
2.3.3.0).
The hydrolytic mechanism of papain (Section 1.2 .1) involves the protonation of the 
carbonyl oxygen. The epoxide oxygen of E-64 (17) and Ep-475 (134) (Section 2.2.1) binds 
in the Pi carbonyl position so the epoxide oxygen is protonated, prior to attack by the 
thiolate nucleophile. Alkylation of the nucleopilic thiolate is rapid as the protonated oxygen 
is a good leaving group. The hydrolysis of both the t-butyl ester (Section 2.4.3) and the 
hydrolysis of the t-butyl urethane (Section 2.4.4) to give t-butanol indicated, that 
nucleophilic attack of the Pi carbonyl carbon occured at the same time or after N- or O- 
protonation of a substrate.
The epoxides (173) and (175) bound wealdy to the proteinase (Section 2.3.4). So, 
assuming that the epoxide oxygen binds in the Pi carbonyl binding pocket, the thiolate 
nucleophile cannot open the epoxide ring, unless protonation of the epoxide oxygen occurs 
in conjunction with or before the attack of the thiolate nucleophile. Since an alkoxide leaving 
group is a poor leaving group compared to a thiolate leaving group.
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The lack of irreversible inhibition of the epoxides (173) and (175) also suggests that 
0 -protonation of the Pi carbonyl oxygen of the substrate does not occur to any significant 
extent.
2.4.6 The nitrile inhibitors
As mentioned previously (Section 2 .3.3.0), the nature of the P4 N-protection affects the 
degree of binding to the proteinase of the Leu-Ala-Gly-aminoacetonitrile inhibitors. 
N-Protecting groups with a polarisable 7t-electron system in the P5-P6 positions, such as a 
benzyl group, tend to bind more strongly to the proteinase.
This evidence suggests that the proteinase has residues that can interact with a 7C-electron 
system, such as a tryptophan or a phenylalanyine residue, 7c-stacldng between the benzyl 
group and the side chain of the aminoacid residue (Fig. 2.29), would enhance the binding of 
the Cbz-protected nitrile, compared with TFA- or t-Boc- protected nitriles.
a) b)
Fig. 2.28; TV-stacking interactions between a benzyl group and; 
a) aphenylalanyl residue and b) a ùyptophanyl residue.
Both Cbz-Leu-Ala-Gly-aminoacetonitrile (78) and t-Boc-Leu-Ala-Gly-aminoacetonitrile 
(79) were reversible noncompetitive inhibitors of the adenovirus proteinase (Section 2.3.3.0) 
with approximate Kfs of 15 |.imol dm'^ and 20 pmol dm'  ^ respectively. Similar nitriles ie.
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acetyl-Phe-aminoacetonitrile (188) (K i 0 .7 3  jamol and benzoyl-aminoacetonitrile
( 7 7 )  (K i 0 . 3 8  mmoi dm'^)/^^ are competitive inhibitors of papain.
Noncompetitive inhibition arises when an inhibitor binds to an enzymatic intermediate 
species and the free enzyme to the same extent (Section 1.2.3.1.3) and the level of inhibition 
varies with substrate concentration. It is therefore possible that the substrate could bind at 
the active site of the proteinase and the nitrile inhibitors bind to the proteinase, elsewhere, 
modifying the conformation of the proteinase and reducing the rate of proteolytic hydrolysis. 
Alternatively the inhibitor could bind at the active site of a proteinase-substrate intermediate 
as well as the free enzyme.
From the series of TFA-protected nitriles (Table 2 .6, Section 2 . 3 . 3 . 0 ) ,  the nitrile inhibitors 
show the same residue sequence specificity as the natural substrates. The removal of the P4 
leucyl residue results in an 8 0 %  loss of initial-rate-percentage-inhibition, and the loss of the 
P 3 alanyl residue results in the 1 0 0 %  loss o f initial-rate-percentage-inhibition. This implies 
that the nitrile inhibitors bind in the P side substrate binding pocket, as the probability of 
another region of the proteinase requiring the same sequence specificity as the active site is 
extremely low.
Cbz-Leu-Ala-Gly-aminoacetonitrile (78) and t-Boc-Leu-Ala-Gly-aminoacetonitrile (79) 
do not contain any residues in the P ' positions. It may be possible for the nitriles to mimic the 
P side acid leaving group, after the cleavage of the Pi-Pf amide bond. It seems likely that the 
nitriles can bind to the free enzyme, mimicing the substrate and bind to the proteinase after 
the P side acid group has left while the P’ side amine product is still attached to the 
proteinase. The nitriles would be binding at the active site of the proteinase and behave as a 
noncompetitive inhibitor which fits the observed results.
From this it is clear that the order of product release and the rate determining step differs 
between papain and the adenovirus type 2 proteinase. Papain initially cleaves the Pi-Pf
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amide bond by the formation of a thioester and the P ’ side amine product (step i. Scheme
2.48). The amine product diffuses away from the the active site of papain (step ii, Scheme
2.48) and the thioester is hydrolysed by water to give the His-Cys ion pair and the P side acid 
product (step iii, Scheme 2.48). In papain cleavage of the carbon-nitrogen bond is the rate 
determining step.^^  ^The P side acid product then diffuses away from the active site of papain, 
leaving papain free for fiuther catalytic cycles (step iv. Scheme 2.48).
P side mimics, such as acetyl-Phe-aminoacetonitrile (188) and benzoyl-aminoacetonitrile 
(77) are only able to inhibit the free enzyme, as at all other steps during the catalytic cycle 
the S side o f the proteinase is blocked by the P side of the substrate.
-NR'Hc
+ H20 /  n
R ^ oh - RCOgH
Scheme 2.48: The mechanism o f  papain.
The noncompetitive nature of the nitriles suggests that the adenovirus proteinase behaves 
differently, as the hydrolysis products leave in a different order compared to papain. Initially 
the adenovirus proteinase cleaves the P i-P f amide bond by the formation of a thioester and 
the P ’ side amine product (step i. Scheme 2.49). However the amine does not leave the
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active site of the proteinase and the thioester is hydrolysed by water to give the His-Cys ion 
pair and the P side acid product (step ii, Scheme 2.49). The P side acid product then diffuses 
away from the active site of papain, leaving the P ’ side amine still attached to the proteinase 
(step iii. Scheme 2.49). The P’ side amine product then diffuses away from the active site of 
the proteinase, leaving the adenovirus proteinase free of further catalytic cycles (step iv).
For the adenovirus proteinase, inhibited by the nitriles, the loss of the P ’ amine product 
must be the rate determining step in the hydrolysis reaction, otherwise an inhibitor binding to 
the enzyme-P' amine complex would have no effect on the overall reaction rate. The lack of 
hydrolysis o f the simple amides (Section 2.4.0) has shown that if the carbon-nitrogen bond is 
planar and rotation of the carbon-nitrogen bond is restricted, additional interactions between 
the P’ side o f the substrate and the proteinase are required for the potential substrate to bind 
to the proteinase. As the cyanides contain no P ’ residues it is reasonable to suppose that the 
nitrile functionality is able to adopt the amide binding conformation without the need for P ’ 
interaction.
+ H2O
- RCO2H -NR'Hc
Scheme 2.49: The possible mechanism for the adenovirus proteinase.
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The mode of binding of Cbz-Leu-Ala-Gly-aminoacetonitrile (78) and t-Boc-Leu-Ala-Gly- 
aminoacetonitrile (79) is also rather intriguing. The nitrile binds to free papain allowing the 
thiolate nucleophile to attack the nitrile carbon. The sp hydridised nitrogen becomes an sp  ^
hybridised thioamidate nitrogen and moves up into the Pi carbonyl oxygen pocket (Scheme 
2.50). The Pi carbonyl oxygen binding pocket contains hydrogen bond donors, which 
normally polarise the Pi carbonyl bond. In this case the protons also act to stabilise the 
thioamidate adduct between papain and the nitrile inhibitor (Scheme 2.50). The formation of 
the adduct is reversible and deprotonation of the thioamidate nitrogen results in the 
reformation of the nitrile inhibitor and papain again.
(
carbony l
binding
pocket
Nitrogen
binding
pocket
V 1
carbonyl
binding
pocket
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Scheme 2.50: The formation o f  a thioamidate adduct between papain and a nitrile inhibitor.
In the case of the adenovirus proteinase, hydrolysis of the t-butyl ester (Section 2.4.3) and 
the t-butyl urethane (Section 2,4.4) along with the nature of inhibition by the epoxides 
(Section 2.4.5), alcohol and the bromide (Section 2.4.7), all suggest that there is no 
significant protonation of the carbonyl oxygen during proteolytic hydrolysis by the 
adenovirus proteinase. When the nitrile inhibitor binds to the adenovirus proteinase-amine 
complex, the nitrile carbon can again mimic the carbonyl carbon of the amide substrate and is 
attacked by the thiolate nucleophile. However when the nitrogen moves up into the Pi 
carbonyl oxygen binding pocket, there is no significant protonation, so a thioamidate anion
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(190) is formed (Scheme 2.51). The thioamidate anion (190) is not as stable as a thioamidate 
and would tend to expel the thiolate nucleophile, reforming the nitrile.
carbonyl
binding
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S
carbonyl 
binding
N " \  pocket
I II
R S u  Nitrogen
I v V *  binding 
(1 9 0 )   ^ p ocket
Scheme 2.51: The formation o f  a thioamidate adduct (190) between the adenovirus
proteinase and a nitrile inhibitor.
As no significant Pi carbonyl oxygen protonation appears to occur during the proteolytic 
hydrolysis mechanism of the adenovirus proteinase, the nitrile would be a less potent 
inhibitor than for papain where significant protonation of the carbonyl oxygen occurs.
However direct comparison of the Kj values of inhibitors for the adenovirus proteinase 
and papain is not possible, as the inhibitors also have different peptide sequences. There are 
two effects on the affinity of the proteinase for the inhibitor: One is due to the cyanide 
functionality and the other, to the peptidyl sequences. These effects can not be separated and 
direct comparison of the Kfs for inhibitors is not usefial.
Retention of the P ’ amine product in the proteinase’s active site is enhanced by the 
formation of a partial bond between the thioamidate group’s carbon and the P ’ amine’s 
nitrogen (Fig. 2.29a). In this case, the thioamidate (190)-P’ amine complex (191) could 
mimic the substrate (Fig. 2.29c) or the transition state complex where the carbon-nitrogen 
bond of the amide is breaking while the thiolate-carbony! carbon and the nitrogen-proton 
bonds are forming (192) (Fig. 2.29b).
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Fig. 2.29:
a) The possible bonding interactions o f  the thioamidate anion (190) and the P  ’ side amine;
b) the substrate transition state and c) substrate.
This leads to the possibility that the proteinase could catalyse the formation of the amide 
analogues (194) and (195) by the reverse reaction of amide bond hydrolysis (Scheme 2.52). 
After debinding from the proteinase the amide analogue (195) would be hydrolysed to give 
the simple amide (19) and the P’ amine product. The nitrile has effectively been hydrated to 
an amide.
Hydration o f the nitrile by the proteinase could be confirmed by the loss o f inhibition with 
time as the simple amide (19) did not inhibit the proteinase, and by the presence of the amide 
(19) in the hydrolysis mixture.
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Scheme 2.52: The possible formation o f  an amide from  a nitrile by the proteinase.
2.4.7 The alcohol and bromide inhibitors
N-(Cbz-Leu-Ala-Gly)-ethanolamine (75) and N-(Cbz-Leu-Ala-Gly)- 2-bromo-ethylamine 
(130) were weak reversible inhibitors of the adenovirus proteinase, reducing the initial rates 
by 15 and 18% respectively (Sections 2.3.1 and 2.3.4). The K fs of the alcohol (75) and the 
bromide (130) were estimated as 1.2 mmol dm'^ and 1.1 mmol dm'^ respectively. No 
evidence of irreversible alkylation o f the proteinase by the bromide (130) was observed.
Inhibition of the adenovirus proteinase by the alcohol (75) is in complete contrast to 
papain where the Ki for N-benzoyl-ethanolamine (187) is greater than or equal to 
1 mol dm'^,^^° suggesting significant differences in mechanism between the two proteinases. 
As mentioned previously (Section 2.1.2), the alcohol functionality can bind at either the Pi 
carbonyl oxygen position or the P i’ amide nitrogen position. The bromide is likely only to
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bind in the P i’ amide nitrogen position, as the carbon-bromide bond is much longer than the 
carbon-oxygen double bond (Section 2.2.0).
If  both the alcohol (75) and the bromide (130) are competitive inhibitors it is likely that 
the alcohol and the bromide functionalities both bind in the P i’ amide nitrogen binding 
pocket. This also fits with the observation that the bromide (130) is a slightly better inhibitor 
than the alcohol (75), as the proteinase may bind a transition state in which the Pi-Pi’ 
carbon-nitrogen bond is weakened and is thus longer than a normal amide bond.
The bromide (130) and alcohol (75) inhibitors and, the ester, t-butyl urethane and amide 
substrates all contain a group at the P i’ amide nitrogen position that can accept a proton 
donor. Therefore the adenovirus proteinase could partially protonate the P i’ amide nitrogen, 
at some point during the proteolytic hydrolysis mechanism.
If the alcohol (75) and the bromide (130) are noncompetitive inhibitors of the proteinase, 
the hydroxy group of the alcohol (75) could bind in the Pi carbonyl binding pocket of the 
free enzyme and the thiolate nucleophile could displace the hydroxyl group of the alcohol to 
give allcylate proteinase (196) (Scheme 2.53). As the alcohol is a reversible inhibitor of the 
proteinase, the hydroxide is unable to leave the active site of the proteinase and attacks the 
alkylated proteinase to give the alcohol again.
carbonyl carbonyl
binding _______  binding
pocket pocket
-  K J  \  -
S ‘ X = OH(79);  ^ X = OH(196);
I Br (130). Br{197).
Scheme 2.53: The reversible formation o f alkylated proteinase from the alcohol (75) and
bromide (ISO) inhibitors.
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As in the case for the nitrile (Section 2.4.6) and the dimethyl acetal (Section 2.4.8) the P’ 
amine product could also be trapped in the alkylated enzyme (Fig. 2.30a) and mimic the 
transition state as in Fig. 2.30b and the substrate (Fig. 2.29c).
a )
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\  1 4 9  binding
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Fig 2.29 a) The possible boricling iniemctions o f  the alkylated proteinase (191) and the P ’ 
side amine and b) the substrate transition state.
If the bromide group is not too big for the carbonyl binding pocket, the bromide (130) 
could also act as a noncompetitive inhibitor, binding to the free enzyme and the P’ amine- 
enzyme complex in a similar manner to the alcohol (Scheme 2.53 and Fig. 2.30).
Unfortunately the bromide (130) and the alcohol (75) were not sufficiently soluble in 
water for their K j’s and mode of inhibition to be determined, so their binding modes are 
unknown.
2.4.8 The dimethyl acetal, aldehyde and methyl ketone inhibitors
Cbz-Leu-Ala-Gly-aminoacetaldehyde dimethyl acetal (114) is a reversible noncompetitive 
inhibitor o f the adenovirus proteinase, reducing the initial rate by 68% and having an 
approximate K; of 96 pmoldm'^ (Section 2.3.3). The dimethyl acetal inhibitor (114) binds to 
the same enzyme species as the nitrile inhibitors (Section 2.4.7) ie. the free enzyme and the 
amine proteinase complex. The dimethyl acetal (114), does not require P’ interactions to
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bind the free enzyme, unlike the simple amides (Section 2.4.0). One of the methoxy groups 
of the dimethyl acetal (114) probably binds in the Pi carbonyl binding pocket but the location 
of the second methoxy group of the dimethyl acetal in the active site of the proteinase is 
unknown. The second methoxy group does not bind in the P f  amide nitrogen binding pocket 
as the dimethylacetal is a noncompetitive inhibitor so this position is already occupied by the 
P ’ side amine product in the enzyme-P’ amine complex.
In both enzyme species, The dimethylacetal (114) could be attacked by the thiolate 
nucleophile to give a hemithioacetal (200) and methoxide (Scheme 2.54). No evidence of 
hydrolysis of the dimethyl acetal functionality was obseiwed by 'H-NMR spectroscopy after 
the dimethyl acetal (114) was incubated with the proteinase for 3 hours. Therefore, if the 
methoxide is produced in the carbonyl binding pocket it is unable to leave the active site of 
the proteinase and attacks the hemithioacetal (200) to give the dimethylacetal (114) again.
carbonyl carbonyl
binding   \  binding
p ocket \  pocket
O R ' \
H H '
—
S
R = CH3 (114); f  R = CHg (200); ^H (129). I H (201).
Scheme 2.54: The reversible formaiion o f  a hemithioacetal (200) (or hemithiodiol (201)) 
from  the dimethylacetal (114) (or diol (129)) inhibitors.
The P ’ amine could again be trapped in the hemithioacetal (200) to give transition state 
and substrate mimic as in Fig. 2.31 and Fig. 2.29c, respectively in a similar manner to the 
thioimidate anion (190) (Section 2.4.6).
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Fig. 231: , a) The possible bonding interactions o f  the hemithioacetal (192) and the P ’ side
amine and b) the substrate transition state.
Cbz-Leu-Ala-Gly-aminoacetaldehyde (112) is a powerful reversible inhibitor of the 
adenovirus proteinase which can reduce the initial rate by 68% and an has an estimated K, of 
10 p,mol dm'^. Cbz-Leu-Ala-Gly-1-amino propanone (116) is a much weaker reversible 
inhibitor, only reducing the initial rate by 17% and has an estimated Ki of 130 fxmol dm'^ 
(Section 2.3.3).
The aldehyde (112) and methyl ketone (116) could interact with the proteinase in a 
number of ways. The aldehyde exists in a hydrated diol form (129) (Section 2 .1.4.0) and may 
interact with the proteinase in a similar manner to the dimethyl acetal (114) (Fig. 2.31 and 
Scheme 2.54). Less than 1% of the methyl ketone (116) exists in the hydrated diol form and 
this correlates well with the low level of inhibition by the methyl ketone (116) compared to 
the aldehyde (112).
However the diol functionality is a lot more polar than the dimethyl acetal functionality so 
the 70% loss of activity in méthylation the hydroxyl groups of the diol could be due to the 
proteinase preferring a polar functionality at the Pi carbonyl binding pocket.
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The aldehyde (112) and ketone (116) could also form a hemithioacetal (206) or a 
hemithioketal (207) adduct with the proteinase (Section 2.1.4) (Scheme 2.55).
s i s 'l lI: S S pocket
R* = H (112); R' = H (204); R'=,H (206);
Me (116). Me (205). Me (207).
Scheme 2.55: The formation o f a hemithioacetal and hemithioketal adduct.
The hemithioketal adduct is more difficult to form than the hemithioacetal adduct, as the 
methyl group of the methyl ketone donates negative charge to the carbonyl carbon, reducing 
it’s electrophilicity. This fits with the methyl ketone (116) being a worse inhibitor than the 
aldehyde (112).
As there is little O-protonation of the Pi carbonyl group a hemithioacetal (or ketal) adduct 
formed between an aldehyde (or ketone) would exist as an hemithioacetal anion (204) (or 
hemithioketal anion (205)) rather than the neutral hemithioacetal (206) (or hemithioketal 
(207)). I f  this is the case the hemithioacetal anion (204) (or hemithioketal anion (205)) would 
not be very stable and collapse back rapidly to give the proteinase-bound aldehyde (or 
ketone).
At present it is not known whether the aldehyde (112) and ketone (116) form covalent 
adducts with the proteinase or not. Papain certainly does form covalent adducts with 
aldehyde and ketone based inhibitors (Section 2.1.4).
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If the proteinase was more stable, the use of [1-^^C]-NMR on labelled aldehydes and 
ketones could establish the nature of the binding interactions between the aldehyde and 
ketone with the proteinase.
2.4.9 Alkenic inhibitors
Preliminary results show that Cbz-Leu-Ala-Gly-1 -amino prop-2-ene (115) and Cbz-Leu- 
Ala-Gly-1-amino 2-methyl prop-2-ene (118) are both noncompetitive reversible inhibitors of 
the adenovirus proteinase reducing the initial rate by 17 and 27% respectively and have 
estimated Ki of 130 )imol dm'^ and an approximate Ki of 45 pmol dm'^ respectively (Section 
2.3.3). The simple alkene inhibitors (115) and (118) bind to both the amine-proteinase 
complex and free enzyme.
There are two possible bound conformations for the simple alkene inhibitors (115) and 
(118). In the extended form (Fig. 2.32a), the alkene moiety binds across the Pi-Pi’ amide 
bond, while in the compact form (Fig. 2.32b) the alkene moiety binds in the Pi carbonyl 
binding pocket of the proteinase. In the extended conformation, the 1-amino 2-methyl prop- 
2-ene inhibitor (118) would place a lipophilic methyl group in the polar P% carbonyl binding 
pocket. This would be a rather unfavourable interaction, and suggest that the 1-amino 2- 
methyl prop-2-ene inhibitor (118) would be a worse inhibitor of the proteinase than the 1- 
amino prop-2-ene inhibitor (115).
carbonyl -------
\  binding carbonyl
H R' \ pocket ux u \  bindingJ. I V  I f  \ n n r î l f o t
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R' = H for (115) and = Me for (118).
Fig. 2.32: The h.o possible conformations o f  the simple alkene inhibitors; a) extended
and b) compact.
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However the alkene (118) is the more potent inhibitor of the two, suggesting that they 
bind in the compact conformation. In this case the alkene moiety is positioned in the Pi 
carbonyl binding pocket of the proteinase. The Pi carbonyl binding pocket would be 
probably slightly positively charged to attract the carbonyl oxygen and this positively charged 
environment would polarise the 7t-electrons of the alkene moiety (Fig. 2.33). The close 
proximity of the thiolate nucleophile and perhaps the P ’ amine product would also polarise 
the 7c-electrons o f the alkene.
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Fig. 2.33: The polarisation o f an alkene in the Pi carbonyl binding pocket: a) o f  the 
substrate and b) o f the P ’-amine enzyme complex.
An electron donating group such as a methyl group at R ’ would enhance this polarisation, 
by counteracting the accompanying increase in positive charge on the carbon attached to R’. 
The 1 -amino,2-methylprop-2-ene inhibitor (118) would be expected to be the better 
inhibitor, as is the case experimentally.
0-(Cbz-Leu-Ala-Gly)-1 -carboxymethyl,3 -hydroxyprop-2-ene (132) is a reversible 
inhibitor of the adenovirus proteinase which reduces the initial rate by 66% and has an 
estimated K, 10 juimol dm‘^  (Section 2.3.3). Such Michael acceptors are however potent 
competitive, irreversible inhibitors of papain (Section 2.2.0). The Michael acceptor (132),
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like the simple alkenes (115) and (118) could bind in two possible conformations to the 
proteinase (Fig. 2.34).
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Fig. 2.34: The two possible conformations o f the Michael acceptor; 
a) extended and b) compact.
If  the Michael acceptor (132) were to bind in the compact form, the carboxymethyl group 
would be required to enter the Pi carbonyl binding pocket of the proteinase. This is unlikely 
owing to the size of the carboxymethyl group, suggesting that the Michael acceptor (132) 
binds in the extended conformation.
2.4.10 The aldehyde dimer
N ,N’-di“(Cbz-Leu-Ala-Gly)- 2,4-diaminobut-2-ene aldehyde (122) is the most potent 
competitive reversible inhibitor found. The initial rate is reduced by 89% and the 
approximate K; is 6 |amol dm'^ (Section 2.3,3). The aldehyde dimer (122) binds to the free 
enzyme as the P’ side of the inhibitor prevents the P ’ side amine product from being bound at 
the same time as the inhibitor.
The aldehyde dimer (122) could in principle bind in either the aldehyde or diol forms or as 
a Michael acceptor (Fig, 2.35).
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Fig. 2.35: The possible binding modes o f  the aldehyde dimer inhibitor;
a) as an aldehyde; b) as a diol; c) as a Michael acceptor and an aldehyde and d) as a
Michael acceptor and a diol
It would be difficult to determine which conformation the aldehyde dimer (122) bound in, 
as both the Michael acceptor (132) and the aldehyde (112) have similar Kj’s and no 
irreversible inhibition of the aldehyde dimer (122) was detected.
The aldehyde dimer is able to bind to the free enzyme, like the natural substrates, the 
esters (Section 2.4.1) and the p-nitroanilide (45) (Section 2.4.0) substrates, as the aldehyde 
dimer (122) contains the necessary P’ side residue(s) to interact with proteinase. Since the 
residues in the amide backbone of the P’ side of the aldehyde dimer (122) are reversed, it 
follows that only a limited number of P’ side backbone interactions are required for binding 
to the proteinase. If  the entire P ’ amide backbone was required for inhibitor binding to the 
proteinase, the aldehyde dimer (122) would find it impossible to present all the required 
functionalities in the correct sequence.
The P ’ side of the aldehyde dimer (122) is sufficiently flexible to allow the necessary P ’ 
functionalities to interact with the S’ side of the proteinase. So the aldehyde dimer (122) can. 
bind to the free proteinase.
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2.4.11 Summary
A series of P4 (Cbz and t-Boc) N-protected potential substrates and inhibitors, containing 
the Pi to P4 substrate recognition sequence o f the type 2 adenovirus proteinase (Leu-Ala- 
Gly-Gly) were prepared by solution phase peptide coupling techniques and tested for activity 
against the proteinase. The potential substrates contained the amide and ester moieties at Pi 
carbonyl position and the potential inhibitors contained the alcohol, acid, bromide, aldehyde, 
ketone, dimethylacetal, nitrile, alkenic, malonyl and epoxysuccinate moieties at Pi carbonyl 
position.
The esters, the t-Boc urethane and the p-nitroanilide moieties were substrates for the 
proteinase and the acid and the amides did not bind to the proteinase. Preliminary results 
suggest that the other inhibitors were mostly noncompetitive inhibitors for the adenovirus 
proteinase with approximate K fs between 15 and 200 p-mol dm" .^
The test results indicate that;
® the amides must contain a carbonyl group at P2’ to bind to the proteinase, the
p-nitroanilide (24) was the only amide to be hydrolysed;
® P2 carbonyl binding pocket may be essential for the Pi-Pi’amide bond to adopt a non-
coplanar conformation to allow catalysis, as the ester moiety is turned over without the 
need for P2’ interaction.
® the loss of the P i’ amine product is the rate limiting step for the hydrolysis of a substrate
by the adenovirus proteinase, as the nitriles, dimethyl acetals and alkenic inhibitors were 
able to bind to both the enzyme-P’ amine product complex and the free enzyme, 
inhibiting in a noncompetitive manner;
® the P acid product leaves before the P ’ amine product, which is in complete contrast to
classical cysteine proteinases such as papain;
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• little protonation o f the P i’amide nitrogen or the Pi carbonyl oxygen of the adenovirus
proteinase-substrate complex occurs before the nucleophilic attack of the Pi carbonyl 
carbon of the adenorirus proteinase-substrate complex, as the t-butyl esters and the t-Boc 
urethane were hydrolysed to give t-butanol and the epoxy succinates (173) and (175) and 
the bromide (130) failed to inhibit the adenovirus proteinase irreversibly.
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3.0 Compound synthesis
3.0.0 General procedures for reagent and solvent preparation.
Dry solvents were prepared as follows: acetone was dried over CaS04  for 4 hours under a 
CaS04 drying tube, refluxed for 2 h, distilled and stored under argon. The dry acetone was 
used as soon as possible. Acetonitrile was stirred over CaHa under a silica drying tube until 
no more H2 was evolved. Then fresh CaH2 was added and the acetonitrile refluxed under N2 
for 2 h, distilled and then stored under argon. The dry acetonitrile was used as soon as 
possible. Dichloromethane was dried over CaH2 for 2 h, distilled under N% and then stored 
under argon. The dry dichloromethane was used as soon as possible. 
N,N-Dimethylformamide (DMF) was stirred overnight with activated Linde 4A molecular 
sieves under a silica drying tube and distilled at reduced pressure onto freshly activated Linde 
4A molecular sieves. The dry N,N-dimethylformamide was used within 4 weeks. Ethanol 
and methanol were dried using magnesium turnings and a catalytic amount of iodine under a 
silica drying tube, refluxed for 1 h, distilled and then stored under argon. The dry alcohol 
was used within 3 weeks. Diethyl ether and tetrahydrofuran were dried with KOH, then 
treated with sodium and benzophenone until a purple / blue colour was observed. The 
solvent was distilled under nitrogen, stored under argon and used, as soon as possible.
Ethereal diazomethane solution was prepared from the action of KOH on N-methyl, 
N-nitrosotoluene-/?-sulphonamide. If dry ethereal diazomethane solution was required the 
solution was carefully dried for 1 h over KOH pellets at -5°C. Iodine was removed fi-om 
hydriodic acid by washing 3 times with a suspension of Amberlite LA-2 in petrol (4%, 10 
cm  ^ per 100 cm  ^ of acid)^ "^^  and after separation from the organic layer, the aqueous phase 
was distilled at reduced pressure. Triethylamine was stirred for 3 h over CaH2 under a drying 
tube, refluxed for 2 hours under N2, distilled and stored under argon. The dry triethylamine
3.0. Compound synthesis ___________        158
was used on the same day. N-methyl morpholine was stirred with ninhydrin over a silica 
drying tube for 16 h, then distilled and used within a month. Thionyl chloride was refluxed 
under N 2 with sulphur and distilled twice.
3.0.1 Compound characterisation
Melting points were measured on an electrothermal melting point apparatus and are 
uncorrected. Optical rotations were measured at room temperature using an optical activity 
AA-1000 polarimeter, and are given in 10'  ^ g cm'^ and the solution concentration is given in 
g cm'^.
Elemental analyses were performed by Silvia Smith at the St Andrews University 
microanalytical seiwice and are quoted to the nearest 0.05%. Accurate mass determination 
and low resolution mass spectroscopy were carried out by the SERC service at Swansea 
using a VG AZB-E instrument or by Colin Millar at the St Andrews University mass 
spectrometry service using a Kiatos MS-50 or a Fisons VG autospec instrument. The major 
fragments are given as percentage o f the most abundant fragment.
Infrared specra were recorded on a Perkin-Elmer 1710 Fourier transform injfrared 
spectrophotometer. If solid, the samples were prepared as Nujol mulls, or as thin films 
between sodium chloride disks, or as dispersions in potassium bromide disks, or as 
chloroform solutions between sodium chloride disks. If oils, the samples were prepared as 
thin films between sodium chloride discs. Absorption maxima are given in wave numbers 
(cm‘ )^ and are referenced to a polystyrene standard at 1603 cm‘\
NMR spectra were recorded using a Varian Gemini 200 (200 MHz and 50.31 MHz 
^^C), or a Bmker AM-300 (300 MHz ^H and 74.76 MHz or the SERC service at 
Warwick (400 MHz ^H and 100 MHz ^^C) NMR spectrometers. The chemical shifts are
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given in parts per million and the splitting constants are given in Hz and the following 
abbreviations are used s, singlet; d, doublet; t, triplet;, q, quartet; quin, quintette; sex, sextet 
and sep. septet. For ^H-spectra the chemical shifts were referenced to the ^H in the remaining 
monoprotonated solvent, taken relative to TMS as follows; in ^H-chloroform to CHCI3 
(7.23 ppm), in % -w a te r to ^HOH (4.90 ppm), in %-dimethylsulphoxide to H^H2CSOC^H3 
(4.60 ppm), in ^H4-methanol to H^H2C0 ^H (3.35 ppm), in ^Hg-acetonitrile to CH^H2CN 
(1.95 ppm) and in ^Hg-acetone to CH^H2COC^H3 (2.15 ppm). For ^^C-spectra the chemical 
shifts were referenced to the in the deuterated solvent, taken relative to TMS as follows; 
in ^H-chloroform to C^HCls (77.0 ppm), in ^H2-water to 2,2-dimetyl,5-sulphonic 
acid-sila-pentane (0 ppm), in ^H^-dimethylsulphoxide to ^H3ÇSOC^H3 (39.5 ppm), in 
^H4-methanol to ^H3Ç0 ^H (49.0 ppm), in % -acetonitrile to C % C N  (1.3 ppm) and in 
^Hô-acetone to C ^H sC O C ^ (30.6 ppm).
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3.0.2 Synthetic methods and compound characterisation.
Aminoacetonitrile hydrochloride (85) was purchased from the Aldrich chemical 
company, glycyl p-nitroanilide hydrochloride (64) was purchased from the Sigma chemical 
company and t-butyl (2R)-alaninate acetate (89) and t-butyl glycinate acetate (30) were 
purchased from the Nova Biochemistry company.
3.0.2.0 Carbobenzyloxy-(2S)-leucyl (2S)‘^ alanyl giycy! glycinamide
(19)
Carbobenzyioxy-(2S)-leucyl (2S)-alanyl glycine (27) (0.397 g, 1.01 mmol) was dissolved 
in dry THF (25 ml). i-PrzEtN (0.35 cm ,^ 2.02 mmol), glycinamide hydrochloride (28) (112 
mg, 1.01 mmol) and TBTU (324 mg, 1.01 mmol)^^  ^ were added and the suspension stirred 
overnight. The solvent was removed at reduced pressure to give a white solid which was 
dispersed in water and filtered. The solid was washed with water (20 cm^), sodium 
hydrogencarbonate (saturated, 5 cm^), water (5 cm^), citric acid (10%, 5 cm^), water (5 cm^) 
and brine (saturated, 5 cm^) to give a white solid (221 mg, 49%), m.p. 196-198°C; (Found: 
C, 56.4; H, 6 .8; N, 15.65. C21H31N5O6 requires C, 56.1; H, 6.95; N, 15.60%; m/z (Found: 
[M + 450.2353. C21H32N5O6 requires 450.2353); [a]o -36.4 (c 0.25 in MeOH); Om»
(KBr disk)/cm‘  ^ 3475, 3425, 3335 (3 xNH), 3085 (aromatic CH), 2960 (aliphatic CH) and 
1680, 1670, 1655, 1630, 1615 ( 4 x CONH and CO2NH); 5h (300 MHz; % CO ^H ) 7.54 
(5H, m, CgHs), 5.28 (2H, s, C A CH z), 4.46 (IH, q, Jch,  7.06, CHCH3), 4.33 (IH, t, Jch^  
7.50, NHCHCH2), 4.12 (IH, d, Jh  ^ 16.86, % % ) ,  4.08 (IH, d, Jh  ^ 17.07, CHaHb), 4.00 
(IH, d, Jh,  17.10, CHcHd), 3.99 (IH, d, Jff^ 16.97, CHcHa), 1.90 (IH, quin, Jcff 6.71, 
CH(CH3)2), 1.74 (2H, t, JcH 2 7.31, CHCH2CH), 1.57 (3H, d, Jch 7.14, CHCH3) and 1.13
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(6H, t ,  J6 .6 9 , CH(CH3)2); 5 c  (75.5 MHz, C2H3O2H) 176.24, 176.14, 174.70, 172.38, (4 x 
CO), 159.13 (CO2NH). 138.44 (/-CcHs), 129.79 (m -C A ), 129.34 (p-CtHs), 129.10 (o- 
C«H;), 68.13 (CH2C6H5), 55.33 (ÇHCH2), 51.29 (ÇHCH3). 44.13, 43.50 (CH2CO), 42.11 
(CHCH2), 26.14 (ÇH(CH3)2), 23.73, 22.14 (CH(ÇH3)2) and 17.55 (CHCH,); m/z (FAB) 
472 (100%, [M + N af), 450(12, [M + H]'), 413 (21 [M + Na - CH3CONH2]*) and 391 (13, 
[M + H - C H 3CONH2D
3.0.2.1 Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl, N ’-methyl-
glycinamlde (20)
This compound was prepared in a manner identical to that described for carbobenzyloxy- 
(2S)-leucyl (2S)-alanyl glycyl glycinamide (19) using N-methyl-glycinamide hydrochloride 
(55) (126 mg, 1.01 mmol) to give a white solid (316 mg, 68%). m.p. 213°C; (Found: C, 
57.0; H, 7,3; N, 14.95. C22H33N5O6 requires C, 57.0; H, 7.2; N, 15.10%); m/z (Found; [M + 
Na]*, 486,2320. C22H33N;06Na requires 486.2329); [a]u -28.8 (c 0.13 in MeOH); u„,„ (KBr 
disk)/cm‘‘ 3290 (NH), 3090 (aromatic CH), 2955, 2870 (2 x aliphatic CH), 1690 (CO2NH) 
and 1675, 1660, 1645, 1630 (4 x CONH); S„ (300 MHz; % C 02H) 7.34 (5H, m, C A ) , 
5.09 (IH, d, 12.5, CsHsCaHt), 5.06 (IH, d, \  12.5, CcHsCHaH,,), 4.26 (IH, q, JcH, 
7.2, CHCH3), 4.13 (IH, t, J ch , 7.70. NHCHCII2), 3.91 (IH, d, 7,,  ^ 16.90, C H A ). 3.87 
(IH, d, Jh^ 16.90, CH,Hb), 3.79 (IH, d, J„, 16.90, CH.Ha), 3.78 (IH, d, 16.90, CH.Ha). 
2.71 (3H, s, NCH3), 1.70 (IH, m, Jc„ 6.80, CH(CH3)2), 1.53 (2H, t, J c ,  7.30, CHCH2CH), 
1.37 (3H, d, Jai 7.20, CHCHj), 0.94 (3H. t , ./ 6.70, CH(CH3)2) and 0.92 (3H, t, J  6.60, 
CH(CH3)2); 5 c  (75.5 MHz, C^HjO^H) 175.80, 172.03 (4 x CO), 158.77 (CO2NH), 138.10 
(i-CcHs), 129.44 (m-CcH,), 129.01 (/)-CcH;), 129.76 (o -C A ), 67.85 (ÇH2C A ) , 55.10 
(ÇHCH2), 51.00 (ÇHCH3), 43.94, 43.55 (NHCH2), 41.88 (CHCH2), 26.33 (CH(CH3)2),
3.0. Compound synthesis 162
25.87 (NCH3). 23.45, 21.87 (CH(CH3)2) and 17.27 (CHCH3); m/z (FAB) 486 ( 100%, [M + 
Na]*), 464 (10, [M + H]*), 444 (29 [M + Na - CH2CHCH3]*), 352 (12, [M + H + Na - 
CO2CH2C6H5]*) and 330 (10, [M + 2H - CO2CH2C5H3]').
3.0 2.3 CarbobenzySoxy-(2SHeucy! (2S)-alany! giycyS, N \ N-
dimethyi-glycinamide (21)
CarbobenzyIoxy-(2S)-leucyI (2S)-alanyI glycine (27) (0.142 g, 0.36 mmol) was dissolved 
in di*y THF (25ml). i-Pi'2EtN (0.968 cm^, 0.72 mmol), N', N-dimethyl glycinamide 
hydrochloride (55) (50 mg, 0.36 mmol) and TBTU (0.116 g, 0.36 mmol) were then added 
and stirred overnight. The solvent was removed under reduced pressure and the oil was 
partitioned between ethyl acetate (40 cm^) and water (40 cm^), washed with water (2 x50 
cm^), citric acid ( 10%, 30 cm^), NaHCOa (saturated, 30 cm^), brine (saturated, 20 cm^) and 
dried (MgS04). The solvent was removed under reduced pressure and the last traces of ethyl 
acetate were azeotropically removed with methylene chloride to give an off white solid 
which was reciystalised from acetone / ether to give a white solid (59 mg, 34%), m.p. 
163°C; m/z (Found: [M + H ]\ 478.2663. C23TI36N5O6 requires 478.2666); [ajo -28.2 (c 0.09 
in MeOH); Umax (KBr disk)/cm'^ 3295 (NH), 3065 (aromatic CH), 2960 (aliphatic CH), 1720 
(CO2NH) and 1690, 1670, 1650, 1635 (4 x CONH); Ôh (300 MHz; C^UCh) 7.60, 7.45 (2H, 
t, NHCH2), 7.40 (IH, d, J c h  7.40, NHCFI3), 7.31 (5H, m, CcHs), 5.99 (IH , d, J c h  8.13, 
NHCO2), 5.10 (IH, d, Jhi^  12.5, CûHsCHJ-ïi,), 5.00 (IH, d, Jh^ 12.5, CgHgCHaHb), 4.73 (IH,
t, J c h 2  7.20, NHCHCH2), 4.38 (IH, q, JcH^ 6.63, CHCH3), 4.14, 4.06 (4H, t, NHCH2 and
NHCH2), 2.91, 2.90 (6H, s, NCH3), 1.65 (IH, m, J a /3 6.57, Jch 5.97, C H ( C H 3 ) 2 ) ,  1.54 ( 2 H ,
q, J e n  5.94, 7.17, CHCH2CH), 1.38 (311, d, ./f // 6.75, CIICH3) and 0.89 (6H, d, J ch 6.33,
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CH(CH3>2; 5 c  (75.5 MHz, C^HClj) 172.57, 172.44, 168.56, 167.66 (4 x CO), 156.56 
(CO2NH), 136,43 (/-CsHs), 128.48 (/n-CeHj). 128.11 (p-C^Hs), 127.98 (o -C A ), 
66.92 (CH2C6H5), 53.61 (ÇHCH2), 48.87 (ÇHCH3), 43.00 (CHCH2), 42.02, 41.41 
(NHCH2), 35.93, 35.60 (NCH3), 24.75 (CH(CH3)2), 23.03, 21.94 (CH(CH3)2) and 18.81 
(CHCH3); m/z (Cl) 478 (100%, [M + H]'). 433 (9 [M + H -H N (C H 3)2]*) and 370 (30, [M - 
OCH2C6H5]*).
3.0.2.4 Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl, N'-ethyl, N -
methyl-glycinamlde (21)
This compound was prepared in a manner identical to that described for carbobenzyloxy- 
(2S)-leucyl (2S)-alanyl glycyl, N', N-dimethyl-glycinamide (21) using N'-ethyl, N'-methyl- 
glycinamide hydrochloride (60) (116 mg, 0.76 mmol) to give a white solid which was 
recrystalised from acetone / ether (238 mg, 64%), m.p. 170“C; (Found; C, 58.5, H, 7.8; N, 
14.20. C24H37N5O6 requires C, 58,6; H. 7.6; N, 14.30%); m/z (Found; [M + H ]\ 492.2817. 
C24H38N5O6 requires 492.2822); [a],, -29.7 (t- 0.33 in MeOH); u,„„ (KBr disk)/cm‘‘ 3300 
(NH), 3100, 3060 (2 x aromatic CH), 2955, 2930, 2850 (3 x aliphatic CH), 1715 (CO2NH) 
and 1695, 1650, 1635, 1625 (4 x CONH); 5„ (300 MHz; C^HCb) 7.91, 7.79 (3H, m, 2 x 
NHCH2 and NHCH3), 7.29 (5H, m, CcHs), 6.38 (IH,  d, Jen 6.15. NHCO2), 5.07 (IH, d, ,/„j
27.09, CfiHsCaHb), 5.03 (IH, d, Jh^  27.3, C«H;CH,Hb), 4.92 (IH, m, /  6.09, NHCHCHj),
4.49 (IH, m, CHCH3), 4.19 (4H, m, NHCH2 and NHCH2), 3.36 (3H, sex, J  7.5, NCH2), 
3.24 (3H, q, J6 .77 , NCH2), 2.86, 2.82 (3H, s, NCH3), 1.66 (IH, m, J6 .48 , CH(CH3)2), 1.54 
(2H, t, J ch 6.89, CFICH2CH), 1.37(31-1, d, Jch 6.57, CHCH3) 1.10 (3H. t, J  7.02, 
NCH2CH3), 0.99 (3H, t , ,76.90, NCH2CH3), and 0.877 (6H, d. Jcti 6.33, CH(CH3)2 (cis and 
tmns isomers possible); 8c (75.5 MHz, C^HCIs) 172.79, 172.43, 168.58, 167.16, 167.11 (5 x
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CO), 156.32 (CO2NH), 136.67 (/-CsHs), 128.37 (m-CsH,), 127.92 (p-CsHs), 127.82 
(o-CsH,), 66.60 (CH2CSH5), 53.45 (CHCH2), 48.64 (ÇHCH3), 43.27 (CHCH2), 43.04, 42.60 
(N(CH3)CH2), 42.76 (NHCHj), 41.67, 41.25 (NH CH A ), 33.29, 32.71 (NCH3), 24.72 
(CH(CH3)2), 22.99, 22.07 (CH(CH3)2), 19.42 (CHÇH3) and 13.19, 12.08 (NHCH2CH3); m/z 
(Cl) 492 (80%, [M + H]"), 420 (9, [M - HNC(CH3)CH2CH3]*) and 384 (100 [M - 
OCH2C6H 5]*).
3.0.2.5 Carbobenzy!oxy-(2S)-!eucyl (2S)-aIanyl giycyS, N \ O- 
dimethyl-glydnamide (22)
This compound was prepared in a manner identical to that described for carbobenzyloxy- 
(2S)-leucyl (2S)-alanyi glycyl, N', N-dimethyl-glycinamide (21) using N, 0 , dimethyl 
glycinamide hydrochloride (61) (158 mg, 1.02 mmol) to give an off white solid which was 
recrystalised from acetone / ether (315 mg, 63%), m.p. 141-142°C; (Found: C, 55.95; H, 
7.15; N, 14.20. C23H35N5O7 requires C, 55.95; H, 7.15; N, 14.20%); m/z (Found: [M + H]% 
494.2630. C23H36N5O7 requires 494.2615); [a]o -28.1 (c 0.19 in MeOH); (KBr 
disk)/cm‘‘ 3300 (NH), 3085 (aromatic CH), 2960, 2875 (2 x aliphatic CH), 1720 (CO2NH) 
and 1705, 1680, 1655, 1635 (4 x CONH); 5h (300 MHz; C^HClj) 7.59 (3H, s, 2 x NHCH; 
and NHCHs), 7.30 (5H, m, C«Hs), 6.05 (IH, s, NHCO2), 5.08 (IH, d, Jff^ lS.S.
CsHsCaHb), 5.04 (IH, d, Jh^  18.6, C «H :C H a), 4.74 (IH, m, NHCHCH2), 4.40 (IH, m, J
6 .6 , CHCH3), 4.20 (2H, d, Jvff 3.99, NHCH2) 4.15 (2H, d, J m  6 .00, NHC&), 3.65 (3H, s, 
OCH3), 3.12 (3H, s, NCH3), 1.65 (IH, m, J  6.49, CH(CH3)z). 1.54 (2H, m, J  6.21, 6.63, 
CHCH2CH), 1.36 (3H, d, Jch  6.75, CHCH3) and 0.88 (6H, d, Jen 6.33, CH(CH3)2; 5c (75.5 
MHz, C^HCU) 177.32, 172.74, 172.54, 168.92 (4 x CO), 156.37 (CO2NH), 136.50 (t-CbH;),
128.46 (m-ca), 128.06 (p-CsH), 127.93 (o-C«H;), 66.85 (ÇH2C5H;), 61.46 (OCH3),
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5 3 . 5 4  ( C H C H j ) ,  4 8 . 8 5  ( C H C H 3) .  4 3 . 0 8  ( N H C H j ) ,  4 2 . 1 4  ( C H C H j ) ,  4 0 . 8 4  ( N H C H 2) ,  3 2 . 3 3  
( N C H 3) ,  2 4 . 7 2  ( C H ( C H 3) 2) ,  2 3 . 0 3 ,  2 2 . 0 0  ( C H ( C H 3) 2)  and 1 8 .9 8  ( C H Ç H 3) ;  m/z (Cl) 4 9 4  
( 5 4 % ,  [ M  +  H ] ' ) ,  4 3 3  ( 2 8 ,  [ M  -  N ( O C H 3) C H 3] ' ) ,  3 7 6 ( 2 5  [ M -  N H C H 2C O N ( C H 3) O C H 3]* )
and 319 (22, [M - CH(CH3)CONHCH2CON(CH3)OCH3]*]).
3.0.2.6 Tertiary butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycyl
glycyl p-nltro anillde (24)
This compound was prepared in a manner identical to that described for carbobenzyloxy- 
(2S)-leucyl (2S)-alanyl glycyl-, N', N-dimethyl-glycinamide (21) using t-Boc-(2S)-leucyl 
(2S)-alanyl glycinate (46) (200 mg, 0.557 mmol) and glycine p-nitroanilide hydrochloride to 
give a pale yellow solid which was reciystallised from MeOH / ether to give a white solid 
(248 mg, 83%). m.p. 188°C; (Found; C, 53.4; 1-1, 6.45; N, 15.55. C jA sN sO j requires C, 
53.7; H, 6.75; N, 15.65%); m/z (Found; ([M + H ]', 537.2680). CjÆtNôOs requires 
537.2680); [a]o -45.0 (c 0.10 in MeOH); u,„„ (KBr disk)/cm'‘ 3380, 3300 (NH), 3180, 
3110, 3050 (3 X aromatic CH), 2990, 2900, 2870 (3 x aliphatic CH), 1680 (CO2NH) and 
1720, 1650, 1640, 1635 (4 x CONH); S„ (300 MHz; ^H3C O %  8.25 (2H, d, J c h  9.27, 
CHCNO2), 7.99 (2H, d, J c h  9.25, CHCNHCO), 4.33 (IH, q, JcH; 7.14, CHCH3), 4.16 (IH,
d, Jh^  17.09, CH.Hb), 4.10 (IH, m, NHCHCH2), 4.05 (IH, d, Jh^  17.06, CH.H.). 4.02 (IH, 
d, Jh^  16.89, CHcHd), 3.89 (IH. d, 16.90, CHHj), 1.67 (IH , m, 7  6.70, CH(CH3)2),
1.46 (IIH , s, C(CHj)3 and CI-ICH2CH), 1.45 (3H, d, J a i  7.02, CHCH3), 0.89 (3H, d, ,/ 
6.55, CH(CH3)2 and 0.85 (3H, t, J  6.53, CF^CH,),); 5c (75.5 MHz, C ^ O ^ H ) 176.71, 
176.62, 172.57, 170.48 (4 x CO), 158.48 (CO2NH), 146.00, 144.99 (/-CsHs), 126.05, 
120.84 (» :-C A  and o -C A ), 80 99 (£ (0 0 3 )3). 54.64 (ÇHCH2), 51.50 (CHtZH;), 44.60,
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44.44 (NHCH2), 42.23 (CHCH2), 29.04 (C(CH3)3), 26.06 (CH(CH3)2), 23.82,
22.04 (CH(£H3)2) and 17.74 (CHÇH3); m/z (Cl) 537 (6%. [M + H ]'), 437 (68 [M + 2H - 
C02C(CH3)3D  and 185 ( 100, [NHCHCH3CONHCH2CONHCH2CO]*).
3.0.2.7 (2S)-Leucyl (2S)-alanyl glycyl glycinamide acetate (25)
To a stirred solution of carbobenzyloxy-(2S)-leucyl (2S)-aIanyl glycyl glycinamide (19) 
(86 mg, 0.191 mmol) in glacial acetic acid (5 cm^) was added hydrogen and the hydrogen 
atmosphere was maintained for 3 h. The reaction mixture was filtered through celite and the 
solvent was removed under reduced pressure to give a white solid (65 mg, 92%), m.p. 
126°C (decomp.); m/z (Found: [M + H - HO Ac]* 316.1980, C13H2SN5O4 requires 316.1985); 
[a]o -9.23 (c 0.26 in MeOH); (KBr disk)/cm ' 3600 - 2800 (NH and CH), 1705, 1685,
1670, 1655 (4 X CONH) and 1630 (CO2); 5 h  (300 MHz; % CO^H) 4.38 (IH, q, J c h  ^ 6.85, 
CHCH3), 4.00 (IH, d, Tffj 16.83, CH.H,), 3.91 (2H, s, NHCH2), 3.87 (IH, d, Jf,^ 20.04, 
CH,Hb), 3.80 (IH, m, NHCHCH2), 1.99 (5H, s, CONH2 and COCH3), 1.70 (3H, m, 
CH2CH(CH3)2), 1.45 (3H, d, J c h  6.96, CHCH3) and 1.03 (6H, t, 7  5.50, CH(CH3)2); 5c 
(75.5 MHz, C% O^H) 175.45, 174.38, 173.09, 172.01 (4 x CO), 53.31 (ÇHCH2), 51.14 
(ÇHCH3), 43.87, 43.22 (CH2CO), 42.70 (CHCHz), 25.53 (^ (C H ;) ;) ,  22.38 (CO2ÇH3), 
23.29, 22.18 (CH(CH3)2) and 17.52 (CHÇH3); m/z (Cl) 316 (100%, [M + H - HOAc]*) and 
185 (23. [M - HOAc - NHCH2CONHCH2CONH2]*).
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3.0.28 (2S)-Leucyi (2S)-aianyi glycyl glycinamide-N'-methyl acetate
(26;
This compound was prepared in a manner identical to that described for (2S)-leucyl (2S)- 
alanyl glycyl glycinamide acetate (25) using carbobenzyloxy-(2S)-leucyl (2S)~alanyl glycyl, 
N-methyl-glycinamide (20) (60 mg, 0.13 mmol) to give a white solid (49 mg, 94%), m.p. 
130°C; m/z (Found: [M + H - HOAc]' 330.2144. C14H27N5O4 requires 330.2141); [a]u -4.0 
(c 0.08 in MeOH); (KBr disk)/cnf’ 3600 - 3000 (NH), 2960 (aliphatic CH), 1670, 1665, 
165, 1650 (CONH) and 1640 (CO2); 5n (300 MHz; ^HgCO^H) 4.37 (IH, q, Jch^ 7-10,
CHCH3), 3.99 (IH, d, 16.8, CH,Hb), 3.89 (211, s, NHCH2), 3.86 (IH, d, J//^ 16.4, 
CHaHb), 3.74 (IH, m, NHCHCH2), 2.78 (3H, s, NCH3), 1.98 (3H, s, CO2CFI3), 1.68 (3H, m, 
CH2CH(CH3)2), 1.45 (3H, d, CHCH3) and 1.02 (6H, t, J 6 .00, CH(CH3)2); 5c (75.5 MHz, 
C^sO^H) 175.58, 174.09, 172.11, 172.04 (4 x CO), 53.41 (ÇHCH2), 51.01 (ÇHCH3),
43.87 (NI-ICHaHb), 43.47 (NHCH2), 43.20 (CHCH2), 26.35 (NCH3), 25.50 (CH(CH3)2), 
22.35, 22.10 (CH(CH3)2) and 17.45 (CIÏÇH3); m/z (Cl) 330 (100%, [M + H - HOAc]") and 
185 (20, [M - HOAc - HNCIHCONHCl UCONHMe]').
3.0.2.9 Carbobenzyloxy-(2S)-leucyi (2S)-alànyl glycine (27)
Tertiary-butyl carbobenzyloxy-(2S)-leucy! (2S)-alanyl glycinate (38) (2.07 g, 4.61 mmol) 
was dissolved in formic acid (95%, 30 cm^) and stirred for 3 h.^^ ° The solution was 
neutralised to pH 8 with NaOH (1 moldin'^) and reacidified to pH 3 with HCl (1 moldm'^). 
The mixture was extracted with ethylacetate (3 x 30 cm^) and the combined organic extracts 
washed with brine (saturated, 40 cm^), dried (MgS04) and the solvent was removed under 
reduced pressure. The last traces of ethylacetate were azeotropically removed with
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methylene chloride to give a yellow solid which was recrystalised from acetone / ether. 
Usually a gel resulted from reciystalisation, which was triturated with ether to give a white 
solid (1.49 g, 83%), m.p. 131 °C; (Found: C, 57.8; H, 6.7; N, 10.50. C19H27N3O6 requires C, 
58.0; H, 6.9; N, 10.70 %); m/z (Found: [M + E ] \  394.1978. C19H28N3O6 requires 
394.1978); [a]p -50.3 (c 0.32 in MeOH); u,„„ (KBr disk)/cm'‘ 3307 (NH), 3035 (aromatic
CH). 2960, 2870 (aliphatic CH), 1735, 1690 (CO2NH and CO2H) and 1652, 1623 (2 x 
CONH); 5„ (400 MHz; C % 0 %  7.39 (5H, m, C A ) ,  5.15 (IH, d, 7* 12.56, C«H;CH.Hb),
5.11 (IH, d, Ja 12.44, CsHsCHJHt), 4.42 (IH, q. Ja-i^ 7.13, CHCHj), 4.20 (IH, dd, 76.32, 
8.76, NHCHCH2), 3.94 (IH, s, NHCH.H,,), 3.92 (IH, s, NHCH.Hb), 1.75 (IH, sep, J e n  
6.71, CH(CH3)2), 1.61 (2H, m, CHCH2CH). 1.41 (3H, d, JcH  7.16, C H C ft), 0.99 (3H, d, 
J ch  6.67, CH(CH3)2) and 0.97 (3H, d, JcH  6.75, CH(CH3)2); 5c (100 MHz; C % O H )
175.28, 175.03, 175.96 (2 xNHCO and CO2H), 158.76 (CO2NH), 138.14 ( /-C A ), 129.48 
(m-CsHs), 129.03 (p-C«H;). 128,86 (o-C«Hs). 67.80 (C Æ C H 2), 41.88 (CHCH3), 41,88 
(NHCH2 and ÇH2CH), 25.85 (£H(CH3)2), 23.46, 21.80 (CH(CH3)2) and 18.00 (CHÇH3); 
m/z (Cl) 411 (12 %, [M + H + NH3]'), 394 (40, [M + H ]'), 319 ( 10, [M - CH3 - 
CH2CO2H]*), 303 (38, [M + H -  C6H5CH2] ')  and 286 (100, [M - OCHjCsHs]').
3.0.2.10 Glycyl-amide hydrochloride (28) 108
Methyl glycinate hydrochloride (54) (1.00 g, 8.00 mmol) was dissolved in NH3 solution 
(cone, 30 cm^) and stirred for 2 days. The ammonia was flushed from the solution with N2 
for 10 min and the solvent was removed under reduced pressure to give a white solid which 
was reciystallised from methanol. (0.78 g, 89%), decomp. 182°C (lit.,'°^ 200-203°C); m/z 
(Found: [M - C\]\ 75.0557. requires 75.0558); (Nujol)/cm'' 3300, 3200,
3120, (3 X NH), 1710 (CONH); 0» (200 MHz; % 0 )  3.71 (2H, s, C H j; 6c (50.3 MHz;
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% 0 )  172.13 (CO2) and 42.91 (CH ); m/z (El) 74 (4%, [M - HCl]'). 44 (12, [M - 
NHaCHJ') and 30 (100, [M - HCl - CONH^]').
3.0.2.11 Carbobenzyloxy-(2Syieucyl-(2S)-alanine (29f^
To a solution of methyl carbobenzyloxy-(2S)-leucyl (2S)-alaninate (37) (2.0 g, 5.7 mmol) 
in methanol (30 cm^), NaOH (1 moldin'^, 6.85 cm’, 6.85 mmol) was added at 35°C. The 
reaction mixture was followed to completion by silica TLC eluting with 5% methanol / 95% 
methylene chloride (416 hours).
The methanol was removed under reduced pressure and water (20 cm’) was added to the 
aqueous phase. This was acidified to pH 2 using HCl (4 moldin’). The aqueous layer was 
extracted with chloroform (3 x 100 cm’) and the combined chloroform extracts were washed 
with brine (saturated, 50 cm’), dryed (MgS04) and the chloroform was removed under 
reduced pressure to give a white solid which was recrystalised from ether / hexane to give 
white ciystals ( 1.68 g, 88%), m.p. 146-I47°C (lit.,® 152-153°C); (Found: C, 60.7; H, 7.15; 
N, 8.40. C17H24N2O5 requires C, 60.7; H, 7.2; N, 8.35%) (lit.,® Found: C, 60.4; H, 7.2; N, 
8.44.); m/z (Found: [M + H]', 337.1763. C,7H2sN20s requires 337.1763); [a]n -30.8 (c 0.32 
in MeOH); (Nujol)/cm ' 3290, 3280 (2 x NH), 1720 (CO2H), 1710 (CO2NH) and 1700 
(CONH); 5h (300 MHz; C2HCI3) 7.26 (5H, m, C4H5), 6.85 (IH, d, J a , 6 .66, OCONH), 6.35 
(IH, s, CO2H), 5.03 (2H, s, C6H5CH2), 5.51 (111, d, JCH  8.67, NHCHCH3), 4.48 (IH, sep, 
CHCH,), 4.23 (IH, m, NHCHCH2), 1.52 (3 H. m, CH2CH(CH3)2), 1.35.(3H, d, J c ,  7.05, 
CHCH3) and 0.85 (6H. d, Ja , 2.91, CH(CH3)2); 5c (50.3 MHz, C2HCI3) 176.15 (CO2H),
173.14 (CONH), 157.01 (OCONH), 136.51 ( /-C A ), 129.04 (m-CsHs), 128.75 (p-CcHs),
128.51 (0-C4H5), 67.72 (C A C H ;), 53.85 (NHÇHCH2), 48.68 (CHCH3), 41.80
(CHCH2CH), 25.06 (CH(CH3)2), 23.39, 22.47 (CH ÇH,);) and 18.36 (CHÇH3); m/z (Cl)
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337 (7%, [M + H]'), 293 (3, [M + H - CO2]'), 246 (26, [M + H - CsHjCHa]'), 229 (100, [M 
- OCHîCeHs]') and 203 (10, [M + 2 H -C 6H5CO2]*).
3.0.2.12 Carbobenzyioxy-(2S)-leucine (32f^
(2S)-Leucine (2.97 g, 22.6 mmol) was dissolved in NaOH (1 moldm^, 25 cm^) and the 
solution cooled to -5°C. NaOH (1 moldm \  25 cnf) and benzylchloroformate (4.24 g, 24.9 
mmol) were added in alternate portions over 30 min in 6 aliquots with vigorous at room 
temperature. After for 2 h, the solution was washed with ether (2 x 25 cm^) and the aqueous 
layer was acidified to pH 4 with HCl (5 moldm'^) and then to pH 2 with HCl (2 moldnr^) at 
0°C. The acidified aqueous layer was extracted with ether (3 x 50 cm^) and the combined 
ethereal extracts were washed with HCl (1 moldm'^, 50 cm^), brine (saturated, 50 cm^) and 
dryed (MgSO^). The solvent was removed under reduced pressure to give a colourless oil 
(5.29 g, 88%), m/z (Found: [M ]\ 265.1321. Calc, for 265.1314); [a]o -19.2
(c 0.37 in MeOH) (lit./^ -7.86 {c 0.31 in MeOH)); (thin film)/cm*  ^ 3320, 3120 (OH and 
NH), 3090, 3070, 3040 (2 x aromatic CH), 2960, 2870, 2290 (3 x aliphatic CH), 1720, 1710 
(COzNH and CO^); 5„ (200 MHz; C^HCU) 9.5 (IH, s, COJT), 7.36 (5H, m, CcHs), 6.05 (IH, 
d, NH), 5.13 (2H, s, CH2C6H5), 4.38 (IH, m, NCH), 1.65 (3H, m, CHaCH(CH3)2) and 0.97 
(6H, d, Jch 3.94, CH(CH3)a); 5c (50.3 MHz; C^HCls) 178.71 (CO^H), 156.71 (OCONH),
136.59 (i-CeUsl 129.04 (m-CgHs), 128.74 (p-C.Hs), 128.62 (o-CgHs), 67.69 (CAÇH^),
52.88 (NCH), 41.94 (CHCHgCH), 25.25 (^ (C H ))^ ) and 23.34, 22.20 (CH(CH3)2); ni/z (El) 
265 (2%, [M ]'), 174 (1, [M - CHaCrHs]’), 130 (3, [M - COgCHzCA]^ and 91 (100, 
[C6H5CH2]").
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3.0.2.13 Methyl (2S)~alaninate hydrochloride (33
To a suspension of (25)-aIanine (6.75 g, 75.8 mmol) in dry methanol (50 cm’) was added 
dropwise SOCI2 (12 cm’, 0.165 mol) at 0°C. The reaction mixture was refluxed for 2 h. Dry 
ether was then added dropwise until the solution went cloudy and the product was allowed 
to crystallise out at -20°C. After 2 days the white needle shaped crystals were filtered under 
Nj. The very hydroscopic methyl (25)-alanate hydrochloride was dried under vacuum (9.45 
g, 89%), m.p. 110-112°C (fit.,® 110.5-1 i r C ) ;  (Found: C, 34.35; H, 7.3; N, 10.3. Calc, for 
CJiioNOjCI C, 34.4; H, 7.2; N, 10.05%); m/z (Found [M - Cl]', 104.0712. C^HnNO- 
requires 104.0712); [a]D +7.59 (c 0.29 in MeOH) (lit ,® +5.8 (c 0.29 in MeOH)); 
(Nujol)/cm-' 3430 (NH) and 1740 (CO); 5h (200 MHz; % 0 )  4.10 (IH , q, Jc„, 7.30, CH),
3.74 (3H, s, OCHj) and 1.53 (3H, d, Vo, 7.30, CH,); 6c (50.3 MHz; % 0 )  174.13 (CO,),
56.43 (OCH,), 51.84 (CH) and 17.95 (CH,); m/z (Cl) 121 (10%, [M + NH, - Cl]'), 104 
(100, [M - Cl]*), 88 (2, [M - HCl - CH,]*) and 30 (44, [M - Cl - CH, - CO,CH,]').
3.0.2.14 Carbobenzyloxy-glycine (34
This compound was prepared in a manner identical to that described for the 
carbobenzyloxy-(2S)-leucine (32) using glycine (3.00 g, 40.0 mmol). The work up was 
modified as follows; after neutralisation the white solid was filtered, washed with water, 
dried and recrystallised fi'om methylene chloride / petrol to give white crystals (7.31 g, 87%), 
m.p. 118-119°C (lit,’‘ 121°C); (Found: C, 57.4; H, 5.35; N, 6.60. Calc, for CioH.NO^ C, 
57.4; H, 5.3; N, 6.7%); m/z (Found: [M ,+ H + NH,]', 227.1032. CioH.sHO, requires 
227.1032); u™. (Nujol)/cm’‘ 3330 and 3030 (OH and NH), 1730, 1710 (2 x CO,NH) and 
1690, 1680 (2 X CO2H); 5„ (200 MHz; ( C ^ S O )  7.61 (IH, t, Jch, 5.90, NH), 7.38 (5H, m, 
C4H5), 5.06 (2H, s, C sH CH ) and 3.69 (2H, d, J *  6.2, NCH,); 5c (50.3 MHz; (C’H,),SO)
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171,88 (CO2H), 156,78 (CONH), 137,28 (/-C„CHs), 128.64 (m-CÆ ), 128.10 (p-C«H,), 
128.01 (0-C0H5), 65.73 (CcHsCH,) and 42.40 (NCH,); m/z (Cl) 227 (23%, [M + H + NH,]'), 
210 (10, [M + H]'), 166 (18, [M + H - CO,]'), 119 (7, [M + H - C4H5CH,]*), 104 (100, [M 
+ 2H - C«H,CH,0]'), 91 (12, [M - CO,NHCH,CO,H]') and 76 (27, [M + 2H - 
C«H,CH,0,C]').
3.0.2.15 Methyl carbobenzyloxy-(2S)~leucyl alaninate (37
Carbobenzyloxy-(2S)-leucine (3.00 g, 11.3 mmol) was dissolved in diy THF (50 cm^) 
with stirring and NMM (1.24 cm \l 1.3 mmol) was added. The mixture was stirred for 5 
minutes and cooled to -15 °C. i-BCF (1.48ml, 11.3 mmol) was added and a white precipitate 
ofNMM.HCl formed. Methyl alaninate hydrochloride (1.58 g, 11.3 mmol) was dispersed in 
diy DMF (6ml) and NMM (1.24ml, 11.13 mmol) was added to the DMF solution. When a 
clear solution formed (heat may be iiecessaty) this was added to the THF solution 5 min. 
after the i-BCF and the reaction mixture was allowed to stir for 5 min. at -15°C and then for 
2 h at room temperature.
The NMM salts were filtered from the reaction mixture (sometimes they dissolved in the 
DMF / THF solution) and the THF was removed under reduced pressure .W ater was added 
to the DMF solution so an azeotrope formed and the solvent was removed under reduced 
pressure. This was repeated several times to give a white solid which was dissolved in ether 
(70 cm^), washed with citric acid (10%, 50 cm^), NaHCO] (saturated, 50 cm^) and brine 
(saturated, 30 cm^). The organic layer was dried (MgS04) and the solvent was removed 
under reduced pressure to give a white powder which was reciystallised from ether / hexane 
to give a white solid (3.76 g, 95%), m.p. 91°C, (lit/" 92-93C); (Found: C, 61.5; H, 7.4; N,
8.25. Calc, for CisHzcNgOs C, 61.7; H, 7.5; N, 8.00%); w/z (Found: [M + R ] \  351.1920.
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Calc, for C18H27N2OS 351.1920); [a]n -41.1 (c 0.28 in MeOH); (Nujol)/cm'‘ 3300 (NH), 
1740 (C02Me), 1690 (CO2NH) and 1650 (CONH); 5h (200 MHz; C’HCIs) 7,35 (5H, m, 
CsHs), 6.58 (IH, d, JcH  5.32, CONH), 5.26 (IH , d, JcH  7.96, CO2NH), 5.11 (2H, s, 
CbHCHz), 4.56 (IH, sep, JcH  7.16, CHCH,), 4.20 (IH  m, JcH  5.14, NHCHCH2),
3.75 (3H, s. O CH ), 1.62 (3H  m, ClfcCffiCH,),), 1.39 (3H, d, Jch  7.04, CHCH,) and 
0.94 (6H  d, Jc h  6.60, CH CH ,),); 8c (50.3 MHz; C’HCI,) 173.71 (ÇO2CH,),
172.54 (NHCO), 156.77 (CO2NH), 136.71 (l-CeH), 129.00 (w -C A ), 128.64 (p-C«H),
128.51 (o-C«Hs), 67.49 (C«H£H2), 53.84 (OCH,), 52.94 (NHÇHCH2), 48.48 (CHCH,),
42.10 (CHCH2CH), 25.07 (£H(CH,)2), 23.41, 22.47 (CH(£H,)2) and 18.56 (CH£H,); 
m/z (Cl) 351 (23%, [M + H]'), 243 (100, [M - OCHzC&H,]'), 183 (2, [M - QHiCHiCO, - 
C H ,0H ]1 and 155 (2, [M + H - C5H5CH2CO2 - COjCH,]*).
3.0.2.16 Tertiary-butyl carbobenzyloxy-(2S)~leucyl (2S)-alanyl
glycinate (38)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alaninate (15) using carbobenzyloxy-(2S)-leucyl (2S)- 
alanine (29) (1.76 g, 5.24 mmol) and tertiary-butyl glycinate acetate (30) (1.00 g, 5.24 
mmol) and THF instead of DMF. The work up was modified as follows; the crude product 
was extracted into ethyl acetate before washing and the remaining ethyl acetate was 
azeotropically removed with methylene chloride. The white solid was recrystalised from 
acetone /  water to give white needle shaped crystals (2.07 g, 88%). m.p. 111-112°C; (Found: 
C, 61.8; H, 7.95; N, 9.25. C23H35N3O6 requires C, 61.45; H, 7.85; N, 9.35%); m/z (Found: 
[M + H ]', 450.2604. C24H35N3O6 requires 450.2604); [ot]n -48.5 (c 0.33 in MeOH); 0^» 
(Nujol)/cm-‘ 3300 (NH), 1755 (C02C(CH,),), 1733 (COjNH) and 1690, 1640 (2 x CONH);
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5h (200 MHz; C’HCI,) 7.35 (5H, m. CcH), 6.94 (IH, t, NHCHa), 6.80 (IH, d, J e n  7.28, 
NHCHCH,), 5.52 (IH, d, JcH  8 04, NHCHCH2), 5.12 (IH, d, Jcnj, 12.16, CsHsCHCH),
5.11 (IH, d, Jcn„  12.28, CbHsCHCHi,), 4.61 (IH, quin, Jmi. 7.14, Jcf/5 6.76, CHCH), 
4.23 (IH , q, Jiv//8.21, Jc ffj 4.0, NHCHCH), 3.89 (2H, d, Jm ! 5.0, NHCHj), 1.65 (IH, m, 
JCH3  -6.4. JcH 2  7.84, CH(CH),), 1.58 (IH, m, J en  56, Jn^ 9.36, JcH; 5.6, CHCHHCH),
1.51 (IH, m, J o y  4.06, 9.28, J™ , 5.54, CHCH.HCH), 1.43 (9H, s, C(CH)s), 1.36
(3H, d, J c h  6.84, CHCH) and 0.90 (6H, d, JcH  6.4, CH(CH>2); 5c (50.3 MHz; C’HCb) 
172.13, 171.99, 168.61 (NHÇO), 156.22 (CO2NH), 136.09 (;-C«H), 128.39 (ni-CbH), 
128.05 (p-CbH), 127.94 (o-CsH), 82.18 (Q C H ),), 66.95 (C«H CH), 53.47 (CHCH),
48.59 (CHCH), 41.90 (NHCH), 41.56 (CHCH), 27.88 (C(CH),), 24.55 (CH(CH)2), 
22.85, 21.73 (C H Ç H );) and 18.27 (NHCHCH); m/z (Cl) 467 (4%, [M + H + NH3)]'), 450 
(13, [M + H]'), 394 (88, [M + H - C (C H ),]'), 376 (5, [M + H + NH, - C «H C H ]'), 342 
(15, [M - O C H C cH ]'), 303 (15, [M + 2H - C (C H ), - C cH C H ]') and 286 (100, [M + H - 
C sH C H O  - C(CH)3]').
3.0.2.17 Ethyl carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycinate (39)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alaninate (37) using carbobenzyloxy-(2S)-leucyl (2S)- 
alanine (29) (1.76 g, 5.24 mmol) and ethyl glycinate hydrochloride (40) (0.73 g, 5.24 mmol). 
The work up was modified as follows; the crude product was extracted into ethyl acetate 
before washing, and the remaining ethyl acetate was azeotropically removed with methylene 
chloride from the white solid, which were reciystalised from acetone / water to give white 
crystals (1.54 g, 70%). m.p. 129°C; m/z (Found: [M + 422.2291. C21H32N3O6 requires
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422,2290); (nujol)/cin‘ 3460 (NH), 3270 (aromatic CH), 2500 (aliphatic CH), 
1750 (CO^Et), 1710 (CO2NH) and 1680, 1640 (2 x CONH); 6» (200 MHz; C’HCl,)
7,34 (5H, m, CgH,), 6.68 (IH, t, Ja , 3.8, NHCH,), 6.71 (IH, d, Jc„ 6.8, NHCHCH,),
5.33 (IH, d, TC7/7.8, NHCHCH,), 5.11 (2H, CcHCH,), 4.56 (IH, m, Jnh. 6.8, CHCH,),
4.19 (3H, m, JcHj 7,10. OCH, and NHCHCH,), 4.0 (2H, d, Jn h  4.8, NHCH,), 1. 66 (3H, 
m, CH,CH(CH,),), 1.38 (3H, d. Jc h 7.0, CHCH,) 1.27 (3H, t, Jcn^ 7.1. OCH2CH3) and 0.93
(6H, d, J ch  5.8, CH(CH,),); 8c (50.3 MHz; C’lICl,) 172.84, 172,76, 170.17 (NHÇO),
156.89 (CO2NH), 136.64 (i-C«H;), 129.06 (w-C«H;), 128.69 (p-C«H;), 128.52 (o-CsH,), 
67.61 (CbHsCH,), 61.98 (OCH,), 54.17 (CHCH,), 49.21 (CHCH,), 42.03 (NHCH,), 
41.82 (ÇH2CH), 25.17 (£H(CH,),), 23,45, 22.30 (CH(ÇH,),), 18.67 (NHCHCH,) and
14.60 (O CH £H ,); m/z (Cl) 439 (3%, [M + H + NH,)]'), 422 (9, [M + H]'), 331 (10, [M + 
H - CcHCH,]*), 314 (100, [M - OCH,Cf,H,]').
3.0.2.18 Ethyl glycinate hydrochloride (40)^ ^^
This compound was prepared in a manner identical to that described for the methyl 
alaninate hydrochloride (33) using glycine (5.69 g, 75.8 mmol) and dry ethanol and the work 
up was modified as follows; The solvent was removed under reduced pressure to give white 
needle shaped crystals which were reciystallised from ethanol / ether to give white needle 
shaped crystals (8.05 g, 76%), m.p. 143°C (lit.,"" I45-148°C); (Found: C, 34.55; H, 7.25; 
N. 9.9. Calc, for C,H,oNO,CI C, 34.4; H, 7.2; N, 10.05%); m/z (Found: [M - Cl]', 104.0712. 
C4H,oNO, requires 104.0712); u.„„ (Nu]ol)/cm ' 3480 (NH), 1750 (CO); 8„ (200 MHz; 
’H ,0) 4.27 (2H, q, Jc„, 7.17, OCH,). 3.88 (2H, s, NHCH,), 1.26 (3H, t, J c ,  7.18, CH,); Sc 
(50.3 MHz, % 0 )  171.04 (CO), 66.21 (OCH,), 43.12 (CH,NH) and 16.11 (CH,); m/z (Cl) 
104 (100%, [M - Cl]'). 76 (2, [M - Cl - CO]') and 45 (3, [M - Cl - NH,CH,CO]').
3.0, Compound synthesis   176
3.0.2.19 Tertiary»butoxycarbonyl“(2S)-leucine,H20 (41)^ °^
(2S)-Leucine (3.68 g, 2.81 mol) was dissolved in NaOH (1 moldm’^  30 cm^) with 
stirring. Di-tertiary-butyl dicarbamate (7.94 g, 3.38 mol) was dissolved in tertiary-butyl 
alcohol (30 cm’) and added to the solution which was stirred vigorously for 2 h. The tertiary- 
butyl alcohol was removed under reduced pressure and the remaining solution was washed 
with ether (2 x 25 cm’). The aqueous layer was acidified at 0“C to pH 2 with H ,S04 (2 
moldm ’). The white crystals were filtered, washed with distilled water (50 cm’ and dried to 
constant mass in a CaCl, desiccator (6.40 g, 91%), m.p. 82-84°C (lit.,’® 83-84°C); (Found: 
C, 52.1; H, 9.3; N, 5.45. Calc, for Ci.HaNO, C, 52 0; H, 9.3; N, 5.60%); m/z (Found: [M - 
OH]' Calc, for 232.1549. CnH„NO, 232.1549 ); [a]D -40.0 (c 0.14 in MeOH); 
u„„(Nujol)/cm-' 3500 (OH), 3380 (NH). 2740 (alkyl CH), 1720 (CO,NH) and 1670 
(CO,H); 8tt(200 MHz; C’HCl,) 8.30 (IH, s, CO,H), 4.90 (IH, d, JCH 8.34, NH), 4.32 (IH, 
m, CHCH), 1.54 (3H, m, CHCH(CH),), 1.45 (9H, s, C(CH,), and 0.96 (6H, d, JCH 6.26, 
CH(CH:),); 8c (75.74 MHz; C’HCl,) 177.78 (CO,H), 155.64 (CONH), 80.07 (OC(CH),),
53.95 (NHCH), 41.32 (CH), 28.18 (C(CH)3), 24.67 (CH(CH),) and 22.73, 
21.66 (CH(CH),); m/z (Cl) 249 (10%, [M + H + NH,]'), 232 (30, |M  + H]*), 193 (100, [M 
+ NH, + 2H - C(CH,),]'), 176 (65, [M + 2H - C(CH,),]'), 149 (6 , [M + NH, + 2H - 
CO,C(CH,),]'), 132 (100, [M + 2H - CO,C(CH,),]'). 116 (4, [M -
CH(CHCH(CH,),)CO,H]'), 86 (98, [M - CO, - CO,C(CH,),]') and 70 (4, [M - 
NHCO,C(CH,), - COjH]').
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3.0.2.20 Methyl tertiary-butoxycarbonyl-(2S)~leucyl (2S)’’alaninate
(42)^°^
This compound was prepared in a manner identical to that described for the methyl 
benzoxycarbonyI-(2S)-leucyl (2S)-aIaninate (37) using anhydrous tertiary-butoxycarbonyl- 
(2S)-leucine which was prepared as follows; tertiary-butoxycarbonyl-(2S)-leucine.H20 ( 4 1 )  
(6.38 g, 2.55 mmol) was dissolved in methylene chloride (100 cm^) and dried (Na2S04). The 
solution was filtered and the solvent removed at reduced pressure to give a yellow oil. The 
cmde dipeptide ( 4 2 )  was reciystallised from ether / hexane to give white ciystals ( 7 . 9 2  g, 
98%). m.p. no°C , (lit.,'"’ 114-116°C); (Found: C, 56.9; H, 9.05; N .  8.65. C i& H O ,  
requires C, 56.95; H, 8.9; N ,  8.85%); m/z (Found: [M + H ]', 3 17.2076. C 15H29N2O5 requires 
317.2076); [a]n -65.2 (c 0.25 in MeOH); (Nujol)/cm ' 3320, 3250 (2 x NFl), 3080
(CH), 1740 (CO2CH2CA), 1680 (CO2NH) and 1640 (CONH); 5„ (200 MHz; C’HCh) 6.79 
(IH. d. J c h  6.4, NHCHCH3), 5.03 (IH, d, J c h  8 .2 , NHCHCH), 4.54 (IH, pent, JcHs 7.2,
C H C H 3) ,  4 . 1 8  ( I H ,  m, N H C H C H 2) ,  3 . 7 2  ( 3 H ,  s, O C H 3) ,  1 . 5 4  ( 3 H ,  m, C H C I K C H , ) ; ) ,  
1 .3 7  ( 3 H ,  d, J c t / 7 . 2 ,  C H C H s ) ,  1 .4 2  ( 9 H ,  s, C(Cll3)3) and 0 .9 1  ( 6H , m, C H C H );); S c  ( 5 0 .3  
MHz; C ’ H C U )  1 7 3 .6 6 ,  1 7 2 . 8 2  ( 2  x C O ) ,  1 5 6 . 1 7  ( C O 2N ) ,  8 0 .4 1  (HCFb),), 5 3 . 3 5  ( O C H 3) ,  
5 2 . 8 7  ( N H Ç H C H 2) ,  4 8 . 3 9  ( C H C H j ) ,  4 1 . 8 1  ( C H , ) ,  2 8 . 7 6  ( C ( £ H 3) 3) ,  2 5 . 1 1  ( C H C H , ) , ) .  
2 3 . 4 3 ,  2 2 . 4 2  ( C H C H , ) , )  and 1 8 .5 9  ( C H Ç H 3); m/z (Cl) 3 1 7  ([M + H ] ' ,  2 3 % ) ,  2 7 5  ( 1 8 ,  [M 
+  2H  -  C H C H s ) , ] ' ) ,  2 6 1  ( 8 2 ,  [M + 2H  -  C ( C H 3) 3] ' ) ,  2 4 3  ( 3 4 ,  [M + H  -  C H C H , ) ,  - 
0 C H 3] ' ) ,  2 3 1  ( 3 8 ,  [M + 2 H - C H ( C H 3) C 0 2 C H 3] ' )  and 2 1 7  ( 1 0 0 ,  [M + 2 H -  C O ,C ( C H 3) 3] ' ) .
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3.0.2.21 Tertiary’-butoxycarbonyl-(2S)"leucyl-'(2S)-alanme (43^ "^^
This compound was prepared in a manner identical to that described for the carboxy 
ben2yl-(2 S)-leucyl (2S)-alaninate (29) using methyl tertiary-butoxy carbonyl-(2S)-leucyl 
(2S)-alaninate (42) (6.00 g, 19.0 mmol) except that the hydroscopic tertiary-butoxycarbonyl- 
(2S)-leucyl (2S)-alanine crystals were filtered under nitrogen to give white crystals (4.73 g, 
82%), m.p. 135°C (lit.,™ 132-133%); (Found: C, 55.5; H, 8.4; N, 9.10. Calc, for 
C14H26N2O5 C, 55.6; H, 8.65; N, 9.25%); m/z (Found: [M + H ]', 303.1920. Calc, for 
C iÆ rN jO s 303.1920); [a]n -32.2 (c 0.34 in MeOH) (lit.,™ -32.6 (c 1.01 in MeOH)); u „„  
(Nujol)/cm-' 3370, 3330 (2 x NH), 3090 (CH), 1730 (CO2NH), 1670 (CO2H) and 1640 
(CONH); 5 h  (400 MHz; C’HCIa) 7.80 (IH, s, CO2H), 7.02 (IH, d , J c h  6.72, NHCCH3), 
5.22 (IH, d, J c h  8.36, NHCHCH,), 4.54 (IH, q, CHCH,), 4.21 (IH. dd, NHCHCH,), 1.63 
(IH, m, CH(CH3),), 1.48 (2H, m, CHCH,CH, 1.44 (3H, d, CHCH,), 142 (9H, s, C(CH3),) 
and 0.91 (6H, m. CHCH,),); 5c (54.3 MHz; C’HCI,) 176.03 (CO,H), 173.45 (CONH), 
156.53 . (CO2NH), 80.88 (HCH,),), 53.39 (NHCHCH,), 48.62 (ÇHCH3), 41.64 
(CHCH2CH), 28.77 (C(ÇH3)s), 25.10 (CHCH,),), 18.41 (CHCH,) and 23.30,
22.48 (CH(CH,)2); m/z (Cl) 303 ( 10%, [M + H]'), 246 (33, [M + H - C(CH,)3]'), 229 (100, 
[M - C(CH,)3 - OH]'), 203 (40, [M + 2H - C0 ,C(CH,)3] '), 185 (5, [M - H - 
C0 NHCH(CH3)C02H ]') and 86 (20, [(NH2)CH(CH2CN(CH,)2]').
3.0.2.22 Benzyl glycinate tosylate salt C44/®®
Glycine (8.22 g, 112 mmol) was dispersed in toluene (150 cm’) and benzyl alcohol (55 
cm’, 512 mmol) and p-toluene sulphonic acid.H ,0 (127.77 g, 134 mmol) were added. The 
reaction was refluxed under Dean and Stark conditions for 5 h. On cooling yellow needle 
shaped crystals formed which were filtered and washed with ether (150 cm^) and
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recrystalisation from methanol /  ether gave white needle shaped crystals (30.58 g, 81%), 
m.p. 123°C (lit,™  132-134%); (Found: C, 57.25; H, 5.5; N, 4 .20 . Calc, for C,«H„NO;S C, 
56.95; H, 5.7; N, 4.15%); m/z (Found: [M - C,H,SO, + H + N H ,]' Calc, for 183.1134. 
CgH uN A  183.1143); (Nujol)/cm'' 1750 (CO); 5„ (200 MHz; % 0 )  7.62 (2H, d, J c
8.02, CHCSOa), 7.37 (5H, s, C«H,), 7.29 (2H, d, J c  4.72, CHCCHa), 5.22 (2H, s, 
CsHsCa), 3.88 (2H, s, NCH,) and 2.31 (3H, s, CH,); 5c (50.3 MHz; % 0 )  170.85 (CO), 
145.32, 142.22, 147.50 (i-CÆH,), 132.29, 131.81, 131.72, 131.40, 128.20 (C A ),
71.20 (C5H5CH,), 43.00 (NCH,) and 23.33 (CH,); m/z (Cl) 183 (17%, [M + H + NH, - 
C,H,SO,]'), 166 (100, [M + H - C,H,SO,]') and 108 (18, [M + H - COCH,NH, - 
C,H,SO,]').
3.0.2.23 Benzyl tertlary-butoxycarbonyl-(2S)-léucyl (2S)-alanyl
glycinate (45)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2 S)-leucyl (2S)-alaninate (37) using butoxycarbonyl-(2S)-leucyl (2S)- 
alanine (29) (2.50 g, 8.27 mmol), benzyl glycinate tosylate (44) (2.79 g, 8.27mol), THF 
instead o f DMF. The work up was modified as follows; the crude product was extracted into 
ethyl acetate, before washing and the remaining ethyl acetate was azeotropically removed 
with methylene chloride to yield a clear, colourless hydroscopic oil which was stored under 
N2. The oil was recrystalised from acetone / water to give mono hydrated white needle 
shaped crystals. (3.27 g, 88%). m.p. 68-69°C; (Found: C, 61.8; H, 8.15; N, 9.35. 
C23H35N3O6 requires C, 61.45; H, 7.85; N, 9.35%); m/z (Found: [M + H]% 450.2604). 
C23H36N3O6 requires 450.2604); [a]o -41.5 (c 0.27 in MeOH); Umax (KBr disk)/cm'^ 3490 
(H2O), 3120 (aromatic CH), 2980, 2965, 2936 (3 x aliphatic CH), 1751, 1700 (CO2NH and
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CO2H),) and 1655, 1651 (2 x CONH); 5h (200 MHz; C’HCk) 7.34 (5H m, C«H;), 6.82 
(IH, s, NHCHCHs), 6.57 (IH, d, JcH  7.44. NHCHCH;), 5.17 (IH, d, JCH* 12.28,
CsHsCIiHb), 5.14 (IH, d, 12.48, CsHsCHJEfc), 4.86 (IH, m, CHCH), 4.51 (IH, quin., 
J m  7.16, J ch  7.26, CHCH,), 4.08 (IH, dd, J m  5.46, JcH^ 17.90, NHCHCH), 4.03 (IH, 
dd, Jh h  5.20, JcHa 8.20, NHCHHb), 1.67 ( 2H, m, CHCHCH), 1.61 (2H, s, H O ), 1.49 
(IH, m, CH(CH)2), 1.42 (9H, s, C(CH),), 1.39 (3H, d, Jc i7 7.12, CHCH,). 0.94 (3H  d, 
J ch  6.04, CH(CH)2) and 0.92 (3H  d, J qh  5.76, CHCH,),); 5c (50.3 MHz; C’HCl,) 
172.42, 172.07, 169.28 (NHCO), 155.90 (CO2NH), 135.08 (;-C«H), 128.52 (m-CÆ ), 
128.41 (p-CbH), 127.28 (o-CeH), 80.47 (C(CH,),), 67.06 (C «H £H ), 53.32 (CHCH),
48.60 (CHCH), 41.23 (NHCH), 40.76 (ÇHCH), 28.15 (C(£H,),), 24.66 (£H(CH);), 
22.87, 21.68 (CH(£H,)2) and 17.69 (CH £H ); m/z (Cl) 467 ( 11%, [M + H + NH,]'), 
450 (30, [M + H]*), 411 (20, [M + 2H + NH, - C(CH,),]'), 394 (60, [M + 2H - C(CH,),]'), 
376 (13, [M + H + NH, - C A C H ]* ) and 350 ( 100, [M + 2H - C02C(CH,),]’).
3.0.2.24 Tertiary butoxycarbonyl-(2S)-leucyl-(2S)-alanyl-giycine (46)
To a solution of palladium (II) acetate (5 mg, 0.022 mmol) in dry acetone (20 cm^), in a 
flame dried flask, under argon, was added dimethylethylsilane (0.88 cm^ 0.668 mmol) and 
then dry triethylamine (10 mm ,^ 71.2 pmol). The solution immediately went black.
Benzyl t-butoxycarbonyl-leucyl-alanyl-glycinate.H20 (45) (200 mg, 0.445 mmol) was 
dissolved in dry dichloromethane, dried (MgS04), filtered and the solvent removed under 
reduced pressure to give a yellow oil. The dried benzyl tertiary butoxycarbonyl-(2S)-leucyl 
(2S)-alanyl glycinate was dissolved in acetone under argon and after 5 min, was added to the 
reaction mixture and stirred for 12 h (yielding the silyl ester). The resulting solution was
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filtered through celite and methanol (3 cm^) was added to the filtrate, which was stirred for a 
further 3 h. The solvent was removed under reduced pressure to give a yellow oil which was 
recrystallised fi'om AnalaR acetone / ether to give a gel which was triturated to give a white 
solid (153 mg, 96%), m.p. 111-112°C; (Found: C, 53.25; H, 8.45; N, 11.65. CieHzgNsOg 
requires C, 53.45; H, 8.15; N, 11.70%); m/z (Found: [M + H f, 360.2135. C i& N sO g 
requires 360.2135); [a]o -58.3 (c 0.18 in MeOH); Umax (KBr disk)/cm'^ 3344, 3314 (2 x 
NH), 2966 (aliphatic CH), 1735 (COgH), 1700 (CO2NH) and 1681, 1653 (2 x CONH); 
Sy (300 MHz; C’HjO’H) 4.46 (IH, q, JcH^ 7.06, CHCH,), 4.18 (IH, dd, /  5.69, 9.26,
CHCH), 3.96 (IH, d, 17.94, N H C H H ), 3.89 ( IH  d, Jh^  17.85, NHCHHb), 1.72 (IH  
sep, JcH j 6.76, CH(CH)2), 1.59 (2H  dd, 7  5.22, 2.55, CHCHCH), 1.48 (9H  s, C(CH,),), 
1.42 (3H  d, J c h  7.14, CHCH,), 0.99 (3H, d, J c h  6.40, CHCH ,),) and 0.97 (3H, d. J c h  
6.06, CH(CH,)2); 5 c  (75.6 MHz; C’H O ’H) 175.80, 175.24, 173.33 (2 x NHCO and CO2H).
158.44 (CO2NH), 81.05 (C(CH),), 54.98 (CHCH), 50.37 (CHCH), 42.31 (NHCH),
42.19 (CHCH), 29.00 (C(CH),), 26.19 (CH(CH,)2), 23.77, 22.14 (CHCH,),) and
18.44 (NHCHCH); m/z (Cl) 377 (10%, [M + H + NH,]'), 360 (47, [M + H]*), 321 (18, [M 
+ N H  + H - C (C H ),]'), 304 (40, [M + H - C(CH,),]') and 260 (100, [M + 2H - 
C02C(CH),)]').
3.0.2.25 Glycyl-N’, methylamide hydrochloride
This was prepared in a manner identical to that described for the glycinamide 
hydrochloride (28) using methylamine solution (saturated) to give white needle shaped 
crystals (0.94 g, 78%), m.p. 148% (Ut.,‘® 153.5-156%); (Found C, 28.65; H, 7.5; N, 22.3. 
Calc, for C3H N 2OCI C, 28.95; H, 7.3; N, 22.5%); m/z (Found: [M - HCl]', 88.0635. Calc, 
for C3H N O 2 88.0636); u„„ (Nujol)/cm'' 3250, 3050 (2 x NH) and 1662 (CONH); 5„ (200
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MHz, % 0 )  3.62 (2H, s, C H ) and 2.61 (3H, s, CH ); 6c (50.3 MIIz, % 0 )  170.12 (CO),
43.12 (C H ) and 28.56 (CH); m/z (El) 88 (8%, [M - HCl]*) and 58 (9, [M - HCl - 
NHCH]').
3.0.2.26 Methy! glycinate hydrochloride (54)'^ ^^
This compound was prepared in a manner identical to that described for the methyl 
alaninate hydrochloride (33) using glycine (5.69 g, 75.8 mmol) and the work up modified as 
follows; On cooling white needle shaped crystals formed, which were filtered and 
recrystallised from methanol / ether to give white needle shaped ciystals (8.87 g, 94%), 
m.p.l78°C (lit.,"" 175%); (Found C, 34.35; H, 7.3; N, 10.3. Calc, for C^HNO^Cl C, 34.5; 
H, 7.25; N, 10.05%); m/z (Found: [M - Cl]', 90.0555. Calc, for CjHNO, 90.0555); u™ 
(Nujol)/cm-' 3310 (NH), 2690, 2640 (2 x aliphatic CH) and 1750 (CO); 5„ (200 MHz, % 0 )
3.85 (2H, s, C H ) and 3.76 (3H, s, OCH,); Sc (50.3 MHz, % 0 )  171.52 (CO,), 49.92 (CH) 
and 56.22 (C H ); m/z (El) 90 (52%, [M - Cl]'), 75 (100, |M -  Cl - CH,]') and 57 (30, [M - 
HC! - H O  - CH,]').
3.0.2.27 Glycyl- N ’, N ’, dimethylamide hydrochloride (55)
Ethyl acetate (30 cm’) was saturated with MCI at -5%  for 30min. Then a solution of 
tertiaiy-butyl-glycyl N ’, N ’, dimethylamide (57) (0.35 g, 1.73 mmol) in ethyl acetate (5 cm’) 
was added and the solution was stirred at -5°C for one hour."" The HCl gas was flushed 
from the solution with for 10 min and the solvent was removed under reduced pressure to 
give a white solid which was reciystallised from methanol / ether to give hydroscopic white 
needle shaped ciystals (125 mg, 53%), (Found: C, 34.35; H, 7.95; N, 20.10. C.HuN^OCI 
requires C, 34.65; H, 8 .6; N, 20.20%; m/z (Found: [M - Cl]', 103.0871. CqH'nNaO requires
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103.0871); u„,„(KBr disk)/cm' 3420 (NH) and 1660 (CONH); 5„ (200 MHz, % C 0 % ) 
3.99 (2H, s, CH,) and 3.05, 3.01 (6H, ds, CH,); 5o (50.3 MHz, % C O ’H) 167.48 (CO),
41.47 (CH,) and 36.88, 36.22 (CH,); m/z (Cl) 205 (4%, [2M - 2CI - H f), 103 (100, [M -
Cl]"), 72 (4, [M - HCl - CH,NH,]') and 70 (M - HCl - NH, - CH,]').
3.0.2.28 Tertiary-butoxycarbonyl-glycine (58)^ ^^
This compound was prepared in a manner identical to that described for the tertiary- 
butoxycarbonyl-(2S)-leucine (41) using glycine (1 g, 13.0 mmol),with the following 
modifications; After neutralisation the product was extracted into ether (3 x 50 cm^), washed 
with brine (saturated, 50 cm^) and dried (MgS04). The solvent removed under reduced 
pressure to give a clear oil, which was recrystallised from ether / hexane to give white needle 
shaped crystals (1.92 g, 85%), m.p. 86°C (lit.,” '* 85-89°C); Umax (Nujol)/cm'^ 3400 (OH), 
3340 (NH), 1740 (CO^NH) and 1670 (CO^H); 6.] (200 MHz; C ^C L ) 7.02 (IH, d, Jch 2.4, 
NH), 5.22 (IH, d, Jch 4.2, NH), 4.01 (2H, d, Jhh 5.6, CH,), 3.95 (2H, d, Jhh 5.2, CH,), 
1.50 (9H, s, CHs) and 1.47 (9H, s, CH3); Ôc (75.74 MHz; C^HCb) 175.48, 174.47 (CO2H), 
157.89, 156.52 (CONH), 82.34 (OC(CH3)3), 43.91, 42.73 (CH,) and 28.79, 28.50 (CH3).
3.0.2.29 N-Tertiary-butoxycarbonyl-N\ N-Dimethyl glycinamide (57)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyI alaninate (37) using tertiaiy-butoxycarbonyl glycine (56) (0.40 g,
2.28 mmol) and dimethylamine solution (0.34 cn/, 22.8 mmol). The work up was modified 
as follows; the mixture was extracted into ethyl acetate and the solvent removed at reduced 
pressure to give a white powder which was reciystallised from methanol to give white 
ciystals (186 mg, 40%), m.p. 74°C; (Found; C, 53.8; H, 9.35; N, 13.9. C()HigN203 requires
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C, 53.45; H. 8.95; N, 13.85%); m/z (Found: [M]' 202.1324. CgHisNiOs requires 202.1317);
(KBr disk)/cm‘‘ 3274 (NH). 3040, 3019, 3010, 2978, 2939 (5 x aliphatic CH), 1720 
(COjNH) and 1641 (CONH); 5» (200 MHz; C2HCI3) 5.52 (IH, s, NH), 3.93 (2H, d. 7 ^ 4 .4 , 
C H ), 3.97, 2.95 (6H  ds, C H ) and 1.43 (9H  s, C H ); 5c (50.3 MHz; CiHCb) 168.73 (CO),
156.33 (CO2NH), 80.04 (C(CH )3), 42.75 (C H ), 36.31, 36.06 (NCH) and 28.84 (C (£H )3); 
m/z (El) 202 (1%, [M]*), 146 (23, [M + H - C (C H )3]'), 129 (14, [M - 0 C(CH)3]'), 102 (3, 
[M + H - C02C (C H )3]'), 72 (83, [M - CHNHC02C(CH)3]') and 28 (100, [CNH2]').
3.0.2.30 N-Tertiary butoxycarbonyl-, -N'-ethyl, N'-methyl
glycinamide (58)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyIoxy-(2S)-leucyl-alaninate (37) using tertiary-butoxy carbonyl glycine (56) (2.00 
g, 11.4 mmol) and ethylmethylamine (1.04 cm’, 11.4 mmol.). The work up was modified as 
follows; the mixture was extracted into ethyl acetate and the solvent removed under reduced 
pressure to give a white powder which was recrystallised from methanol to give white needle 
shaped crystals (1.66 g, 67%), m.p. 86°C; (Found C, 55.75; H  9.6; N, 13.05. C10H 0N2O3 
requires C, 55.5; H, 9.35; N, 12.95%); m/z (Found: 217.1548 [M + H f , C10H 1N2O3 
requires 217.1552); Umax (KBr disk)/cm'' 3274 (NH), 2968, 2938 (2 x aliphatic CH), 1718 
(CO2NH) and 1635 (CONH); 5y (200 MHz; C2HCI3) 5.54 (IH, s, NH), 3.94, 3.90 (2H, dd, 
Jnu,  4.0, J m ,  14.8, C H ), 3.42, 3.25 (2H, dq, Jca, 7.2, C H C H ), 2.92, 2.90 (3H, ds,
N CH ), 1.42 (9H, s, C H ) and 1.12 (3H, dt, Jch,  7.2 C H C H ); 6c (50.3 MHz; C2HCI3)
168.15 (CO), 156.29 (CO2NH), 79.99 (^(C H );), 43.75, 43.23, 42.90, 42.47 (C H ), 33.78,
33.30 (NCH), 28.84 (C (£H )3) and 13.75, 12.76 (CH2ÇH3).
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3.0.2.31 N-Tertiary butoxycarbonyl-N',0-dimethylglycyl-
hydroxylamide (59)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl-alaninate (37) using tertiary butoxycarbonyl glycine (56) (1.00 g, 
5 .7 mmol) and IST, 0-dimethyl glycine hydroxylamine. The work up was modified as follows; 
the mixture was extracted into ethyl acetate and the solvent was removed under reduced 
pressure to give a white solid which was recrystallised from methanol to give white crystals 
(1.00 g, 81%), m.p. lO rC ; (Found: C, 49.75; H, 8.65; N, 12.9. CÆsNzOs requires C, 49.5; 
H, 8.3; N, 12.85%; m/z (Found: 219.1339 [M + H]% C9H 19N2O4 requires 219.1345); 
(Nujol)/cm‘‘ 3288 (NH), 3042, 3006, 2988, 2976, 2963, 2918 (6 x aUphatic CH), 1717 
(CO2NH) and 1696, 1658 (2 x CONH); 5h (200 MHz; C2H3O2H) 4.00 (2H, s, CH2), 3.77 
(3H, s, 0 CH3), 3.20 (3H. s, CH3) and 1.46 (9H, s, CH3); Sc (75.5 MHz; C2H3O2H) 174.50 
(CONH), 158.90 (CO2NH), 80.85 (aC H ,);), 62.16 (OCH3), 42.55 (CH2), 32.97 (NCH,) 
and 28.99 ( € ( ^ 3)3); m/z (Cl) 219 (20%, [M + H]*), 163 (100, [M + 2 H - C(CH3)3]"), 157 
(10, [M - HNCH3(0 CH3)]"), 145 (10, [M - OC(CH3)3]0 and 119 (53, [M + 2H - 
C02C(CH)3]*).
3.0.2.32 Glycyl-N’,N’,ethylmethylamide hydrochloride (60)
This compound was prepared in a manner identical to that described for the glycyl- 
N,N, dimethylamide hydrochloride (55) using tertiary butoxycarbonyl-glycyl-Af , i f -  
ethylmethylamide (58) (1.00 g, 4.63 mmol) to give a yellow oil (781 mg, 99%), m/z (Found: 
[M + H - Cl]*, 117.1028. CsHnNjO requires 117.1023); u . .  (thin film)/cm ' 3480, 3430 (2 x 
NH) and 1730, 1650 (2 x CONH); 5„ (300 MHz, C % 0"H ) 4.04, 4.00 (2H, s, CH2CO), 
3.50, 3.40 (2H, q, Jc„, 7.7, CHjCN), 3.06, 3.01 (3H, s, NCH,) and 1.27, 1.17 (3H, t, Jew,
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7.2, N C H C a ); 5c (73.5 MHz, C % 0 'H ) 166,60, 166.50, (2 x CO), 44.58, 43.92 (2 x 
NCHjCO), 41.27, 40.98 (2 x NÇH2CH3), 34.09, 33.17 (2 x NCH,) and 13.34, 12.40 (2 x 
CH2CH3); ?n/z (Cl) 117 (100%, [M - HCl]*), 99 (20, [M - Cl - NH,]*) and 70 (8, [M + H - Cl 
-N H 3 - 2CH,]*).
3.0.2,33 Glycyl‘‘N',0'-dimethylhydroxylamide hydrochloride (61)
This was prepared in a manner identical to that described for the glycyi-N’,N’- 
dimethylamide hydrochloride (55) using tertiary butoxycarbonyl-glycyl N’,0 ’- 
dimethylhydroxylamide (59) (0.52 g, 2.38 mmol) to give a clear oil (0.34 g, 93%), m/z 
(Found; [M - Cl]^, 119.0825. C4H 13N2O2 requires 119.0821); o^ ax (KBr disk)/cm'^ 3440 (MH) 
and 1670 (CONH); 5h(300 MHz, % C 0 % )  7.80 (3H, s, NH3+), 3.56 (10.5H, s, CH2), 3.49 
(3H, s, OCH3), 3.32 (15.75H, s, OCH3), 2.87 (2H, s, CH2), 2.77 (15.75H, s, NCH3) and 2.51 
(3H, s, NCH3) (cis and trans isomers); 5C (73.5 MHz, % C 0 % ) 169.47, 167.84 (2 x CO), 
62.19, 62.00 (2 x OCH3), 40.83, 40.71 (2 x CH2) and 35.53, 32.48 (2 x NCH3); m/z (Cl) 119 
(100, [M - Cl]"), 89 (6, [M - Cl - 2CH3]"), 72 (7, [ M - C I - C H 3 - NH3]") and 62 (15, [M - Cl 
-N H 3CH2 -CO]").
3.0.2.34 Methyl carbobenzyloxy-(2S)‘-leucyl (2S)-aianyl glycyl
glycinate (65)
To a solution of carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycine (27) (0.30 g, 0.762 
mmol) in dry THF (25ml). i-Pr2EtN (0.265 cm ,^ 1.52 mmol), methyl glycinate hydrochloride 
(54) (96 mg, 0.762 mmol) and TBTU (0.245 g, 0.76 mmol) were added and stirred 
o v e rn ig h t.T h e  solvent was removed under reduced pressure and the oil was partitioned 
between ethyl acetate (40 cm^) and water (40 cm^), washed with water (2 x50 cm^), citric
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acid (10%, 30 cm^), NaHCOs (saturated, 30 cm^), brine (saturated, 20 cm"*) and dried 
(MgS04). The solvent was removed under reduced pressure and the last traces of ethyl 
acetate were azeotropically removed with methylene chloride to give a white solid which was 
recrystalised from methanol to give white crystals (219 mg, 62%), m.p. 145-146°C; (Found: 
C, 57.05; H, 6.9; N, 12.1. C22H32N4O7 requires C, 56.85; H, 6.95; N, 12.05%); m/z (Found: 
[M + H]", 465.2350. C22H33N4O7 requires 465.2350); [a]o -45.5 (c 0.17 in MeOH); Umax 
a<Br disk)/cm‘‘ 3300 (NH), 3065 (aromatic CH), 2955, 2875 (2 x aliphatic CH), 1750, 1685 
(CO2NH and CO2R), and 1665, 1655, 1635 (3 x CONH); 5h (300 MHz; % CO^H) 7.38 
(5H, m, CsHj), 5.12 (2H, s, C A CH z), 4.34 (IH, q, Jch, 7.22, CHCH3), 4.19 (IH, t, Jch, 
7.52, NHCHCHj), 4.00 (2H, s, NHCHb), 3.94 (2H, q, Jca 16.98, J  49.77, NHC&), 3.73 
(3H, s, OCH3), 1.74 (IH, sep, CH(CH3)2), 1.60 (2H, t, Jch 6.81, Jai 7.56, CHCH2CH), 1.42 
(3H, d, Jch 7.14, CHCH3) and 0.98 (6H, m, CH(CH3)2); 5c (150 MHz, C% O^H) 175.77,
175.28, 172.09 (3 x CO), 158.76 (CO2NH), 138.10 (i-CsHs), 129.43 (m-C«Hs), 128.99 
(p-CfiHs), 128.82 (o-CsHs), 67.82 (ÇH2C5H5), 55.01 (CHCH2), 52.63, 52.60 (OCH3), 50.87,
50.85 (CHCH3), 43.35, 43.32 (ÇH2CO), 41.81 (CHCH2), 25.85 (CH(CH3)2), 23.52, 23.49, 
23.46, 21.87, 21.82 (CH(CH3)2) and 17.40 (CHCH3); m/z (Cl) 482 (47%, [M + H + NH3]), 
465 ( 100, [M + H]*), 374 (22, [M + H - CHzC^H;]*) 357 (27, [M - OCH2C6H5]*) and 331 
(18, [M + 2 H - COîCHîCsHs]*).
3.0.2.35 Ethyl carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl
glycinate (66)
This compound compound was prepared in a manner identical to that described for 
methyl carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) ethyl glycinate 
hydrochloride (40) to give a white solid which was recrystallised from methanol to give
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white crystals (228 mg, 63%), m.p. 142-144°C; (Found: C, 55.58; H, 7.11; N, 11.37. 
C23H34N4O7 requires C, 55.62; H, 7.31; N, 11.29%); m/z (Found: [M + H]", 479.2506. 
C23H35N4O7 requires 479.2506); [a]n -30.8 (c 0.13 in MeOH); Umax (Nujol)/cm*^ 3400 (NH), 
3300 (aromatic CH), 3330 (aliphatic CH) and 1740 (CO2CH3), 1700 (CO2NH) and 1680, 
1660. 1630 (3 X CONH); 5n (400 MHz; C^HCb) 7,33 (IH, t, Jch^ 7,16, NHCH2CO), 7.32
(5H, m, CgH)), 7 .1 9 -7 .1 5  (2H, m, NHCHCHj and NHCH2CO2), 5.62 (IH, d, Jai 7.48, 
CO2NHCI-I), 5.08 (2H, s, CsHsCHj), 4.53 (IH. m, ,/«„ 7.00, CHCH3), 4.30 (IH, in, ,/m, 
7.48, NHCHCH2), 4.15 (2H, q, ./c„, 7.16, OCH2), 4.10 (2H, d, /nh 7.20, NHCIfcCOîCH),
4.00 (2H, d, Jnh 5.36, NHCHj), 3.73 (3H, s, OCH3), 1.74 (IH, sep, CH(CH3)2), 1.60 (2H, t, 
Jai 6.81, Jai 7.56, NHCH2CO), 1.58 (3H, m. CH2CH(CH3)2) 1,23 (3H, t, Jai^ 7.16, 
OCH2CH3), 1.36 (3H, d, Jai 7.04, CHCHj) and 0.91 (6H, m, CH(CH3)2); Sc (100 MHz; 
C^HCk) 172.55, 172.37, 169.54, 168.95 (NHCO), 156.35 (CO2NH), 135.95 (l-C A ), 
128.38 (m -C A ), 128.10 (p-CcHj), 127.85 (0-C4 I5), 67.03 (CsHjCHj), 61.31 (ÇH2CH3),
53,59 (CHCH2), 49.08 (ÇHCH3), 42.79 (CH2CO2CH2), 41.38 (NHÇH2CO),
41.12 (CHCH2CH), 24.54 (CH(CH3)2), 22.78, 21.72 (CH(CH3)2). 18.01 (CHCH3) and 
13.93 (CH2CH3); m/z (Cl) 496 (4%. [M +11 + N I I 3] ) ,  479 (47, [M + H]*), 388 (17, [M + H 
- CH2CSH5]*), 371 (100, [M - C A C H 2O]') and 345 (16, [M + 2H-COjCHjCsH ,]*).
3.0.2.36 t-Butyl carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl
glycinate (67)
This compound was prepared in a manner Identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) using carbobenzyloxy-(2S)- 
leucyl (2S)-alanyl glycine (27) (0.150 g, 0.381 mmol) and tertiary-butyl glycinate acetate (73 
mg, 0.381 mmol) to give a white solid (228 mg, 72%), w/z (Found: [M + H]*, 507.2808.
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C25H39N4O7 requires 507.2819); 8» (300 MHz; ^HaCO^H) 7.38 (5H, m, CsHs), 5.14 (IH, d.
Jc% 12.46, CACH.Hb), 5.11 (IH, d, Jcn„ 7.39, CsHsCaHb), 4.36 (IH , q, Jai, 6.64, 
CHCHj), 4.21 (IH, t, Ja i, 7.45, NHCHCHj), 4.01 (IH, d, Jch,, 16.74, NHCH.HbCO), 3.88
(3H, m, NHCHHbCO and CH2CO2), 1.74(11-1, sep, J  6.43, CH(CH3)2), 1.61 (2H, t, Jai 
6.57, CI-ICH2), 1,50, 1.49 (9H, ds. € (01-13)3), 1.42(311, d. Jai 7.00, CHCH3), 0.98 (3H, d, 
J c h  5.56, C H (C H 3)z )  and 0.97 (3H, d, Jai 5.94, CH(CH3)2); 5 c  (75.5 MHz; ^H 3C 0 ^H ) 
175.67, 175.21, 171.94, 170.24 (4 x CO), 158.71 (CO2NH), 138.08 (/-CeHs), 129.44 
(m-CcHs), 129.00 (p-CcHs), 128.82 (o-C«Hs), 82.82 (C(CH3)3), 67.79 (C6H5ÇH2), 
54.98 (ÇHCH2), 50.76 (ÇHCH3), 43.32 (ÇH2CO2CH2), 42.84 (CH2CO), 
42.72 (CHÇH2CH), 28.28 ( € ( ^ 3)3), 25.80 (ClfrCHs);), 23.49, 21.87 (CH(CH3)2) and
17.48 (CHÇH3); m/z (Cl) 507 (4, [M H-11]'), 451 (30, [M 4-2H - C(CH3)3]*) and 136 (100, 
[CoHsCH20CHOr).
3.0.2.39 Methyl carbobenzyloxy-glycyl glycinate (68)^ ^^
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl--alaninate (29) using carbobenzyloxy-glycine (34) (3.51 g, 16.8 
mmol) and methyl glycinate hydrochloride (54) to give a white solid (2.86 g, 61%), m.p. 
63°C (lit.,'"  63-65°C), m/z (Found: [M + H ]'. 281.1137. Calc, for C,3Hi7N203 281.1137); 
Oma. (Nujol)/cin' 3350, 3330 (2 x Nil), 3050 (aromatic CH), 1730 (C02Me) and 
1710 (CO2NH); 5„ (200 MHz; C^HCij) 7.33 (5H, m, C A ) ,  6.66 (IH, t, NHCO). 5.60 (IH, 
t, NHO2C), 5.13 (2H, s, CbHsCHz), 4.04 (2H, d, Jmi 5.12, CH2C02Me), ), 3.92 (2H, d, Jwu
5,78, CONHCH2), 3.75 (3H, s, OCH3); S<- (74,8 MI-lz; C^HCI,) 170.08, 169.46 (2 x CO), 
156.56 (CO2NH), 135.95 (/-CbHs), 128.37 (m-Cf,Hs), 128.06 (p-CjHs), 127.88 (o-C^Hs), 
67.03 (C6H 5ÇH2), 52.22 (OCH3), 44.17 (CFkCOiMe), 40.89 (NHÇH2CO); m/z (Cl) 281
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(100%, [M + H]*), 237 (50, [M + H - CO2]*), 209 (5, [M + H - CO2 - CO]*), 190 (20, [M + 
H - C6H5CH2]*), 173 (3, [M - C6H5CH2O]*) and 147(31, [M + 2 H -C 6H5CH2O2C]*).
3,0.2,38 Ethyl carbobenzyloxy-glycyl glycinate (69/^^
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl-alaninate (29) using carbobenzyloxy-glycine (34) (3.51 g, 16.8 
mmol) and ethyl glycinate hydrochloride (40) to give a white solid (2.93 g, 59%), m.p. 78°C 
(lit.,'"  78-80°C), (Found: C, 56.95; H, 6.0; N, 9.4. Calc, for Cifrf^NzO; C, 57.1; H, 6.15; 
N, 9.5%); OmaK (Nujol)/cm'' 3300, 3250 (NH), 3080 (aromatic CH), 1750, 1740 (NHCO and 
COiEt), and 1690 (CONH); 5„ (200 MHz; C^HClj) 7.34 (5H, m, C«H,), 6.88 (IH, t, 
NHCO), 5.81 (IH, t, NHO2C), 5.12 (2H, s, C A C H ;), 4.18 (2H, q, J ch ,  7.11, OCH2), 4.00 
(2H, d, Jnh 5.42, CI&COEt), ), 3.91 (2H, d, Jnh 5.58, CO2NHCH2) and 1.26 (3H, t, J c h ,
7.14, CH3); 5c (50.3 MHz; C'HCl;) 170.31, 170.04 (CONH and COzMe), 157.21 (CO2NH), 
136.63 (z-CgH;), 129.04 (m-CsHs), 128.72 (p-CMs), 128.57 (o-C«Hs), 67.69 (C«H5CH2),
62.10 (0 CH2), 44.85 (ÇH2CO2CH2), 41.72 (O2CNHÇH2) and 14.60 (CH3); m/z (Cl) 295 
(29%, [M + H]*), 269 ( 100, [M - C2H2]*), 249 (17, [M - OEt]*) and 114 (49, [M + H - OEt 
- CÆ 5CH2O2C]*).
3.0.2.39 Methyl glycyl glycinate (70)
To a stirred solution of methyl carbobenzyloxy-glycyl glycinate (68) (1.77 g, 6.3 mmol) in 
methanol (20 ml) was added wet carbon/palladium catalyst (5%, 185 mg, 10% Pd by mass). 
The flask was sealed, flushed with argon, then hydrogen and the mixture was stirred under an 
atmosphere of hydrogen with vigorous stirring. The reaction was followed to completion by 
silica chromatography eluting with 5% methanol / 95% methylene chloride (414 h). The
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reaction mixture was filtered through celite and the methanol removed under reduced 
pressure to give a white solid (0.74 g, 81%), m.p. 198°C (sublimes), 209 (decomp.); Umax 
(Nuiol)/cm‘‘ 3300, 3170 (NH), 3050 (aromatic CH), 1710, 1700, 1680 (2 x CONH and 
COzMe); 5h (300 MHz; ^C O '^H ) 4.05 (2H, s, CHzCOzMe), 3.47 (2H, s, NHCH2CO) and
3.44 (3H, s, OCH3); m/z (El) 146 (25, [M]*), 115 (4, [M - OM ef) and 86 (6, [M - CO - 
MeOH]*).
3.0.2.40 Ethyl glycyl glycinate (71)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-glycyl glycinate (70) using ethyl carbobenzyloxy-glycyl glycinate (69) (1.86 
g, 6.3 mmol) to give a white solid (0.82 g, 81%), m.p. 80°C (sublimes at 77°C); m/z (Found: 
[M]*. 160.0848 CsHijNzOj requires 160.0848); u„„ (Nujol)/cm'‘ 3400, 3310 (2 x NH), 
1740 (COzEt) and 1650 (NHCO), 5 h  (200 MHz; "H3CCN) 4.15 (2H, q, Jen, 7.12, OCH3), 
3.92 (2H, d, Jnh 6.02, CHzCOEt), ), 3.23 (2H, s, NH2CH2) and 1.24 (3H, t, J ch,  7.13. CH3);
5c (100 MHz; ^HsCCN) 174.47, 171.07 (2 x CO), 61.79 (OCH2), 45.25 (CH2CO2CH2),
41.45 (O2CNHÇH2) and 14.44 (CH,); m/z (Cl) 161 ( 100%, [M + H]*), 146 (2, [M + H - 
Me]*), 132 (2, [M + H - OEt]*), 115 (2, [M + H - Et - NH3]*) and 104 (5, [M + 2H - 
NH2CH2CO]*).
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3.0.2.41 Benzyl tertiary-butoxycarbonyl-(2S)-leucyl (2S)-alanyl 
glycyl glycinate (72)
This compound was prepared in a manner identical to that described for methyl 
oarbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl-glycinate (65) using tertiary-butoxycarbonyl- 
(2S)-leucyl (2S)-alanyl glycine (46) (0.200 g, 0.557 mmol) and benzyl glycinate tosylate (44) 
(197 mg, 0.557 mmol) to give a white solid (189 mg, 65%), m/z (Found: [M + H]*, 
507.2826. C25H39N4O7 requires 507.2819); 5 h  (300 MHz; % CO ''H ) 7.38 (5H, m, QHs), 
5.20 (2H, s, C6H5CH2), 4.36 (IH, q, Jca, 7.06, CHCH3), 4.12 (IH, t, Jen, 7.32, NHCHCH2),
4.44 (2H, s, CH2CO2), 4.02 (IH, d, J ch,, 22.56, NHCHJÏbCO), 3.88 (IH, d, J ch .  16.96, 
NHCH.HbCO), 1.72 (IH, sep, J6 .51, CH(CH3)2), 1.56 (2H, t, Jch 6.80, CHCH2), 1.47 (9H, 
ds, C(CH3)3), 1.42 (3H, q, J ch  7.14, CHCH3), 0.98 (3H, d, J ch 6.49, CH(CH3)2) and 
0.97 (3H, d, J ch  9.32, CH(CH3)2); 5 c  (75.5 MHz; % CO^H) 176.02, 175.94, 175.26, 127.01 
(4 X CO), 158.09 (CO2NH), 137.10 (z-C^Hs), 129.52 (zn-CsHs), 129.24 (p-CMs),
129.15 (o-CsHs), 80.68 (C(CH3)3), 67.82 (C A C H ;), 54.49 (ÇHCH2), 50.84 (ÇHCH3),
43.34 (CH2CO2CH2), 42.02 (ÇH2CO), 41.87 (CHÇH2CH), 28.71 (C(£H3)3),
25.81 (CH(CH3)2), 23.48, 21.89 (CH(CH3)2) and 17.59 (CHÇH3); m/z (Cl) 507 (5%, [M + 
H]) 451 (17, [M + 2 H - C(CH3)3]*), 433 (38, [M - OC(CH3)3]*) and 407 (100, [M + 2H - 
C02C(CH3)3]*).
3.0.2.42 Tertiary butyl tertiary-butoxycarbonyl-(2S)~leucyl-(2S)~ 
alanyl-glycyl glycinate (73)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl-(2S)-alanyl-glycyl-glycinate (65) using tertiary butoxycarbonyl- 
(2S)-leucyl (2S)-aIanyl glycine (46) (400 mg, 1.11 mmol) and tertiary butyl glycinate acetate
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(212 mg, 1.11 mmol). Recrystallisation from methanol / ether gave white crystals (197 mg, 
75%), m,p. 153“C; (Found: C, 55.7; H, 8.55; N, 11.7. C22H40N4O7 requires C, 55.9; H, 8.55; 
N, 11.85%);ZM/z(Found: [M + H]*, 473.2975. C22H41N4O7 requires473.2975); [a]n-27.3 (c 
0.15 in MeOH); (KBr disk)/cm'‘ 3400, 3305, 3086 (3 x NH), 2980, 2925, 2860 (3 x 
aliphatic CH), 1735, 1710 (CO2NH and COjt-Bu), and 1690, 1655, 1635 (3 x CONH); 5h 
(300 MHz; C^HClj) 7.70 (2H, m, NHCH; and NHCHj), 7.55 (IH, t, NHCHj), 6.23 (IH, d, 
Jch 7.00, COjNH), 4.37 (IH, sex, Jca, 6.09, NHCHCHj), 4.14 (IH, q, J7.16, CHCH3), 3.88 
(4H, qd, Jch 13.04, Jch 3.99, NHCH2), 1.74 (IH, sep, CH(CH3)2), 1.60 (2H, m, 
CHCH2CH), 1.44 (9H, s, NC02C(CH3)3), 1.41 (9H, s, C02C(CH3)3), 1.35 (3H, d, Jch 7.08, 
CHCHs) and 0.918 (6H, q, J  5.30, CH(CH3)2); 5c (50.3 MHz; C^'HCb) 174.45, 173.88,
170.29, 169.88 (4 x NHCO), 157.19 (CO2NH), 81.04, 79.89 (C02C(CH3)3 and 
NC02£(CH3)3), 54.42 (ÇHCH2), 50.92 (CHCH3), 43.62, 42.84, 42.18, (CH2CONHÇH2, 
CHÇH2CH), 28.84 (NHC02C(CH3)3), 28.57 (C02C(CH3)3), 25.76 (£H(CH3)2), 23.88, 
22.32 (CH(CH3)2) and 18.37 (CHÇH3); m/z (Cl) 490 (20%, [M + H + NH,]), 473 (50, [M + 
H]*), 434 (40, [M + H + NH3 - C(CH3)3]*), 417 ( 100, [M + H - C(CH3)s]*), 361 (34, [M + 
2 H - 2C(CH3)3]*) and 317 (50, [M + 2 H - 2C(CH3)s - CO2]*).
3.0.2.43 Ethyl (2S)-leucyl (2S)-alanyl glycyl glycine (74)
This compound was prepared in a manner identical to that described for the the methyl 
carbobenzyloxy-glycyl glycinate (70) using ethyl carbobenzyloxy-(2S)-leucyl (2S)-alanyl 
glycyl glycine (66) (400 mg, 0.762 mmol) to give a yellow oil (287 mg, 100%), zztz'z (Found: 
[M + H]*, 345.2141. C15H28N4O5 requires 345.2138); 5h (200 MHz; % CO^H) 4.31 (IH , q, 
JcH; 7.13, CHCH3), 4.18 (2H, q, Jch,  7.11, OCH2), 4.00 (IH, d, Jh,, 12,45, NHCHJHb), 3.94
(2H, s, CmCOzEt), 3,84 (IH, d, J„^ 17.05, N H C H & ), 3.45 (IH, t, Jcu, 6.70, NHCHCHa),
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1.71 (IH, sep. J  6.59, CIKCH;):), 1.53 (2H, t, .A.i, 7.08, CHCHzCH), 1.40 (3H, d, Jch 6.15, 
CHCHa) 1.29 (3H, t, 7.57 CH2CH3), 0.97 (3H, d, ./ 6.15, CH(CH3)z) and 0.94 (3H. d, J
5.78, CH(CH3)2); 5c (50.3 MHz, C^HjO^H) 177.99, 175.73, 172.39, 171.49 (4 x CO), 62.62 
(OCH2), 54.49 (NHÇHCH2), 51.15 (CHCH3), 45.22, 43.69 (ÇH2CO), 42.27 (CHCH2),
25.96 (CH(CH3)2), 23.80, 22.67, (CH(CH3)3), 17.89 (CHCH3) and 14.30 (CH2ÇH3); m/z
(Cl) 345 (5%, [M + H]*), 288 (39. [M + 11 - CH2CH(l\4e)2]*) and 231 (100, [M + H - 
COCH(NH2)CH2CH(Me)2]').
3.0.2.44 N-(Carbobenzyloxy-(2S)-leucyl-(2S)-alanyl-glycyl)-
ethanolamine (75)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) using ethanolamine 
hydrochloride (99 mg, 1.02 mmol) to give a clear yellow oil (169 mg, 33%), [a]n -32.3 (c 
0.28 in MeOH); (thin film)/cm"' 3300 (OH), 3100 (aromatic CH), 2800 (aliphatic CH), 
1700 (CO2NH) and 1680, 1630, 1620 (4 x CONH); 5,i (300 MHz; % C O % , 7.37 (5H, m, 
C A ) , 5.12 (2H, s, CbHsCIfc), 4.29 (IH, q. J  6.29, CHCH3), 4.20 (IH, I, NHCHCH2), 3.96 
(IH, d, Jen 16.83, NHCH.Hb), 3.78 (IH, d, Jc„ 16.79, NHCH.H1,), 3,64 (2H, t, J a t ,  5.19, 
OCH2), 3.36 (2H, t, Jcu, 3.24, NCH2CH2), 1.74 (IH, sep, J6 .07 , CH(CH3)2), 1.61 (2H, d, J  
6.21, CHCH2CH), 1.41 (3H, d, Jen 6.37, CHCW3), 0.99 (3H, d, Jc„ 5.79, CH(CH3)2 and 
0.97 (3H, d, Jen 6 .12, CH(CH3)2); 5c (75.5 MHz, ^C O ^ 'H ) 175.88, 175.33, 171.70 (3 x 
CO), 158.69 (CO2NH), 138.11 (/-C0H5), 129 47 (zn-CsHs), 129.08 (p-CsHj), 128.80 (o- 
C A ) ,  67.77 (ÇH2C A ) ,  61.44 (CH2O), 54.98 (CHCH2), 51.07 (ÇHCH3), 43.56 (NHCHj),
43.21 (NHCH2CH2), 43.10 (CIIÇH2), 25.79 (CH(CH3)2), 23.44, 21.90 (CH(CH3)2) and 
17.26 (CHCH3).
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3.0.2.45 Sodium carbobenzyioxy-(2S)-ieucyi (2S)-aianyi giycyi
glycinate (76)
This compound was prepared in a manner identical to that described for the 
carbobenzyloxy-(2S)-leucyl (2S)-alanine (29) using methyl carbobenzyloxy-(2S)-leucyl (2S)- 
alanyl glycyl glycinate (65) (1.32g, 2.83 mmol) without acidification to give a white solid 
(1.32 g, 98%). m.p. 140°C; u„,„ (Nujol)/cm ' 3400 (NH), 2550 (aliphatic CH), 1730 
(CO2H), 1705 (CO2NH). 1650, 1670, 1680 (3 x CONH); Bn (300 MHz; "HjCO^H) 7.38 
(5H, m, CcHs), 5.16 (IH . d, 12.51, CsHsCH,Hi,), 5.16 (IH , d, Jn. 12.42, CcHsCHaHu), 
4.39 (IH . q, Jen, 7.14, CHCHj), 4.20 (IH , t, 7.05, NHCHCH2), 3.99 (IH , d, 16.77, 
NHCH,Hb), 3.86 (IH , d, \  16.74, NHCH,Hb), 3.85 (IH , d, 17.3, NHCHoHj), 3.74 
(IH , d, J„^ 17.07, NHCHcHd), 1-74 (IH , sep, J  6.61, CIKCH;);), 1.61 (2H, t, Jai 7.17,
7 . 4 1 ,  C H C H 2C H ) .  1 .4 3  ( 3 H ,  d, Jai 7 . 1 4 ,  C H C H 3)  and 0 . 9 8  ( 6H ,  t, J  6 . 3 9 ,  C H ( C Ï Ï 3) 2) ;  5c 
( 7 5 . 5  M H z ,  C ''H 3 0 ' 'H ) 1 7 6 . 5 3 ,  1 7 5 . 8 4 ,  1 7 5 .5 8 ,  1 7 1 .3 7  ( 4  x  C O ) ,  1 5 9 . 0 0  ( C O 2N H ) ,  1 3 8 .4 3  
(/-CbHs), 1 2 9 . 7 7  ( n i - C o H s ) ,  1 2 9 . 3 0  (/z-C^Hs). 1 2 9 . 1 4  (o -C A ) ,  6 8 . 0 9  (ÇH2C6H5),
5 5 . 2 8  ( Ç H C H 2) ,  5 1 .0 1  ( G H C H 3) ,  4 4 . 6 7 ,  4 3 . 8 8 ,  ( C H 2C O ) ,  4 2 , 1 4  ( C H C l f c ) ,
2 6 . 1 3  ( C H ( C H 3) 2) ,  2 3 . 8 1 ,  2 2 . 12 , ( C H ( £ H 3) 3)  and 1 7 .9 7  ( C H C H 3) .
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3.0.2.46 Carbobenzyloxy-(2S)-leucyl-(2S)-alanyl-glycyl-amino
acetonitrile (78)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) using amino acetonitrile 
hydrochloride (85) (94 mg, 1.02 mmol). Recrystallisation from MeOH / ether gave white 
crystals (370 mg, 78%), m.p. 159°C; (Found: C, 58.55; H, 6.5; N, 16.2. C21H29N3O5 requires 
C, 58.45; H, 6.8; N, 16.25%); m/z (Found: [M + H  + NH;]*, 449.2510. C21H33N6O5 requires 
449.2510); [ajn -24.6 (c 0.13 in MeOH); (chloroform solution)/cm‘‘ 3330 (NH), 3020 
(aromatic CH), 2400 (CN) and 1735, 1701, 1685, 1676, 1642 (CO2NH and 4 x CONH); 
5h (400 MHz; ^C O C '^H a) 7.97 (IH , t, NHCH2), 7.88 (IH. d, J c h  4.32. NHCH,), 7.73 (IH . 
t, NHCH2), 7.37 (5H, m, CgH,), 6.65 (IH , d. Jch 7.44. CO2NH), 5.10 (IH , d, J»^ 20.43, 
CaBbCsHs), 5.07 (IH , d, J„, 20.46, C H aC gH ;), 4.27 (2H, m, CHCHj and NHCHCH2), 
4.17 (2H, d, Jnh 5.76, NHCHz), 3.95 (IH , dd, Jnh 6.56, J ch ,  10.48, NHCH,Hb), 3.79 (IH , 
dd, Jnh 6.22, Jch, 11.44, NHCH,Hb), 1.75 (IH , sep, J c h ,  6.71, CfKCH,);), 1.62 (2H, t, J c h ,
7 . 2 6 ,  C H C H 2C H ) ,  1 .3 4  ( 3 H ,  d, Jch 7 . 0 4 ,  C H C H 3)  and 0 . 9 2  ( 6 H ,  ra, CniCEzh); 5c ( 1 0 0  
MHz; (^H3C)20) 1 7 4 .4 6 ,  1 7 3 .3 7 ,  1 7 0 . 3 9  (3  x N H C O ) ,  1 5 7 .4 0  ( C O 2N H ) ,  1 3 8 .0 1  ( i - C « H : ) ,
1 2 9 . 1 9  (zM -C b H ;), 1 2 8 .6 5  ( p - C g H ; ) ,  1 2 8 . 5 9  ( o - C s H j ) ,  1 1 7 .5 2  ( C N ) ,  6 6 . 9 4  (C S H 5Ç H 2) ,  5 4 .5 3  
( Ç H C H 2) ,  5 0 . 7 3  ( C H C H 3) ,  4 3 .2 1  ( C H 2C O N H C H 2) ,  4 1 . 7 6  ( C H Ç H 2C H ) ,  2 7 . 6 8  ( C H j C N ) ,
2 5 . 3 1  (CH(CH3)2), 2 3 . 3 7 ,  2 1 . 8 9  ( C H ( C H 3) 2)  and 1 7 . 2 6  ( C H Ç H 3) ;  m/z (Cl) 4 4 9  ( 5 7 % , [M + 
H + N H 3] ) ,  3 4 1  ( 100 , [M + N H 3 -  C 5H 5C H 2O ]* ) .  3 2 4  ( 2 3 ,  [M - O C H j C s H s ] * )  and 2 9 7  ( 3 0 ,  
[M + H - C O 2C H 2C 6H 5]* ) .
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3.0.2.47 Tertiary-butoxycarbonyl-(2S)4eucyH2S)-alanyl- 
glycyl amino acetonitrile (79)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)“leucyl (2S)-alanyl glycyl glycinate (65) using tertiary butoxycarbonyl- 
(2S)-leucyl (2S)-alanyl glycine (46) (200 mg, 0.556 mmol) and aminoacetonitrile 
hydrochloride. Recrystallisation from MeOH / ether gave white crystals (125 mg, 56%), m.p. 
162°C; (Found; C, 54.35; H, 7.7; N, 17.35. C18H31N5O5 requires C, 54.4; H, 7.85; N, 
17.65%); m/z (Found: [M + H]", 398.2403. C18H32N5O5 requires 397.2325); [a]o -29.3 (c 
0.15 in MeOH); Umax (KBr disk)/cm'^ 3320 (NH), 3065 (aromatic CH), 2965, 2875 (2 x 
aliphatic CH), 2280 (CN), 1700 (CO2NH) and 1685, 1675, 1650 (3 x CONH); Ôh (300 
MHz; % C O C % ) 8.01 (IH, t, NHCH2), 7.87 (IH, d, NHCH3). 7.79 (IH, t, NHCH2), 6.30 
(IH, d, J ch 7.50, CO2NH), 4.26 (IH, m, Jch, 6.78, J nh 6.39, NHCHCH2), 4.18 (2H, d, J nh 
5.97, CH2CN), 4.12 (IH, m, Jnh 7.0, CHCH3), 3.94 (IH, dd, J nh 6.41, Jch, 10.74. 
NHCHaHb), 3.79 (IH, dd, J nh 5.79, Jch, 11.28, N H C H * ), 1.734 (IH, sep, Jch, 6.65, 
CH(CH3)2), 1.60 (2H, dd, Jch, 6.69, 7.25, CHCH2CH). 1.40 (9H, s, C(CH3)3), 1.35 (3H, d, 
J ch 7.11, CHCH3), 0.93 (3H, d, J  6.45, CH(CH3)2) and 0.91 (3H, d. J  6.12, CH(CH3)2); 
5c (75.3 MHz. (''H3C)20C) 175.28, 173.90, 170.84 (3 x NHCO), 157.34 (CO2NH), 117.94 
(CN), 80.04 (C(CH3)3), 54.53 (ÇHCH2), 51.13 (ÇHCH3), 43.62 (CH2CONHCH2), 42.04 
(CHÇH2CH), 28.93 (C(£H3)3), 28.11 (CH2CN), 25.73 (CH(CH3)2), 23.79, 22.35 
(CH(CH3)2) and 17.77 (CHCH,); m/z (Cl) 415 (24%, [M + H + NH3]*), 398 (9, [M + H]*), 
359 (22 , [M + NH3 + H - C(CHs)3]*), 341 (8, [M + H - C(CH3)3]*), 297 (30, [M + H - 
C02C(CH3)3]*) and 298 (100, [M + 2H - C02C(CH3)3]*)-
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3.0.2.48 Carbobenzy!oxy‘-(2S)-leucyl (2S)-alanyl (2S)-alanyl
aminoacetonitrsle (80)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) using carbobenzyloxy-(2S)- 
leucyl (2S)-alanyl (2S)-alanine (88) (200 mg, 0.49 mmol) and aminoacetonitrile 
hydrochloride (45 mg, 0.49 mmol) to give a white solid which was recrystallised from 
MeOH / ether to give white crystals (144 mg, 66%). m.p.l61-162°C; (Found: [M + H]", 
446.2410. C22H32N5O5 requires 446.2417); [a]n -50.8 (c 0.13 in MeOH); Umax (KBr 
disc)/cin‘ 3290 (NH), 3060 (aromatic CH), 2930, 2910, 2880, 2850 (4 x aliphatic CH), 
2260 (CN) and 1710, 1680, 1650, 1640 (CO2NH and 3 x CONH); Sn (300 MHz; ^HgCO^H) 
7.38 (5H, m, C«Hs), 5.14 (2H, m, CcHsCHj), 4.35 (2H, q, Jc„, 7.11, CHCHj), 4.19 (2H, s,
CH2CN), 4. 19 (IH, m, NHCHCH2), 1.71 (IH, sep, .7 6.74, ClgCHs);), 1.60 (2H, t, J7 .26 , 
CHCH2CH), 1.41 (3H, d, J c h  5.16, CHCH3), 1.39 (3H, d, J c h  5.39. CHCH3), 1.00 (3H, d, 
J c h  6 .88, CH(CH,)2) and 0.97 (3H, d, J ch 7.04, CH(CHb)2); Sc (75.5 MHz; % C 0 %  
175.78, 175.05, 174.68 (3 x NHCO), 158.70 (CO2NH), 138.13 ( / - C * ) ,  129.47 (z» -C *),
129.00 (p - C * ) ,  128.71 (o-CbHs), 117.42 (CN). 67.76 (CjHsCHj), 54.24 (NHCHCH2), 
50,66, 50.28 (CHCH3), 41.85 (ÇH2CH), 28.03 (CHjCN), 25.84 (CH(CHs)2), 23.38, 21.92 
(CH(CH3)2) and 17.57, 17.63 (CHÇII3); m/z (Cl) 446 (50%, [M + H]*), 408 (45, [M + H - 
CH2CN]*), 338 ( 100, [M - OCHjCcHs)]') and 312 (30, [M + 2H - O2CCH2C6H5)]*).
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3.0.2.49 Carbobenzyloxy-(2S)-leucyl-(2S)-alanyl (2R)-alanyl-
aminoacetonlMIe (81)
This compound was prepared in a manner identical to that described for methyl 
carhobenzyloxy-(2S)-leucyI (2S)-alanyI glycyl glycinate (65) using carbobenzyloxy-(2S)- 
leucyl (2S)-alanyl (2R)-alanine (91) (200 mg, 0.49 mmol) and aminoacetonitrile 
hydrochloride (85) (45 mg, 0.49 mmol) to give a white solid which was recrystalised from 
MeOH / ether to give white crystals (144 mg, 66%), m.p.l40“C; (Found: [M + H]*, 
446.2408. C22H32N5OS requires 446.2417); [a]n -16.6 (c 0.20 in MeOH); (KBr 
disc)/cm'‘ 3300 (NH), 3030 (aromatic CH), 2920, 2900, 2850 (3 x aliphatic CH), 2250 (CN) 
and 1690, 1670, 1650, 1640 (CO2NH and 3 x CONH); 5» (300 MHz; % CO^H) 7.36 (5H, 
m, C«H;), 5.16 (IH, d, 12.44, C A C H * ) ,  5.16 (IH, d, Jh 12.45, C * C H * ) ,  4.38
(IH, q, Jch , 7.23, CHCH3), 4.28 (IH, q, Jch , 7.21, CHCHj), 4.20 (IH, d, Jh^ 7.47, 
CH.HbCN), 4.17 (IH, m, NHCHCH2), 4.13 (IH, d, J h J -4 6 , C H *C N ), 1.74 (IH, sep, J  
6.69, CH(CH3)2), 1.60 (2H. t, J  7.27, CHCH2CH), 1.43 (3H, d, Jch  7.36, CHCH3), 1.40 
(3H, d, Jch  7.15, CHCH3), 0,98 (3H, d, Jch 5.97, CH(CH3)2) and 0.96 (3H, d, Jch 6.26, 
C H (C a )2); 5c (75.5 MHz; ^HsCO^H) 176.17, 175.59, 175.23 (3 x NHCO), 159.03 
(CO2NH), 138.44 (z-CsHs), 129.77 (zzz-C*), 129.32 (p-CgH;), 129.15 (o -C * ) , 
117.73 (CN), 68.11 (C6H5CH2), 55.23 (QHCHz), 51.20, 50.63 (CHCH3), 42.20 (CHjCH),
28.45 (CH2CN), 26.14 (£H(CH3)2), 23.71, 22.21 (C ^C H ;):) and 17.77, 17.45 (CHCH3); 
m/z (Cl) 446 ([M + H)]*, 100%), 338 (15, [M - OCHiC^H;)]*) and 312 (18, [M + 2H - 
OiCCHzC*)]*).
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3.0.2.50 Trifluroacetyl-(2S)-leucyl-(2S)-alanyl-glycyl-amino
acetonitrile (82)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) using trifluoroacetyl-(2S)-leucyl 
(2S)-alanyl glycine (97) (172 mg, 0,484 mmol) and amino acetonitrile hydrochloride (85) (45 
mg, 0.484 mmol) to give an orange oil which was purified by silica chromatography eluting 
with 3:1 dichloromethane / 40 / 60 petroleum ether until the impurities eluted off and then 
elution with ethylacetate to give a pale yellow oil (156 mg, 82%), m/z (Found: [M + H]*, 
394.1711. CisHisNsOjFs requires 394.1702); [a]n -11.9 (c 0.16 in MeOH); Um>x (thin 
film)/cm‘‘ 3295, 3075 (2 x NH), 2960, 2875 (2 x aliphatic CH), 2280 (CN) 1710 (CO2NH) 
and 1680, 1675, 1665 (3 x CONH); 5» (300 MHz; % C 0 %  4,54 (IH, q, Jch, 4.53,
CHCH3), 4.33 (IH, sep, J6 .94, NHCHCH2), 3.96 (IH, d, Jch, 12.39, NHCH.Hb), 3.89 (IH, 
d, J c h ,  9.8, NHCH.Hb), 1.84 (IH, m, CH(CH3)2), 1.72 (2H, t, J c h ,  9.03. CHCH2CH), 1.43 
(3H, d, J ch 7.15, CHCH3), 1.03 (3H, d, J  6.44, CH(Ca,)2) and 1.01 (3H, d, J  3.30, 
CH(CÏÏ3)2); 5 c  (75.5 MHz; % C 0 C''H3) 175.40, 173.85, 173.68, 171.90(4 x NHCO),
159.23 (q, J c F , 36.96, COCF3). 109.25 (CF3), 109.14 (CN), 53.86, 53.29 (CHCH2), 51.11, 
51.06 (ÇHCH3), 43.33 (CH2CONHCH2), 41.28, 41.23 (CHCH2CH), 25.97, 25.91 (CH2CN), 
24.77, 24.74 (CH(CH3)2). 23.35, 23.29, 21.94, 21.73 (CH(CH3)2) and 19.35, 17.29 
(CHCHs); m/z (Cl) 394 (100%, [M + H]*), 376 (14, [M + H - H2O]*), 355 (50, [M - HF - 
F]*) and 281 (65, [M - NHCOCFsf).
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3.0.2.51 Tnfluoroacetyl-(2S)-alanyl-glycyl-amidoacetonitr!le (83)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyioxy-(2S)-leucyI (2S)-alanyl glycyl glycinate (65) using trifluoroacetyl-(2S)-alanyI 
glycine (100) (181 mg, 0.748 mmol) and aminoacetonitrile hydrochloride (69 mg, 0.748 
mmol). A white solid resulted which was recrystallised from dichloromethane / hexane to 
give white crystals (72 mg, 35%), m.p. 149°C; m/z (Bound: [M + H]", 281.0860. 
C9H 12N4O3F3 requires 281.0862); [a]o -41.3 (c 0.16 in MeOH); (KBr disk)/cm'‘ 3370, 
3300 (2 X NH), 3060, 2990, 2950 (3 x aliphatic CH), 2255, 2240 (2 x CN) and 1720, 1710, 
1695, 1675, 1665, 1655 (6 x CONH); 6» (300 MHz, C%O^H) 4.50 (IH, q, Jca, 7.19,
CHCH3), 4.22 (2H, s, CH2), 3.98 (IH, d, Jh^ 16.86, C H * ) ,  3.91 (IH, d, Jh, 16.87, C H * )  
and 1.49 (3H, d, Jch 7.17, CH3); 5c (73.5 MHz, C2H3O2H) 174.35, 171.99 (2 x CO), 159.24 
(q, JcF, 37.5, COCFs), 117.66 (CN), 117.61 (q, Jp, 286, CF3), 51.30 (CH), 43.55 (CH2CO),
28.23 ( C H 2C N )  and 17.65 ( C H 3) ;  m/z (Cl) 281 ( 100%, [M + H]*), 260 (22, [M - HF]*) and 
225(31, [M + H - H 2N C H 2C N ] * ) .
3.0.2.52 Trifluoroacetyl-glycyl-amidoacetonitrile (84)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) using trifluoroacetyl-glycine 
(98) (0.41 g, 2.41 mmol) and aminoacetonitrile hydrochloride (85) (0.22 g, 2.41 mmol) to 
give an off white solid which was recrystalised from methanol to give white needle shaped 
crystals (283 mg, 57%), m.p. 143°C; (Found: C, 34.4; H. 2 .6; N, 19.85. CANsOzF , 
requires C, 34.45; H, 2.9; N, 20.10%; m/z (Found: [M + H]*, 210.0491. C6H7N3O2F3 
requires 210.0491); u™, (KBr disk)/cm‘‘ 3300, 3100 (2 x NH), 2990, 2940, 2795, 2710 (4 x 
aliphatic CH), 2270 (CN) and 1730, 1670 (2 x CONH); 5h (200 MHz, ^C O '^H ) 4.20 (2H,
3.0 Compound synthesis______________________________________________________ 202
s. CH2CON) and 3.99 (2H, s. CH2CN); 5c (73.5 MHz, 2H3CO2H) 170.54 (CO), 159.60 (q, 
JcF, 148.2, ÇOCF3), 117.65 (q, Jp-, 570.0, CF3), 115.80 (CN), 43.27 (CHj) and
28.26 (CI-tCN); i)i/z (Cl) 210 ( 100%, [M + H]').
3.0.2.53 Aminoacetonitrile hydrochloride (85)
Methyleneaminoacetonitrile (40 mg, 0.74 mmol) was dissolved in ethanolic HCl 
(l.Omoldm'^j 0.88 cm^) at -5°C and stirred for 1 li. The solvent was removed under reduced 
pressure and the white light sensitive solid was reciystallised from ethanol / ether to give 
white crystals (8.5 mg, 13%), ô» (300 MHz, "lECO^H) 4.13 (s, CH2); 5c (75.5 MHz, 
% CO^H) 115.08 (CN) and 28.31 (CHg).
3.0.2.54 [  1-^^C]-Carbobenzyloxy-(2S)-leucyl-(2S)-alanyl-glycyl-
amino acetonitrile (86)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) using [l-"C]-aminoacetonitrile 
hydrochloride (102) (39 mg, 0.417 mmol). Recrystallisation from MeOH / ether gave white 
crystals (162 mg, 90%), m/z (Found: [M + 11]*, 433.2279. C2o"CH3oN50s requires 
433.2280); 8,., (300 MHz; H c O ^ H ) 7,38(511, m, CsHs), 5.15 (IH, d. 13.45, 
C H * C * ) ,  5.11 (IH, d, Jh, 12.70, C H * C „H 5), 4.32 (IH, q, Jch^  6.98, CHCHj), 4.19
(2H, d, Jc 8.23, C H A C N  and NHCHCH2), 4.19 (IH, d, Jc 7.49, C H * C N ), 4.00 (IH, d, 
Ja\, 17.05, N H C H * ), 3.83 ( 111, d. Jch, 17.08, N H C H *),), 1.76 (IH, sep, Ja\, 6 .68, 
CH(CFl3)2), 1.61 (2H, t, Jca, 5.71, CHCHjCH), 1.44 (3H, d, J c h  7.11, CHCH3), 1.00 (3H, 
d, J c h  6.38, C ^C H ;);) and 0.98 (3H, d, Ja i 6.27, CH(CH3)2); 5c (75.5 MHz; ^H3C0 ^H)
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175.96, 175.47, 171.99 (3 x N H C O ) ,  158.20 ( C O 2N H ) ,  138.13 ( / - C * ) ,  129.48 (w -C * ) ,
129.03 0>C«H5), 128.81 (o-CbHs), 117.40 ( C N ) ,  67.80 (CjHsCHj), 54.98 ( C H C H 2) ,
50.92 ( C H C H 3) ,  43.30 ( N H C H 2C O ) ,  41.81 ( C I I C H 2C H ) ,  27.94 (d, Je 129, C H 2C N ) ,  25.82 
( C H ( C H 3) 2) ,  23.46, 21.84 (CIKCH,);) and 17.26 ( C H Ç H 3) ;  m/z (CI) 433 (25%, [M + H]*) 
and 325 ( 100, [M - O C l k C c H , ] ' )
3.0.2.55 Methyl carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2S)-
alaninate
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alaninate (37) using carbobenzyloxy-(2S)-leucyl (2S)- 
aianine (29) (0.88 g, 2.62 mmol), methyl (2S)-alaninate hydrochloride (33) (360m g, 2.62 
mmol) and the work up was modified as follows; ethyl acetate was used as a solvent rather 
than ether, the remaining ethyl acetate was azeotropically removed with methylene cliloride 
from the white solid which was then reciystallised from acetone / water to give white ciystals 
(1.27 g, 87%). m.p. 149-I50»C, (lit.,'“  172-173°C); [afc -64.1 (c 0.37 in MeOH); u„,„ 
(KBr disk)/cm‘‘ 3290 (NH), 3080 (aromatic CH), 2980, 2960, (2 x aliphatic CH), 
1750 (C02Me), 1710 (CO2NH) and 1650 (CONH); 5,,(300 MHz; H C O ^H ) 7.38 (5H, m, 
Cbl-lj), 5,13 (21-1, s, C6H5CH2), 4.45 (IH, q, Jai, 7.06, CHCH3), 4.40 (IH, q, J c ,  7.19, 
CHCH3), 4.20 (IH, t, Jen, 7.45, NHCHCHj), 3.75 (3H, s, OCH3), 1.72 (IH, sep, J.6.58, 
CH(CH3)2), 1.59 (2H, t, J  7.03, CHCH2CH), 1.42 (3H, d, Jen 6.61, CHCH3), 1.40 (3H, d, 
Jch 5.25, CHCH3), 0.99 (3H, d, 6.28, C ^C H ;);) and 0.97 (3H, d, Jen 6 .22, CH(CH3):); 
5c (75.5 MHz; % CO^H) 175.13, 174.55, 174.50 (3 x NHCO), 158.56 (CO2NH), 136.19 
(/-CsHs), 129.47 (m -C * ) , 128.99 (p-CcH,), 128.77 (o -C * ) , 67.76 (CA CHz), 54.91 
(CHCH2), 52.72 (OCH3), 50.00, 49.43 (CHCH3), 42.03 (CHjCH), 25.21 (^ (C H ;) ;) ,
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23.44, 21.86 (CH(ÇH3)2) and 18.07, 17.36 (CHÇH3); m/z (Cl) 422 (100%, [M + H]") and 
314(42, [M -O C H 2C6H5)]").
3.0.2.56 Carbobenzyloxy-(2S)-leucyl-(2S)-alanyl (2S)-alanine (88)
This compound was prepared in a manner identical to that described for the 
carbobenzyloxy-(2S)“leucyl (2S)-alaninate (29) using methyl carbobenzyloxy-(2S)-leucyl 
(2S)-alanyl (2S)-alaninate (87) (1.00 g, 2.37 mmol) to give a white solid which was 
recrystallised from MeOH / ether to give white ciystals (661 mg, 69%), m.p. 84-86°C; [a]o -
8 0 .5  (c 0 . 2 2  in MeOH); u,„ax (KBr disc)/cm 3 1 10 ( N H ) ,  3 0 5 0 ,  3 0 3 0 ,  3 0 0 0  (3  x aromatic 
CH), 2 9 2 0 ,  2 8 9 0 ,  2 8 5 0  (3  x aliphatic C H ) ,  1720, 1710 ( C O 2N H  and C O 2H ) ,  and 1 6 8 0 ,  1 6 4 0  
( 2  X C O N H ) ;  S »  ( 3 0 0  MHz; % C O ^ H )  7 . 3 6  ( S H ,  m. C * ) .  5 . 1 3  ( 2 H ,  s, C e H C H z ) ,  4 .4 3  
( 2 H ,  q, Jch, 7 . 1 0 ,  6 . 9 3 ,  2 x C H C H j ) ,  4 . 2 2  ( 111, I, Jch, 8 .2 2 , 6 . 4 9 ,  N H C H C H j ) ,  1 .7 2  ( I H ,  
sep, J . 6 .6 1 ,  C H ( C H 3) 2) ,  1 .6 1  ( 2H , t, .7  6 . 7 6 ,  C H C H J C H ) ,  1 .4 2  ( 6H ,  t ,  J c h  7 . 5 7 ,  8 . 0 6 ,  2  x 
C H C H 3) ,  0 . 9 9  ( 3 H ,  d, J c h  6 . 3 3 ,  C H ( C H 3) 2)  and 0 . 9 7  ( 3 H ,  d, J c h  6 . 0 9 ,  C H ( C H 3) 2) ;  5c ( 7 5 .5  
MHz; ''H aC O ^'H ) 1 7 5 ,6 8 ,  1 7 5 . 1 1 ,  1 7 4 . 3 7  ( 3  x N H C O ) ,  1 5 8 .5 1  ( C O 2N H ) ,  1 3 6 . 1 6  ( / - C e H s ) ,
1 2 9 .4 5  (z n -C b H i) ,  1 2 8 . 9 7  ( p - C * ) ,  1 2 8 . 7 6  (0 - C J - I 5) ,  6 7 . 7 4  ( C A C H ; ) ,  5 4 . 8 5  ( C H C H 2) ,
5 0 . 0 2  ( 2  X Ç H C I-I3) ,  4 2 . 0 4  ( C H j C H ) ,  2 5 . 8 4  ( C H ( C H 3) 2) ,  2 3 . 4 7 ,  2 1 . 9 4  ( C l f r C H , ) ; )  and 
1 8 .0 6 ,  1 7 .6 5  ( C H C H 3) ;  m/z ( C l )  4 0 8  ( 1 0 0 % ,  [M +  H ] * ) ,  3 9 0  ( 2 2 ,  [M -  O H ] * ) ,  3 6 4  ( 1 4 ,  [M +  
H  -  C O 2]* ) ,  3 1 9  ( 1 7 ,  [M -  N H C H C H 3C O 2H ] ' )  and 2 7 4  ( 1 0 ,  [M +  2 H  -  O j C C H j C b H s ] ' ) .
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3.0.2.57 Teritary butyl carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2R)-
alaninate (90)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl (2S)-aIaninate (37) using carbobenzyloxy-(2S)-leucyl-(2S)- 
alanine (29) (0.88 g, 2,62 mmol), tertiaiy butyl (2R)-alaninate hydrochloride (89) and the 
work up was modified as follows; ethyl acetate was used as the extraction solvent, the 
remaining ethyl acetate was azeotropically removed with methylene chloride from the white 
solid which was reciystallised from acetone / water to give white needle shaped crystals (962 
mg, 79%). m.p. 121-122°C; m/z (Found: [M + H]", 464.2764. requires
464.2761); [a]o -23.0 (c 0.10 in MeOH); Um» (KBr disk)/cm-l 3300 (NH), 3050, 3030 (2 x 
aromatic CH), 2950, 2930, 2900, 2820 (4 x aliphatic CH), 1720 (CO2R), 1700 (CO2NH) and 
1640 (CONH); 8„ (300 MHz; % C O "H ) 7.36 (5H, m, CjHs). 5.17 (IH , d, Jen, 12.63,
C * C H . H b ) ,  5 . 1 2  ( I H ,  d, J c h ,  1 2 .4 2 ,  C s H s C H * ) ,  4 . 4 6  ( I H ,  q, J c h ,  7 . 0 5 ,  C H C H s ) ,  4 . 2 9  
( I H ,  q, J c h ,  7 . 2 1 ,  C H C H s ) ,  4 . 1 6  ( I H ,  t, , / c / ; , 7 .4 5 ,  N H C H C H s ) ,  1 . 7 4  ( I H ,  sep, J 6 . 7 3 ,  
C H ( C H s ) s ) ,  1 .5 9  ( 2 H ,  t, .7  7 . 3 0 ,  C H C H s C H ) ,  1.41 ( 3 H ,  d, J c h  5 . 3 8 ,  C H C H s ) ,  1 . 3 9  ( 3 H ,  d. 
J c h  5 . 2 2 ,  C H C H s ) ,  0 . 9 9  ( 3 H ,  d, J c h  6 . 7 0 ,  C H ( C H s ) s )  and 0 . 9 7  ( 3 H ,  d, J c h  6 . 7 5 ,  C H ( C H s ) s ) ;  
5c ( 7 5 .5  MHz; ^ H sC O ^ H ) 1 7 5 . 2 6 ,  1 7 4 . 3 3 ,  1 7 3 .4 9  (3  x N H C O ) ,  1 5 8 . 7 8  ( C O s N H ) ,  1 3 8 .0 9  
( z - C * ) ,  1 2 9 . 4 9  (m-CeHs), 1 2 9 .0 5  ( p - C c H s ) ,  1 2 8 .8 9  ( o - C s H s ) ,  8 2 . 7 9  ( C * C H ; ) ,
6 7 . 8 8  ( C c H j C H s ) ,  5 5 . 3 6  ( C H C H j ,  5 0 . 2 8 ,  5 0 . 0 6  (2  x C H C H s ) ,  4 1 . 9 3  ( C H s C H ) ,  2 8 . 2 2  
( C ( C H s ) s ) ,  2 5 . 8 9  ( C H ( C H s ) j ,  2 3 . 4 3 ,  2 1 . 8 9  ( C F f r C H s ) : )  and 1 7 .5 7 ,  1 8 .0 2  ( C H C H s ) ;  m/z 
( C l )  4 6 4  ( 100% , [M +  H ]  j  and 4 0 8  ( 7 7 ,  [M +  2 H  -  C ( C H s ) s ]  j .
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3.0.2.58 Carbobenzyloxy-(2S)-leucyl (2S)-alanyl (2R)-alanine (91)
This compound was prepared in a manner identical to that described for the 
Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycine (27) using tertiary butyl carbobenzyloxy- 
(2S)-leucyl"(2S) alanyl (2R)-alaninate (90) (800 mg, 1.73 mmol) to give a white solid which 
was recrystallised from MeOH / ether to give white crystals (408 mg, 58%). m.p. 82-84°C; 
[a]o -32.1 (c 0.23 in MeOH); u»., (KBr disc)/cm'‘ 3500 - 3200 (OH), 330 (NH), 3020, 2940 
(2 X aromatic CH), 2800 (aliphatic CH), 1720, 1710 (CO2H and OCONH) and 1680, 1640 
(2 X CONH); 5 h  (300 MHz; % CO^H) 7.39 (5H, m, C * ) ,  5.17 (IH, d, Jh , 12.48, 
CsHsCHJib), 5.11 (IH, d, J h ,  12.38, CbHsCHaHb), 4.47 (IH, q, J c h ,  7.15, CHCH3), 4.40 
(IH, q, J c h ,  7.24, CHCH3), 4,16 (IH, t, J c h ,  7.48, NHCHCHz), 1.76 (IH, sep, J.6.64, 
CH(CH3)2), 1.61 (2H, dd, J7 .14 , 7.31, CHCHjCH), 1.46 (3H, d, J c h  7.31, CHCH3), 1.39 
(3H, d, J c h  7.13, CHCH3), 0.99 (3H, d, J c h  676, CH(CH3)2) and 0.97 (3H, d, J c h  6 .68. 
CH(CH3)2); 5 c  (75.5 MHz; ^H3C0 ^H) 176.00, 175.60, 174.55 (3 x NHCO), 159.10 
(OCONH), 138.35 ( i - C * ) ,  129.76 (m -C * ) , 129.33 (p -C * ) , 129.22 (o -C * ) , 68.20 
(CbHsCHj), 55.69 (CHCH2), 50.36 (ÇHCH3), 42.15 (CH2CH), 26.17 (^ (C H s );) , 23.70,
22.15 (CH(CH3)2) and 18.23, 18.07 (CHÇH3); m/z (Cl) 408 ([M + H]*, 88%), 390 (14, [M 
+ H - H2O]*), 320 (60, [M + H - NHCHCH3CO2H]j  and 264 (100, [M + H - 
CHCH3C0 NHCHCH3C02H ]j .
3.0.2.59 Trifluoroacetyl-(2S)‘ leucine (92f^^
To a stirred solution of (2S)-leucine (4.00 g, 30.0 mmol) in trifiuoroacetic acid (15 cm^) 
was added trifiuoroacetic anhydride (5.2 cm^, 39.0 mmol) was added dropwise at -10°C with 
stirring. After 5 min the salt / ice bath was removed and the reaction was stirred at room 
temperature for 30 min. The trifiuoroacetic acid was removed by distillation under reduced
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pressure to give a white amorphous solid which was recrystallised from dichloromethane to 
give white plate like crystals (5.60 g, 82%), m.p. 71-72°C (lit.,^^ 71-73°C); (Found; 
C, 42.55; H, 5.5; N, 6.60. Calc, for CgHizNOgFa C, 42.3; H, 5.35; N, 6.20%); m/z (Found: 
[M + NHa + H f, 245.1115. Calc, for CgHuNgOsFg 245.1113); [a]c -39.9 (c 0.6 in EtOH); 
u„„(nujol)/cm'' 3290, 3110 (NH and OH), 1730 (CO:NH) and 1710 (CO-H); S» (200 MHz; 
C H C y  10.42 (IH, s, COjH), 6.97 (IH, d, Jch 8.14, NH), 4.67 (IH, m, CH^CH), 1.72 (3H, 
m, CH2CH(CH3) j  and 0.97 (6H, d, J ch  4.68, CH (Ca),); 6c (50,3 MHz; CHCk) 177.09 
(COjH), 157.77 (q, Ja,, 38.0, COCF3), 116.06 (q, Jcf, 288, CF3), 51.57 (NHCH), 41.18 
(CH;), 25.31 (ÇH(CH3) j  and 23.08, 22.05 (CH(CH,);); m/z (Cl) 245 (100%, [M + H + 
NH3] j ,  225 (4, [M + NH3 - F] j ,  182 (3, [M + NH, - F - COJ*), 168 (4, [M - CO; - CH;]") 
and 114 (2, [M + 2H - CH(CH;CH(CH;);)CO;H] j .
3.0.2.60 Benzyl (2S)-alaninate tosylate salt (93)
(2.5)-Alanine (5.00 g, 56.1 mmol) was dispersed in toluene (100 cm') and benzyl alcohol 
(30 cm', 280 mmol) andp-toluene sulphonic acid.H;0 (13.95 g, 0.067mol) were added. The 
reaction was refluxed under Dean and Stark conditions for 5 h. On cooling yellow needle 
shaped crystals formed which were filtered and washed with ether (150 cm'). 
Recrystallisation from methanol / ether gave white needle shaped crystals (18.45 g, 89%), 
m.p. 198-199°C; [a]n +5.8 (c 0.36 in MeOH); u _  (KBr disk)/cm' 1750 (CO); 6h (300 
MHz, ('H 3C)zS0 ) 8.38°(3H, s, N H ;j, 7.51 (2H, d, J ch 8.0, C * ) ,  7.40 (5H, m, C * ) ,  7.13 
(2H, d, J ch 7.86, C * ) ,  5.23 (2H, s, C & C * ) ,  4.19 (IH, m, CHCH,), 2.29 (3H, s, 
C A C H ;) and 1.41 (3H, d, Jch 7.2,CHCH,); 5c  (73.5 MHz, 'H 3ÇS0 C % ) 170.00 (CO), 
145.64, 137.95, 135.41 (z '-C * and z '-C *), 128.68, 128.53, 128.24, 125.67 ( C * ,  C * ) ,  
67.20 (C H ;C * ), 48.14 (CH), 20.96 (CHjCbH,) and 15.87 (CHCH,).
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3.0.2.61 Benzyl tnfluoroacetyl-(2S)-leucy!-alaninate (94)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyIoxy-(2S)-leucyl alaninate (37) using trifluoroacetyl-(2S)"leucine(92) (2.79 g,
12.3 mmol) and benzyl alaninate tosylate salt (93) (4.54 g, 12.3 mmol) to give an orange oil 
which solidified to a white waxy solid on standing (3.87 g, 77%), m/z (Found: [M + FI]", 
389.1693. C18H23N2O4F3 requires 389.1688); [a]n -34.1 (c 0.34 in MeOH); Um=x (KBr 
disk)/cm-‘ 3290 (NH), 3070 (aromatic CH), 2961, 2875 (2 x aliphatic CH), 1745 
(CO2CH2C * )  and 1715, 1700, 1660 (3 x NHCO); 5» (300 MHz, C'HjO'H) 7.34 (5H, m, 
C * ) ,  5.18 (2H, m. C H bC *), 4.57 (2H, m, CHCH3 and CHCH2). 1.63 (3H, m, 
C H 2C H ( C H 3) 2) ,  1.42 (3H, d, J c h  7.26, CHCH3) and 0.923 (6H, m, CH(CH3)i); 5c (70.3 
MHz, C'HsO'H) 172.34, 172.25, 170.76, 170.96 (CO2CH2 and CONH), 156.96 (q, 
ÇOCF3), 135.27, 135.21 ( t - C * ) ,  128.57 (o-C^H,), 128.41 (p - C * ) ,  128.09 (m-CsHj), 
115.81 (q, Jp, 288, CF3), 67.19, 67.14 (C ltC ^H j, 52.09 (CHCH2), 48.28 (ÇHCH3) 41.28, 
41.25 (CH2CH(CH3)2) 24.73, 24.60 (ClfrCH,);), 22.74, 22.65, 21.95, 21.90 (CH(CH3)2) 
and 17.86, 17.60 (CH3); m/z (Cl) 389 ( 100%, [M + H] j ,  371 (18, [M - O H ]j and 280 (17, 
[M - H2O - CH2C6FI5] j .
3.0.2.62 Trifluoroacetyl-(2S)-leucyl-alanine (95)
This compound was prepared in a manner identical to that described for tertiary- 
butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycine (46) using benzyl trifluoroacetyF(2S)-leucyl 
(2S)-alanine (0.51 g, 1.27 mmol) and dry dichloromethane as the solvent to give a yellow oil 
which solidified to a white solid on standing (299 mg, 83%), m.p. 92°C; m/z (Found: [M + 
H]", 299.1224. C11H 18N2O4F3 requires 299.1219); [a]o -39.5 (c 0.21 in MeOFI); Umnx (KBr 
disk)/cm ' 3280, 3150 (NH and OH), 2965 (aliphatic CH), 1720 (CO2H), and 1670,
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1660 (2 X CONH); 5h (300 MHz, C % 0 %  -50°C) 4.82, 4.73 (IH, dd. CHCHj, 4.52, 
4.50 (IH, q, CHCHj, 1.81 (3H, m, CH2CH(CH3) j ,  1.60 (3H, dd, Jch  6.70, 6.46, CHCH,) 
and 1.13 (6H, t, 8.84, 4.28, C H (C Ii)j; 5c (70.3 MHz, C^HsO'H) 176.27, 176.21, 173.92,
173.74, (CO2H and CONH), 158.80 (m, COCF3), 117.69, 117.64 (q, Jp, 286.2, 286.5, C Fj,
53.08, 52.84 (ÇHCH2), 49.70 (ÇHCHj 41.79, 41.25 (ÇH2CH(CH3) j  26.11,
25.98 (£H(CH3) j ,  23.90, 23.86, 21.73, 21.57 (CH(CH3) j  and 17.17, 17.50 (C H j; m/z (CI) 
299(100%, [M + H ]ja n d 2 8 1  (22, [M -O H ]j.
3.0.2.63 Benzyl trlfluoroacetyl-(2S)-leucyl-(2S)-alanyl-glyclnate (96)
This compound was prepared in a manner identical to that described for methyl 
carboben2yloxy-(2S)-ieucyl (2S)-alaninate (37) using trifluoroacetyl-(2S)-leucyl (2S)-alanine 
(94) (136 mg, 0.456 mmol), benzyl glycinate tosylate (44) (154 mg, 0.456 mmol) and the 
work up was modified as follows; the crude product was extracted into ethyl acetate before 
washing and the remaining ethyl acetate was azeotropically removed with methylene chloride 
from the clear oil to give a white solid (187 mg, 92%), m,p. 121°C; m/z (Found: [M + H]", 
446.1902). C20H27N3O3F3 requires 446.1903); [a]o -27.2 (c 0.18 in MeOH); (KBr 
disk)/cm'^ 3310, 3300 (2 x NH), 3090, 3040 (2 x aromatic CH), 2960, 2880 (2 x aliphatic 
CH), 1740 (CO2CH2C6H5) and 1720, 1700, 1690, 1675, 1655, 1640 (6 x CONH); 5h (300 
MHz; C'HsO^H, -50°C) 7.57 (5H, m, C«Hj, 5.33 (2H, s, C A C H i), 4.71 (IH, m. CHCHj,
4.52 (IH, q, Jch  6.98, CHCH3), 4.27 (2H, d, J ch , 17.80, NHCHaHj, 4.12 (IH. d, Jch ,
14.08, NHCHaHb), 4.07 (IH, d, J ch , 14.22, NHCHaHb), 3.04 (IH, q, Jcp , 19.47, 
NHCOCFj, 1.83 (3H, m, CHC*CH(CH3) j ,  1.57 (3H. d, Jch  5.39, CHCH3), 1.37 (3H, d, 
Jch  5.39, CH(CH;)j and 1.34 (3H, d, Jch  5.39, CH(CH3) j ;  Sc (73.5 MHz; C'HjO'H) 
176.12, 175.92, 173.88, 170.93 (CO2H and 2 x NHCO), 159.17 (m, ÇOCF3), 137.36
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Q-CcBs), 19.92 (ni-CfiHs), 129.75 (p-CMs, o-CsH,), 117.66 (q, 286.6 CFs), 117.61 (q,
285.8, CFs), .68.16 (CjHsCHj), 53.71, 53.07 (CHCH2), 50.75, 50.56 (CHCH3), 42.02 
(NHCH2), 41.28, 41.09 (ÇH2CI-I), 26.12, 26.04 (ÇH(CH3)2>, 23.94, 23.60 (CH(CH3)2) and 
18,24 (CHCH3); m/z (Cl) 446 (100%, [M + H]^) and 281 (11, [M - NHCH2CO2CH2C6H5]*).
3.0.2.64 Trifluoroacetyl-(2S)‘leucyl (2S)-alanyl-glycine (97)
Trifluoroacetyl-(2S)-leucyl (2S)-alanyl glycine (97) was prepared in a manner identical to 
that described for tertiary-butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycine (46) using benzyl 
trifluoroacetyl-(2S)-leucyl (2S)-alanyl glycinate (96) (472 mg, 0.106 mmol) and dry 
dichlorometliane to give a yellow oil (172 mg, 46%), m/r (Found: [M]% 355.1349. 
C13H20N3OSF3 requires 355.1355); [a]n -24.4 (c 0.39 in MeOH); u„,„ (thin film)/cm‘‘ 
3360 (OH), 3295, 3080 (2 x NH), 2960, 2875 (2 x aliphatic CH), 1735 (CO2H) and 1720, 
1665 (2 X CONH); 5„ (300 MHz; C% O^H) 4.53 (IH, m, CHCH2), 4.45 (IH , q, Ja,^ 7.00,
CHCH3), 3,95, 3.93 (2H, s, NHCH2), 1.62 (31-1, m, CH2CH(CH3)2), 1.43 (3H, d, Jen 7.22, 
CHCHs) and 0.98 (6H, m, CH(CHs)2); 5c (73.5 MFIz; C % 0 %  174.94, 173.07, 172,64 (2 
X NHÇO and CO2H), 53.96, 53.50 (CHCI-I2), 50.34, 50.21 (ÇHCH3), 41.74 (NHCH2), 
41.32 (CH2CH), 24.73 (^ (C H s );) . 23.31, 23.17, 21.76, 22.02 (CFI(CH3)2) and
17.88 (CHCHs); m/z (Cl) 355 (70 %, [M]'), 281 (15, [M - NHCH2CO2H]") and 176 ( 100, 
[M - HF -2CH3 - CHCH3CONHCH2CO2H]').
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3.0.2.65 Tnf!uoroacety!-(2S)~alanine (98)^ ^^
This compound was prepared in a manner identical to that described for trifluoroacetyl- 
(2S)-leucine (92) using (25)-alanine (2.00 g, 22.4 mmol) to give a yellow oil which solidified 
on standing overnight to oily white needle shaped ciystals (3.55 g, 93%), (Found: C, 32.8;
H, 3.35; N, 7.70. Calc, for C A N O A  C, 32.45; H. 3.25; N, 7.55%); m/z (Found: [M + H]*. 
186.0379. Calc, for C5H7NO3F3 186.0378); [a]o -46.7 (c0.14 in MeOH); (thin 
film)/cm-' 3304, 3100(2 x N H ) ,  1720 (COjH) and 1670, 1655 (2 x CONH); 0„ (300 MHz, 
C^HCl,) 11.20 (IH, s, CO3H), 7.19 (IH, d, Jen 7.19. NH), 4.63 (IH, q, Jc„, 7.25, CH) and
I.55 (3H, d, Jc„ 7.26, CH,); 5c (73.5 MHz. C-HCI,) 176,30 (CO), 157.26 (q, Jen, 38.0, 
COCFj), 115.5 (q, Jen, 287.0, CF,), 48.57 (CH,) and 17.26 (CH,); m/z (Cl) 186 (100%, [M 
+ H ]*) and 168 (36, [M - OH]*).
3.0.2.66 Benzyl trifluoroacetyf-aianyl glycinate (99)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl alaninate (37) using trifluoroacetyl alanine (98) (0.50 g, 2 . 7 0  
mmol) and benzyl glycinate tosylate salt ( 4 4 )  ( 0 . 9 9  g, 2 . 7  mmol) to give a white solid which 
was recrystallised from dichlorometliane / hexane to give white ciystals (0.86 g, 96%), m.p. 
8 4 - 8 6 X ;  (Found: C , 5 0 .6 5 ;  FI, 4 .5 ;  N, 8 . 1 5 .  C,4Hi5N204F3 requires C , 5 0 .6 ;  H, 4 .5 5 ;  N, 
8 .4 5 % ;  w Æ  (Found: [M + FI]", 3 3 3 . 1 0 6 6 .  C w H ,6N 204F 3 requires 3 3 3 . 1 0 6 2 ) ;  [ a ] o  - 5 4 . 2  (c 
0 .2 3  in MeOH); (KBr disk)/cm ' 3 3 2 0  (Nil), 3 0 9 0 ,  3 0 4 0 ,  3 0 1 0 ,  ( 3  x aromatic CH), 
2 9 8 5 ,  2 9 5 0 ,  2 8 9 0  ( 3  x aliphatic CH), 1 7 5 0  (CO2CH2) and 1 7 2 0 ,  1 6 7 0  (2 x NFICO); 6» (300 
MHz, C^HbO^H) 7 . 3 9  ( 5 H ,  m, C « H ,) ,  5 . 2 0  (2H, s, C H j C c H s ) ,  4 . 5 3  ( I H ,  q, J c ,  7 . 1 3 ,  C H ) ,  
4 . 1 0  ( I H ,  d, 1 7 .6 3 ,  C H ,H b ) ,  3 . 9 8  ( I H ,  d, 1 7 .6 7 ,  C H .H b ) ,  2 . 9 0  ( I H ,  q, Jcf, 1 7 .5 ,
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TMHCHCHb) and 1.46 ( 3 H ,  d, ,/c„ 7.16, C H 3) ;  5 c  (70.3 MHz, C^HbO^H) 174.00, 170 89 
( Ç O 2C H 2 and C O N H ) ,  158.67 (q, Jcf, 39.0, COCFb), 137.12 ( l - C e H s ) ,  129.54 ( o - C c H j ) ,
129.31 (p-CcFIs), 129.28 (r a -C c H s ) ,  67.94 (CHjCsHb), 117.33 (q, J f, 287.0, C F 3) ,  50 64
(CH), 42,14 (CH2) and 17.67 (CH3); m/z (Cl) 333 ([M +H]', 100%) 315 (5, [M - OH]*) and 
243 (12, [M + 2H - CHbCcHs]*).
3.0.2.67 Trifluoroacetyl-alanyl-glycine (100)
This compound was prepared in a manner identical to that described for tertiary 
butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycine (46) using benzyl trifluoroacetyl-(2S)-alanyl 
glycinate (99) (0.40 g, 1.20 mmol) and dichlorometliane as the solvent to give a yellow oil 
(182 mg, 63%), m/z (Found: [M + H]*, 243.0593. CbHioNbOjFb requires 243.0593); [a]u 
-27.7 (c 0.07 in MeOH); u,„„ (KBr disk)/cm ' 3395 (NH and OH), 2960 (aliphatic CH), 
1720 (CO2H) and 1710, 1670 (2 x CONH); 5„ (300 MHz, C^HbO^H) 4.53 (IH, q, Jcu, 7.17, 
CH), 3.94 (IH, d, ./cw, 34.72, CH.Hu), 3.89 ( 1H. d, Ja,„ 27.67, CH.Hu), and 1.49 (3H, d, Jen 
7.18, CHb); 5o (70.3 MHz, C% O^H) 173.84, 172.69 (CO2H and CONH), 158.67 (q, J cf,
37.51, CO CFb), 117.35 (q, Jp, 286.5, CFb), 50 65 (CH), 41.80 (CH;) and 17.66 (CH3); m/z
(CI) 243 ( 100%, [M + H]*) and 225 (14, [M - H2O]*).
3.0.2.68 Trifluoroacetyl-glycine (101)^^“*
This compound was prepared in a manner identical to that described for trifluoroacetyl- 
(2S)-leucine (92) using glycine ( 5 . 0 0  g, 6 6 . 7  mmol) to give white plate like crystals ( 9.99  g, 
88%), m.p. 115-117°C (lit.,"'' 114-116,4°C); (Found: C, 28.25; H, 2.05; N, 8.15. Calc, for 
CiH^NObFb C, 28.05; H, 2.35; N, 8.15%); m/z (Found: [M]* 171.0135, C A N O iF , requires
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171.0143); Umax (Nujol) /cm"* 3300, 3110 (2 x NH), 2590 (OH), 1825 (CO2NH) and 1705 
(CO2H); ÔH (200 MHz, % 0 )  4.08 (2H, s, % ) ;  6c (50.3 MHz, % 0 )  174.73 (CO2H),
162.22 (q, 37.52, COCF3) 118.58 (q, 285.75, CFg) and 43.82 ( % ) ;  (El) 171
(2%, [M]"), 126 (81, [M - CO2H ]"), 102 (4, [M - CF3]"), 97 (6, [M - NHCH2CO2H]") and 
28 (100, [CNH2]").
3.0.2.69 [1-^^C]-Aminoacetonitrile hydrochloride (102^^^
This compound was prepared in a manner identical to that described for aminoacetonitrile 
(85) using [l-*^C]-methylene aminoacetonitrile (103) (30 mg, 0.43 mmol) to give white 
crystals (39 mg, 96%), 8» (300 MHz, ^HaCO^H) 4.18 (d, Jc 9.03, CHz); 6c (75.5 MHz, 
% C O "H ) 114.80 (*'CN) and 28.01 (d, Jc 64.4, % ) .
3.0.2.70[1-^^C]-Methylene aminoacetonitrile (103f^^
Formaldehyde solution (0.57 cnv\ 6.72 mmol) and NH4CI (0.21 g, 3.84 mmol) were 
placed in a flask at -5°C with vigorous stirring. [1-*^C]-KCN (0.25 g, 3.84 mmol) was 
dissolved in water (2 cm^) and added dropwise to the formaldehyde / NH4CI solution over 20 
min. After 10 min acetic acid (0.15 g, 2.53 mmol) in water (1 cm^) was also added dropwise 
to the formaldehyde NH4CI / KCN solution over 10 min and stirring continued for 1 h. 
Removal of the solvent (3 cm^) under reduced pressure gave a white crystaline precipitate 
which was filtered and dried to give white crystals (35 mg, 15%), (Found: [M + H]", 
70.0489. ^^CiCiHgNz requires 70.0486); 8,1 (200 MHz; % CO^H) 3.81 (2H, d, Jc 7.51, 
CH2CN) and 3.70 (2H, s, NCH2); 6c (50.3 MHz; ^HsCO^H) 116.76 (*^CN), 72.32 (NCH2) 
and 40.51 (d, Jc 56.14, CH2CN); ni/z (Cl) 208 (3%, [3M + H]"), 180 (33, [3M + H -
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NCH2)]*), 139 ([2M + H f , 42), 111 (100, [2M + H - NCHj)]*), 70 (33, [M +H - NCH^)]*) 
and 42 (12, [M + H - NCH2]).
3.0.2.71 Methylene aminoacetonitrile (104)^ ^^
This compound was prepared in a manner identical to that described for methylene 
aminoacetonitrile (103) using unlabelled KCN to give white crystals (54 mg, 24%), (Found: 
[2M + H]", 137.0825. C6H9N4 requires 137.0823); 6» (200 MHz; %CO^H) 4.87 (2H, s, 
CH2CN) and 3.66 (2H, s, NCH2); 6c (75.5 MHz; ^HsCO^H) 116.81 (CN), 72.36 (NCH2) and 
40.57 (ÇH2CN); m/z (Cl) 341 (3%, [5M + H]"), 273(15, [4M + H]"), 205 (15, [3M + H)]"), 
137 (77, [2M + H)]"), 110 (100, [2M + 2H - NCH2]") and 69 (33, [M +H)]").
3.0.2.72 1-Acetoxy l-carbobenzyloxy-amino methane (105)
To a stirred solution of carbobenzyloxy glycine (34) (750 mg, 3.59 mmol) in dry 
acetonitrile (40 cm^) under argon in a 2 necked flask was added Pb(0 Ac)4 (1.75 g, 3.95 
mmol) and the mixture stirred for 10 min, to give a yellow solution and a black ppt. LiCl 
(167 mg, 3.95 mmol) was then added and the mixture was kept at 80-90°C for 2 h to give a 
clear solution and a white ppt. The solution was filtered and the solvent was distilled off at 
reduced pressure to give a black solid. The solid was washed with ether (3 x 100 cm^), and 
after filtering, the solvent removed under reduced pressure to give a colourless unstable, 
moisture sensitive oil (490 mg, 62%), 6h (200 MHz; C'HCb) 7.35 (5H, m, CMsX 6.10 (IH, 
t, JcH 5.6, NH), 5.19 (2H, d, ^  7.6, NCH2); 5.13 (2H, s, CgHsCm) and 2.05 (3H, s, CH3); 
6c (50.3 MHz; C^HCb) 172.27 (CO), 156.34 (CONH), 136.28 (/-CgCHg), 129.06 (/w-CgHs), 
128.85 (p-CgHg), 128.75 (o-CgH,), 67.82, 67.12 (CJTsÇHa andNCHzO) and 21.46 (CH3).
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3.0.2.73 Carbobenzyfoxy-ammoacetonitrile (107)
l-Acetoxy 1-carbobenzyloxy-aminomethane (106) (468 mg, 2.10 mmol) was dissolved in 
dry acetonitrile under argon and KCN (150 mg, 2.31 mmol) was added and the solution was 
refluxed for 3 h. The solvent was removed under reduced pressure to give a white solid 
which was dissolved in ethyl acetate (40 cm^), washed with water (3 x 30 cm^), brine 
(saturated, 20 cm^), dried (MgS04) and the solvent removed under reduced pressure to give 
a colourless oil (270 mg, 68%), 6% (200 MHz; C^HCb) 7.35 (5H, m, C Æ ), 5.10 (IH, s, 
NH), 5.14 (2H, m, C^sCHa) and 4.04 (2H, d, 7.6, NCHg); m/z (Cl) 191 (9, [M + H]"), 
152 (15, [M + 2H -C H 2CN]") and 57 (100, [M + 2H-COzCHgCgHs]").
3.0.2.74 Carbobenzyioxy~(2S)-leucyl (2S)-alanyl 
glycyiaminoacetaldehyde (112)
N-(Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl) l-aminoprop-2-ene (115) (30 mg, 
69.4|umol) was dissolved in ethyl acetate (3 cm^) in a 2 necked flask with heating and at 
-5-0°C ozonized oxygen in oxygen (0.3%) was bubbled through the solution until a KI / 
HO Ac solution indicator (5%, 10%, 100 cm^) went red (15 min). The ozone was flushed 
from the flask with O2 and Me2S (12 mm ,^ 166.6 pmol) was added and stirred for 1 h at 
room temperature. The solvent was removed under reduced pressure and the resulting oil 
was dissolved in ethyl acetate (5 cm^), washed with water ( 3 x 3  cm^), brine solution 
(saturated, 3 cm^), dried (MgS04) and the solvent removed under reduced pressure to give 
an unstable, hydroscopic, waxey white solid (22 mg, 70%), Umax (thin film)/cm'* 3260 (NH), 
3000 (aromatic CH), 2960, 2900, 2810 (3 x aliphatic CH), 1720 (CO2NH) and 1710, 1700, 
1690, 1650, 1630 (5 x CONH); 6» (300 MHz; % CO^H) 7.38 (5H, m, CgHg), 5.53 (2H, s, 
CHzCgHg), 4.40 (2H, m, CH(0 H)2 and CHCH3), 4.20 (IH, t, J7 .50, NHCHCH2), 3.96 (IH,
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d, JcH^  1 8 .8 0 ,  N H C H a H b ) ,  3 . 9 2  ( I H ,  d, ,/cv,„ 1 4 .8 6 ,  N H C H a H b ) ,  1 .7 4  ( I H ,  sep, Jch,  6 . 7 0 ,  
C H ( C H 3) 2) ,  1 .6 3  ( 2H , t, Jcft, 7 . 8 4 ,  C H C H j C H ) ,  1 .4 2  ( 3 H ,  d. Jet, 7 . 0 6 ,  C H C H j ) ,  0 . 9 9  ( 3 H ,
d, JcH 6.38, CH(CHb)2) and 0.97 (3H, d, Jen 6.25, CH(CH3)z); 6c (75.5 MHz; % CO^H)
175.74, 175.31, 171.99 (3 x NHCO), 158.78 (CO2NH), 138.14 (/-C«H;), 129.47 (/n-CjHs), 
129.01 (p -CuHb), 128.83 (0-QH5), 90.81 (CH(OH)2), 67.80 (C A Ç H ;),
54.99 (NHÇHCH2), 51.19 (CHCH3), 43.36 (NHCH2), 41.82, 41.75 (CHÇH2CH and 
£H 2CH(0 H)2), 25.84 (CH(CH3)2), 23.46, 21.84 (CH(CH3)2) and 17.47 (CHÇH3); m/z (El) 
452 (7%, [M]*), 434 (7, [M - HaOf), 409 (47, [M - CHO]*) and 394 ( 100, [M - 
NHCH2CHO]*).
3.0.2.75 Tertiary-butoxycarbonyl-(2S)-leucyl (2S)-alanyl glycyl 
glyclnal dimethyl acetal (113)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl-alaninate (37) using tertiary-butoxycarbonyl-(2S)-leucyl (2S)- 
alanine (43) (2.71 g, 8.96 mmol) and glycyiaminoacetaldehyde dimethyl acetal (121) (1.45 g, 
8.96 mmol) to give a white solid which was reciystallised from methanol / ether to give 
white crystals(4.00 g, 83%). m.p. 156-I58°C; (Found: C, 54.05; H,8 .6; N  12.55. 
C20H3SN4O7 requires C, 53.78; H, 8.58; N .  12.55%); m/z (Found: [M + H]*, 447.2820. 
C20H39N4O7 requires 447.2819); [a]o - 26.5 (c 0.22 in MeOH); (Nujol)/cm"' 3340, 
3280, 3090 (3 x NH), 1710 (CO2NH), 1690, 1630 (2 x CONH); 5„ (400 MHz, C^'HCb) 7.21 
(IH, t, CHCH3CONH), 6.75 (IH, d, Jen 6 .68, CHCH3NH). 6.61 (IH, t, CH2CONH). 5.05 
(IH, d, 7cf/5.8, CO2NH), 4.41 (2H, t, and m, 5.52, CH(OCH3)2 and CHCH2CH(CH3)2), 
4.08 (IH, m, CHCH3), 4.00 (IH, dd, Jm  6.0, Jen 16.9, NHCH.HbCO), 3.86 (IH, dd, JnH  
5.4, Jen 16.9, NHCH»HuCO), 3.55 (2H, m, CH2CH(OCH3)2), 3.39 (6H, m, OCH3), 1.59
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(2H, m, CH2CH(CH3)2), 1.46 (IH, m, CH(CH3)2), 1.42 (9H, s, € (€ 23)3), 1.40 (3H, d, Jen 
7.2, CHCH3), 0.93 (6H, t ,  CH(CH3)2); 5 c  (74.8 MHz; C '^HCU) 172.95, 172.39, 168.90 (3 x 
CONH), 155.99 (CO2NH), 102.24 (C(OCH3)2), 80.36 (C(CH3)3), 53.98, 53.83 (2 x OCH3), 
53.43 (NHÇHCH2), 49.23 (ÇHCH3), 42.95 (NHCH2CO), 41.07, (CH2CH(CH3)2),
40.84 (CH2CH(0CH3)2), 28.17 (C(£H3)3), 24.63 (^ (C H a );) , 22 .86, 21.74 (CH(CH3)2, 
17.97 (CHCH3); m/z (FAB) 447 (1 %, [M + H]*), 429 (4, [M - OH]*), 415 (37, [M - OMe]*), 
341 (100, [M - H - NHCH2CH(0 CH3)2]*), 315 (10, M + H - OMe - C02C(CH3)3]*) and 
285 (2, [M - NHCH2CH(0CH3)2 - C(CH3)3]*).
3.0.2.76 Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl amino 
acetaldehyde dimethyl acetal (114)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alaninate (37) using carbobenzyloxy-(2S)-leucyl 
(2S)-alanine (2 9 )  (841 mg, 2.50 mmol) and glycyl-aminoacetaldehyde dimethyl acetal (1 2 1 ) 
(405 mg, 2.50 mmol) to give a white solid which was recrystallised from acetonitrile /  40/ 60 
petrol to give white crystals (894 mg, 75%), m.p. 149-15TC; (Found: C, 57.15; H, 7.5; N,
11.45. CasHauNjOr requires C, 57.47; H, 7.55; N, 11.66%); m/z (Found: [M + H]*, 
481.2680. CbîHjbNbO, requires 481.2662); [a]o - 31.5 (c 0.17 in MeOH); o„„x (Nujol)/cin‘ 
3330, (NH), 3091 (aliphatic CH), 1720, 1680, 1660, 1630 (4 x CO); 8„ (300 MHz, 
% C O "H ) 7.51 (5H, m, C«Hs), 5.27 (2H, s, CuHsCHj), 4.63 (IH, t, Jen, 5.48, CfKOCHa);),
4.47 (IH, q, Jen, 7.14, CHCFI3), 4.34 (IH, t, Jen, 7.51, CHCH2 ), 4.10 (IH, d, Jen, 16.89, 
CHxHuCO), 3.95 (IH . d, Jen. 16.89, CH.H,,CO), 3.53 (6H, s, OCH3 ), 3.50 (2H, d, Jen 5.01, 
CH2C(0 CH3)2), 1.90 (IH, m, CH(CH,)2 ), 1.76 (2H, t, CH2CH(CH3)2), 1.56 (3H, d, Jen 
7.14, CHCHj), 1.14 (6H, t, CH(CH3)2); 5c (50.3 MHz, % C O ^ H ) 175.97, 175.58, 171.99,
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159.09 ( C O ) ,  138.42 ( / - C « H s ) ,  129.77 (m -C A ), 129.34 ( p - C g H ,) ,  103.92 ( C H ( O C H 3) 2) ,  
68.11 ( C s H s C H a ) ,  55.34 ( N H Ç H C H 2) ,  54.81, 54.57 (2 x O C H 3) ,  51.17 ( Ç H C H 3) ,  43.72 
( N H C H 2C O ) ,  42.43 (CH2CH(0 CH3)2), 42.13 ( C H C H j C H ) ,  26.13 ( C H ( C H 3) 2) ,  23.77,
22.16 ( C H ( C H 3) 2)  and 17 .70 ( C H C H .,) ;  m/z (FAB) 503 (48%, [M + Na]*), 481 (16, [M + 
H]*) and 449 (100, [M - OMe]*).
3.0.2.77 N-(Carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl) I-
amlnoprop-2-ene (115)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) using allyl amine (58 mm^, 1.02 
mmol) to give a white solid which was recrystallised from acetone / ether to give white 
crystals (132 mg, 34%), m.p. 114°C; (Found: C, 61.05; H, 7.6; N, 12.85. C22H32N4O5 
requires C, 61.1; H, 7.45; N, 12.95%); m/z (Found: [M + H]*, 433.244). C22H33N4O5 
requires 433.2451); [a]o -36.0 (c 0.05 in MeOH); o„„  (KBr disk)/cm’‘ 3280 (NH), 3050 
(aromatic CH), 2890, 2850, 2800 (3 x aliphatic CH), 1710 (OCONH) and 1680, 1660, 1630 
(3 X CONH); 5„ (300 MHz; ^C O '^H ) 7.38 (511, m, C A ) , 5.43 (2H, dt, 71.55, CH2CH),
5.23 (IH, tt, 7  5.87, CH2CH), 5.13 (IH, s. CH zC A ), 4.30 (IH, q, 7ch^ 7.0, CHCH3), 4.17
( I H ,  quin, 7 4 . 7 0 ,  2 . 7 6 ,  N H C H C H 2) ,  3 . 9 7  ( I H ,  d, ./ot^ 1 6 .8 5 ,  N H C H .H u ) ,  3 . 8 5  ( 2 H ,  dt, Jen 
5 . 3 4 ,  Jen, 1 .8 2 ,  C H 2C H ( C H 2) ) ,  3 . 8 0  ( I H ,  d, 1 7 .0 5 ,  N H C F I .H u ) ,  1 .7 5  ( I H ,  sep, Jen,
6 . 6 7 ,  C H ( C H 3) 2) ,  1 . 6 0  ( 2FI, t, Jen, 7 . 1 3 ,  7 . 4 4 ,  C I I C H 2C H ) ,  1 .4 1  ( 3 H ,  d, Jen 7 . 1 7 ,  C H C H 3) ,
1 .0 0  ( 3 H ,  d, C H ( C H j ) 2)  and 0 . 9 7  ( 3 H ,  d, C H ( C H 3) 2) ;  8c ( 7 5 .5  MHz; % C O ^H ) 1 7 5 .8 0 ,  
1 7 5 . 3 6 ,  1 7 1 . 3 5  (3  x N H C O ) ,  1 5 8 .8 1  ( C O 2N H ) ,  1 3 8 .1 3  ( t - C c H s ) ,  1 3 5 . 1 8  ( ( C H 2) C H C H 2) ,
1 2 9 . 4 7  (m-CuHj), 1 2 9 .0 3  (p-CsHs), 1 2 8 .8 2  (o -C A ) , 1 1 6 . 2 2  ( ( Ç H 2) C H C H 2) ,  6 7 .8 3
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(C6H5CH2). 55.08 (NHÇHCI-I2), 50.99 (CHCH3), 43.53 (CHjCHCCHj)), 42.68 (NHCH2), 
41.80 (CHCHzCH), 25.82 (CH(CH3)2), 23.42, 21.89 (CH(CH3)2) and 17.28 (CHCH3); m/z
(Cl) 433 (14%, [M + H ]') and 325 (100, [M - C4H5CH2O]*).
3.0.2.78 Carbobenzyloxy-(2S)'!eucyi (2S)-aianyl giycy! 3- 
aminopropan-2-one (116)
This compound was prepared in a manner identical to that described for Carbobenzyloxy- 
(2S)-leucyl (2S)-alanyl glycyiaminoacetaldehyde ( 112) using N-(carbobenzyloxy-(2S)-leucyl 
(2S)-alanyl glycyl) 1-amino 2-methyl prop-2-ene (118) (35 mg, 78.4 pmol) to give an, 
unstable white solid (31 mg, 88%), (Found: [M + H]*, 449.2406. C22H33N4O6 requires 
449.2400); u„.,x (thin film)/cm'‘ 3300 (NH), 2950, 2920, 2850 (3 x aliphatic CH), 1710, 
1680, 1650, 1640 (4 x CO); 5„ (300 MHz; 'HjCO^H) 7.38 (5H, m, C A ) ,  5.15 (IH, d, Jc„,
12.67, CHACuHs), 5.11 (IH, d, 13.61, CHxHuCuHj), 4.33 (IH, ni, CHCH3), 4.16 (IH, 
m, NHCHCH2). 4.07 (2H, s, CHaCOMe), 4.00 (IH, d, ,/ct;  ^ 16.89, NHCHxHu), 3.86 (IH, d, 
Jcr^ 16.85, NHCHxHu), 2.16 (3FI, s, COCH3). 1.74 (IH, sep. Jen, 6.60, CIKCHs)^). 1.59 
(2H, t, Jen, 7 .00, CI-ICH2CH), 1.42 (3H, d, JCH  7 .10, CHCH3), 0.99 (3H, d, Jen 6.38, 
CH(CH3)2) and 0.97 (3H, d, Jen 6.29, CH(CH3)2); 5c (75.5 MHz; % CO ^H ) 205.78 
(COMe), 175.80, 175.36, 171.96 (3 x NHCO), 158.76 (OCONH), 138.14 (/-C«FT;), 129.46 
(m-CsHs), 129.01 (p-CuH;), 128.82 (o-CuHj), 67.80 (C A Ç H 2), 54.99 (NHÇHCFI2), 
50.86 (ÇFICH3), 50.23 (CHjCOMe), 43.39 (NHCFI2), 41.82 (CHÇH2CH), 
25.82 (CH(CH3)2), 23.46, 21.83 (CH(CH3>2) and 17.40 (CHCH3); m/z (Cl) 449 (100%, [M 
+ H]), 431 (10, [M - OH]*), 393 (8, [M + 2H - CH2COCH3]*) and 336 (10, [M + 2H - 
CH2CONHCH2COCH3]').
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3.0.2.79 N-(Carbobenzyloxy-(2S)»leucyl (2S)‘’alanyl glycyl) l-amino
2-methyl prop-2-ene (118)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl-(2S)-alanyl-glycyl-glycinate (65) using 1-amino 2-methyl prop-
2-ene hydrochloride (90 mg, 1.02 mmol) to give a white solid which was recrystallised from 
acetone / ether to give white crystals (146 mg, 32%), m.p. 148°C; (Found: C, 61.85; H, 
7.75; N, 12.50. C23FI35N4O5 requires C, 61.85; H, 7.65; N, 12.55%); m/z (Found: [M + H]", 
447.2609. C23H36N4O5 requires 447.2607); [a],) - 26.92 (c 0.26 in MeOH); Umax (KBr 
disk)/cm‘‘ 3300 (NH), 3100, 3080 (2 x aromatic CH), 2950, 2940, 2880 (3 x aliphatic CH), 
1710 (OCONH) and 1680, 1660, 1640 (3 x CONH); 8» (300 MHz; % C O ^H ) 7.38 (5H, m, 
C«H;), 5.12 (2H, s, CH2C0H5), 4.85, 4.82 (211, ds, CMe(CHi)), 4.30 (IH, q, Jen, 7.16,
CHCHs), 4.17 (IH, t, 7  7.52, NHCHCH2), 3.96 (IH, d, Jen,, 16.88, NHCHaHbCMe), 3.81 
(IH, d, Jen„ 17.20, NHCH.HbCMe), 3.83 (IH, d, 15.73, NHCH.HuCO), 3.74 (IH, d, 
JcH„ 15.78, NHCHJHbCO), 1.75 (4H, m, CH2CCH3 and ClKCHs);), 1.59 (2H, t, Jen, 6.74, 
CHCH2CH), 1.41 (3H, d ,7c„7.15, CI-ICH3), 0.99 (3H, d, 7  6.71, CH(CH))2) and 0.97 (3H, 
d, 7  6.76, CH(CH3)2); 6 c  (75.5 MHz; ''HjCO^H) 175.85, 175.42, 171.46 (3 x NHCO), 
158.83 (CO2NH), 142.90 ((£H2)CHCH3), 138.14 (/-CsHs), 129.48 (m-CjHs), 129.04 
(p-CcHs), 128.84 (o-CuH;), 111.19 ((CH2)CHCH3), 67.84 (C6HSCH2), 55.07 (NHÇHCH2),
51.02 (ÇHCH3), 45.75 (CH2CH(CH2)), 43.55 (NI ICH2), 41.77 (CHCHjCH), 25.81 (CCH3),
23.45 (ÇH(CH3)z), 21 .86, 20.46 (CH(ÇH3)2) and 17.26 (CHCH3); m/z (Cl) 447 ( 100%, [M 
+ H]) and 339 (53, [M - CuHsCHjO]').
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3.0.2.80 Carbobenzyloxy-glycyl glycinal dimethyl acetal (120)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyI-alaninate (37) using carbobenzyloxy-glycine (34) (3.51 g, 16.8 
mmol) and aminoacetaldehyde dimethyl acetal (119) (1.77 g, 16.8 mmol) and THF instead of 
DMF to give a yellow oil, m/z (Found: [M + H]', 297.1450) C14H21N2O5 requires 297.1450);
и,„ax (thin film)/cm'‘ 3400, 3330 (2 x NH), 3 190, 3 150, 3130 (3 x aromatic CH), 2940 , 2840 
(2 X aliphatic CH), 1730 (CO2NH ) and 1670 (CONH); 5n (200 MHz; C^HClj) 7.40 (5H, m, 
C A ) ,  6.33 (IH, t, NHCH2CO), 5.60 (IH, t, Jc„, 5.60, NHCHjCH), 5.12 (2H, s, CuHsCHa), 
4.36 (IH, t, ,/c«, 5.13, CH(0 CH3)2), 3,86 (2H, d, ./«„ 5.78, NHCH2CO), 3.38 (2H, m, Jm
5.58, CH2CH(0 CH3)2) and 3.37 (6H, s, OCH3); 5c (50.3 MHz; C '^HCU) 169.72 (OCONH),
157.10 (CONH), 136.63 (/-C«H;), 129.04 (m-CuHs), 128.74 (p-C«H,), 128.58 (o -C A ),
102.92 (CH(0 CH3)2). 67.63 (CeHsClh), 54.89 (OCH3), 44.93 (ÇH2CH) and 41.39 
(NHÇH2CO);. m/z (Cl) 297 (4%, [M + H]*), 279 (4, [M - OH]*), 265 (100, [M - OMe]*), 
189 (13, [M - CACHzO]*), 142 (31, [M - CuHjCHjO - MeOH - CH3]*) and 75 (17, [M - 
C A C H 2OCONHCH2CONHCH2]*)
3.0.2.81 Glycyl-aminoacetaldehyde dimethyl acetal (121)
This was prepared in an identical manner to methyl glycyl glycinate (70) using 
carbobenzyloxy-glycyl aminoacetaldehyde dimethyl acetal (121) (1.87 g, 6.3 mmol) to give a 
pale yellow oil (1.94 g, 95%), m/z (Found: [M + H ]\ 163.1083 C6H 15N2O3 requires 
163.1083); u,,,»., (thin film)/cm'' 3300 (NI-I2, Nil), 2940, 2840 (2 x aliphatic CH), 1660 
(CONH);. 5,1 (300MHz; C^HCh) 7.53 (IH , t, 5.48, NH), 4.40 (IH, t, Jen, 5.28, 
CH(0 CH3)2). 3.46 (2H, s, CH2CH), 3.41 (2H, t, Jmi, 5.52, NH2CH2), 3.37 (6H, s, 2 x
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OCH3), 3.17 (2H, s, NH;); 8c (50.3 MHz; C^HCU) 172.39 (CO), 102.95 (C(0 CH3);), 54,60 
(OCH3), 44.60 (CH2NH2), 40.96 (NHCH2); m/z (Cl) 163 (10%, [M + H]*), 131 (100, [M - 
OMe]*), 116 (100, [M - OMe - CH3]'), 99 (7, [M - OMe - MeOH]*), 88 (2, [M + H - 
CH(0 CH3)2]*), 75 (64, [M - CH2NHCOCH2NH2]*), 58 (7, [M - NHCH2CH(0 CH3)2]*).
3.0.2.82 N,N’-Di-(carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl) 2, 4-
diamlno-but-2-ene aldehyde (122)
Propene was bubble through dry dichloromethane (30 cm^) for 15 min in a flame dried 
flask. Carbobenzyloxy-(2S)-leucyl-(2S)-alanyl-glycyl-amino acetaldehydedimethyl acetal 
(112) (152 mg, 316 mmol) dissolved in diy dichloromethane (3 cm^) was added and the 
solution was stined for 2 h under a propene atmosphere. The propene was displaced from 
solution with N; and the solvent was removed under reduced pressure to give a yellow soild 
which was reciystallised from MeOH / ether to give yellow crystals (62 mg, 45%), (Found: 
['AM + H]*, 435.2248. C21H31N4O6 requires 435.2248); 5n (300 MHz; ^H3C0 ^H) 7.35 (5H, 
m, CsHj). 6.59 (IH , d, Jen 5.32, NH), 6.50 (IH, d, Jen 5.88, NH), 5.92 (IH, t, Jen, 4.46 
=CH), 5.08 (2H, s, CH2C6H5), 4.91 (IH. t, Jen, 7.17, CH(0H)2), 4.44 (2H, m, NHCHCH; 
and CHCH3), 4.25 (3H, m, CIBCH^C, NHCHaHb), 4.18 (IH, d. Jch„ 17.31, NHCHaHb),
3.0 (2H, s, OH), 1.84 (IH, sep, CH(CH3)2), 161 (2H, q, CHCH2CH), 1.31 (3H, m, CHCH) 
and 0.98 (6H, m, CFKCHj);); 5c (75.5 MHz; "ll,CO^H) 174.52, 172.98, 171,39, 165.64 (4 x 
NHCO), 157.36 (CO2NH), 138.56 (/-C0H5), 130.37, 129.90, 129.54, 128.95, 128.90(5 x 
C A ) , 112.17 (C=£C(0H)2), 108.82 (C=CC(OH)2), 71.74 (CH(OH)2), 67.08 (C A Ç H 2), 
54.85, 54.67 (NHÇHCH2), 49 .86, 49.10 (CHCH3), 46.65, 46.58 (NFICH2), 42.62,
42.52 (CHÇH2CH), 25.72, (ÇF^CH,);), 23.83, 23.66, 22.23 (CH(CH3)2) and 18.39, 18.29
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(CI-IÇH3); m/z (FAB) 891 (100%, [M -I- H]‘), 457 (52, [V2M -I- Na]'), 435 (5, [Y2M + H]") 
and 391 (32, [M - CH2CHO]').
3.0.2.83 3-Aminopropanone hydrochloride (124)
Trifluoroacetyl 3-aminopropane (127) (137 mg, 0.81 mmol) was dissolved in liCl (5 
moldm"^, 3 cnf) and refluxed for 2 h. The HCl was flushed from solution with N2 and the 
solution was lyophilised to give a yellow, light sensitive, hydroscopic solid (88 mg, 91%), 
(Found: [M - Cl]", 74.0601. C^ihNO  requires 74.0606); 0„ (200 MHz; ^H20) 4.08 (2H, s, 
CH2) and 2.28 (3H, s, CFI3); 5c (50.3 MHz; % 0 )  206.9 (CO), 50.70 (CH2) and 29.63 
(CFI3); m/z (Cl) 90 (8%, [M -i- NI I3 - HCl] ') and 74 (100, [M - Cl)]").
3.0.2.84 Trifiuoroacetyi 1-amino-3-diazo propanone (126)
This compound was prepared in a manner identical to that described for the methyl 
carbobenzyloxy-(2S)-leucyI (2S)-aianinate (37) using trifluoroacetyl glycine (101) (210 mg,
1.22 mmol) and dry etherial diazomethane solution (12.2 mmol).* '^* The following 
precautions were also followed; friction free glass joints were used, the reaction mixture was 
excluded from light and the temperature was not allowed to rise above 0°C. No attempt was 
made to purify the diazoketone and after allowing the excess diazomethane to evaporate 
from the reaction vessel for an hour, the NMM.HCl salts were removed by filtration and the 
solvent was removed under reduced pressure with a cold water bath to give an unstable, 
reddy orange, light sensitive solid, (Found: [M - N2]", 167.0201. C5H4NO2F3 requires 
167.0194); Um=.x (thin fllm)/cm ' 3390 (NH), 2970, 2255 (CHNz), 1730 (CO2NH) and 1650 
(CON2); 5h (200 MHz; C^HCb) 7.35 (IH , s, NH), 5.42 (IH, s, CFIN2) and 4.13 (2H, d, Jmh
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5.00, CH;); S c  (50.3 MHz; C^'HClj) 187.07 (COCHN;), 157.26 (q, J c f  37.5, COCF3). 
115.67 (q, J f ,  284.9, CF3), 66.75 (CFIN;) and 26.14 (CH;); m /z  (El) 167 (15%, [M - N;]*), 
126 (77, [M - COCHN;]*) and 69 ( 100, [CF3]*).
3.0.2.85 Trifluoroacetyl 3-amino propanone (127)
To a stirred solution of trifluoroacetyl 3-amino propane diazoketone (126) (476 mg, 2.44 
mmol) in dichloromethane (30 cm^) was added constant boiling HI (2.60 moldin ’, 2.35 cm’,
6.1 mmol) and the reaction was stirred for 2 h, excluded from light."'' The solvent was 
removed under reduced pressure to give a yellow light sensitive solid (232 mg, 56%), 
m.p.57-58°C; u,,»» (thin fllm)/cm ' 3400 (NH), 2400, (aliphatic CH), 1725 (CONH) and 1700 
(COMe); 5„ (200 MHz; C’HCl;) 7.25 (IH, s, NH), 4.25 (2H, d. Jaw 4.40, CH;) and 2.28 
(3H, s, CH3); 8c  (50.3 MHz; C’HCb) 198.49 (COCH3), 154.82 (q, % f  37.8, COCF3). 
113.37 (q, ' J f ,  287.2, CF3), 47.11 (CH;) and 24.90 (CH3); m / z  (El) 169 ([M]', 2%), and 126 
(20, [M -CO CH 3]*).
3.0.2.86 Trifluoroacetyl 3-amino-1-chloro-propanone (128)
To a solution of trifluoroacetyl 3-aminopropane diazoketone (126) (476 mg, 2.44 mmol) 
in dichloromethane (30 cm^), was added HCl (1.00 moldm'^, 2.68 cm^, 2.68 mmol) and the 
reaction was stirred for 2 h, excluded from light. The solvent was removed under reduced 
pressure to give a yellow light sensitive solid (497 mg, 57%), m.p.53-55°C; Umax (thin 
fllm)/cm'* 3230 (NH), 1740 (CONH) and 1700 (COCCIH2); 0„ (200 MHz; C^HClg) 7.22 
(IH, s, NH), 4.47 (2H, d, /v//4.84, CII2) and 4.20 (2H, s, CClHg); ôc (50.3 MHz; C^HCb)
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1 9 7 . 3 2  (COCHîCl), 1 5 7 . 8 9  (q, , / c p 3 8 . 1 ,  ÇOCFj), 1 1 6 .0 1  (q, J,., 2 8 7 . 2 ,  CF;), 4 7 . 4 4 ,  4 6 . 4 0  
(CH; and CH;C1).
3.0.2.87 2-Bromo, carbobenzyloxy-(2S)-leucyl-(2S)-alanyl-glycyl-
amlnoethane (130)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-ieucyl (2S)-alanyl glycyl glycinate (65) using 2-bromo, aminoethane 
hydrocliloride (164 mg, 1.02 mmol) to give a white solid which was recrystallised from 
acetone / ether to give white monohydrated crystals (388 mg, 70%), m.p. 107°C, (Found: C, 
48.7; H, 6.5; N ,  10.80. CiiHjiNrOsBr requires C , 49.0; H, 6.25; N ,  10.85%); [a]c -32.8 (c 
0.18 in MeOH); (KBr disc)/cm‘‘ 3450-3200 (H;0), 3100, 3050 (2 x aromatic CH), 
2980, 2960 (2 x aliphatic CH), 1750 (OCONH) and 1730, 1700, 1650 (3 x CONH); S„ (300 
MHz; sHsCO^H), 7.38 (5H, m, C A ) ,  5.14 (2H, s, C«H)CH;), 4.38 (3H, m ,,/ 5.40, CH;Br 
and CHCH;), 4.18 (IH, t, J  7.48, NHCHCH;), 4.04 (IH, d, Jen 17.74, N H C H A ), 3.97 
(IH, d, JcH 17.92, N H C H .H u ) ,  3.29 (2H, t, Jc„, 5.00, NCH;CH;Br), 1.75 ( I H ,  sep, J6 .55 , 
CH(CH;);), 1.61 (2H, d, J7 .19 , CHCH;CH), 1.42 (3H, d, Jen 7.15, CHCH;), 1.00 (3H, d, 
JcH 6.79, CH(CH;); and 0.97 (3H, d , ./«; 6.78, CH(CH;);; S c  (75.5 MHz, ;H ;C 0’H) 173.65,
173.51, 168.46 (3 x CO), 156.67 (OCONH), 135.93 (f-CuH), 127.36 (m-CgH;), 126.93 (p- 
C u H ) ,  126.65 (o-CuHs), 65.65 (CHjCuHs), 60.05 (CHCH;), 53.00 (CHCH;), 48.30 
(CH;Br), 39.89 (NHCH;), 39.56 (NHCH;CH;), 37.60 (CHCH;), 23.54 (ÇFI(CH;)2), 21.16, 
19.64 (CH(ÇH;);) and 15.38 (CHCH;).
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3.0.2.88 0-(Carbobenzyloxy-(2S)-leucy!-(2S)-alanyl-glycyl) 1- 
carboxy methyl 2-hydroxy but-2-ene (132)
To a solution of carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycine (27) (300 mg, 0.76 
mmol) was dissolved in DMF (20 cm^) was added methyl y-bromocrotonate (683 mg, 3.82 
mmol) then NaHCOs (128 mg, 1.52 mmol). The solution was then stirred for 12 h.*^ * The 
solvent was removed under reduced pressure and the crude product was purified by silica 
chromatography, eluting with a gradient of dichloromethane through to 1:19 MeOH / 
dichloromethane to give a yellow oil which was reciystallised from MeOH / ether to give 
white crystals (130 mg, 35%), m.p. 89°C; (Found: C, 58.7; H, 7.0; N, 8.55. C24H33N3O8 
requires C, 58.65; H, 6.75; N, 8.55%); ni/z (Found: [M + H]", 492.2340. C24H34N3O8 
requires 492.3346); [a]o - 41.7 (c 0.24 in MeOH); (KBr disk)/cm * 3300 (NH), 3050, 
3020 (2 X aromatic CH), 2950, 2940, 2880 (3 x aliphatic CH), 1760 (COzMe), 1740 
(CO2NH) and 1700, 1680, 1640 (3 x CONH); 5„ (300 MHz; 2H3CO2H) 7.36 (5H, m, CgHj),
6.99 (IH, dt, y  4.53, HC=CHCH2), 6.11 (IH, dt, J  1.91, 15.80, HC=CHCH2), 5.13 (IH, s, 
CH2C6H5), 4.86 (IH  d, Jcti^ 1.88, OCH3H,,), 4,85 (IH  d, 1.88, O C H & ), 4.45 (IH, q,
JcH  ^7.12, CHCH3), 4.19 (IH, d, Jai^ 17.85, NHCH,Hb), 4.06 (2H, s, NHCFI2), 4.03 (2H, s,
NHCFI2), 3.76 (3H, s, CH3), 1.73 (IH, sep, ./ 6.78, CH(CH3)2), 1.60 (2H, t, J  6.85, 
CHCH2CH), 1.42 (3H, d, JcH 7.15, CI-ICH3), 1.00 (3H, d, .76.25, CH(CH3)2) and 0.97 (3H, 
d, y  6.11, CH(CH3)2); 5c (75.5 MHz; 2H3CO2H) 175.31, 175.28, 170.54, 167.84(4 x 
NHCO), 158.73 (OCONH), 143.04 (C=CCO), 138.15 (/-CcHs), 129.48 (/yf-CgHg), 129.09 
(p-CgHs), 128.82 (o-CaHj), 122.56 (C=CCO), 67.78 (CgHgCHi), 64.26 (OCH2), 55.05 
(NHÇHCH2), 52.19 (OCH3), 50.12 (ÇHCH3), 41.90 (CH2CH(CH2)), 25.85 (CH(CH3)2), 
23.48, 21.82 (CH(CH3)2) and 18.00 (CHÇÏI3); m/z (Cl) 492 (100%, [M + H]") and 384 (9, 
[M - C6H5CH2O] ').
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3.0.2.89 Potassium (2R,3R)-methyl 2,3-epoxysucdnate (141)
To a stirred solution of (2R,3R)-dimethyI 2,3 epoxysuccinate (158) (220 mg, 1.17 mmol) 
in dry MeOH (3 cm^) was added KOH (85%, 76 mg, 1.35 mmol) at 0°C. The suspension 
was stirred for 2 h and the product was precipitated from solution by the addition of ether 
(10 cm^ ).*'*‘* The suspension was centrifliged (4000 rpm) for 10 min and the supernatant was 
decanted from the solid (203 mg, 94.3%), m.p. I48°C (decomp.); Umax (thin film)/cm'* 3022, 
2980(2 x aliphatic CH) and 1750 (CO); du (200 MHz; % 0 ) ,  3.73 (3H, s, OCH3), 3.55 
(IH, d, JcH 2.07, CH) and 3.44 (IH, d, Jch 1.95, CH); ôc (50.3 MHz; % 0 )  176.27, 173.27 
(2 X CO), 56.94, 56.05 (2 x  CH) and 54.43 (OCH,).
3.0.2.90 N-(tertiary-Butoxycarbonyi-(2S)-ieucyi-(2S)-alanyl
ethylenediamlne (142)
This compound was prepared in a manner identical to that described for the methyl glycyl 
glycinate (70) using tertiary-butoxycarbonyl-(2 S)-leucyl (2S)-alanyl aminoacetonitrile (170) 
(220 mg, 0.647 mmol) and carbon / palladium catalyst ( 10%, 44 mg, 20% Pd by mass). The 
reaction was complete after 2 days to give a white solid (219 mg, 98%), m.p. 99-102“C; Umax 
(KBr dislc)/cm‘* 3500, 3400, 3200 (3 x NH), 2900, 2850, 2790 (3 x aliphatic CH), 1700, 
1690 (OCONH and CONH); ôc (75.5 MHz; C^HgO^H) 175.61, 175.08 (2 x NHCO), 158.13 
(OCONH), 80.70 (C(CH3)3), 54.68 (ÇHCH2), 50.63 (CHCH3), 41.93 (NHCH2),
39.44 (ÇH2CH), 30.72 (CH2NH2), 28.74 (C(CH3)3), 25.87 (CH(CH3)2% 23.51, 21.89 
(CH(CH3)2) and 17.99 (NHCHÇH3); rn/z (Cl) 345 (4%, [M + H]"), 327 (14, [M + H - 
H2O]"), 245 (12, [M + 2H - C02C(CH3)3)] ') and 71 (100, [CjHsNO]').
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3.0.2.91 Diethylaminoacetonitnle phosphonate (143)
Aminoacetonitrile hydrochloride (85) (2.00 g, 21.6 mmol) was dispersed in CCU (30 cm^) 
and triethylamine (6.02 cm^, 43.2 mmol) was added. At 0°C diethylphosphite dissolved in 
e c u  (10 cm^) was added dropwise over 20 min and a white ppt formed. The reaction was 
stirred for 2 h and the solvent was removed under reduced pressure to give a brown solid. 
The solid was partitioned between ethyl acetate (100 cm^) and water (100 cm^), washed with 
water (2 x 50 cm^), brine (saturated, 40 cm^), dried (MgS04) and the solvent was removed 
under reduced pressure to give a yellow oil (2.47 g, 60%), u^ax (thin film)/cm'* 3570, 3440, 
3200 (3 X NH), 2990, 2970, 2900 (3 x aliphatic CH) and 2200 (CN); 6» (200 MHz; C^HCU),
4.65 (IH, dt, NH), 4.09 (4H, dt, J  7.53, 7.08, CH2O), 3.80 (2H, dd, J7 .4 6 , 6 .35, CH2CN) 
and 1.33 (6H, dt, 7  7.04, 7.08 CH3); ôc (75.5 MHz; C^HCU) 117.89 (CN), 63.54 (d, J  5.3, 
CH2O), 30.19 (ÇH2CN) and 16.56 (d, J7 .2 , C I I 3) ;  m/z (Cl) 193 (100%, [M + H ]‘).
3.0.2.92 N-(Diethyl phosphonate) ethylenediamine (146)
This compound was prepared in a manner identical to that described for the methyl glycyl 
glycinate (70) using diethylaminoacetonitnle phosphonate (145) (150 mg, 0.781 mmol) and 
carbon / palladium catalyst (10%, 23 mg, 15% Pd by mass). The reaction was complete after 
3 h to give a white solid (137 mg, 90%), u,„ax (thin film)/cm"* 3500, 3300 (2 x N H )  and 3000, 
2870, 2810 (3 x aliphatic C H ) ;  0n (300 MHz; C ^ H C U ), 4.04 ( 4 H ,  m, CH2O), 3.70 (IH, s, 
N H ) ,  3.20 (2H, s, N H 2) ,  2.99 (2H, q, J  2.99, C H 2N H )  2.71 (2H, t, J  5.55 CH2NH2), and 
1.28 (6H, dt, J  7.07, 7.08 C H 3); ôc (75.5 MHz; C^HCU) 62.25 (d, J  5.09, C H 2O ) ,  49.77 
( C H 2N H ) ,  40.45 (d, y  7.19 N H C H 2)  and 1 6 .1 5  ( d ,  J  7.19, C H 3); m/z (Cl) 197 ( 100% , [M + 
H]').
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3.0.2.93 N-(Diphenylphosphine)-amino acetonitrile (148)
Aminoacetonitrile hydrochloride (85) (200 mg, 2.16 mmol) was dispersed in diy 
dichloromethane (20 cm^) and at 0°C diphenylphosphinyl chloride (0.41 cm^, 2.16 mmol) 
was added dropwise over 10 min. The reaction was stirred for 2 h and the solvent removed 
under reduced pressure to give a white s o l i d . T h e  solid was partitioned between water (20 
cm^). The ethyl acetate was washed further with water (2 x 20 cm^), citric acid solution 
( 10%, 10 cm^), brine solution (saturated, 10 cm^) and dried (MgS04). The solvent was 
removed under reduced pressure to give a white solid which was reciystallised from MeOH / 
ether to give white needle shaped crystals (146 mg, 52%), (Found; [M + H]', 257.0838. 
C14H14N2O1P 1 requires 257.0844); 0„ (200 MHz; ^FUCO^H) 7.90, 7.55 (5FI, dm, CgHs) and 
3.93 (2H, d, Jp 12.29, CFI2); ôc (50.3 MHz; % C O "H ) 134.84, 134.20, 130.47, 133.46, 
133.27, 130.39, 130.21, 132.75, 132.68, 132.83 (12 x CeFIs), 119.29 (CN) and 29.35 (CH2); 
m/z (Cl) 257 (100%, [M +FI]‘).
3.0.2.94 N-(Diphenyi phosphine oxide)-ethyienediamine (149)
This compound was prepared in a manner identical to that described for the methyl glycyl 
glycinate (70) using N-(diphenylphosphine)-amiiio acetonitrile (148) ( 1.00 g, 3.91 mmol) and 
carbon / palladium catalyst (10%, 200 mg 20% Pd by mass). The reaction was complete after 
2 days to give a white solid (1.00 g, 98%), m.p. 58-59°C; u„,a.x (KBr disk)/cm'* 3400, 3200 
(2 X NH), 3010 (aromatic CH) and 2920, 2750 (2 x aliphatic CH); Ôh (200 MHz; C^HCb) 
7.85, 7.40 (5H, dm, CgHs), 3.04 (2F1, dt, Jp 11.19, Jch^ 6.41, CH2) and 2.74 (2H, t, Jch^ 5.36
CH2NH2); ÔC (75.5 MHz; C^FICU) 133.39, 132.18, 132.05, 131.67, 128.57, 128.4 (12 x 
Cd-isl 49.82 (d, Jp 4.95, NHCFI2) and 40.39 (NFI2CH2); m/z (Cl) 261 (27%, [M]") and 218 
(100, [M + H - (CH2)2NH2] ').
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3.0.2.94 N-(Triphenyl methyl)-glycine (152)
Under argon, glycine (270 mg, 3.6 mmol) was dispersed in diy dichloromethane (30 cm^) 
in a 2 necked flask fitted with a stopper and a reflux condenser. Then at 0°C trimethylsilyl 
chloride (1.37 cm^, 10.8 mmol) and dry NMM (1.18 cnf, 10.8 mmol) were added and the 
mixture was refluxed until the glycine dissolved (15 min). Triphenylmethyl cliloride (1.00 g, 
3.6 mmol) dissolved in warm diy dichloromethane (20 cm^) was added along with dry NMM 
(0.39 cm^, 3.6 mmol) and the solution was refluxed for 2 h. MeOH (5 cm^) was added and 
the reaction was stirred for a further 1 h before filtering and removing the solvent under 
reduced pressure and the resultant pale yellow solid was reciystallised from MeOH to give a 
white crystals (688 mg, 60%), m.p. 179°C (lit.,*'*^  178-179X); (Found: C, 79.3; H, 5.85; N, 
4.30. Calc, for Cz.H.gNiO: C, 76.45; H, 6.05; N, 4.40%); m/z (Found: [M]", 317.1409. Calc, 
for CîiHigNiOî 317.1411); (chloroform)/cm"* 3060, 3010 (2 x aromatic CH), 2830 
(aliphatic CH) and 1640 (CO,H); 0„ (200 MHz; (C'HCU) 7.32 (15H, m, C & ), 5.60 (2H, s, 
NH and OH) and 3.19 (2H, s, CHg); ôc (50.3 MHz; C^HCfi) 174.91 (COaH), 144.44 (/- 
CcCRs), 129.07 (in-CeUs), 128.69 (/;-C,H,), 127.60 (o-CgHj, 72.19 ((0 3 5 )3©  and 46.72 
(NCHa); m/z (El) 317 (10%, [M]"), 299 (15, [M - H2O]"), 258 (30, [M - CH2CO2H]") and 
240 (100, [M - C.3 5 ]").
3.0.2.95 Methy! N-(triphenyl methyl)-glycinate (153)
Triphenylmethyl-glycine (152) (1.00 g, 3.15 mmol) was dissolved with heating in MeOH 
(100 cm^) and at 0°C an etherial diazomethane solution (30 cm ,^ 0.35 moldin'^) was added 
until a yellow colour persisted. The solution was stirred for 2 h and acetic acid was added 
dropwise until the yellow solution went colourless.*"** The solvent was removed under 
reduced pressure to give a cream solid which was reciystallised from MeOH / ether to give
3.0 Compound synthesis    231
white needle shaped crystals (1.02 g, 98%), m.p. 99°C; (Found: C, 79.55; H, 6.45; N, 4.14. 
C^HaiNO; requires C, 79.75; H, 6.4; N, 4.25%); (thin film)/cm-‘ 3400, 3300 (2 x NH), 
3020, 3000 (2 X aromatic CH), 2850, 2800 (2 x aliphatic CH) and 1740 (CO); 6 h  (200 MHz; 
C’HCl,) 7.45 (15H, m, C«H,), 3.62 (3H, s, OCH;), 3.14 (2H, s, CH,) and 2.45 (IH, s, NH); 
5c (50.3 MHz; C’HCl,) 173.45 (CO), 145.83 (t-C«CH;), 129.13 (m -C A ), 128.46 (p-C A ), 
127.03 (o-CuHs), 71.18 ((C A )3C), 52.29 (OCH3) and 46.28 (NCH,); m/z (Cl) 332 (0.2%, 
[M + H]*) and 243 ( 100, [M - NHCHjCOjMe]*).
3.0.2.96 N-P'riphenylmethyl)-glycinamide (154)
Ammonia (30 cm’) was condensed into a 3-necked flask under N , at -78°C and sodium 
(33 mg, 1.53 mmol) was added in small pieces. Iron(in)chIoride hexahydrate (5 mg) was 
added and the solution was stirred until the blue solution went grey (Ih). Methyl N-(triphenyl 
methyl)-glycinate (153) (300 mg, 0.905 mmol) was added and stirred for a further 1 h."® 
The ammonia was allowed to evaporated and the soUd residue was extracted into MeOH (2 
X 40 cm’), filtered and the solvent removed under reduced pressure to give a pale yellow 
solid which was dissolved in water (10 cm’) washed with ethyl acetate (5 cm’) and 
recrystallised from the aqueous phase to give white crystals (200 mg, 70%), m.p. 179°C; 
(Found; C, 79.9; H, 6.35; N, 8.85. Ca.HoNzO, requires C, 79.7; H, 6.35; N, 8.85%); o ,„  
(thin fihn)/cm‘‘ 3410, 3300 (2 x NH), 3200 (aromatic CH), 2850, 2830 (2 x aliphatic CH) 
and 1680, 1640 (2 x CO); 5» (200 MHz; % C O ’H) 7.32 (15H, m, C A )  and 2.97 (2H, s, 
CH;); 5c (50.3 MHz; % C O ’H) 179.08 (CO), 145.33 (f-CsCHs), 128.51 (m -CA ), 
127.51 (p-CM$X 129.04 (o-C«H,), 77.00 ((CJHs);© and 48.29 (NCH,); m/z (Cl) 317 (0 .1%, 
[M + H]*) and 243 (100, [M + H -  NHCH;CO,NH;]*).
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3.0.2.97 (2R,3S)-Dimethyl threo-2-acetoxy-3-bromosuccmate
HBr in acetic acid (30% wt / vol, 120 cm’, 0.87 mol) was added dropwise to (2R, 
3R)-dimethyl tartrate (50 g, 0.28 mol) at 0°C over K li and stirred for 2 h at room 
temperature. The solution was poured onto ice (250 cm*) and extracted into ether (3 x 100 
cm*), washed with brine (saturated, 100 cm*) and dried (MgS04). The solvent was removed 
under reduced pressure to give an orange oil.*^ '* Kugelrohr distillation gave compound (156) 
as a straw coloured oil (11.59 g, 32%), b.p. 136°C at 1.5 mmHg (lit.,*^  ^ 83-86C at 0.1 
mmHg); ô» (200 MHz; ©HCI3) 5.59 (IH, d, Jch 5.5 CHOAc), 4.79 (IH, d, Jch 5.5 CHBr),
3.81, 3.79 (3H, ds, OCH3) and 2.17 (6H, s, CCH3); ôc (50.3 MHz; ©HCI3) 169.92, 167.39, 
166.77 (3 X C O ) ,  72.99 ( C H O A c ) ,  54.04 ( C O C H 3) ,  43.67 ( O C H 3)  and 20.91 ( C C H 3) ;  wÆ 
(Cl) 285, 283 (24%, 25, bromine isotopes, [M + H]"), 145 (82, [M + H - Br - CO2CH3]") 
and 99, 97 (31, 100, bromine isotopes, [B1OH2]").
3.0.2.98 (2R,3S)-dimethyl threo-2-hydroxy-3-bromosuccinate
(157^^^
(2R,3S)-Dimethyl threo-2-acetoxy-3-bromosuccinate (156) (10 g, 36.0 mmol) was 
dissolved in dry MeOH (40 cm*) and HBr in acetic acid (30% wt / vol, 12.7 cm*, 1.37 mol) 
was added and the solution was refluxed under N2 for 2 h. The solvent was removed under 
reduced pressure to give a red oil.' '^* Kugelrohr distillation give compound (157) as straw 
coloured oil (3.15 g, 31%), b.p. 145°C at 1.4 mmHg (lit.,**  ^ 80-82°C at 0.03 mmHg); Um» 
(thin film)/cm'* 3470 (OH), 2960 (aliphatic CH) and 1740 (CO) (lit.,*^ "* 3600-3100, 2985 and 
1750); 5„ (200 MHz; C"HC13),4.71 (IH, d, Jch 4.7 CHOH), 4.66 (IH, d, Jch ^ . 6  CHBr),
3.82, 3.80 (6H, ds, O C H 3)  and 3.55 (IH, s, OH); 5c (50.3 MHz; C^HCb) 171.11, 167.81 (2
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X CO), 72.96 (CHOH) 54.04 (CHBr) and 53.61, 47.04 (2 x CH3); m/z (Cl) 243, 241 (97, 
100, bromine isotopes, [M + H]") and 229, 227 (15, 14, bromine isotopes, [M - CH3]").
3.0.2.99 (2R,3R)-Dimethyl 2,3-epoxysuccinate
A solution of (2R,3S)-dimethyl threo-2-hydroxy-3-bromosuccinate (157) (4.5 g, 19.0 
mmol) in dry MeOH (20 cm*) was added dropwise to a stirred solution of sodium (0.48 g, 
20.9 mmol) in diy MeOH (20 cm*), under nitrogen at 0°C over 20 min. The solution was 
stirred at 0°C for 2 h and the excess sodium was quenched with a drop of acetic acid. The 
solvent was removed under reduced pressure using a cold water bath and the white solid was 
partitioned between water (50 cm*) and ethyl acetate (50 cm*).* ‘^*The ethyl acetate layer was 
washed with brine (saturated, 20 cm*), dried (MgS04) and the solvent removed under 
reduced pressure to give a white solid which was reciystallised from MeOH to give white 
needle shaped ciystals (1.75 g, 58%), m.p. 72°C (lit.,*^  ^ 77-78°C); Umax (thin film)/cm"* 3070, 
3010, 2920 (3 X aliphatic CH) and 1740 (CO); Ôh (200 MHz; C^HCb) 3.68 (2H, s, CH) and 
3.81 (6H, s, OCH3); ÔC (50.3 MHz; C^HCls) 197.95 (CO), 53.87 (OCH2) and 52.34 (OCH3); 
m/z (Cl) 161 (100%, [M + H]") and 145 (7, [M - CH3]").
3.0.2.100 Potassium (2R,3R)-ethyi 2,3 epoxysuccinate (159^^^
This compound was prepared in a manner identical to that described for the potassium 
(2R,3R)-methyl 2,3-epoxysuccinate (117) using (2R,3R)-diethyl 2,3-epoxysuccinate (162) 
(3.00 g, 16.0 mmol), dry ethanol and KOH (85%, 1.03 g, 18.4 mmol) to give a white solid 
(1.39 g, 44%), m.p. 133°C (decomp.), (lit.,*"*"* 159°C decomp.); Umax (thin film)/cm‘* 3040, 
3000 (2 X aliphatic CH) and 1760, 1750 (2 x CO); Ôh (200 MHz; % 0 ) ,  4.20 (2H, q, Jc/r
7.18, CH2), 3.45 (IH, d, Jch 2.16, CH), 3.45 (IH, d, Jch 2.16, CH) and 1.22 (3H, t, Jch^
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7.15 CH;); 5c (50.3 MHz; ’H2O) 171.51, 168.11 (2 x CO), 61.24 (OCH;), 49.87, 52.22 (2 x 
CH) and 11.24(CH;).
3.0.2.101 (2R,3S)-Diethyl threo-2-acetoxy-3-bromosuccinate (160)^^^
This compound was prepared in a manner identical to that described for the
(2R,3S)-dimethyl threo-2-acetoxy-3-bromosuccinate (156) using (2R,3R)-dietliyl tartrate 
(30 g, 0.145 mol) to give an orange oil which was purified by silica chromatography eluting 
with ether to give a straw coloured oil (22.6 g, 50%), (thin film)/cm'* 2990 (aliphatic 
CH) and 1750 (CO) (lit.," ' 2985, 1756); 5h (200 MHz; C’HCI;) 5.57 (IH , d, Jen 5.5
CHOAc), 4.77 (IH, d, Jew 5.5, CHBr), 4.23 (4H, m, OCH;), 2.15 (3H, s, OCCH;) and 1.28
(6H, t, Jch,  7.17, CH;CH;); 5c (50.3 MHz; C’HCI;) 169.84, 166.72, 166.10 (2 x CO), 73.16
(CHOAc), 62.77, 63.46 (2 x OCH;), 44.36 (CHBr), 20.83 (CH;) and 14.47, 14.39 (2 x 
CH;CH;); m/z (Cl) 313, 311 (25%, 26, bromine isotopes, [M + H]'), 271, 269 (99, 100, [M 
+ 2H - COCH;]*) and 233 (14, [M + 2H - Br]*).
3.0.2.102 (2R,3S)-Diethyl threo-2-hydroxy-3-bromosuccinate (161)^^ '*
This compound was prepared in a manner identical to that described for the
(2R,3S)-dimethyl threo-2-hydroxy-3-bromosuccinate (157) using (2R,3S)-diethyl 
tlireo'2'acetoxy-3-bromosuccinate (160) (20 g, 64 mmol) and dry ethanol (100 cm’) to give a 
yellow oil (12.3 g, 72%), u,„„ (thin film)/cm‘‘ 3470 (OH), 2985 (aliphatic CH) and 
1740 (CO) (lit.,'"' 3480, 2985, 1740); 5„ (200 MHz; C’HCI;) 4.69 (IH, d, Jen 3.74 CHOH),
4.65 (IH, d, Jen 4.36 CHBr), 4.30 (4H, q, J  7.05, OCH;), 3.47 (IH, s, OH) and 1.29 (6H, t, 
Jen 6.82, CH;CH;)i 5c (50.3 MHz; C’HCI;) 170.76, 167.13 (2 x CO), 73.00 (CHOH),
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63.33, 63.08 (2 x 0 C % ) ,  48.15 (CHBr) and 14.53, 14.41 (2 x C H 2C H 3) ;  m/z (Cl) 271, 269 
(60%, 63, bromine isotopes, [M + H]'), 191 (13, [M + 2H - B rf), 173 (36, [M + 2H - Br - 
H2O]') and 117 (100, [M + II - Br - CO2CH2CH3]').
3,0.2.103 (2R,3R)-Diethy! 2,3 epoxysuccinate (162)^ "^^
This compound was prepared in a manner identical to that described for the 
(2R,3R)-dimethyl 2,3-epoxysuccinate (158) using dry EtOH and (2R,3S)-diethyl threo-2- 
hydroxy-3-bromosuccinate (161) (6.00 g, 23.0 mmol) to give a yellow oil (3.35 g, 77%), m/z 
(Found: [M + H]*, 189.0760. Calc, for CsH.aOs 189.0763); u„,„ (thin film)/cnt' 2990 
(aliphatic CH) and 1740 (CO) (lit.,” '' 2986, 1748); 8» (200 MHz; C^HCU), 4.27 (2H, q, Jen
7.14, CH:), 4.25 (2H, q, J c n I M ,  CH2), 3.66 (2H, s, CH) and 1.31 (6H, t,Jcn^ 7.18, CH3);
8c (50.3 MHz; C^HCb) 167.24 ( C O ) ,  62.69 ( O C H 2) ,  52.49 ( C H )  and 14.50 ( C H 3) ;  m/z (Cl) 
189 (50%, [M + H]*) and 73 (100, [C O z E t]" ) .
3.0.2.104 Potassium (3S,3S)-ethyl 2,3-epoxysuccinate (163)
Tills compound was prepared in a manner identical to that described for the potassium 
(2R,3R)-methyl 2,3 epoxysuccinate (117) using (2R,3R)-Diethyl-2,3-epoxysuccinate (162) 
(3.00 g, 16.0 mmol), dry ethanol and KOH (85%, 1.03 g, 18.4 mmol) to give a white solid 
(1.41 g, 45%), m.p. 133°C (decomp.); u„„x (thin film)/cm'' 3010, 3000 (2 x aliphatic CH) 
and 1750, 1730 (2 x CO); 5„ (200 MHz; ^HjO), 4.22 (2H, q, Jai^ 7.17, CH2), 3.56 (IH, d,
JcH 2 .00, CH), 3.46 (IH, d, Ja , 1.80, CH) and 1.23 (3H, t, Jcfr  ^ 7.15 CH,); 5c (50.3 MHz;
^ H : 0 )  171.51, 168.09 ( C O ) ,  61.24 ( O C H 2) ,  49.87, 52.26 ( C H )  and 11.25 ( C H 3) .
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3.0.2.105 (2S,3R)-Diethyl eiythro-2~acetoxy~3-bromosuccinate
(i64y^*
This compound was prepared in a manner identical to that described for the 
(2R,3S)-dimethyl threo-2-acetoxy-3“bromosuccinate (156) using (2S,3S)-diethyl tartrate (30 
g, 0.145 mol) to give an orange oil which was purified by silica chromatography eluting with 
ether to give a straw coloured oil (35.7 g, 79%), m/z (Found: [M + H]% 311.0123. 
CioHisOeBr requires 311.0130); u,„ax (thin film)/cm'^ 2990 (aliphatic CFI) and 1750 (CO) 
(lit./'" 3000 and 1765); 5„ (200 MHz; C^HCl3),5.57 (IB, d, Jch 5.41 CHOAc), 4.76 (IH, d, 
Jc// 5.41 CHBr), 4.24 (4H, m, OCH2), 2.15 (3H, s, OCCH3) and 1.28 (6H, t, Jch^  7.04,
CH2CH3); ÔC (50.3 MHz; C^HCls) 169.84, 166.72, 166.10 (3 x CO), 73.16 (CHOAc), 62.77, 
63.46(2 X OCH2), 44.36 (CHBr), 20.83 (CH3) and 14.47, 14.39 (2 x CH2ÇH3); m/z (Cl) 
313, 311 (46%, 48, bromine isotopes, [M + H]'), 271, 269 (3, 4, [M + 2H - COCH3]') and 
75 (100, [Fl2C02Et]").
3.0.2.106 (2S,3R)-Diethyl erythro-2-hydroxy-3-bromosuccînatB
This compound was prepared in a manner identical to that described for the 
(2R,3S)-dimethyI threo-2-hydroxy-3-bromosuccinate (157) using (2S,3R)-diethyl 
threo-2-acetoxy-3-bromosuccinate (164) (20 g, 64 mmol) and dry ethanol (100 cm^) to give 
a yellow oil (14.50 g, 84%), (thin film)/cnf* 3475 (OH), 2985 (aliphatic CH) and 
1745 (CO) (lit.," ' 3500 and 3000, 1750); 5„ (200 MHz; C^HCb) 4.71 (IH, d, Jch 4.23, 
CHOH), 4.66 (IH, d, Jc/r4.19, CHBr), 4.28 (4H, m, OCH2), 3.40 (IH, s, OH) and 1.30 (6H, 
t, JcH_ 7.14, CH 2CH3); ÔC (50.3 MHz; C^HCb) 170.79, 167.16(2 x CO), 73.01 (CHOH),
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63.34, 63.08 (2 x OCH2), 48.13 (CHBr) and 14.52, 14.41 (2 x CH2CH3);/«/z (Cl) 271, 269 
(8%, 9, bromine isotopes, [M + H f), 173 (12, [M + 2H - Br - H2O]*) and 117(100, [M + H 
- Br - COzCHaCHj]^.
3.0.2.107 (2S,3S)-Diethy 2,0-epoxysuccinate (lOOf "^^
This compound was prepared in a manner identical to that described for the 
(2R,3R)-dimethyI 2,3-epoxysuccinate (158) using di-y EtOH and (2S,3R)-diethyI threo-2- 
hydroxy-3-bromosuccinate (165) (6.00 g, 23.0 mmol) to give a yellow oil (3.14 g, 73%), 
(thin film)/cm’^  2990 (aliphatic CH) and 1740 (CO) (lit.," ' 3020, 2960 and 1760); 
ÔH (200 MHz; C2HCI3), 4.27 (2H, q, Jc h 1.\9 CHz), 4.26 (2H, q, Jc//^7.10 CH2), 3.67 (2H,
s, CH) and 1.32 (6H, t, Jcu^ 7.15, CH3); 5c (50.3 MHz; C^HCb) 167.23 (CO), 62.73
(OCH2), 52.50 (CH) and 14.51 (CH3); m/z (Cl) 189 (50%, [M + H]^) 161 (7, [M + 2H - 
E tY l  117 (15, [M + 2 H - C 02Et]') and 73 ( 100, [C02Et]").
3.0.2.108 Disodium cis epoxysuccinate (169f^^
Maleic acid (29 g, 0.25 mol) was dissolved in water (75 cm^) and NaOH (15 g, 0.38 mol) 
in water (25 cm^) was added dropwise over 20 min so the temperature did not exceed 60°C. 
At 60°C sodium tungstate dihydrate (1.65 g, 7.6 mmol) was added and H2O2 solution (30%, 
32 cm ,^ 0.30 mol) was added dropwise so the temperature did not exceed 60°C. Aliquots of 
NaOH solution (2 cm  ^ in total, 5 moldm’^ ) were added periodically to maintain the pH above 
pH 4. The solution was stirred for 1 hour at 60°C, cooled to 40°C and the remaining NaOH 
solution added. The solution was concentrated under reduced pressure to 75 cm  ^ and ethanol 
(100 cm^) was added to give a white ppt was filtered and dried,"*' m.p. 215°C (decomp.);
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Umax (KBr disk)/cm'' 171.75 (CO); 5 h  (200 MHz; ^H;0) 3.65 (IH. s, CH); 3c (50.3 MHz; 
^H:0) 171.75, (CO), 53.36 (CH).
3.0.2.109 Tertiary-butoxycarbonyl-(2S)-leucyi-(2S)-alanyl-
aminoacetonitrlle (170)
This compound was prepared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl (2S)-alanyl glycyl glycinate (65) using tertiary-butoxycarbonyl- 
(2S)-leucyl (2S)-alanine (43) (200 mg, 0.661 mmol) and aminoacetonitrile hydrochloride (61 
mg, 0.661 mmol). Recrystalisation from MeOH /  ether gave white crystals (188 mg, 84%), 
m.p. 134°C; m/z (Found: [M + H]*, 341.2197. C1SH29N4O4 requires 341.2189); [a]n -53.0 (c 
0.25 in MeOH); Om.x(thin film)/cm-l 3380 (NH), 2950 (CH). 2210 (CN). 1680. 1670, 1650 
(CO2NH and 2 X CONH); 5h (200 MHz; C^HCh) 7.57 (IH , t, NgCH:), 6.57 (IH, d, J ch
7.33, NHCHs), 4.95 (IH , d, J ch 5.13, NHCHCH2), 4.51 (IH. quin, J  7.31, NHCHCH2), 
4.30 (IH, d, /cffj 6.27, C&HbNH), 4.22 (IH, d, J ch  ^ 6.15, CHJItNH), 4.02 (IH, m, 
CHCH3), 1.66 (3H, m, CH2CH(CH3)2), 1.47 (9H, s, C(CH3)3) 1.43 (3H, d, J ch 4.04, 
CHCHj), 0.98 (3H, d, J ch 4.40, CH(CH3)2) and 0.95 (3H. d, J ch 4.15, CH(CH3)2); 5c  (50.3 
MHz; C^HCla) 176.09, 175.36 (2 x CO), 158.57 (OCONH), 117.74 (CN), 81.12 (aC H ,);), 
54.95 (NHÇHCH2), 50.48 (CHCH3), 42.20 (CH2). 29.04 ( € ( ^ 3)3, 28.33 (ÇH2CN), 26.16 
(CH(CH3)2), 23.79, 22.17 (CH(CH3)2), and 18.11 (C H Œ 3); m/z (Cl) 341 (29%, [M + H f). 
285 (100, [M - NHCH2CN]*), 267 (4, [M - OC(CH3)3]0 and 241 (19, [M + 2H - 
C 0 2 C (C H 3 )3 ]* ) .
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3.0.2.110 0-(2R,3RMtrans-Carbonyl oxlran-2-yl 3-(ethoxycarbonyl) 
butane] N-(carbobenzyloxy-leucyi alany!)-ethano!amine (173)
This compound was prepared in a manner identical to that described for the methyl 
benzoxycarbonyl-(2S)-leucyl (2S)-alaninate (29) using N-(Carbobenzyloxy-(2S)-leucyl (2S)- 
alanyl)-ethanolamine (174) (93 mg, 0.245 mmol) and pre-neutralised potassium (2R,3R)- 
ethyl 2,3 epoxysuccinate (159) (52 mg, 0.245 mmol) which was prepared as fo llow s/" 
potassium (2R,3R)-ethyI 2,3 epoxysuccinate (156) (80 mg) was dissolved in NaHS04 
solution (5%, 4 cm^) and NaCl was added until the saturation point was reached. The 
(2R,3R)-ethyl 2,3 epoxysuccinate was then extracted into ethyl acetate (3 x 10 cm^), dried 
(MgS04) and the solvent removed under reduced pressure to give a yellow oil. The crude oil 
(173) was purified by silica chromatograpy using ethyl acetate to give a white solid (58 mg,
41%), m.p. 128°C; (Found: C, 57.8; H, 6.85; N, 8 .00 . C25H35N3O9 requires C, 57.55; H, 
6.75; N, 8.05%); m/z (Found: [M + H ]’, 522.2455. C25H36N3O9 requires 522.2452); [a]o 
-5.89 (c 0.82 in MeOFI); o,m.x (KBr disk)/cm’’ 3300 (NH), 3100, 3070, 3040 (3 x aromatic 
CH), 2970, 2930, 2880 (3 x aliphatic CH), 1750, 1730, 1710, 1680, 1640 (5 x CO); 5» (300 
MHz; ^HgCO'H) 7.39 (5H, m, 5.14 (2H, s, CHzCgHg), 4.30 (5H, m, OCH2CH3,
OCH2CH2 and CHCFI3), 4.16 (IH, t, J c h ,  7.52, NHCHCH2), 3.74 (IH, d, J c h  5.19, CHO),
3.74 (IH, d, J c h  5.20, CHO), 3.49 (211, m, CH.HbN), 1.74 (IH, sep, J c h ,  6 .66, CH(CH3)2), 
1.60 (2H, t, J c h ,  7.15, CFICH2), 1.37 (3H, t, J c h ,  6.26, CH2CH3), 1.31 (3H, d, J c h  7.12, 
CFICH3), 0.92 (3H, d, J c h  6.50, CH(CH3)2) and 0.97 (3H, d, J c h  6.44, CH(CH3)2); 6c (75.5 
MHz, "HgCO^H) 175.26, 175.12 (2 x CONH), 168.45, 168.40 (2 x CO2R), 158.76 
(OCONH), 138.99 129.49 (/ff-CgHj), 129.03 (p-CgHg), 128.78 (o-CgHg), 67.89
(C6H5CH2), 65.40 (OÇH2CH2), 63.20 (OÇH2CH3), 55.21 (NHÇHCH2), 53.09, 53.00 (2 x
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CHO), 50,47 (CECHa), 41.84 (CIEN), 39.24 (CHQECH), 25.86 (^ (C H s ) :) ,  23.46, 21.88 
(CH(CH3)2), 17.91 (CHCH3) and 14.34 (CH2CH3); m/z (Cl) 522 (5%, [M + H]*) and 
362 (100, [M + H - C02C1I(0)C1 ICOzEt]').
3.0.2.111 N-(Carbobenzyloxy-(2S)-leucyl (2S)-alanyl) ethanolamine
(174)
This compound was pre[)ared in a manner identical to that described for methyl 
carbobenzyloxy-(2S)-leucyl-(2S)“alanyl-glycyl-glycinate (65) using carbobenzyloxy-(2S)- 
ieucyl (2S)-alanine (29) (300 mg, 0.893 mmol) and ethanolamine hydrochloride (87 mg, 
0.893 mmol) to give a white solid which was recrystallised from acetone / ether to give white
crystals (244 mg, 72%), m.p. 140°C; (Found; C, 60.4; FI, 7.5; N, 11.05. C19H29N3O5 requires 
C, 60.15; H, 7.70; N, 11.05%); [ajo -49.1 (c 0.16 in MeOFI); Umax (thin film)/cm'^ 3240 
(OH), 3050, 3040, 3010 (3 x aromatic CH), 2980, 2900, 2850 (3 x aliphatic CH), 1700, 
1650 (2 X CONH); 5» (300 MHz; % CO ^H ) 7.41 (5H, m, C A ) ,  5.25 (IH, d, J ch,, 12.75, 
CHACcHs), 5.18 (IH, d, Ja,„ 12.40, C H E b C A ), 4.48 (IH, q, Jch^  6.74, CHCH3), 4.30 
(IH, t, Jch,  7.11, NHCHCH2), 3.70 (2H, t, Jch,  5.62, CHjO), 3.40 (2H, t, Jch,  5.54, CH2N), 
1.80 (IH , sep, Jch,  6.43, CH(Cll3)2), 1.86 (2H, t, J a ,, 7.10, CHCH2), 1.45 (3H, d, Jc/f 7.01,
CHCH3), 1.05 (3H. d, J ch 6.52, CH(CH3)2) and 1.03 (3H, d, Jch 6.49, CH(CH3)z); Sc (75.5 
MHz, % C O ^H ) 175.08, 174.83 (2 x CONH), 158.52 (OCONH), 137.99 (/-CsHs), 
129.39 (m-CcHs), 128.94 (p-CsHs), 128.71 (o-CsH,), 67.68 (C^HCHz), 61.39 (OCH2), 
54.97 (NHCHCH2), 50.28 (CHCH3), 42.90 (CH2N), 41.86 (CHCH2CH), 25.74 (^ (C H a);) , 
23.44, 21.87 (2 x CH(CH3)2) and 18.15 (CHCH3); m/z (Cl) 380 (100%, [M + H]*) and 272 
(58, [M - CsHsCO] ').
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3.0.2.112 0-(2S,3S)-[tranS”Carbonyl oxiran-2-yl 3-(ethoxycarbonyl) 
butane] N-(carbobenzyloxy-leucyl-afanyl)-ethanolamine (175)
This compound was prepared in a manner identical to that described for the methyl 
benzoxycarbonyl-(2S)-leucyl (2S)-alaninate (29) using N-(Carbobenzyloxy-(2S)-leucyl (2S)- 
alanyl)-ethanolamine (174) (93 mg, 0.245 mmol) and pre-neutralised potassium (2S,3S)- 
ethyl-2,3-epoxysuccinate (163) (56 mg, 0.264 mmol) which was prepared as follows;"' 
potassium (2S,3S)- ethyl-2,3-epoxysuccinate (163) (80 mg) was dissolved in NaHSO# 
solution (5%, 4 cm^) and NaCI was added until the saturation point was reached. The 
(2S,3S)-ethyl threo 2,3 epoxysuccinate was then extracted into ethyl acetate (3 x 10 cm^), 
dried (MgS04) and the solvent removed under reduced pressure to give a yellow oil. The 
crude oil(17S) was purified by silica chromatograpy using ethyl acetate to give a white solid
(51 mg, 37%), m.p, 150-151 C; m/z (Found: [M + Hj^, 522.2456. C25H36N3O9 requires 
522.2452); [a]o +1.80 (c 0.89 in MeOFI); Umax (KBr disk)/cm‘^  3300 (NH), 3050, 3025, 
3010 (3 X aromatic CH), 2930, 2920, 2880 (3 x aliphatic CH), 1750, 1730, 1710, 1690, 
1650(5 X CO); ô» (300 MHz; ^H^CO^H) 7.39 (5H, m, CgFIj), 5.14 (2FI, s, CHbCgHs),
4.75 (4H, m, OCH2CH3 and OCH2CH2), 4.33 (IH, q, Jch, 5.73, CHCH3), 3.95 (IH, t, Jch^  
5.96, NHCHCHz), 3.75, 3.73 (2FI, ds, CHO), 3.47 (2FI, m, CH,HbN), 3.46 (2H, dt, /  10.66, 
20.38, CHaHbN), 1.78 (HI, sep, Ja,, 6.62, CH(CH3)2), 1.60 (2H, t, .7^/, 7.4, CHCH2),
1.38 (3H, d, J c h  7.19, CFICH3), 1.33 (3H, t, J ch ,  7.14, CH2CH3), 0.94 (3H, d, J c h  6.51, 
CH(CH3)2) and 0.97 (3H, d, J c h  6 A 3 ,  CH(CH3)2); 6c (75.5 MHz, % CO "H ) 178.77, 178.61 
( 2  X CONH), 175.32, 175.17 ( 2  x CO2R), 158.52 (OCONH), 138.23 (i-CgHs), 
129.54 (m-CgHs), 129.08 (p-CgHg), 128.83 (o-CgHs), 67.85 (CgHgCHz), 65.45 (OCH2CH2), 
63.26 (OCH2CH3), 55.26 (NFIÇHCH2), 53.15, 53.06 (CHO), 50.53 (CHCH3), 41.89
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(CH2N), 39.29 (CHÇH2CH), 25.91 (ÇH(CH3)2), 23.52, 21.93 (CH(CH3)z), 17.97 (CHÇH3) 
and 14.40 (CH2CH3); m/z (Cl) 522 (7%, [M + H]*) and 362 ( 100, [M - 
C02CH(0)CHC02Et]*).
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3.1 Biological assays
3.1.0 Initial methods to determine potential inhibitor activity
Three different methods were used to determine the activity of the potential inhibitors. 
The three assay methods were fairly similar, except that different preparations of proteinase 
were used between each of the methods. The following tables show which methods were 
used to test the various potential inhibitors mentioned in the discussion.
Compound Number
Cbz-Leu-Ala-Gly-Gly-NH2 19
Cbz-Leu-Ala-Gly-Gly-NHMe 20
Cbz-Leu-Ala-Gly- Gly-NMe2 21
Cbz-Leu-Ala-Gly-Gly-NMeEt 22
Cbz-Leu-Ala-Gly-GIy-NMeOMe 23
Leu-Ala-Gly-Gly-NH2 . HOAc 25
Leu-Ala-Gly-Gly-NHMe. HOAc 26
Cbz-Leu-Ala-Gly-Gly 76
Cbz-Leu-Ala-Gly-aminoacetonitrile 78
t-Boc-Leu-Ala-Gly-aminoacetonitrile 79
TF A-Leu-Ala-Gly-aminoacetonitrile 82
TF A-Ala-Gly-aminoacetonitrile 83
TF A-Gly-Gly-aminoacetonitrile 84
aminoacetonitrile hydrochloride 85
Table 3.1: The potential inhibitors tested by method 2.
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Compound Number
t-Boc-Leu-Ala-Gly-GIy-/?-nitroanilide 24
Cbz-Leu-Ala-Gly-Gly-OMe 65
Cbz-Leu-Ala-Gly-GIy-OEt 66
t-Boc-Leu-Ala-Gly-Gly-OtBu 73
N-(Cbz-Leu-Ala-GIy)-ethanoIamine 75
Cbz-Leu-Ala-Gly-aminoacetonitrile 78
t-Boc-Leu-Ala-Gly-aminoacetonitrile 79
Cbz-Leu-Ala-Ala-aminoacetonitrile 80
Cbz-Leu-Ala-(2R)-Ala-aminoacetonitrile 81
t-Boc-Leu-Ala-Gly-aminoacetaldehyde dimethyl acetal 113
Cbz-Leu-Ala-Gly-aminoacetaldehyde dimethyl acetal 114
Cbz-Leu-Ala-Gly-1 -amino prop-2-ene 115
Cbz-Leu-Ala-Gly-1 -amino 2-methyl prop-2-ene 118
Cbz-Leu-Ala-Gly-2-bromoethyIamine 130
N, N ’ (di(Cbz-Leu-Ala-Gly))- 2, 4-diamino but-2-ene aldehyde 122
0-(Cbz-Leu-Ala-Gly)- 1-carboxymethyI, 4-hydroxy but-2-ene 132
(2R,3R)-0-[trans-carbonyl oxiran-2-yI 3 -(ethoxycarbonyl) 
butane] N-(Cbz-Leu-Aia-)-ethanolamine
173
(2S,3S)-0-[trans-carbonyI oxiran-2-yl 3-(ethoxycarbonyl) 
butane] N-(Cbz-Leu-Ala-)-ethanolamine
175
Table 3.2: The potential inhibitors tested by method 1.
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Compound Number
Cbz-Leu-Ala-Gly-Gly-OtBu 67
t-Boc-Leu-Ala-Gly-Gly-OBz 72
t-Boc-Leu-Ala-Gly-aminoacetonitrile 79
Cbz-Leu-Ala-Gly-aminoacetaldehyde 112
Cbz-Leu-Ala-Gly- 1-aminopropanone 116
Table 3.3 : The potential inhibitors tested by method 3.
3.1.0.0 Method 1
All solvents used were HPLC grade. Each set o f assays consisted of a control (4% DMSO 
solution) and 4 potential inhibitors dissolved in DMSO and diluted to 4% DMSO with water. 
Each assay was offset by 1 min compared to the previous assay, so overall one reading was 
taken every min.
Each potential inhibitor assay was conducted as follows; proteinase solution (20 mm^, 
3.87 p,mol dm'^ 77.4 nmol), activating peptide (GVQSLKRRRCF) solution (20 cm \ 10 
jLimol dm'^, 0,2 pmol) and tris / NaCl buffer (50 cm^, 2 mmol dm" ,^ tris and 100 mmol dm'  ^
NaCl at pH 8) where mixed in the order shown and incubated at 37°C for 15 min.
Substrate (Acetyl-LRGA-GRSR) solution (25 mm ,^ 4.42 mmol dm" ,^ 9.77 pmol) and 
potential inhibitor 4% DMSO solution (25 mm^, 0,22 mmol dm'^, 4.4 pmol) were mixed and 
also incubated at 37°C for 10 min. After the proteinase had been incubated for 15 min, the 
inhibitor / substate mixture (40 mm^) was added to the activated proteinase solution, mixed 
and incubated at 37°C.
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After 5 min from the addition of the substrate to the proteinase, an aliquot (20 mm^) of 
the first assay solution was added to a trifiuoroacetic acid solution (50 mm^, 1%) and mixed. 
Further aliquots (20 mm^) of the assay solution were quenched with trifiuoroacetic acid 
solution at 10, 15, 20, 25 min time intervals.
Each aliquot was further diluted with water (80 mm^) and filtered through a micropore 
filter at 13000 rpm for 3 min. A clean filter was used for each assay, filtering the first aliquot 
first and reusing the filter for the later aliquots. Each sample was then analysed by capillary 
electrophoresis using a Bio-rad, BioFocus™ 3000 capillary electrophoresis system by Dr 
Kemp at the University of St Andrews Biochemistry department
3.1.0.1 Method 2
The assay was carried out in a manner identical to that described for method 1, using 
proteinase solution (1.74 pmol dm" ,^ 34.8 nmol) and potential inhibitor 6% DMSO solution 
of (8.8 mmol dm'"', 0.176 pmol). All method 2 assays were performed by Dr Heather Murray 
at the University of St Andrews Biochemistry department.
3.1.0.2 Method 3
The assay was carried out in a manner identical to that described for method 1, except 
that all the volumes used were halved, aliquots were taken at 6, 12 and 18 min time intervals 
and using proteinase solution (2.17 pmol dm'^, 21.7 nmol).
3.1.0.4 Treatment of the capillary electrophoresis results
The output from the capillary electrophoresis system is depicted in Fig. 3.1, showing the 
substrate (S) and product (Pi and P2) peaks.
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%
[SI
[Pd
2.90 4.00 6.66
time / min
Fig. 3.1: The output from  a capillary electrophoresis system.
Integration gives the size of each peak as a percentage of the total area of all the peaks. 
The initial rate is determined from the plot of the size of Pi from the integration versus time 
in seconds. Provisionally the initial rates were determined by hand, but then by using the 
Enzfitter program^^^ as the 2 methods of data analysis were identical. Enzfitter was set to 
first-order-rate-plus-offset. The initial rate is given in equation 3.1.
The first order rate equation is given by;
[S]. = [S ]„ [ l-e '“] 3.1
Where the concentration of the substrate at time, t is given by St, the 
concentration of the substrate at t = 0 (the limit in the Enzfitter program) 
is given by So and the rate constant is given by k. Differentiation of 
equation 3.1 gives;
d[S]t = -[S]oke'“ 3.2
But as;
dt
d[S]t = - j n  
dt dt
3.3
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Therefore;
d[P]t = [S]oke“ 3.4
dt
Substituting t = 0 in equation 3.4 gives;
rate at t = 0 = [S]ok 3.5
3.1.1 inactivation studies
3 .1 1 0  Method 1
Proteinase solution (0.1845 cm \ 3.87 |imoldm‘^ , 71.4 nmol), activating peptide 
(GVQSLKRRRCF) solution (0.1845 cm^, 10 pmol dm'^, 1.85 pmol) and tris / NaCl buffer 
(0.461 cm^, 2 mmol dm‘^ , tris and 100 mmol dm'^ NaCl at pH 8) where mixed in the order 
shown and incubated at 0°C for 15 min. This solution was separated out into 2 portions 
(400 cm^) and after 1 min, N ’ N ’-dicarboxybenzyl-Leu-Ala-Gly)- 2, 4-diamino-but-2-ene 
aldehyde (122) 4% DMSO solution (88,9 mm^, 4.4 pmol dm’^ , 0.391 nmol) was added to 
one portion and 4% DMSO solution (88.9 mm^) was added to the other.
After a further 3 min the inhibitor / enzyme solution (0.111 cm^) was added to the 
substrate (Acetyl-LRGA-GRSR) solution (0.020 cm^ 4.42 mmol dm'^, 88.4 nmol) at 37°C 
and mixed. Then after 1, 2, 3, 6.30 and 10 min from the addition of the proteinase solution to 
the substrate solution, aliquots (20 mm^) of the assay solution were quenched with 
trifiuoroacetic acid solution (50 mm^, 1%). A similar procedure was repeated for the control 
/ enzyme solution after the first assay was complete. A further 3 sets of assays for the control 
/ proteinase solution and the blank / proteinase were similarly taken after the first set.
The aliquots were diluted, filtered and analysed as for Section 3.0.2.0.0, method 1. This 
procedure was only successful for a very robust proteinase preparation. One attempt out of 
six gave no proteinase activity in the control.
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3.1.1.1 Method 2
Proteinase solution (10 mm \ 2.17 pmol dm' ,^ 21.7 pmol), activating peptide 
(GVQSLKRRRCF) solution (0.010 cm ,^ 10 pmol dm''", 10 nmol), tris / NaCl buffer (25 
mm^, 2 mmol dm'^, tris and 100 mmol dm'^ NaCl at pH 8) and the 4% DMSO inhibitor 
solution (10 mm^, 0.22 mmol dm'^, 2.2 pmol) were mixed in the order shown and incubated 
at 37°C for 3 min.
Then substrate (Acetyl-LRGA-GRSR) solution (10 mm ,^ 4.42 mmol dm'^, 4.42 pmol) 
was added, mixed and aliquots (10 mm^) were removed and quenched with trifiuoroacetic 
acid solution (0.025 cm ,^ 1%) after 5, 10 and 15 min from the addition of the substrate to the 
proteinase solution. The same procedure was repeated for a control o f 4% DMSO, off 
setting the additions and the aliquots by 1 min from the inhibitor assay.
This procedure was repeated twice more, leaving the inhibitor / control solutions for 5 
and 7 min with the proteinase, before the addition of the substrate. The quenched aliquots 
were diluted with water (40 mm^), filtered and analysed as in Section 3.0.2.0.0 method 1.
3.1.3 Double reciprocal (Lineweaver Burke) plots and K| 
determination
The aim of these plots is to give an estimation of K; and to give an indication as to the 
type of inhibition observed. The concentrations of inhibitor chosen are critical to the 
accuracy of the plots. If too large concentrations are chosen, the gradient of the double 
reciprocal plots are very large and a small error in any of the points, particularly the lower 
concentrations of substrate which are usually the most prone to error will significantly alter 
the 1/v intercept value. If too small inhibitor concentrations are chosen the gradients of the 
double reciprocal plots are too small and a small error in any of the points, particularly the 
lower concentrations of substrate which are usually the most prone to error will significantly
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alter the gradient. These problems can usually be avoided by chosing inhibitor concentrations 
of about Ki, ie Kj, K; and twice K\.
A rough estimate of K; can be determined from the concentration of inhibitor required to 
give 50% inhibition of the proteinase for competitive inhibition. Ki gives around 25% 
inhibition and twice Ki gives approximately 75% inhibition. However saturation of the 
enzyme’s active site by the inhibitor starts to affect the linear relationship between inhibition 
and concentration of inhibitor and 87% inhibition is given by a concentration of inhibitor of 
about four times Ki. Estimations of Kj for the various inhibitors, the concentrations of 
inhibitors used to determine K, and the assay method used for each determination are give in 
Table 3.4.
34 pM of inhibitor 
represents;
Inhibitor
number
Proteinase
conc.
Concentrations used 
/mmol dm'^
Assay
method
Kii (78) 1.04 pmol dm'^ 0.00, 0.11,0.22, 0.44 1
'Æ ; (118) 0.35 pmol dm'^ 0.00, 0.22, 0.44, 0.55 1
Ki (79) 1.04 pmol dm'^ 0.00, 0.11,0.22, 0.44 1
1/3 Ki (114) 1.04 pmol dm"^ 0.00, 0.22, 0.44, 0.55 1
6Ki (122) 2.17 pmol dm'^ 0.00, 0.031, 0.044, 0.073 1
Table 3.4: Concentrations tested and assay methods fo r  various inhibitors 
fo r  double reciprocal plots and K,- determination.
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3.1.3.0 method 1
Each concentration of inhibitor, ie. zero, Vz K; and twice Kj as shown in Table 3.2 were 
assayed for proteinase activity at five different substrate concentrations; 3.87, 4.42, 5.52, 
7.73 and 11.05 mmol dm'^ as follows;
Ten assays were carried out, each staggered by 1 min time. Each assay was conducted as 
follows; proteinase solution (20 mm^), activating peptide (GVQSLKRRRCF) solution (10 
mm^, 20 pmol dm" ,^ 0.2 pmol) and tris / NaCl buffer (15 mm^, 2 mmol dm'^, tris and 100 
mmol dm"  ^NaCl at pH 8) were mixed in the order shown and incubated at 37°C for lOmin.
Substrate (Acetyl-LRGA-GRSR) solution (15 mm^) and potential inhibitor 4% DMSO 
solution (15 mm^) were mixed and also incubated at 37°C. After 10 min the inhibitor / 
substrate solution (0.020 cm^) was added to the activated proteinase solution, mixed and 
aliquots were taken at 10 min intervals for 50 min and quenched in TFA solution (25 mm ,^ 
1%). Each aliquot was diluted with water (40 mm^), filtered and analysed as in method 1 
(Section 3.3.0.0).
3.1.3.1 Treatment of results
The initial rates were determined from the capillary electrophoresis as before (Section 
3.3.0.4). However the concentrations of substrate were different between each assay, so the 
Pi percentage peak area was multiplied by the concentration of substrate in mol dm'^ to give 
the actual concentrations of Pi.
The type of inhibition observed for each inhhibitor and the Ki was obtained from the 
double reciprocal plot (Lineweaver-Burke plot) o f each inhibitor concentration ie 1/v verses 
1/S as described in Section 1.2.3.
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3.2 NMR Spectroscopy
3.2.0 ^H-NMR Assay’s of potential Substrates
It was possible that the proteinase could hydrolyse the amides, the esters, the cyanides 
and the dimethylacetal functionalities. Proteolytic assays with the potential substrates were 
conducted in D2O or phosphate buffer and the course of the reaction followed by ^H-NMR 
to detect any hydrolysis products. If  hydrolysis was observed ie. the ^H-NMR spectrum 
showed the disappearence of the ester signals and the appearence of the product signals, an 
effort was made to identify the new signals. Controls for the proteolytic assays were 
conducted where D%0 or phosphate buffer was added instead of the proteinase solution and 
any change in the substrate was monitored by ^H-NMR spectroscopy at 300MHz.
Two assays were employed to determine if hydrolysis of a potential substrate occurred, 
differing only in the concentration of proteinase used for each assay. Aproximately enough 
proteinase to hydrolyse 1 mg of substrate (2 {.irnol) ten times over in 3 hours was added in 
each case.
3 .2 0 . 0  ^H-NMR assay 1
The following potential substrates were tested by this method (Table 3.5). The 
potential substrate (Img, 2 pmol) was dissolved in C^HsSOC^Hs (4 mm^) and then the 
solution o f potential substrate was added to D2O (365 mm^) after vigorous shalcing and 
heating most of the potential substrate that had precipitated out redissolved. The solution 
was allowed to cool to room temperature and D2O (366.5 mm^) was added.
The proteinase solution (57 mm^ 34.5 pmol dm'^ 1.97 nmol) was added to a mixture 
of activating peptide (GVQSLKRRRCF) solution (4.6 mm^ 43.5 mmol dm’^  200 nmol) and 
1% mercaptoethanol solution (2.9 mm^) and incubated at 0°C for 15 min.
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The activated proteinase solution was added to the potential substrate solution with 
vigorous mixing and the solution was placed in an NMR tube and a ^H-NMR acquisition at 
300MHz was carried out as soon as possible. Further acquisitions were carried out after one, 
two, three and four hours from the addition of the proteinase solution to the potential 
substrate solution.
If  the ^H-NMR spectrum had changed compared to the starting material, the nature of 
the products were determined as follows; The tetrapeptide product was compared with the 
^H-NMR spectrum spectra of Cbz-Leu-Ala-Gly-Gly (76) and N-(Cbz-Leu-AJa-Gly)- 
ethanolamine (75). The nature of the alcohol product (in the case of the esters) and the amine 
product (in the case of the amides) was determined fi-om adding a drop of the relevant 
alcohol or amine to the assay mixture and running another ^H-NMR spectrum to make sure 
the alcohol or amine product signals appeared at the same chemical shift as the authenic 
material.
Compound Number
Cbz-Leu-Ala-Gly-Gly-NMeEt (22)
Leu-Ala-Gly-Gly-NHMe. HOAc (26)
Cbz-Leu-Ala-Gly-Gly-OMe (65)
Cbz-Leu-Ala-Gly-Gly-OEt (66)
t-B 0 c-Leu-Ala-Gly-Gly-OtBu (73)
Cbz-Leu-Ala-Gly-aminoacetonitrile (78)
Cbz-Leu-Ala-Gly-aminoacetaldehyde dimethyl acetal (114)
Table 3.5: Potential substrates fo r  the Adenovirus tested by NMR method 1.
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Two controls were also carried out. The first control consisted o f the same materials as 
the assay but the potential substrate was missed out. The second controls contained the same 
materials as the assay but D2O was added instead of the proteinase solution and the ^H-NMR 
spectra were recorded at one, two, three and four hour time intervals.
3.2.O.I ^H-NMR assay 2
The following potential substrates were tested by this method (Table 3.6);
Compound Number
t-Boc-Leu-Aia-Gly-Gly-pN02 anilide (24)
Cbz-Leu-Ala-Gly-Gly-OMe (65)
Cbz-Leu-Ala-Gly-Gly-OtBu (66)
t-Boc-Leu-Ala-Gly-Gly-OBz (67)
t-Boc-Leu-Ala-Gly-Gly-OtBu (73)
Table 3.6: Potential substrates fo r  the adenovirus tested fo r  method 2.
The potential substrate (Img, 2 pmol) was dissolved in C^HgSOC^Hg (4 mm^) and then 
the solution of potential substrate was added to phosphate buffer (327 mm^, 50 mmol dm-^, 
pD 7.6) and with a lot of vigorous shaking so that most of the potential substrate that had 
precipitated out redissolved. The solution was allowed to cool to room temperature and 
phosphate buffer (0.327 cm^, 50 mmol dm '\ pD 7.6) was added.
The proteinase solution (50 mm ,^ 37.5 pmol dm'^, 1.88 nmol) was added to a mixture 
of activating peptide (GVQSLKRRRCF) solution (50 mm", 4.3 mmol dm*  ^ 215 nmol) and 
1% mercaptoethanol solution (3 mm^) and incubated at 0°C for 15 min.
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The activated proteinase solution was added to the potential substrate solution with 
vigorous mixing and the solution was placed in an NMR tube and a ^H-NMR acquisition at 
300MHz was carried out as soon as possible. Further acquisitions were carried out after one, 
two, three and four hours from the addition of the proteinase solution to the potential 
substrate solution.
If  the ^H-NMR spectrum had changed compared to the starting material, the nature of 
the products were determined as follows; The tetrapeptide product was compared with the 
^H-NMR spectrum spectra of Cbz-Leu-Ala-Gly-Gly (76) and N-(Cbz-Leu-Ala-Gly)- 
ethanolamine (75). The nature of the alcohol product (in the case of the esters) and the amine 
product (in the case of the amides) was determined from adding a drop of the relevant 
alcohol or amine to the assay mixture and running another ^H-NMR spectrum to make sure 
the alcohol or amine product signals appeared at the same chemical shift as the authenic 
material.
Three controls were also carried out. The first control was to check that any new 
signals came from the hydrolysis of a substrate rather than the activated proteinase solution 
and consisted of the same materials as the assay, but the potential substrate was missed out. 
^H-NMR spectra were recorded at one and four hour time intervals. The second controls 
were to check that the observed hydrolysis was due to the proteinase and contained the same 
materials as the assay, but D2O was added instead of the proteinase solution. The ^H-NMR 
spectra were recorded at one, two, three and four hour time intervals. The third control was 
to check that the proteinase was active under the assay conditions used.
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3.2.0 ^^C-NMR Of The "C-labelled Nitrile
As mentioned in the discussion (Section 2.3.3.1) three different ^^C-NMR experiments 
were carried out with adenovirus proteinase solution and [1-^^C]-Cbz-Leu-Ala-Gly- 
aminoacetonitrile (86). The experiments were carried out using the same method, as outlined 
below. The concentrations and volumes of the reagents are given in Tables 3.7, 3.8 and 3.9.
Proteinase, activating peptide, 1% mercaptoethanol solution (if used) and buffer (or 
water) were mixed together and the ^^C-NMR spectrum was recorded at 125.80 MHz at 
30°C for 1 hour. Then the inhibitor DMSO solution was added and another ^^C-NMR 
spectmm was recorded over 3 hours.
A control spectrum was also recorded over 3 hours, which contained the same amounts of 
reagents as used in the adduct experiment, however the appropriate buffer was added instead 
of the proteinase solution.
Reagent Volume / cm^ Conc. / mol dm‘^ moles
proteinase in D2O 0 . 5 5 4 . 3 5  X 10'^ 2 . 3 9  X 10'^
activating peptide 
(GVQSLKRRRCF)
0 . 0 8 9 2 . 4 4  X 10'^ 2 . 3 9  X 1 0 ‘®
d®-DMSO + (86) 0 . 0 1 6 0 . 1 4 2 . 3 1  X 1 0 ’®
mercaptoethanol solution 0 . 0 6 2 1% not applicable
Table 3.7:
Concentt'ations and volumes o f  the reagents used in the first ^^C~NMR experiment.
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Reagent Volume / cm^ Conc. / mol dm'^ moles
proteinase in D2O 0.400 1.30 X 10"^ 5.22 X lO"'^
activating peptide 
(GVQSLKRRRCF)
0.200 3.20 X 10'^ 6.40 X 10'"
d^-DMSO + (86) 0.004 0.174 6.94 X 10"^
Tris buffer"" 0.100 not applicable not applicable
Table 3.8:
Concentrations and volumes o f the reagents used in the second ^^C-NMR experiment.
Reagent Volume / cm^ Conc. / mol dm'^ moles
proteinase in H2O 2.5 8.70 X 10'^ 2.17 X 10'^
activating peptide 
(GVQSLKRRRCF)
added as solid 22mg 2.17 X 10'^
DMSO + (86) 0.011 0.079 8.68 X 10"^
Posphate buffer*’ 0.2 not applicable not applicable
D2O for locldng 0.29 10% of final vol. not applicable
Table 3.9:
Concentrations and volumes o f  the reagents used in the third ^^C-NMR experiment.
a 50 mmol dm'^ Tris, 0.2 mol dm'^ NaCl, 10 mmol dm"^ ethylenediaminetetraacetic acid in D^O at pH 8 . 
b 50 mmol dm'^ pospahte buffer at pH 7.6.
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Preliminary double reciprocal plots for Cbz-Leu-Ala-Gly= 
aminoacetonitrile (78)
The double reciprocal plots are graphical representations of the mode of inhibition, for 
each inhibitor. The data points shown have been calculated from the rate of appearance of 
product, which were obtained from non-linear regressional analysis of the [P] verses time 
data, using the enzfitter program (Section 3.1.3, Experimental).
Each rate was determined once as problems were encountered with the proteinase 
preparation which was unstable and denatured readily. The best fit lines for the estimated 
type o f inhibition are shown on each plot.
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Approximate Ki determination for Cbz-Leu»Ala-Gly-aminoacetonitrile (78)
Dr Heather Murray also carried out similar rate determination experiments and also found 
that Cbz-Leu-Ala-Gly-aminoacetonitrile (78) was a noncompetitive inhibitor of the 
adenovirus proteinase, with a Kj of 16 pmoldm'^/^^ A Ki of 15 pmoldm'^ was determined 
from this experiment.
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Preliminary double reciprocal plots for t-Boc-Leu-Ala-Gly-
aminoacetonitrile (79)
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Approximate Ki determination for t-Boc-Leu-Ala-Gly-aminoacetonitrile
(79)
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Preliminary double reciprocal plots for Cbz-Leu-Ala-Gly 
aminoacetaldehyde dimethyl acetal (114)
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Approximate Ki determination for Cbz-Leu-AIa-Gly-aminoacetaldehyde 
dimethyl acetal (114)
Dr Heather Murray also carried out similar rate determination experiments and also 
found that Cbz-Leu-Ala-Gly-aminoacetaldehyde dimethyl acetal (114) was a noncompetitive 
inhibitor o f the adenovirus proteinase, with a K; of 380 pmoldm'^/^^ A Ki of 96 jj,moIdm'^ 
was determined from this experiment.
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Preliminaiy double reciprocal plots for Cbz-Leu-Ala-Gly» 1-amino 2-
methyl prop-2-ene (118)
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Approximate Ki determination for Cbz-Leu-Ala-Gly-l-amino 2-methyl
prop-2-ene (118)
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Preliminary double reciprocal plot for N,N’ (di(Cbz-Leu-Ala-Gly))-2,4«
diamino but-2-ene aldehyde (122)
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Approximate K; determination for NjN’ (di(Cbz=Len"AIa-GIy))-2,4° 
diamino but-2-ene aldehyde (122)
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